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Introduction and review of literature
This  section introduces end  stage renal  failure,  its prevalence,  demographics and 
treatment in the renal population.  A brief history of haemodialysis treatment and 
some key clinical issues contributing to dialysis mortality and morbidity today are 
discussed  with particular emphasis  on  volume  dependent  hypertension  and  other 
cardiovascular  aspects.  Evolution  of  concepts  in  dry  weight  on  dialysis,  fluid 
pathophysiology  in  humans  and  its  regulation  during  dialysis  and  blood  volume 
based studies are reviewed to provide the essential knowledge base for understanding 
body responses to ultrafiltration during dialysis. Stating the aims and objectives of 
the current research concludes the section.
Methods
Details of methodology, machines and tools used for experimental studies have been 
described in this section. A short description of algorithms and systems required for 
simultaneous data acquisition are included as an important part of current research. 
Study designs and their rationale briefly alluded to here have been more extensively 
discussed in subsequent chapters.
Experimental Clinical Studies
This  section  has  been  arranged  in  separate  chapters  (describing  individual 
experiments), which address specific aspects of monitoring fluid management. There 
are three main subdivisions. Chapters 1&2 investigate blood pressure measurements, 
bioimpedance determined fluid compartments and nutritional markers in relation to 
fluid management Chapters 3,4,5 & 6 describe relative blood volume responses to 
ultrafiltration and  Chapters  7,8,9  &  10  describe  experiments  to  directly  measure 
absolute  blood  volume  changes  during  dialysis,  its  relationship  with  other  fluid 
compartments and relative blood volume changes. Finally it provides an insight into 
interesting pathophysiological responses to ultrafiltration during haemodialysis.
Overview
This section summarises the contribution of knowledge resulting from the current 
research and recommendations for further work.
Appendices
The appendices include additional material and demonstrate a number of derivations 
flowsheets used and practical examples of data analysis.
References
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Abstract
The aim of the research was to characterise the pathophysiology of ultrafiltration 
(UF) during haemodialysis (HD) using a range of assessment tools. The hypothesis 
was that objective  monitoring  would  facilitate  accurate  estimation  of dry  weight 
(DW) and help optimise UF.
Measurement  timing,  white-coat  effect,  UF  prescription  and  volume  status 
influenced blood pressure (BP) readings, particularly predialysis and immediate post­
dialysis  measurements.  The  20-min  post-dialysis  BP  best  reflected  interdialytic 
control.  Extracellular  volume  measurements  (ECF)  using  Bioimpedance 
spectroscopy  (BIS)  were  reproducible,  accurate,  and  confirmed  the  tight  link 
between  nutritional  and  volume  status.  The  late  increase  in  ECF  and  decline  in 
nutritional status as end-stage approached, were only partially corrected by dialysis.
Relative  blood  volume  (RBV)  characteristics  were  investigated  using  short  UF 
pulses (perturbation analysis), at different hydration states, to identify predictors of 
hypotension  and  approaching  DW.  RBV  change  was  greater  as  predicted  DW 
approached. The critical level of RBV reduction leading to hypotension showed a 
wide inter-individual variation. The approach to linearity of RBV decay curve was a 
surrogate for plasma refill (PR) and predicted impending hypotension. The role of 
heat exchange on cardiovascular stability was also examined.
Indocyanine green emerged as a suitable tracer for determining PV repeatedly during 
HD. The method was employed simultaneously with BIS to demonstrate abnormal 
proportional compartmental fluid distribution and assess fluid shifts and PR during 
UF.  A  significant  relationship  was  demonstrated  between  ECF  change,  PR  and 
haemodynamic stability. The dissociation between simultaneous absolute and RBV 
measurements  was  explained  by  a  changing  Fcell  ratio,  suggesting  significant 
intravascular shifts within the microcirculation during UF.
Objective monitoring has  improved  understanding  of the pathophysiology  of UF 
during HD. However, the main factors limiting fluid removal during HD are patient- 
specific responses to UF. Individualised prescriptions will require use of systems to 
characterise patient responses,  and prompt appropriate adjustments.  These  studies 
may contribute.
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AH Antihypertensive drugs
ABPM Ambulatory blood pressure monitoring
ACEI Angiotensin converting enzyme inhibitors
BV Blood volume
BSA Body surface area
BVM Blood volume monitor
BTM Blood temperature module
BMI Body mass index
CrCl Creatinine clearance
CRF Chronic renal failure
CO Cardiac output
CV Coefficient of variation
CHD Conventional haemodialysis
DPI Dietary protein intake
ECF Extracellular fluid
ECW Extracellular water
ESRF End stage renal failure
ESRD End stage renal disease
ECC Extracorporeal circuit
EDW  estimated dry weight
GFR Glomerular filtration rate
HD Haemodialysis
HHD Home haemodialysis
ICG Indocyanine green
ICF = intracellular fluid volume
ICW Intracellular water
8IBW Ideal body weight 
IDH Intradialytic hypotension 
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MAP mean arterial pressure 
P02 Partial pressure Oxygen 
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Pv  Pressure in blood compartment of dialyser
Pd  Pressure in dialysate compartment of dialyser
Qd Dialysate flow rate
Qb Blood flow rate
RRT Renal replacement therapy
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RAS  Renin Angiotensin system
SBP Systolic Blood pressure
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SNS Sympathetic nervous system
TMP  transmembrane pressure
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URR Urea reduction ratio
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9INTRODUCTION
10Chapter 1  End stage Renal failure
The principal functions of the kidneys are excretion of potentially toxic metabolites, 
volume  and  osmoregulation,  maintaining  acid  base  homeostasis  and  hormonal 
functions  related  to  erythropoietin,  1,25  dihydroxycholecalciferol  and  renin. 
Progressive loss of kidney function is often described as chronic renal insufficiency 
in the early stages, chronic renal failure (CRF) when it is obvious and end stage renal 
failure (ESRF) when the disease reaches a terminal stage. The majority of patients 
with chronic renal disease progress relentlessly to ESRF.
The true prevalence of CRF is not known because many patients are unrecognised 
and not referred. Estimates have been made of 2000 p.m.p based on the prevalence of 
abnormal  serum creatinine measurements in the population.  Diabetes is a leading 
cause of ESRF (approximately 38 and 14 percent of newly diagnosed cases of ESRF 
are caused by diabetes in the US and UK respectively). Other causes of ESRF include 
hypertension,  glomerulonephritis,  primary  and  secondary  glomerulopathies,  cystic 
and interstitial renal diseases, and obstructive uropathy. (Table 1)
Symptoms and signs of renal failure tend to manifest quite late in the disease and can 
vary  between  nonspecific  tiredness,  anaemia,  breathlessness,  hypertension  and 
generalised accumulation of excess body fluid. The major consequences of severe 
renal  failure  include  cardiovascular  disease,  hypertension,  sodium  and  water 
retention, anaemia, bone disease, hyperkalemia, metabolic acidosis and malnutrition.
One of the earliest effects of chronic renal disease is the power of the kidneys to 
compensate  for changes  in  sodium  and  water intake.  At GFR above  10  ml/min, 
patients with CRF but otherwise in good health maintain salt and water balance by a 
large increase in the proportion of filtered water and salt by magnification of the 
tubular response or fractional excretion of sodium. This capacity to handle water load 
is further impaired during procedures like surgery when factors such as nonosmotic 
vasopressin release operate and with in approaching end stage renal failure with loss 
of residual renal function.
11la  Prevalence and treatment of ESRF
Individuals with end stage renal failure (ESRF) untreated will usually die within a 
few  weeks.  The  life  saving  treatment  options  for  renal  replacement  therapies 
(RRT)  are  either  renal  transplantation  or  dialysis  (  peritoneal  dialysis  or 
haemodialysis). The aim of RRT should be to restore patients to as normal a level of 
health as possible and to ensure full social and physical rehabilitation.
A well-functioning renal transplant is regarded as the optimal therapy of end-stage 
renal failure. Imbalance between demand and supply of cadaver organs, increase in 
waiting lists despite rigorous selection criteria and the increasing numbers of elderly 
patients with non-renal co-morbidity has created an ever-increasing population of 
patients who remain permanently on dialysis.  In many units, this group constitutes 
well over 50% of the dialysis population. The sole future of these patients with end 
stage renal failure is that of a dialysis patient.
i)  Prevalence of ESRF
End-stage renal disease creates a large burden for both individuals and society as a 
whole. The incidence rates in the United Kingdom, as well as in every other country, 
are rising steadily and continue to rise. UK is now treating over 30000 patients with 
end stage renal failure, at a rate of 566 per million populations. Approximately 53% 
of these are on dialysis. [1] The acceptance rate for new adult patients to dialysis is 
96 per million populations. The annual increase in prevalent RRT patients is 4%. The 
estimated RRT population is over 45000 patients by 2010. This trend is being seen 
elsewhere (US over 250 new cases per million per year).
ii)  Age, comorbidity and ESRF incidence
The prevalence of CRF rises with age and is higher in certain ethnic groups. The 
epidemic of renal disease and therefore patient acceptance for dialysis is particularly 
rising in the elderly. The increasing trend in incidence is much steeper for over 65 
than in the younger age groups. (Fig 1) The median age of all patients on RRT in UK 
is approximately 55.9 years. This is 64.5, 58.3,49.6 years for HD, PD and transplant
12patients respectively. The median age of prevalent patients on HD has increased over 
the past 4 years [1]
In England and Wales 44% patients are over 65 and 1  in 6 over 75 years of age at the 
start of renal replacement therapy. The acceptance rate peak in those aged between 
65 and 74. The UK Renal Registry data suggest that there is an unmet need in the 
65+-age range.  Presence of non-renal comorbidity  in patients of ESRF  is on the 
increase. This is not surprising when seen in the context of rising elderly population 
and  liberal  acceptance  programs.  Fig  2  compares  two  incident  cohorts  from  the 
USRDS  from  1986  and  1996  for both  Peritoneal  and  Haemodialysis  showing  a 
dramatic rise in comorbidity. [2]
iii)  Treatment of ESRF
Dialysis remains the predominant mode of renal replacement therapy in patients with 
ESRF. This can be delivered by either peritoneal dialysis or haemodialysis, both of 
which utilise the same fundamental principles of solute clearance and fluid removal 
across a semipermeable membrane but differ in their apparatus and technology.
Peritoneal dialysis (PD)
More than 22 years after its inception as an accepted modality of renal replacement 
therapy, the acceptance of PD varies across the world from a 40% usage in UK and 
New Zealand to 75% in Mexico. In the initial years PD is probably as effective as 
haemodialysis and is acceptable to many patients. It has certain social, logistical and 
medical advantages especially early in the course of RRT. Whether PD has a major 
or minor role in later years is unclear. Hospitalisation, long term technique survival 
and mortality is however not as good as in HD. USRDS data in the late 1980s have 
also suggested a worse prognosis  for elderly and diabetics on peritoneal  dialysis 
which constitute a significant majority of patients with ESRF.
Haemodialysis (HD)
At its inception, chronic haemodialysis was viewed as a therapy applicable to young 
adults with primary kidney disease and no substantive malfunction of other organ 
systems e.g. diabetics and elderly were excluded from dialysis therapy. By the 1990s
13however the number of ESRF had risen beyond all expectations. The rising trend of 
treated ESRF can be attributed to an increase in incidence of ESRF as well as to a 
more liberalised acceptance of patients into dialysis programs. The rise in prevalence 
of ESRF has to be met in future with substantial increase in HD, especially in the 
elderly. In parallel with this growth, there has been considerable diversification both 
in the available technologies and the methods for provision.  Haemodialysis can be 
"centre-based"  in units located in hospitals or in free-standing  facilities  in cities, 
towns or rural areas. A comorbidity gap seems to be developing between PD and 
haemodialysis.  Sicker,  older,  frailer patients seem to be directed preferentially to 
haemodialysis. The predominant form of dialysis at all ages is haemodialysis (Fig 3) 
and especially in the older age groups with a steep rise in prevalence of hospital 
based haemodialysis compared to other modalities.
lb  Haemodialysis  -   historical aspects
The history of dialysis, only 40 years old, owes it’s invention to Thomas Graham 
(1805-1869), the father of modem dialysis, who laid the foundation of what later 
became  colloid  chemistry and  demonstrated that vegetable parchment acted  as  a 
semi-permeable membrane.  Parchment was coated with albumin to close defects, 
stretched over a wooden hoop and floated on water. Into this was placed, as on a 
sieve, a fluid containing crystalloids and colloids. He found that only the crystalloid 
material  diffused  through  the  parchment  into  the  water.  This  phenomenon  was 
termed “dialysis ".
The  artificial  kidney
The next step, removing solutes through a semi-permeable membrane from the blood 
of an  animal,  was  undertaken  in  1913  by  John  Abel  and  his  colleagues.  Their 
dialyser, for which they coined the name artificial kidney, had a series of fragile and 
delicate celloidin tubes fastened by tying with a string to a system of glass manifolds. 
Thus, the flow of blood took place horizontally twice in each direction through 8 
tubes  in  parallel.  The  capacity  of their dialyser was  limited  and  insufficient  for 
human application. Hirudin, which they obtained by grinding up heads of leeches in 
solution, seemed to be toxic for human beings and was difficult to handle.
1425 years later Pim Kolff started his experiments which led to the construction of an 
artificial kidney that was suitable for human application. The two main problems, 
anticoagulation and a suitable membrane, remained major obstacles.  In  1914, V. 
Hess and McGuigan used Abel's vividiffusion method in a series of experiments on 
the  dog  improved  the  apparatus  by  creating  a  pulsatile  bloodflow  through  the 
celloidin  tubes,  which  apparently  inhibited  clotting.  They  also  enhanced  the 
procedure  by  mixing  the  dialysate  at  short  intervals  or  continuously,  preventing 
formation of a stagnant layer of fluid around the dialysing tubes.
First human dialysis
The  credit  for  the  first  human  dialysis  must  go  to  Georg  Haas  from  Gieszen, 
Germany.  [3,4] He circulated the blood of his animals through reed stalks, which 
apparently  worked  as  dialysis  membranes.  On  18th  February  1926,  Haas  finally 
attempted dialysis in a 20-year-old girl in the terminal stage of uraemia using hirudin 
and a continuous circulation technique.  Haas later stated that his first attempts at a 
"Blutauswaschung" in a human  during World War 1   in 1915 and  1916. Two years 
elapsed before Haas again tried the new haemodialysis procedure  for therapeutic 
purposes: in 1928 he reported on two cases on 13th January 1928. In the second case, 
after  dialysing  500  ml  of blood  through  a  2.1  m2  celloidin  dialyser,  2.5  g  of 
nonprotein  nitrogen  was  removed  with  a  gratifying  symptomatic  improvement. 
Blood pressure decreased from 205/110 to 145/95 mm Hg.  Haas noted a decrease in 
the volumes of the blood during the extracorporeal circulation. Actually, a loss of 
100 ml from the 500 ml aliquot occurred during 30 min of dialysis.  Haas discussed 
the explanation of this phenomenon, which actually was caused by ultrafiltration, not 
by osmotic water removal because the dialysate was isotonic Ringer solution.  Then 
followed  a  nine-year  interval  of silence  on  the  subject  during  which  time,  two 
important  advances  were  subsequently  made:  firstly  heparin  was  purified  and 
became available for human application and secondly a new cellulose product named 
cellophane was marketed, mainly for commercial use.
15Dialysers
KOLFF'S Rotating Drum Dialyser
In the late 1930‘s, Willem ("Pim") Johan Kolff in Netherlands, had to treat a uraemic 
22-year-old  farmer's  son,  who  subsequently  died.  Kolff began  to  think  about  an 
apparatus that could replace renal function and eventually he constructed a dialyser 
with large surface area, assisted by an engineer and a managing director of an enamel 
factory.  It consisted  of a  cylindrical  drum  with  a 40m  length  of sausage  tubing 
wound around it to be perfused with the patients blood through a rotating coupling 
which according to Kolff was copied from a Ford automobile waterpump.  Kolff s 
rotating  dialyser  was  the  first  model  that  in  practice  was  suitable  for  human 
application and made clinicians interested in the treatment of uremia.
Soon after Kolff s first series of publications other dialysers were constructed, all 
based on the  same principles and using cellophane  tubing.  Nils  Alwal,  in  Lund, 
Sweden, was the first to design a stationary coil type dialyser. This dialyser had the 
advantage that a controllable ultrafiltration could be achieved. [5]
Repeated  access  to  the  circulation  and  lack  of a  suitable  dialysis  technique  for 
chronic  renal  failure proved  a  major stumbling block  until  in  1960,  Dillard  and 
Schribner reported on a bypass device made of Teflon which made the application of 
repeated  haemodialysis  in  chronic  renal  failure  a  possibility.  At  the  same  time, 
Scribner  and  co-workers  presented  a  new  technique  for  circulatory  access  by 
arteriovenous  cannulation  which  allowed  repeated  dialysis  in  a  single  patient. 
Scribner used modified Kill dialyser with a low volume in the blood compartment 
that could be primed by the patient at the start of dialysis with a washback using 
saline at the end.
Emphasis on various body spaces and disequilibrium
Claude Bernard was the first to point out that the kidneys don't have simply the role 
of excreting poisons but regulating our interior milieu. In 1923 Haas first observed 
that dialysis could remove volume from patients body, 20 yrs later Alwall designed 
the first dialyser with a specific UF device. Overhydration as part of uraemic toxicity 
had always been the interest of Alwall. He was the first to emphasise uraemic fluid
16overload  and  became  concerned  about  what  he  termed  "uraemic  fluid-retention, 
lung." He also suggested that dialysis not only detoxified but also dehydrated —  one 
of his biggest contributions. This was the first use of the term ultra-filtration and 
overhydration added to  the  spectrum  added  to  the  spectrum  of uraemic  toxicity. 
Alwall performed the  first hemofiltration treatment and  was  the  first to  describe 
sequential  ultrafiltration,  which  was  later brought  into  clinical  practice  by  Jonas 
Bergstrom.
The first chronic patients
On 9th March 1960, a Teflon arterio-venous cannula system was inserted in the arm 
of Clyde  Shields,  a  39-year-old  machinist  in  terminal  renal  failure  and  on  23rd 
March, another pair of cannulae was placed in the right arm of Harvey Gentry, a 23- 
year-old shoe sales-man.
The results of repeated haemodialyses in these first two patients were surprisingly 
good: both became successful chronic dialysis patients.  The system appeared to be 
so  safe  and  reliable  that patients  with  chronic  uraemia  could  be  haemodialysed 
entirely by nurses. [6,7] In April 1962, the Seattle group reported on eight patients 
who were on the treatment programme for intervals of four months and two years. 
Others, using somewhat different techniques, had more limited success but it soon 
became apparent that successful replacement of renal function and rehabilitation by 
regular haemodialysis in cases of irreversible, terminal renal failure had become a 
reality.
In 1966, a surgically created arterio-venous (A-V) fistula was introduced for access 
to the circulation by Brescia, Cimino, Appel and Hurwich another landmark in the 
history of dialysis. [8]
Central dialysate supply system
The introduction of the single pass technique (dialysate was pumped from the tank, 
heated to 37C and discarded after a single pass through the dialyser) and substitution 
of acetate  for bicarbonate;  in  the  dialysis  fluid  [9]  led  to  the  development  of a 
centralised  dialysate  fluid  supply  system.  A  central  multipatient  system,  a 
concentrated  solution  of salts  and  dextrose  had  to  be  diluted  with  (pre-treated) 
tapwater by means of an accurate proportioning system for a continuous supply of
17dialysis fluid.  Sodium bicarbonate unlike sodium acetate could not be mixed with 
concentrated calcium and magnesium salts without adjusting pH to 7.4 or less.
The Start of regular dialysis
In August  1965,  some  160 chronic patients were on treatment in  Europe and 40 
centres had started treating patients with chronic renal failure. Soon, the number of 
chronic  patients  requiring  treatment outnumbered  the  available  facilities,  both  in 
Europe and in the United States.
Home dialysis
Despite a gradual increase in treatment facilities, enormous problems of financing 
and training of doctors and nurses had to be faced and in an effort to achieve at least 
a partial solution of the dilemma Shaldon and co-workers of the Royal Free Hospital 
in London introduced the concept of self dialysis in September 1964. [10] From self 
dialysis in the hospital to home dialysis was the next step.
The Seattle group started their home program in September 1964.  The Royal Free 
team began home dialysis two months  later,  their first patient being a registered 
nurse.  However through the years with acceptance of more complicated and elderly 
patients,  advent  of  peritoneal  dialysis  and  other  reasons,  home  haemodialysis 
numbers have decreased dramatically.
Basic  research  on  haemodialysis  focused  on  haemodynamics,  kinetics  of solute 
removal  and  development  of  new  membranes.  After  1965,  industry  became 
increasingly interested in dialysis and a growing number of proportioning machines, 
monitoring equipment, blood pumps and ancillary equipment was constructed and 
introduced.  A plethora of types of dialysers was made available, the performance of 
which was further improved by replacement of the cellophane with thin Cuprophan 
membrane.
Around 1965, a new design, the hollow fibre artificial kidney, or capillary dialyser 
was introduced.  [11,12] With a short length of the blood path, a thin blood film, 
highly  permeable  membranes  and  excellent  convective  capability,  this  improved 
dialyser could control uraemia very well.
18The square metre/hour and middle molecule hypotheses
In the early years of regular peritoneal dialysis for chronic renal failure,  Scribner 
noted despite a certain amount of "underdialysis' with chronic peritoneal dialysis, 
peripheral neuropathy either did not occur or did not progress. Suspicion arose that 
the so called middle molecules played an important role in the toxicity of uraemia. 
Because of their size, it was suggested that they were very slowly removed compared 
to  urea.  The  cellulose  membranes  used  in  haemodialysis  (e.g.  cellophane  and 
Cuprophan)  have  a  high  membrane  diffusion  resistance  for  these  species  of 
molecules.
This  speculation  correlated  with  the  hypothesis  that  using  a  given  membrane, 
prevention of peripheral neuropathy depended on a minimum number of hours of 
dialysis per week,  rather than on maintaining specified  levels of blood  urea and 
creatinine.  Further,  it was suggested that larger toxic  solutes must permeate  the 
peritoneum better than cellulose membranes.  These considerations in relation to the 
adequacy  of dialysis  led  to  the  square  metre/hour hypothesis  [13,14]  and  to  its 
modification,  the  middle  molecule  hypothesis.  [15]  Both  theories  suggest  that 
inadequate removal of the middle molecules (molecular weight between 300  and 
2000 daltons) cause complications such as peripheral neuropathy, pericarditis and 
perhaps others.
Since the removal rate of middle molecules is slow, the diffusion gradient remains 
high  throughout  dialysis,  unlike  urea.  Thus,  the  net  removal  rate  of  middle 
molecules  remains  rather  constant  during  protracted  dialysis  and  net  removal  is 
proportional to the total number of haemodialysis hours/week unlike urea, which has 
flow dependent removal, which decreases with the decreasing plasma concentration 
as dialysis proceeds.
Short dialysis
The square metre/hour and middle molecule hypotheses have profoundly influenced 
dialysis strategies in recent years.  The array of protocols used resulted in conflicting 
clinical results. [16,17] In many dialysis centres, protocols were changed according 
to the new theories, resulting in short dialysis schedules either with large surface area 
dialysers  or  with  the  same  type  of  dialyser  and  increased  dialysis  frequency.
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high clearances for molecules in the critical range of 300-2000 molecular weight. 
Since Wolff described the 8 cases of uremia treated by HD and UF, extracorporeal 
technology has advanced and has been broadly applied throughout the world in more 
than  1   million patients who have developed acute and chronic renal  failure.  The 
proportional distribution of these patients across the globe has been heterogeneous. 
(Fig 4)
lc  Dialysis Adequacy and Mortality
When the euphoria of the first years after introduction of dialysis treatment was over, 
it became evident that mortality remained unacceptably high and life expectancy 
with ESRF is poor despite renal replacement therapy.  (Fig 5) Improvements have 
occurred in dialysis machines, in water-purification systems, and in the composition 
of dialysate and the performance and biocompatibility of dialysers.  Despite these 
improvements,  mortality  and  morbidity  among  patients  treated  with  dialysis, 
particularly mortality related to cardiovascular diseases and morbidity resulting from 
complications of vascular and peritoneal access, continue to be unacceptably high.
i)  Mortality among Patients on Dialysis
The dialysis outcomes and practice patterns study (DOPPS) in an analysis of patient 
survival in UK, noted a significantly higher mortality rate compared to some other 
European countries.  The adjusted risk of mortality in haemodialysis patients in the 
UK is 36% higher than in four other European countries participating in DOPPS. 
[18]
Deaths  in  haemodialysis  subjects  are  due  mainly  to cardiovascular  diseases  and 
infections  (approximately  50  percent  and  15  percent  of  deaths,  respectively). 
Hypertension continues to be a major risk factor for cardiovascular disease; recent 
surveys  show  that  more  than  50  percent  of  patients  undergoing  outpatient 
haemodialysis have a systolic blood pressure before dialysis of more than 150 mm
20Hg  [19] Other common risk factors for cardiovascular disease includes depressed 
high-density  lipoprotein cholesterol  levels,  coronary-artery  calcification,  diabetes, 
and left ventricular hypertrophy.
Malnutrition has been estimated to be present in up to 50 percent of patients with 
ESRD and to be independently associated with increased morbidity and mortality. 
[20]
ii)  Adequate Haemodialysis
Inadequate  haemodialysis  not  only  shortens  survival  but  leads  to  anemia, 
malnutrition, functional impairment and frequent hospitalisations that increase health 
care  costs.  Because  inadequate  HD  is  often  undetected  unless  it  is  severe  and 
prolonged, it is important monitor adequacy indices.
The large differences in treatment outcome between centres and countries strongly 
suggested that these were related to the way treatment was practised.  In  1975 the 
National Institute of Health decided to investigate this problem. This resulted in the 
concept of urea kinetic modelling that showed not only insufficient dialysis but also 
low  urea  levels  due  to  inadequate  nutrition  and  low  protein  catabolic  rate  were 
associated  with  increased  mortality  [21].  Subsequent  analysis  suggested  that  the 
effectiveness of the treatment should be expressed in the Kt/V formulae [22]. In this 
concept, Kt/V is a dimensionless index based on the urea clearance rate, K, and the 
size of the urea pool, represented as the urea-distribution volume, V. K, the sum of 
clearance by the dialyser plus renal clearance,  is multiplied by the time spent on 
dialysis, t. In short the formula represented total urea clearance standardised by body 
volume. Measurement of the "delivered dose" of dialysis has therefore focused on the 
removal of urea, an easily measured surrogate marker for uremic toxins. The quantity 
of urea removed during HD is a clinically accepted surrogate to define the patients 
risk profile. The other commonly accepted measure of HD dose is urea reduction 
ratio  (URR),  based  on  fractional  reduction  of blood  urea  concentration  during  a 
single dialysis treatment, calculated by dividing the decrease in urea (predialysis - 
postdialysis)/ predialysis concentration expressed as a percentage. Factors that may 
adversely affect the adequacy of dialysis include recirculation between venous and 
arterial limbs in the dialysis catheter, inadequate blood or dialysate flow rates, poor-
21quality reprocessing of the dialyser, and skipping or early termination of dialysis 
treatments. The most frequent cause of premature termination of dialysis was found 
to be hypovolemic symptoms of hypotension, cramps and nausea.
There is overwhelming evidence that the amount of delivered haemodialysis is an 
important modifiable predictor of death in HD patients  Patient mortality is higher 
when the  amount of urea removed  is  less.  The  relationship between  URR  and 
mortality is nonlinear. Retrospective studies of mortality outcome for patients with 
ESRD suggest that odds of death progressively increase when URR falls lower than 
60% to 65% [23]. Such findings and an evidence based professional consensus led to 
national  organisations  in  the  UK  (Renal  Association)  and  USA  to  advocate  a 
minimum  URR  of  65%  or  Kt/V  1.2  as  thresholds  for  adequate  HD  [1]. 
Unfortunately,  based  on  these  standards  many  patients  still  have  a  suboptimal 
dialysis dose. [24] The use of modem membranes made it possible to achieve a high 
Kt/V (surrogate for “adequate dialysis”) within a shorter time. Increasing burden of 
ESRF, dialysis economics favoured the use of shorter dialysis time. Such a policy 
however has made volume control difficult and often dialysis unpleasant with the use 
of more cardiovascular medications.
iii)  Optimal  dialysis
The relationship between dose of dialysis and outcome remain complex. Adequate 
dialysis  represents  a  treatment that rehabilitates  the  patient,  minimises  treatment 
related side effects and corrects biochemical abnormalities associated with loss of 
renal  function.  What  constitutes an  "optimal"  dose  of dialysis,  above  which  no 
further  improvement in  survival  or  well  being  can  be  achieved,  is  not  known. 
Retrospective data in one study showed that survival rates do not rise as the urea- 
reduction ratio rises above 70 percent, or as Kt/V rises above  1.3.  [25] In a more 
recent study, [26] patients treated with URR >75% had a substantially lower relative 
risk than patients treated with URR 70 to 75% (P < 0.005 each, for medium and 
small BMI groups). It was concluded that a higher dialysis dose, substantially above 
the  Dialysis  Outcomes  Quality  Initiative  guidelines  (URR  >65%),  is  a  strong 
predictor of lower patient mortality for patients in all body-size groups. The HEMO 
Study  was  a  controlled  trial  of  dialysis  dose  and  membrane  flux  in  1846 
haemodialysis patients followed up for 6.6 years in 15 centres throughout the United
22States. [27] The study attempted to determine whether the type of dialysis membrane 
used  in  haemodialysis  or  the  amount  of dialysis  (measured  by  Kt/V)  that  is 
prescribed could influence well-being and survival.  The data suggest that mortality 
and morbidity might be reduced by increasing the dialysis dose above the current 
standard in women but not in men.  This effect was not explained by differences 
between men and women in age, race, or in several indices of body size.
The HEMO study measured dialysis therapy using the Kt/V index and focussed on 
urea as the surrogate uremic toxin. Efforts to improve disappointing mortality figures 
have been unfortunately concentrated on urea removal, neglecting BP and volume 
control and other important factors. The replacement of the kidneys task of 
regulating body fluids, circulation and blood pressure, bone metabolism and nutrition 
are not included in the current measures of adequacy. Yet the major cause of 
morbidity and mortality is cardiovascular complications that are closely related to 
correction of circulatory disturbances.
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Cardiovascular complications of dialysis
Cardiovascular disease is much more common and widely prevalent in the ESRF 
population compared with the general population (Fig 6) and accounts for nearly 50 
percent of all deaths in patients on haemodialysis. There is an increased incidence of 
congestive cardiac failure, ischemic heart disease and myocardial infarction among 
patients  with  end  stage  renal  disease  attributable  to  hypertension,  anemia, 
hyperlipidemia,  hyperhomocysteinemia,  accelerated  atherosclerosis,  and  possibly 
impaired oxygen delivery to the myocardium induced by uremic toxins.
2a  Hypertension in Haemodialysis
While  hypertension  occurs  in  approximately  15%  of the  general  population,  its 
frequency is much higher in patients with renal disease. The incidence increases in 
parallel with progression of renal failure, and approximately 80- 90 % patients with 
progressive  renal  failure  approaching  maintenance  dialysis  have  hypertension. 
Systolic hypertension with or without diastolic hypertension is a major problem in 
haemodialysis  (HD)  patients;  isolated  diastolic  hypertension  is  uncommon. 
Accelerated age-related changes in vascular stiffriess, together with factors peculiar 
to uraemia, lead to loss of large and small vessel distensibility and profound changes 
in circulatory function that includes an increase in systolic pressure and widening of 
the pulse pressure. The appearance of hypertension is related to the nature of the 
renal disease.  It is most frequent - and may start before functional impairment - in 
various glomerular diseases and polycystic kidneys, while its onset is later in primary 
tubular and interstitial disorders.  This difference is probably due to differences in 
salt excretion impairment and/or in activity of the renin-angiotensin system.  Once 
the patient has become anuric, the relation of BP to the underlying disease is less 
clear, but this subject has not been sufficiently analysed. When dialysis treatment is 
started and excess of body fluids is removed by UF, hypertension disappears in many 
patients during the first months.
24Available reports show large regional differences in prevalence of hypertension in 
dialysis patients.  In one Italian centre, hypertension decreased gradually from 80% 
to  40%  of the  patients  during  the  first  half year  of treatment.  In  an  EDTA 
questionnaire survey in 1992: Pre-dialysis systolic BP was greater than 140 mmHg in 
70% of the patients and diastolic pressure above 90 mmHg in 30% haemodialysis 
patients.  The  median  BP  was  145/85.  In  1994  the  Health  Care  Financing 
Administration reported a mean BP of 152/79 mmHg in the USA. Based on an in- 
depth review of the literature the HCFA committee could not find 'enough data to 
submit an evidence-based clinical practice guideline'.  Another study (28) found that 
blood  pressures  greater  than  160/90  in  62%  of  the  patients  and  conclude 
hypertension is not adequately controlled. These figures are even more striking if one 
considers that the majority of the patients were treated with antihypertensive drugs. 
Recent UK registry data reports no significant improvement in BP adequacy in HD 
over the past few years. [24] In sharp contrast, several other reports have much better 
BP values.  These were from centres where much attention was given to volume 
control and salt restriction.
The failure to achieve BP control by the great majority of dialysis centres the world 
has led to speculation that the present-day patients case-mix is different from the past 
and also varies between populations. However in one centre [29] 72% of the patients 
had normal BP without drugs (MAP 89 + 12 mmHg) the others had a mean MAP of 
97 + 9 mmHg. A Turkish centre reported a mean BP of 131/80 + 17/9 mmHg in all 
67 patients treated with volume control during one year [30] The most impressive 
results were obtained in Tassin [31] where BP could be normalised in 97% of the 712 
patients (Charra et al.  1992). An important element of dialysis treatment in these 
centres is strictly restricted sodium intake and better volume control with intensive 
ultrafiltration sessions . It is probable that these factors contribute to better outcomes.
Hypertension and mortality
Although relationship between BP and mortality in dialysis patients is complicated 
there  is  now  strong  evidence  that  hypertension  is  a  significant  factor  in  late 
mortality.[32] (Fig 7) Previously, when no effective treatment of hypertension was
25available, the conviction prevailed that high blood pressure was inescapable and that 
lowering  it  might  even  be  harmful.  Large  trials  have  shown  such  significant 
decreases in morbidity and mortality after antihypertensive treatment that this may be 
considered one of the most important  successes of modem medicine.  In  dialysis 
patients’  hypertension was  likewise  considered  to be  a  risk  factor  for their high 
cardiovascular morbidity and mortality.
Indeed, hypertension is a major contributor to well-established risk factors such as 
increases  in  left  ventricular  mass  index  and  volume  as  well  as  atherosclerosis, 
ischemic heart disease and de novo cardiac failure in dialysis patients.  Therefore it is 
likely that hypertension itself is involved in the development of these complications. 
There  is  a  considerable  body  of epidemiological  data  suggesting  a  relationship 
between hypertension and mortality in dialysis. But there is also data suggesting the 
lack of a relationship between blood pressure and mortality, and even that lower 
predialysis blood pressure may increase mortality risk. In one large study from the 
USA only systolic BP >  180 was associated with decreased survival. It was found 
that low blood pressure has a particularly bad prognosis [32] (Fig 8). A recent survey 
of 649 HD patients found an inverse relationship with survival over the entire BP 
range: patients with MAP >115 mmHg had 56% longer survival that those with 
MAP >101  mmHg. [19] Others have also concluded that the association between 
predialysis hypertension and mortality was surprisingly small [33].
In  sharp  contrast,  a group  of investigators  [34],  who  applied  meticulous  volume 
control with long dialysis sessions, not only achieved better BP control than almost 
all  other  centres,  but  also  had  better  survival  figures,  and  found  a  significant 
reduction in death rates with lower BP values even for levels within the normal 
range. It is well known that heart failure causes a decrease in blood pressure. The T 
or 'U' curve seen in elderly patients with essential hypertension can be explained by 
the  fact that the previously high BP decreases before the patient dies  from heart 
failure. Unfortunately, most multi-centre studies that suggest that hypertension is not 
harmful in dialysis patients do not provide information on the condition of the heart. 
However, the authors of one study  [35]  suggest that a similar explanation of this 
paradox applies to dialysis patients: BP fell when heart failure developed, and heart 
failure pre-dated most deaths in their study.
26Similar  data  from  other  group  of investigators  confirm  a  U-shaped  relationship 
between blood pressure and relative death risk in dialysis patients for systolic and 
diastolic values. [36] Therefore both elevated and low blood pressures are potential 
risk factors in the dialysis population.
Optimal blood pressure control (achieving normotension and avoiding hypotension) 
is an essential prerequisite to patient longevity.  This  is of importance in patients 
treated with dialysis who are at a veiy high cardiovascular morbidity. Hypertension 
is of greater prognostic significance in the elderly who form a major group in present 
dialysis population because of their markedly higher background risk. In the normal 
population studies such as the HOT study [37] show that the benefits from treating 
the elderly are similar to that in young patients. The British Hypertension Society, 
WHO guidelines adopt the same treatment thresholds and targets for the elderly as 
for younger patients, stressing the need for such accurate BP control in an average 
dialysis patient.  The  standards  set  for BP  control  have become  more  difficult to 
achieve in dialysis patients [24].
Some problems in the treatment of hypertension in dialysis arise perhaps with the 
diagnosis itself of hypertension in HD patients. Among nephrologists, owing to the 
intermittent nature of the treatment, there is still debate concerning the appropriate 
target blood pressure for patients because of the intermittent nature of haemodialysis 
andUF.
272b  Hypertension in haemodialysis: The role of 
volume overload
The first patient surviving on chronic haemodialysis (1960) suffered from malignant, 
seemingly  intractable  hypertension,  but  became  normotensive  after  aggressive 
ultrafiltration.  B.  Scribner then  stated,  "As  in  the  case  of nephrectomized  dogs, 
hypertension appears to be influenced by the size of the extracellular space.  The 
combination of dietary sodium restriction and ultrafiltration during dialysis permits 
regulation of the extracellular volume." [38]
One of the most harmful consequences of uncontrolled uraemia is the excess saline 
retained. Fluid retention during progressive renal failure leads to the almost universal 
presence of hypertension at the initiation of dialysis. This aggravates hypertension 
and increases the left ventricular load.
Several  studies  have  shown  that  expanded  blood  volume  and  extracellular  fluid 
volume is increased in early and late renal failure and that this correlates to elevated 
blood pressure.  [39] Fluid overload, by increasing venous return to the heart, may 
contribute to the increased cardiac output observed in patients with renal  failure. 
Some degree of extracellular volume expansion is present in the majority of patients 
with renal  failure  and may contribute  to  the  apparent  well  being  of the  patients 
despite clinical and biochemical evidence of malnutrition. The well-documented post 
transplant  diuresis  is  attributed  to  extracellular  volume  expansion  in  the 
nonoedematous patient.
BP control -  what can be achieved
Thompson  et  al  followed  by  several  others  in  the  1970’s  reported  achieving 
normotension in 90% dialysis patients. [40] Different groups in France (Tassin) [41], 
and New Zealand (Christchurch)  [42], using long dialysis, have reported excellent 
drug-free BP control, as was the case for 90% of patients on dialysis in the early 
1970s.  Tassin has reported excellent BP control with meticulous salt and volume 
removal, long dialysis and with minimal use of antihypertensives. These results have 
also been reported from other units using conventional dialysis (normotension 70 -
2896%)  with  aggressive  and  often  extra  UF  sessions.  [43]  Table  2  The  quoted 
incidence of dialysis resistant hypertension in the 1970s varied from less than 5% to 
more than 30%. The percentage of dialysis patients quoted to have dialysis resistant 
hypertension  and  therefore  antihypertensive  medications  varied  considerably 
depending  on  the  approach  of the  specific  dialysis  unit  and  of the  individual 
physician.  Demographic differences, differences in the  spectrum of renal disease, 
variable  ultrafiltration  policies,  differences  in  defining  hypertension  in  dialysed 
patients and ease of acceptance of medication by the patient population may have all 
contributed to the reported differences. Figure 9 illustrates this in a state in the USA 
where  nearly  70%  patients  have  been  reported  as  hypertensive  despite  a  large 
majority  of them  being  on  antihypertensives.  The  high  prevalence  of  dialysis 
hypertension  despite  the  extensive  use  of  antihypertensives  suggests  that 
antihypertensives alone are ineffective.
2c  Other Mechanisms of Hypertension (Table 3)
i)  Renin angiotensin mechanism (RAS)
The RAS plays an important role in the regulation of BP in normal man and in 
some  hypertensive  patients.  Renin  secretion  by  the  non-functioning  kidney  in 
dialysis patients is not completely abolished and sometimes may be inappropriately 
high. In such cases, hypertension is resistant to volume control but may be lowered 
by  bilateral  nephrectomy  or  renin  lowering  drugs,  in  particular  angiotensin 
antagonists  or  converting  enzyme  inhibitors  (ACEI).  Unfortunately,  hardly  any 
systematic,  long- term investigation has been performed on this  subject and as a 
result contradicting conclusions have been drawn which are difficult to reconcile. 
Because renin acts as a hormone and is subject to feedback regulation in normal man, 
it is plausible to assume that this regulation must be disturbed when normal function 
and structure of the regulating organ is completely lost.  Indeed available reports 
indicate that changes in plasma renin activity (PRA) which occur in normal persons 
upon changes in posture and volume are absent or diminished in dialysis patients. In 
particular,  PRA  is  not  influenced  by  the  dialysis  procedure.  However,  not 
unexpectedly there seem to be differences in sensitivity of the renin secretion to UF
29between individual patients. [44] Several reports have indicated that PRA is too high 
in relation to the volume status of hypertensive patients and that BP cannot be related 
to the product of (log) PRA and volume.  However, others could not confirm this 
contention.  While some authors consider that the contribution of the RAS to BP is 
minor; others conclude that it plays an important role in nearly every dialysis patient. 
The latter view is strengthened by the fact that bilateral nephrectomy decreases BP in 
most patients including those whose PRA is not elevated. However the influence of 
RAS seems to be minor when overhydration is present.  Part of the divergence of 
views  may  be  due  to  the  large  interindividual  variability.  Vascular  reactivity  to 
vasoconstrictive stimuli is often diminished in dialysis patients. Besides 'volume' and 
'renin',  several  other  abnormalities  have  been  detected  in  dialysis  patients  and 
thought to have a role in the genesis of hypertension.
ii)  Sympathetic system
As in essential hypertension, much effort has been expended looking for signs of 
increased  sympathetic  activity  in  dialysis  patients.  Most  tests,  in  particular 
measurement of plasma catecholamines, have yielded negative or equivocal results. 
However,  the  large  decrease  in  BP  observed  after  pharmacological  sympathetic 
blockade  has  provided  indirect  evidence  for  a  role  of this  system.  This  was 
confirmed by the use of a new technique: direct measurement of sympathetic nerve 
discharge (SND).  Converse et al.  found that SND in HD patients was 2.5  times 
higher than  in healthy  control  subjects.  Remarkably,  bilateral  nephrectomy  was 
associated  with normalisation  of sympathetic  tone.  Thus  sympathetic  activation 
seemed to be mediated by an afferent signal arising in the diseased kidney.  SND was 
unrelated  to  plasma  norepinephrine  levels,  confirming  that  they  constitute  an 
inadequate  tool  to measure  sympathetic  activity.  There  was  also  no  correlation 
between SND rate and PRA.  On the other hand, Ligtenberg et al. [46] showed that 
chronic (but not acute) ACE inhibition decreased  SND together with BP  in CRF 
patients  not  on  dialysis  treatment.  Cardiac  congestion  is  also  accompanied  by 
increased SND, which decreases with treatment.  Some of Converse's patients had 
severe  hypertension  and  may  well  have  been  overhydrated.  It  cannot  yet  be
30concluded  with  certainty  the  degree  to  which  increased  SND  contributes  to 
hypertension, if at all.
iii)  Circulating substances
Elevated levels of blood-pressure-increasing factors have been detected in the blood 
of HD patients and implicated as causes of their elevated BP levels.  Among these 
are  endogenous  digitalis-like  substances,  endothelin-1  and  asymmetric  dimethyl 
arginine (ADMA). [47,48] The latter is an inhibitor of the synthesis of a potent local 
vasodilator nitric oxide (NO) and is insufficiently cleared by dialysis.  Insufficient 
production of vasodilator factors like prostacyclin has also been implicated. [49,50] 
There are a number of factors, which also operate in the normal population, such as 
cardiac  status,  vascular  elasticity,  rigidity  and  contractility,  autonomous  nervous 
function,  catecholamines,  the  renin-angiotensin  system,  PTH,  nitric  oxide, 
endothelin, erythropoietin and of course antihypertensive drugs.
iv) Paradoxical hypertension
When  volume  is  reduced  by  ultrafiltration  during  dialysis,  the  most  frequent 
complication is an excessive decrease in BP.  In some patients, however BP rises 
despite fluid removal. This has often been described as paradoxical hypertension.
This is not reversed by ACE inhibition making it less likely to be renin mediated. In 
some studies with repeated UF their BP decreased, intradialytic rises subsided and 
the cardiac volumes improved. Hypervolemia therefore appears to be an important 
factor in this phenomenon.  Several studies show that even so-called resistant and 
paradoxical hypertension in most cases are due to saline overload and are responsive 
to fluid extraction (51,52).
Even in units in which there has been a particular interest in hypertension in dialysis 
patients, 15-25% needs hypotensive drugs, and this may rise to 50% in other units. 
The higher figures suggest that there has been inadequate salt and water removal 
during HD and that patients have not controlled their intake  sufficiently between 
dialysis sessions.  The fact that even when this has apparently been achieved with 
dialysis  duration  12hrs  /wk,  hypotensive  drugs  may  be  needed  in  a  quarter  of 
patients, while in Tassin (24hrs/wk dialysis) they are hardly ever used, raises the
31possibility that longer hour may confer an as yet undefined advantage.  The best 
evidence available in terms of a comparative study refutes this hypothesis Recently, 
Swedish normotensive and hypertensive patients were compared with normotensive 
patients in Tassin using bioimpedance and vena cava ultrasound.  [53]  The results 
clearly  showed  that  predialytic  and  postdialytic  extracellular  volume  space  was 
greater in hypertensive as compared to normotensive dialysis patients. The Tassin 
patients  achieved  adequate  volume  and  salt removal  by  virtue  of the  long  time 
available  for this  in each  dialysis  session,  but it appears  that  it was  possible  to 
achieve in shorter times. The achievement of normovolemia is not in itself a reason 
for advocating dialysis sessions of 8 hours three times weekly.  Indeed, in Parma, 
Cambi has obtained survival similar to that reported by the Tassin group using 12 h 
HD weekly. [54]
There is convincing evidence that hypervolemia is an important contributant to the 
large proportion of hypertensive dialysis patients. Although there is also convincing 
evidence that a host of vasoactive factors are involved in the pathogenesis of dialysis 
hypertension (nitric oxide synthase inhibitors, increased sympathetic outflow, RAS 
activation  etc.)  they  appear  to  operate  in  relation  to  a  degree  of  fluid  excess. 
Hypertension adds a pressure load to the volume load on the heart and therefore 
prevention of fluid overload is essential. Removal of the excess fluid in a safe and 
regulated  manner  constitutes  a  primary  goal  in  the  reduction  of  an  important 
cardiovascular risk factor in dialysis patients.
32Chapter 3 
Vascular instability syndromes
The most important outcome in HD is, of course, survival. Less emphasis has been 
placed  on  factors  less  easily  measured  e.g.  morbidity  associated  with  treatment 
(interventions,  intradialytic  morbidity,  hospitalisations)  or  quality  of life  issues. 
Dialysis related complications contributes to  significant morbidity  and negatively 
affect  patient  outcome.  The  most  frequent  complications  during  HD  are  in 
descending order of frequency hypotension (20 - 40 %), cramps (5 - 20%), nausea 
and vomiting (5-15%), headache (5%), chest pain (2 -  5%), back pain (2 - 5%), 
itching (5%), and arrhythmias, hypoxemia fever and chills (less than 1%) and rarely 
anaphylactic  reactions.  The  first  three  major  complications  (30  -  70%)  are 
predominantly related to  disturbances  in  fluid  balance  and  overall  blood  volume 
regulation.
3a  Intradialytic hypotension  (IDH)
The realisation that a drop in blood pressure can adversely affect patient morbidity 
and mortality is not a new concept but its impact on outcome is less appreciated. A 
number of physiologic abnormalities and treatment related complications heighten 
the link between hypotension and adverse outcomes in ESRF.
Despite the fact that the quality of life of patients undergoing haemodialysis and the 
growing  understanding  of  the  pathophysiologic  mechanisms  that  contribute  to 
haemodynamic instability during haemodialysis has improved in the last 20 years, 
hemodialysis-associated  hypotension  still  remains  a  significant  cause  of patient 
morbidity.  Symptomatic  hypotension is  still  one  of the  major and  most  frequent 
complications  occurring  during  dialysis  therapy.  It  is  characterised by  symptoms 
such as dizziness and nausea. The incidence of intradialytic hypotension is estimated 
at 25-30%  [55]  and  is expected  to  increase because  of an  increasing number of 
elderly  and  cardiovascularly  compromised  dialysis  patients.  In  these  patients, 
structural cardiovascular abnormalities such as decreased left ventricular compliance,
33systolic dysfunction, and decreased venous compliance are common. These structural 
cardiovascular changes have important clinical implications, making dialysis patients 
more susceptible to the development of intradialytic hypotension. The incidence of 
hypotension increases with age. (Table 4) In the United Kingdom now the average 
age of the haemodialysis population is over 60 yrs. [24]
Recent reports also suggest that patients with sustained hypotension are at a greater 
risk of death than chronically high BP readings. Zager et al in a study of more than 
5000 HD patients followed up for a mean of 2.9 +_1.8 years noted that 49% patients 
entered into the study died.  [32] Using Cox regression analysis they reported a U 
shaped relationship between SBP and cardiovascular mortality.  The relative death 
rate for patients with predialysis or postdialysis hypotension increased to 4 times 
normal or 2 .5 times normal respectively. Tisler et al noted lower survival in patients 
with frequent intradialytic hypotension. [56] Considering the potential risks of low 
BP, IDH can no longer be treated as a benign condition.
Theoretically hypotension can contribute to an increased relative risk of death in 
ESRF  by  several  mechanisms,  which  include  acute  coronary  syndrome, 
autoregulation  dysfunction,  ischemia  and  arrhythmogenicity.  Endothelial 
abnormalities  (altered procoagulants,  thrombogenicity  and  alterations  in  coronary 
flow reserve) and altered vascular distribution within the myocardium provide an 
environment for vascular injury. Despite the lack of hard evidence, it seems desirable 
to attempt to minimise the frequency of IDH episodes. There is evidence that life 
threatening conditions such as nonocclusive mesenteric ischemia are associated with 
frequent intradialytic hypotension and corollary damage to brain and cardiac tissue 
might also be expected. Another reason to avoid intradialytic hypotensive episodes is 
that  they  often  result  in  underdialysis,  because  they  often  engender  treatment 
interruptions, lowering of blood flow rate etc and when associated with symptoms, 
may be responsible for patients reluctance to extend dialysis time. Studies have also 
shown  that IDH  and hypovolemic  symptoms  are  frequent reasons  for premature 
termination of dialysis or missing dialysis sessions (Fig  10) ultimately leading to 
inadequate dialysis.
Intradialytic hypotension is characterised by an abrupt decline  in blood pressure. 
Episodes may occur early (< lhr), late (>lhr) or unremitting posttreatment. It may be 
abrupt, temporary or sustained. Identifiable risk factors for IDH include diabetes, left 
ventricular  hypertrophy  and  diastolic  dysfunction,  CCF  or  previous  MI,  high
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patients  are  at  a  unique  risk  for  IDH  based  on  their  underlying  reason  for 
hospitalisation, suboptimal metabolic status, cardiovascular status and perioperative 
condition. These clinical conditions may compromise a person’s ability to respond to 
volume during dialysis.  The ESRF population at risk of IHD continues to grow as 
age and number of comorbidities of incident patient increases every year.
The morbidity of IDH ranges from subtle complaints of not feeling well, through the 
mild to moderate of visual complaints, cramping and nausea to the more, serious, 
vascular complications that include cerebral  infarction, cardiac  ischemia,  vascular 
access thrombosis, nonocclusive mesenteric ischemia and arrhythmias. IDH episodes 
may resolve with treatment in the unit or persist after the patient leaves the unit and 
returns home. IDH events not only carry an increased risk of end organ damage but 
also are disruptive to the unit and distressing to the patients.
3b  Pathways to Hypotension  (Fig 11)
i)  Volume depletion
Dialysis hypotension occurs because a large volume of blood water and solutes are 
removed over a short period of time. These overwhelm compensatory mechanisms, 
including plasma refilling and  reduced venous capacity. Symptomatic hypotension 
may occur as a result of a decrease in blood volume and reduced vascular reactivity 
during dialysis in combination with structural abnormalities of the cardiovascular 
system. Haemodialysis treatment requires the removal of fluids from the circulating 
blood to return the hydration state in the patients undergoing chronic treatment to 
normal.  During  HD  (diffusion  combined  with  ultrafiltration),  the  plasma  water 
removal  induces  a  progressive  reduction  in  blood  volume  (BV).  The 
haemoconcentration is  followed by a  fluid shift from  the  interstitial  and  cellular 
spaces toward the vascular compartment.  Hypovolemia triggers the activation of the 
sympathetic system, which induces vasoconstriction and an increase in myocardial 
contractility and heart rate.  The maintenance of blood pressure is related to two 
fundamental  mechanisms:  BV  preservation  and  cardiovascular  compensation. 
Arterial hypotension occurs when central hypovolemia causes an underfilling of the 
cardiac  chambers,  thereby  compromising  the  circulatory  load,  while  either  the
35vascular arteriolar or venous tone decreases or is inadequate in relation to the stroke 
volume reduction.
Studies have suggested that some patients whose volume is depleted by ultrafiltration 
exhibit a paradoxical withdrawal of efferent sympathetic tone.  [57] This response 
represents  a  type  of  autonomic  dysfunction.  This  dysfunction  is  caused  by  a 
distortion of the mechanoreceptors in the left ventricle, triggering a response that 
leads to a paradoxical sudden decrease in efferent sympathetic tone and eventually to 
profound hypotension. Although autonomic dysfunction related to volume depletion 
is probably far less common than the other type, it may be a significant factor in 
patients  who  undergo  severe  volume  loss  during  dialysis.
ii)  Decline in Plasma Osmolality and other mechanisms
Decreased plasma osmolality is another important cause of intradialytic hypotension. 
If the dialysate sodium is below 135 mEq/L, removal of ultrafiltrate during dialysis is 
achieved via a disproportionate depletion of the extracellular vs intracellular space. If 
the dialysate concentration is increased to greater than 140 Meq/L, more volume is 
recruited from the intracellular space during ultrafiltration, thereby preserving the 
integrity of the extracellular space and plasma volume. This technique has the net 
effect of sustaining blood pressure.
Acetate Dialvsate Buffer
Acetate dialysate buffer has been shown to be associated with a greater number of 
untoward hemodynamic  reactions as compared with bicarbonate  dialysate buffer. 
These reactions are believed to be related to the vasodilatation that is caused by 
acetate.  [58] Most dialysis units now use bicarbonate dialysate to circumvent this 
problem.
Limited Cardiac Reserve and Myocardial Ischemia
Several cardiac abnormalities may contribute to intradialytic hypotension. [59]
Overt or silent coronary ischemia, which occurs at a high rate in patients with ESRF, 
may impair myocardial reserve. During periods of stress, inadequate responses to the 
loss of plasma volume may ensue.
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While congestive heart failure is estimated to occur in approximately 25% of patients 
with ESRD, the majority of this population show echocardiography evidence of left 
ventricular hypertrophy,  which  is  another  factor in  impaired  myocardial  reserve. 
When plasma volume is reduced during dialysis, the inability of the left ventricle to 
sufficiently  respond  to  this  alteration  leads  to  hypotension. 
Several  types  of left ventricular hypertrophy  are present  in patients  with  ESRF. 
Patients may exhibit either systolic dysfunction; characterised by low cardiac output 
and a widely dilated left ventricular cavity, or diastolic dysfunction, characterised by 
a relatively small left ventricular cavity and a normal ejection fraction. In diastolic 
dysfunction, the primary derangement is the inability of the left ventricle to relax 
during diastole. Another aspect of left ventricular dysfunction is that patients may not 
only have hypotension due to impaired myocardial reserve but also an inability to 
accept  large  volumes  of  fluid,  especially  if  they  have  diastolic  dysfunction. 
Arrhythmias  may  also  occur  during  dialysis,  particularly  in  patients  with  left 
ventricular  hypertrophy  and  underlying  myocardial  ischemia.  [60]  Occasionally, 
arrhythmias may result in hypotension. Any medications that affect cardiac rhythm 
should be scrutinised if they are being administered during hypotensive episodes.
Hypoxemia
Another complication that is often seen during dialysis is hypoxemia. [61]  Whether 
the usually mild hypoxemia that occurs during dialysis is capable of causing adverse 
events is still a source of debate. Arterial partial pressure of oxygen (PO2) typically 
falls between 5-8 mm Hg during the first hour of dialysis. If bicarbonate dialysate 
buffer is being used, the subsequent decrease in arterial PO2 may be attributed to a 
slight decrease in minute ventilation. In most patients, a mild reduction in PO2 is not 
a  significant  problem.  However,  in  patients  with  underlying  chronic  pulmonary 
disease and an already compromised PO2, dialysis may exacerbate the hypoxemia 
leading  to  untoward  symptoms.  This  is  usually  treated  by  supplemental  oxygen 
during  dialysis.
Food ingestion
The ingestion of food during dialysis can cause splanchnic vasodilatation, which can 
be an etiologic cofactor in lowering blood pressure. [62]
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Anaphylactic reactions are classified into two main types. Type A has been described 
as the classic anaphylactic reaction that is essentially believed to be an allergic 
response to an allergen in the dialyser. Type B is less severe but more common than 
type A. The type B reaction is characterised by pain in the chest or back and usually 
occurs within the first few minutes to the first hour of dialysis. The aetiology of type 
B reactions is unknown.
Preventive measures include an accurate evaluation of dry body weight, the use of 
bicarbonate  as  buffer,  and  an  adequate  sodium  concentration  in  the  dialysate. 
However, the impairment of both myocardial and venous compliance can make the 
patient  more  susceptible  to  a  volume  contraction  making  these  remedies  only 
partially  successful.  Developing  a  preventive  strategy  or  a  tool,  which  has  the 
response of the individual patient, as it would be an important contribution.
38Chapter 4  Concept of dry weight
4a  Definition of dry weight
Even though the concept of dependence of blood volume regulation in HD on the 
ECF appeared with maintenance dialysis itself, it was at least 7 yrs before Thomson 
et  al  [64]  coined  the  term  dry  weight  and  defined  it  as  achieving  a  state  of 
normovolemia  with  hypotension  not  explained  by  other  causes.  Subsequently  in 
1970, even if they did not call it by that name, most authors used the dry weight 
concept and reported 90% dialysis pts achieved normotension. Blumberg confirmed 
at the same time that normotension at dry weight correspond to an ECF in the normal 
range.  [65]  3  years later Kim showed that the presence of hypotension  does not 
necessarily  mean  dry  weight  has  been  achieved.  [66]  Fishbane  and  others  also 
reported that a limited proportion of patients resisted fluid or sodium removal. [67] 
Clinical wisdom suggests that dry weight is often not assessed accurately during 
routine HD therapy, and this notion is supported by the observation that hypertension 
is present in a significant fraction of chronic HD patients. Although the mechanisms 
leading to hypertension are multifactorial,  fluid overload  is  frequently  cited as a 
major  contributing  factor.  The  HD  Work  Group  (NKRF)  was  unable  to  find  a 
practical clinical measure of estimated dry weight (EDW).  The  volume  status of 
ESRF  patients  cannot  be  directly  measured  and  dry  weight  is  instead  defined 
clinically  by  exclusion  of  signs  and  symptoms  indicating  overhydration  or 
underhydration.
'Dry body weight' has been surprisingly difficult to define.  Zucchelli and colleagues 
[68] emphasise that the attainment of 'dry body weight', a prerequisite for salt and 
water control and so for minimising the load imposed on the heart by excess volume, 
is not achieved as often as it could be. From a conceptual standpoint, dry weight is 
the postdialysis weight at which the patient is in a state of normohydration or at 
which  the  extracellular volume  is  normal.  With  few  exceptions  normalisation  of 
blood volume accompanies this state of hydration and consequently no sign of hyper
39or hypovolemia should be found on physical examination or other tests. Dialysis is 
aimed at restoring such an euvolemic condition by ultrafiltration and the weight at 
which euvolemia is present is the dry weight. In clinical practice the semantics can 
get confusing too: dry weight v target weight v post dialysis weight v end-dialysis 
weight v ideal weight... etc. are attempts in trying to define a state of optimal fluid 
removal where the goal is subjective, variable and often ill-defined.
Clinicians usually attempt to assess dry weight by determining the lowest possible 
weight  that  would  not  elicit  excessive  hypotension  and  muscle  cramps  during 
dialysis.  It has been stated that a normal predialysis BP without antihypertensive 
medications can be taken as a gold standard of dry weight.  The exclusive use of 
arterial  hypertension  can be justified  from  a  prognostic  point of view  based  on 
studies in the general population and casual office based readings. The latter may not 
be necessarily true in the dialysis patient.
Using a slightly different approach, dry weight may be defined as the postdialysis 
weight at which the blood pressure is lowered into the presumed normal range ( less 
than  150 mmHg systolic or less than 90 mmHg diastolic), if possible, without the 
development of intradialytic hypotension.  [69]  In addition, the patient should not 
exhibit signs of pulmonary or peripheral oedema.  The emphasis of this approach is 
on  the  blood  pressure,  but  the  postdialysis  weight  may  be  greater  than  that 
representing a state of normohydration.  The failure to remove sufficient fluid when 
using this approach could be detrimental because chronic fluid overload adds burden 
to the heart.
In  another  approach  summarised  by  Charra  et  al,  [70]  postdialysis  weight  is 
progressively decreased and fluid removal is progressively increased during long (5 
to  6  hours)  HD  treatments  until  symptoms  of  intradialytic  hypovolemia  and 
hypotension  are  consistently  observed.  Severe  muscle  cramps  frequently  occur 
during  this  process.  After  several  weeks,  however,  blood  pressure  gradually 
decreases to a level at which all antihypertensive medications can be eliminated, and 
a dry weight is established.  This process has been called “probing for dry weight” 
and can be an unpleasant experience for both the patient and the clinical staff.
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excessive hypotension and muscle cramps during dialysis. [71] By that definition, of 
course, virtually everybody who has very large weight gains would be dialysed 
below their dry weight routinely. Patients who gain above 4 litres will develop 
hypotension when they are clearly still volume overloaded; i.e. are oedematous and 
well above their dry weight. This definition can only be used if intradialytic weight 
gain is not excessive.
Published definitions of dry weight state that the patient should not have orthostatic 
hypotension at the end of the session.  While this may be true  for a continuous 
procedure (like CAPD) it is not true for intermittent HD. However clinical practice 
of  routinely  and  deliberately  provoking  hypotension  to  operationally  define  a 
patient's estimated dry weight (EDW) is difficult to justify.
The degree of volume expansion in a dialysis patient is defined historically.  It is 
based on the increase of the patient's weight above the value at discharge from the 
previous haemodialysis session. However, this assumes that the previous discharge 
weight  was  appropriate.  For  many  patients,  this  assumption  is  incorrect.  For 
example, the historical EDW may change because of unappreciated alterations in the 
patient's nutritional status.  Alternatively, the historical dry weight may have been 
erroneous but well tolerated. It is important to realise that dry weight may fluctuate 
from week to week or month to month. [72] It has to be understood therefore that the 
hydration status of these patients is in a state of constant flux and never reach a 
steady state. Assessment of a dry weight is made more challenging by this fact.
BP  measurements  before  dialysis  can  fluctuate  and  are  affected  by  factors 
other than  fluid  status.  Interdialytic  weight gains  reflect  changes  in  extracellular 
volume only when effective osmolality does not change. As a decrease in plasma 
sodium concentration indicate an excess of water in the intracellular compartment, 
the use of body weight will lead to an overestimation of extracellular volume. In 
clinical  practice  sodium  concentration  seldom  show  important  variations  except 
perhaps in hyperglycemic states. Apart from this situation interdialytic weight gain 
can be wholly accounted for by salt and water retention.
414b  Clinical assessment of fluid status
Relatively  few  clear-cut  guidelines  exist  for  assessing  a  patient's  volume.  The 
amount of fluid that should be removed is often difficult to evaluate and is clinically 
determined by assigning a dry weight to each patient. Symptoms of dyspnoea, weight 
gain, lack of appetite ( indicating overhydration) and lassitude, dizziness,  fatigue, 
nausea and  cramps  for underhydration  are  rather non-specific.  Clinical  signs  are 
based  solely  on volume  overload  or rigorous  symptoms  of intravascular volume 
depletion during or post dialysis. The most often used clinical signs to assess fluid 
status are BP, JVP, oedema, postural hypotension and interdialytic weight gain. Most 
clinical signs and symptoms are found to be lacking in sensitivity and those few that 
are relatively sensitive (dyspnoea) tend to be nonspecific. In fact it may be more 
useful  to  consider  signs  and  symptoms  in  terms  of their  negative  and  positive 
predictive values. Signs and symptoms of ECF status can sometimes be discordant. 
Raised JVP  is  a useful  sign of elevated right atrial pressure but may be  due  to 
hypervolemia or cardiac dysfunction. Oedema clearly typifies the dilemma.  Many 
litres of excess fluid may be present. It may occur early in heart failure, even before 
rise  in JVP  and  its  immediate  cause  is  salt and  water retention.  However using 
objective  data  it has  been  shown  that  fluid  in  patients  with  intact  venous  tone, 
especially young individuals can often be stored in truncal areas that escape clinical 
detection.  Lower extremity venous tone, recumbency, hypoalbuminemia are well 
known  factors  that  affect  fluid  redistribution  between  the  trunk  and  dependent 
extremities manifesting as presence or absence of oedema. The lack of sensitivity of 
clinical techniques in being able to detect subtle  fluid  imbalances has  led to the 
existence of a clinical state of “silent hypervolemia”.
Muscle cramps often accompany IDH and are innocent but extremely unpleasant. 
They usually involve the lower leg and affect 25% of patients.  As with nocturnal 
cramps the pathophysiology is obscure. Its occurrence is related to ultrafiltration and 
its rate and is no proof that all excess fluid has been removed.  The incidence of 
cramps does decrease with attainment of dry weight and normal blood pressure [73]
Chest X-ray (CXR) is probably the most sensitive of the available tools in daily 
clinical practice and can be used to monitor hypervolemia,  cardiomegaly,  fissural
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diagnose fluid overload.  However the absence of features of increased blood volume 
in CXR do not argue against hypervolemia. The positive predictive value is enhanced 
by presence of an increased cardiothoracic ratio which is the most reliable sign and 
correlates strongly with UF volume.  Despite the number of inaccuracies,  it gives 
valuable  information  especially  with regard  to  the  follow-up  of the  patient.  The 
accuracy can improve by better standardisation but this has not been attempted so 
far.  Despite these features the diagnosis of congestive heart failure and its distinction 
from congested state of ESRF may be difficult from a CXR. These changes also take 
place over a period of time and are of limited value to prescribing fluid removal for 
each dialysis.
Careful assessment of the underlying pathophysiology of a congested state in ESRF 
patients by careful clinical examination and radiography alone is a challenge. The 
methods  are  rather  insensitive  in  distinguishing  normovolemia  from  silent 
hypervolemia. Clinical bias favours overload and hypertension because on clinical 
grounds, physicians will more often overlook saline overload than depletion.
Use  of symptom  and  sign  score  is  subjective,  incomplete  and  non-specific  and 
observer dependent. Symptom Scores can be partly useful but may be fraught with 
dangers.  Scores based on dyspnoea during exercise, recumbency,  and  sitting and 
standing,  oedema  (ankles, tibial)  during the previous  week,  symptomatic  dialysis 
hypotension on the last session has been used in some units in Europe. However their 
use has only served to highlight the problems of assessing the volume  state and 
limitations of such scoring systems. [74]
Prescription of fluid removal during dialysis requires knowledge of the dry weight 
and the compensatory mechanisms that allow extraction of the desired amount of 
fluid during a fixed period of time.  Assessment of the latter is lacking in the clinical 
parameters advocated for assessing fluid status.
434c  Inaccurate dry weight estimation - consequences
i)  Dry weight too high  (The overhydrated patient)
Overestimation  of dry  weight  may  have  serious  consequences.  Inadequate  fluid 
removal may lead to fluid overload, hypertension and possible pulmonary oedema. 
Fluid overload causes not only hypertension; it is also a potent contributor to left 
ventricular hypertrophy (LVH), another independent predictor of cardiac death on 
dialysis.  Hypervolemia promotes  LVH by  increasing left ventricular wall  stress. 
This is brought about not only by increasing cardiac afterload, but also by increasing 
preload.  It is therefore not surprising that regression of LVH could be achieved in 
haemodialysis  patients  just  by  ultrafiltration  and  reduced  salt  intake  without 
antihypertensive drugs [75]. The only method systematically proven to be successful 
in controlling hypertension in dialysis patents is adequate salt and water removal. 
The  benefits  of adequate  volume  control  also  include  improvement  in  angina, 
regression  in  LVH  (an  independent  risk  factor)  and  better  efficacy  of 
antihypertensives.
ii)  Dry weight, too low
If dry weight has been underestimated —  hypotension and cramps during dialysis, 
large blood volume changes sustained signs and symptoms of hypovolemia increases 
morbidity and often culminate in hospital admissions, clotted fistulas and inadequate 
solute  clearance.  There  are  also  risks  of  inducing  ischemia  to  vital  organs. 
Persistently low BP is an independent risk factor for mortality.
Dry  weight  is  clearly  a  dynamic  target  that  can  fluctuate  over  time.  Increased 
acceptance rates of patients for haemodialysis outpacing the infrastructure (in centre 
facilities, trained nurses and dialysis doctors) have created busy dialysis units with 
rapid turnover. It is now accepted that quality of care and appropriate management of 
a dialysis patient is proportional to the staff and the time available to care for these 
patients. The increased pressure has a particular impact on ultrafiltration and fluid 
balance. The empiricism and lack of close monitoring partly accounts for some of the 
difficulties in maintaining dry weight and achieving satisfactory BP control. Scribner 
commented  “Dry  weight  and  the  normal  blood  pressure  that  goes  with  it  is  a 
constantly  changing  value  that  must  be  redetermined  with  each  dialysis.”  This 
emphasises a hugely important aspect of the problem.Chapter 5 
Body  Fluid  compartments  and  their 
relationship
5a  Compartmental distribution of body water
One century after Claude Bernard described milieu interior, the anatomy of body 
fluid  compartments  were  described.  [76,77]  Approximately  60%  of the  body  is 
composed of water; two thirds of total body water is intracellular, and one third is 
extra  cellular.  [78]  Extracellular  fluid  can  be  further  divided  into  the  plasma 
compartment, the interstitial compartment, and the transcellular compartnent.  (Fig 
12) The transcellular compartment is normally a fraction of the extracellular fluid 
and is often neglected. However it may be an important in ESRF patients since it 
includes the peritoneal cavity. Approximately 1/5 of the extracellular fluid is located 
within plasma and four fifths located extravascularly. Blood volume, comprises of 
erythrocytes, other formed components and plasma. Albumin is the main marker of 
plasma. The proportion of blood taken up by erythrocytes is called haematocrit.
A healthy nonobese man of  70kg has approximately an intracellullar volume of 
28L(ICF), an extracellular volume of 17L(ECF), a plasma volume of  3L and an 
erythrocyte volume of 2L, and as a consequence a haematocrit of 0.4(40%). If we 
subtract the plasma volume from ECF, the resulting volume is interstitial volume, 
which in this case 14L.
The volume of total body water can be determined with an accuracy of about 3% 
(±1.5  L)  by  determining  the  dilution  of  a  marker  substance  that  distributes 
throughout this space, such as isotopic water or antipyrine. [78] As measured by such 
techniques, the fraction of body weight that consists of water varies considerably 
among individuals and depends on several factors: age, gender, body fat content, and 
the presence of altered physiological or pathophysiological states. The determination 
of extracellular  fluid  volume  by  dilution  techniques  is  less  rigorous  because  an 
adequate marker substance that is exclusively confined with compartment does not
45exist. Dilution techniques have not routinely been evaluated in ESRF patients. It is 
often assumed that the distribution of ESRF patients is similar to normal individuals 
but this contention has not been adequately examined.
The cell membranes separate ICF from ECF and are freely permeable to water. The 
normal  inter-relationship  of  these  compartments  is  maintained  by  selective 
permeability to osmotic  solutes.  Despite the different composition of solutes, the 
osmolality of the ICF and ECF compartment is always the same.  Any change in 
extracellular  osmolality  will  immediately  be  followed  by  similar  change  in 
intracellular osmolality. Adding pure water to ECF will cause majority of it to move 
to ICF because it is larger. Conversely water withdrawal will mainly cause decrease 
in ICF.
Aquaporins  (AQP)  are  integral  membrane proteins  that  serve  as  channels  in  the 
transfer of water, and in some cases, small solutes across the membrane. They are 
conserved in bacteria, plants, and animals. Structural analyses of the molecules have 
revealed the presence of a pore in the center of each aquaporin molecule. The prime 
function of aquaporins (AQPs) is generally believed to be that of increasing water 
flow rates across membranes by raising their osmotic or hydraulic permeability. In 
mammalian cells, more than 10 isoforms (AQP0-AQP10) have been identified so far. 
They are differentially expressed in many types of cells and tissues in the body. 
Aquaporin  1   is present in capillaries and venules and appears to be  important in 
peritoneal dialysis, where it appears to represent the "ultrasmall pores" of the three- 
pore model. Furthermore, during glucose-induced osmosis during PD, nearly 40% of 
the  total  osmotic  water  flow  occurs  through  molecular  water  channels,  termed 
"aquaporin-1. "Decreased expression or function of AQP1  may be responsible  for 
some cases of ultrafiltration failure, but further evidence will be required to establish 
whether this is the case.
Although  a  large  number  of particles  constitute  plasma,  the  only  quantitatively 
important solute are sodium and its accompanying ions (Cl- and HC03-).  ECF is 
determined by the total body sodium  [ECF (1) = total body  sodium-*-140].  Hence 
when  ECF  is  expanded,  a  large  excess  of Na  is  also  present.  Determination  of 
sodium concentration does not give us an idea on Na content of the body.  Blood 
sodium concentration is a reliable estimate of cellular hydration.
Osmolarity indicates the number of osmotic particles in a litre of the solution, while 
osmolality is expressed per kg of water.  There is approximately a 7% difference
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significantly with respect to  their water/weight ratio;  women  have  a  lower body 
water content when expressed as a fraction of body weight. Body fat has a low-water 
content and makes up a larger fraction of body weight on average in women, which 
accounts for the gender difference. Use of V as a denominator essentially eliminates 
body fat content as a deciding factor for dosing dialysis. In other words, body fat is 
acknowledged not to be a determinant of need for dialysis, and in accordance with 
the  concentration toxicity  theorem,  fat  would  not be  a  source  of uremic  toxins. 
Although fat is a major component of all cell membranes and is especially prevalent 
in neural membranes, the majority of fat in the body is found in adipose tissue that is 
distributed primarily in the skin in which it is found in more abundance in women 
compared with men. Adipose tissue has long been considered an inert tissue serving 
as a repository for energy storage and heat insulation. More recent studies suggest 
that adipose tissue is more active metabolically than was previously appreciated, so 
eliminating  fat  as  a  source  of  uremic  toxins  could  be  premature.  [79] 
On the  other side  of the  coin,  body  edema  fluid,  which  represents  an  excessive 
expansion of the extracellular volume and is probably more inert than adipose tissue, 
is  included  in  the  denominator.  Body  water  content  is  increased  in  edematous 
individuals, but it is unlikely that this addition to total body water increases the need 
for dialysis.  So it is reasonable to question the wisdom of using urea distribution 
volume as a universal denominator for dosing dialysis.
The interstitial space
Approximately  10 litres is contained in the interstitial  space.  The volume of this 
compartment  is  generally  expanded  in  order  to  accommodate  excess  fluid 
accumulation. The fluid is bound in a proteoglycan matrix, which prevents fluid from 
flowing  easily  through  tissues.  The  proteoglycan  elements  behave  rather  like  a 
sponge,  which maintains  the  compartment at a  slightly  negative  pressure.  In  the 
nonoedematous state this heterogeneous system has a gel fluid property. (Fig 13) The 
interstitial space thus serves as a reservoir of extracellular fluid that can be mobilised 
in the event of transient loss from the circulation. The expanded space in overloaded 
dialysis  patients  give  rise  to  interstitial  pressure  causing  oedema.  Under  these 
conditions,  fluid  moves  easily  through  the  very  compliant  subcutaneous  tissue
47underneath the skin. Large volumes of fluid may be stored without increasing the 
interstitial pressure significantly. [80,81,82]
5b  Control of body fluid volumes
Regulating mechanisms in normal man 
i) Antidiuresis, thirst and salt
An  important  factor to  control  homeostasis  preserved  in  dialysis  subjects  is  the 
appetite  for  salt.  Strieker  [83]  pointed  out  that  osmotic  dilution  stimulates  salt 
appetite in rats and this is probably as important as a mechanism for control of body 
fluid  volumes.  Decrease  in plasma  volume  and  increase  in  osmolality,  the  same 
factors that affect antidiuretic action also stimulate thirst.
ii)  Natriuresis
Extracellular space expansion particularly by saline infusion in normal subjects is 
associated with marked natriuresis. This effect occurs without much plasma volume 
expansion but is highly correlated with an increase in interstitial fluid volume. The 
effect is promoted  more by  changes  in  the  sodium  load  than  by  changes  in  the 
volume  load  per  se.  Whether  or not  a  natriuretic  factor  exists  is  still  not  fully 
explored.  ESRF  patients  are  most  unfortunately  deprived  of  such  protective 
natriuresis.
iii)  ECF regulation
Volume  regulation  is  dependent  on  sodium  excretion  by  the  kidney,  which  is 
influenced by an integrated regulatory system in which blood pressure and renin- 
angiotensin-aldosterone play the most important roles. [84]
In normal man kidneys are constantly engaged in excreting the excess ingested with 
the food, over and above the minute losses by sweat and stools. The anephric patient 
is thus constantly threatened by extracellular overhydration.
48The ability of the kidney to excrete salt is limited.  Overhydration tends to occur 
when the amount that needs to be excreted is more than 5% of the filtered load. 
When  kidney  function  drops  to  below  20%  of normal,  5%  of the  filtered  load 
represents less than salt content of normal diet. The regulation of ECF is not fully 
understood.  Changes  in  blood  volume  or  ECF  by  an  afferent  pathway  mediate 
pressure natriuresis (efferent pathway). This mechanism is closely regulated by RAS. 
This is activated by hypovolemia and inhibited by hypervolemia. Despite the fact 
that abnormalities of the RAS play an important role in hypertension, this system 
seems to be primarily related to both salt and volume homeostasis. This is important, 
since as discussed in next chapter, in dialysis patients normal BP can be achieved in 
a large majority by manipulating their volume state. Normotension can be associated 
with  a  broad  range  of renin-angiotensin  levels.  However  hypervolemia  leads  to 
hypertension even in the absence of renin.
iv) Osmoregulation
Osmolality is regulated by the kidney, which can produce urine containing more or 
less water than body fluids. However normal osmolality can be maintained in the 
absence of kidney function.
The extracellular osmolality (sodium concentration) indirectly controls the ICF. This 
is maintained by two mechanisms, the regulation of thirst and by the ability of the 
kidney  to produce  hyper  or hypotonic  urine  mediated  by  ADH.  [84]  This  is  an 
amazingly precise and efficient control system that is rapid and sensitive.
v)  Regulation of interstitial fluid volume
The interstitial fluid volume can be regulated precisely. The interstitial fluid exists in 
two phases: as free fluid and as fluid imbibed in a gel like ground substance. Under 
normal  conditions essentially  all  the  fluid  is  in the  latter  form.  When  free  fluid 
increases even slightly, lymphatic flow also increases tremendously thereby acting 
normally as a negative feedback mechanism to prevent any significant increase in 
free fluid in the tissue spaces. Lymphatic flow removes protein and water from the 
tissue  spaces  decreasing  tissue  colloid  osmotic  pressure  and  increasing  capillary 
reabsorption of fluid. [83] The interstitial fluid gel on the other hand pulls fluid from
49the free fluid phase. Its imbibition forces determine the amount of fluid held in the 
gel and this fluid quantity is stable at least for short-term haemodynamic function. 
(Fig  13)  The  lymphatic  system and capillary reabsorption normally maintain  the 
interstitial spaces relatively dry of free interstitial fluid. The normal interstitial fluid 
volume is almost entirely that volume imbibed in the tissue gel. When the normal 
drying mechanism for the interstitial spaces fail to maintain the dry state, then large 
quantities of free fluid begin to collect and oedema ensues.  [82]
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The intravascular compartment and its 
regulation in haemodialysis
Haemodialysis treatment removes surplus body water from overhydrated tissues in 
addition to removing toxic substances and metabolites.  The total amount of fluid 
removed during a single dialysis session may vary from  1.5-4 litres. As plasma 
volume  is  only  4.5  -5  %  of body  weight  at  a  haematocrit  of  30%,  the  total 
ultrafiltered  water  removed  during  a  single  dialysis  session  may  in  some  cases 
exceed the total circulating plasma volume.  To preserve haemodynamic  stability, 
physiological  responses  intervene  such  as  a  fall  in  venous  capacitance  and  an 
increase  in  sympathetic  activity  to  maintain  blood  pressure.  Similarly  the  fluid 
retained in the interdialytic period is redistributed in the extracellular compartment 
through  passive  and  active  blood  volume  regulatory  mechanisms  to  maintain 
haemodynamic stability.
6a  Effects of fluid retention on the blood volume 
compartment and cardiovascular  system
An increase  in the  ECF  that results  from  salt and  water retention will  lead  to  a 
cascade  of events  that  affect  the  blood  volume  compartment  and  its  dynamics. 
Because blood volume and ECF are so closely linked, the terms fluid retention and 
overfilling are often used interchangeably. In general the terms fluid retention and 
overhydration  are  used  to  describe  an  increase  in  the  ECF  while  hypervolemia 
describes an increase in the blood volume.
As plasma is a part of the extracellular volume, plasma volume and therefore blood 
volume change concomitantly with the ECF. Because the Starling forces, (Fig  14) 
which  govern  the  partition  between  BV  and  the  interstitial  compartment,  may 
change,  this  relationship  is  not  the  same  in  all  circumstances.  For  instance  in
51conditions with hypoalbuminemia BV increases are less despite large increase in the 
interstitial volume.
The ECF - BP relationship is not linear. [78] BV increases only slowly when ECF 
expansion exceeds 5L, which is the amount when oedema appears. It is evident that 
the volume of blood within the vascular system cannot increase indefinitely although 
there is no apparent limit to expansion of ECF.
The increased volume will be distributed within the cardiovascular system according 
to the relative compliance of its different compartments. In addition the elasticity of 
the  vascular  compartment,  which  has  muscular  walls,  may  actively  change 
compliance. As the venous system has the largest compliance it will be affected first, 
with a small but a significant increase in pressure. There will also be an increase in 
the diastolic dimensions. The diameter of the heart on CXR decreases 0.5-1 cm after 
UF  2-4  L  during  dialysis.  According  to  Starling’s  law,  hypervolemia  must  be 
accompanied by increase in cardiac output and a hyperdynamic state. Fluid retention 
leads to hypervolemia, which leads to hypertension. The rise in BP as ECF increases 
parallels the ECF - BV relationship. The relationship is non-linear suggesting that 
the main determinant of blood pressure is blood volume. The hypercirculatory state 
causes  hyperperfusion  of  tissues;  the  blood  delivers  more  oxygen  which 
downregulates blood flow by vasoconstriction. The autoregulation leads to increase 
in TPR and hypertension.
Guvton’s Auto regulation Concept - Relationship of BP to BV
The fluid status-BP control relationship is usually explained by Guyton's concept of 
autoregulation  of systemic  blood  flow  [85].  The  basic  pathophysiology  of this 
concept  is  that  fluid  homeostasis  is  maintained  at  the  expense  of BP  elevation. 
According to this theory, blood flow to peripheral tissues is regulated by changes in 
local vascular resistance.  Any increase in cardiac output induced by expansion of 
extracellular or blood volume (or both) augments peripheral blood flow, which in 
turn elicits an increase in peripheral vascular resistance to restore local blood flow 
toward baseline.  The normal operating point for a 70kg man with the ideal fluid 
status  is  5  litres  of blood  volume  and  151  of extracellular  fluid.  Under  these
52conditions, the patients BP is typically within a normal range. If a blood volume 
becomes depleted below the normal value, it is clear that this will be insufficient to 
maintain a BP, leading to hypotension. In the opposite direction from the normal 
operating  point,  then  initially,  blood  volume  rises  linearly  with  ECF  eventually 
leading to hypertension in order to keep BP to certain limits.
At "high-normal ECF" a very small saline load suffices to trigger a wide BP increase 
On the other hand, at this higher basal ECF, intradialytic hypotension is less likely. 
The practical evaluation of the ideal ECF at a given time rests on attaining the ideal 
postdialysis weight.
However,  studies  of  the  relationship  between  volume  status  and  BP  are  not 
conclusive.  Whereas de Planque et al. [86] found a good correlation between BP and 
extracellular volume in hypertensive patients who had advanced renal  failure and 
were not yet treated with dialysis, Dathan et al. [87] could not confirm these findings 
in a study of 10 dialysis patients who underwent salt and water loading only one 
patient followed the classic pattern of Guyton's autoregulation hypothesis.  In two 
patients, BP did not change after increasing dry weight. Schultze et al. [88] studied 
haemodialysis patients who were normotensive and those who were hypertensive in 
spite of efforts to reduce dry weight.  The hypertensive patients were found to be no 
more volume-expanded than the normotensives.
Autoreeulation  and  hypertension
Dialysis patients are constantly threatened by fluid overload and it would therefore 
be remarkable if most of them did not suffer from some hypervolemia. Increased BV 
leads  to  a  slight increase  in right atrial  pressure.  A  normal  heart reacts  to  this 
increased 'pre-load' according to the Frank- Starling law by increasing cardiac output 
(CO).  This  hypercirculation  induces  vasoconstriction  in  the  tissues  (so  called 
autoregulation), that increases BP further [89].
Although a hypercirculatory state is present in many dialysis patients it is not easy to 
prove  that  this  is  caused  by  fluid  overload  because  of confounding  factors  like 
anaemia and A-V fistulas.  It is even more problematic to prove that this also leads to 
hypertension along the sequence shown above.  While one author described these 
events in a dialysis patient, others did not detect an increase in cardiac output when 
BP rose after overhydration, while in some patients BP did not increase at all [90].
53Nevertheless, whenever hypertension develops after volume expansion, it is always 
characterised by an increase in total peripheral resistance. This, in turn, leads to a 
search for vasoconstrictive substances and drugs that cause vasodilatation and the use 
of drugs that cause vasodilatation.
Reflex control of the circulation
A detailed discussion of blood pressure control  is well beyond the  scope of this 
thesis, however there are a few aspects worth highlighting, since blood volume and 
blood pressure  are  intrinsically  linked.  While  excessive blood  volume  can  affect 
blood pressure, there are many mechanisms allowing blood pressure to be controlled 
independently of blood volume i.e. vagal afferent stimulation, chemoreceptors and 
baroreceptor system in man. Kumada and Sagawa demonstrated that blood volume 
changes of 10 -20 % cause a 21-31 % change in impulse traffic in the rabbit aortic 
nerves with only a 6 % increase in arterial pressure.  Therefore they suggest that 
arterial baroreceptors act as volume receptors in the same way as atrial receptors.
[91]
In view of the great emphasis placed on pulse pressure as a stimulus to baroreceptors 
in recent years Kumada et al demonstrated that the pulsatile component of the carotid 
sinus reflex does not improve the reflex response of an animal to haemorrhage. This 
experiment was performed by preventing pulses from reaching the carotid sinus area.
[92] Vascular Stretch reflexes exert their effects only during the first few hours to the 
first  few  days  after  pressure  changes.  Long-term  regulation  depends  on 
chemoreceptor reflexes or intrinsic control of the circulation itself.
Autonomic control
The failure of normal compensatory mechanisms to sustain adequate venous return 
results in a drastic reduction in right ventricular volume. In susceptible individuals 
the acute reduction in ventricular volume is accompanied by a paradoxical increase 
in  afferent  inhibitory  output  of  the  cardiac  mechanoreceptors,  which  abruptly 
decreases the sympathetic output. A second potential pathway involves the activation 
of the parasympathetic system (Bezold-Jarisch reflex). [93] Both pathways result in 
hypotension  with  relative  bradycardia  and  are  akin  to  vasovagal  syncope.  Non­
54diabetic patients have normal baroreflex function and the acute hypotensive episodes 
were  linked  to  paradoxical  withdrawal  of  sympathetic  activation  similar  to 
vasodepressor syncope.
Compliance
The best way of describing the factors determining the distribution of volume excess 
is  the  compliance  of the  compartments,  a  kind  of elasticity.  A  high  compliance 
indicates a high elasticity, while low compliance stiffness.  Mathematically this  is 
defined as change in hydrostatic pressure, which occurs at a given change in volume 
(P/V).
Compliance  may  change  in  pathological  conditions.  For  instance,  the  interstitial 
space normally has a rather low compliance with a negative pressure and exists in a 
gel like state, which is not freely movable. With accumulation of fluid when oedema 
appears the gel structure is broken and many litres of fluid can accumulate without a 
measurable  change  in  interstitial  pressure.  The  equilibrium  between  the  blood 
compartment and the interstitial volume depends on the difference in their pressures 
the former or intracapillary pressure principally determined by precapillary vascular 
resistance and the venous pressure. The dynamic nature of the compliance explains 
why the Guyton curve is non-linear.  The haematocrit, compliance and the function 
of the heart, which vary from patient to patient may have important influences on the 
ECF/BP relationship in dialysis patients and has not been studied.
556b  THE  MICROCIRCULAHON
The  total  blood  volume  can  be  physiologically  described  as  comprising  of two 
haemodynamic  compartments.  The  large  arteries  and  veins  are  termed  the 
macrocirculation. The microcirculation on the other hand is defined as one including 
all  microvessels  with  a  diameter  smaller  than  250  um.  The  microcirculation  is 
distensible, harbours 40 - 50% of the total blood volume and more than 90% of the 
total  peripheral  flow  resistance.  The  microcirculation  is  the  principal  site  of 
transcapillaiy exchanges involving the delivery of oxygen, the removal of carbon 
dioxide and metabolic wastes and the transport of fluid flux and solutes. Other than 
mass transport, the microcirculation and endothelial cells have a role in regulation, 
signal  transduction,  proliferation  and  repair.  The  microcirculation  plays  a  more 
important role as a reservoir of blood volume than the venous system. Micro  vascular 
pooling rather than hypovolemia is a likely factor in many instances of hypotension 
in HD and in endotoxin shock. Understanding the role of the microcirculation could 
lead  to  more  effective  diagnosis  of  cardiovascular  deficiency  and  therapy  for 
hypotension or low cardiac output with intervention through the microcirculation. 
[94]
Smooth muscles surround the arterial end of the capillary, called the arteriole, which 
behaves like a valve allowing the flow of blood through the capillary to be regulated. 
A venule at the venous end of the capillary has a similar function. By adjustment of 
the arterioles and venules both the resistance of the capillary to the flow of blood and 
the  pressure  inside  the  capillary  may  be  controlled.  Consequently  the  combined 
microcirculation may perform a vital role in the control of blood volume and blood 
pressure. Blood from the microcirculation passes into the veins and the great veins, 
which provide considerable degree of vascular compliance. This elastic capacity of 
the vascular space allows it to contract during reduced blood volume to maintain 
pressure.
With  the  development  of  intravital  microscopy,  Chambers  and  Zweifach  [95] 
mapped out the intravascular network and marked the distribution of vascular smooth 
muscle in arterial walls or around some capillary entrances. They observed that the 
arterioles and capillary sphincters could constrict to alter the degree of perfusion and 
affect  the  flow  heterogeneity  of the  network,  leading  to  the  suggestion  that  the
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local  regulation  from  individual  microvessels  to  the  whole  organ  allows 
autoregulation  of the  total  blood  flow.  Neural  and  humoral  factors  along  with 
autoregulation control the performance of the circulation.
The mapping of the microvascular networks in thin tissues such as the mesentry, 
cremaster, and gracilis muscle and the subsequent modelling of the microvascular 
flows indicate that each tissue may have a different network organisation, capillary 
density and pressure distribution. The microvascular function of the heart, lung and 
liver has been studied with their surface vasculature, fixed tissue samples or indicator 
dilution methods. Morphometric measurements from three organs have established 
that the microcirculation could contain 40 -50% of blood volume. Multifocal X-ray 
imaging and a new generation of contrast agents are now available for assessing the 
heterogeneous microvascular or regional  flow of solid organs in vivo or in vitro. 
These  could  lead  to  precise  characterisation  of  microvascular  morphometry, 
exchange and regulation.
The endothelial cells can release endothelin and nitric oxide to regulate the blood 
vessels downstream.  The cells are in communication with each other and play  a 
pivotal  role  in  signal  transduction.  This  role  may  be  influenced  by  mechanical 
stresses imposed by blood flow. Endothelial cells may play a role in the growth of 
microvesssels as collateral channels improving blood flow.  Since most endothelial 
cells reside in the microcirculation, this provides an effective site for drug and gene 
targeting with therapeutic benefits.
The morphometry of the pulmonary vascular networks was mapped out by Horsfield 
and Gordon [96].  The arterial macrocirculation has two vessel groups:  arteries (d 
>2mm) and the small arteries (2mm>d>250um).  The microcirculation consists of 
three groups: the arterioles (250um>d>8um, the capillaries (d<8um), and the venules 
(250um>d>8um). (Fig 15) Finally the two groups in the venous macrocirculation are 
the small veins (2mm>d>250um) and the veins (d>2mm). The capillaries of the heart 
and lung contain the majority of the microvascular blood volume and their arterial 
macrocirculation is volumetrically comparable with their venous macrocirculation. 
The mesentry has most of its microvascular blood volume in the venules and most of 
its macrovascular volume  in the  veins and  small  veins.  The  distensibility  of the 
microcirculation is comparable to the macrocirculation.
576c  Blood volume regulation during Ultrafiltration
During  HD  (combined  diffusion  and  ultrafiltration)  the  plasma  water  removal 
induces a progressive reduction in blood volume. Hemoconcentration is followed by 
a fluid shift from the interstitial and cellular spaces toward the vascular compartment. 
Hypovolemia triggers the sympathetic system, which induces vasoconstriction and 
an increase  in myocardial  contractility  and heart rate.  The maintenance of blood 
pressure is related to two fundamental mechanisms, blood volume preservation and 
cardiovascular compensation. Arterial hypotension occurs when central hypovolemia 
causes an underfilling of the cardiac chambers, thereby compromising the circulatory 
load, while either the vascular arteriolar or venous tone decreases or is inadequate in 
relation to the  stroke volume reduction.  In a stable HD patient,  the most critical 
period of instability is in the latter half of the session. The mechanism that explains 
this is failure of microvascular resistance vessels to constrict during treatment in 
response to a declining vascular volume.
i )  Blood volume and intradialytic hypotension
The  blood  volume  in  a  typical  dialysis  patient  varies  from  4.5  to  61,  with  a 
corresponding  plasma  volume  of 3  -  4  1 .  In  patients  undergoing  thrice  weekly 
dialysis schedules and gaining 1.5kg/d, the therapeutic requirement is to remove 3 1  
of fluid per dialysis treatment or nearly the entire plasma volume It is a tribute to the 
compensatory  mechanisms  present  in  the  body  that  patients  routinely  not  only 
survive such as a marked insult to their circulatory system, but also do so with little 
decrease in BP. The compensatory mechanisms are cardiac, plasma refilling, passive 
venoconstriction and active increases in arterial tone.
Further more when fluid is ultrafiltered from the vascular compartment during HD, 
intercompartmental  shifting  of  intracellular  and  extracellular  fluids  occurs,  in 
disequilibrium syndrome, hypotension, and other symptoms, and these complications 
reflect the poor physiological compatibility of rapid fluid removal during HD.
58The changes in cardiac rate in response to hypovolemia are often impaired in dialysis 
patients. [97] Whereas cardiac rate changes may be important in increasing cardiac 
output from baseline (e.g., during physical activity), they appear to be less important 
in maintaining cardiac output under conditions of decreased  filling.  For example, 
studies in dogs receiving propranolol during haemorrhage indicate that this cardiac 
rate  change  is  of  minimal  importance  in  maintaining  cardiac  output  during 
hypovolemia. Another cardiac compensatory mechanism is increased contractility. 
[97] Whether this is of clinical importance during hypovolemia is open to question. 
A  number  of electrolyte  changes  that  occur  during  dialysis  (decrease  in  serum 
potassium, increase in serum bicarbonate and change in serum ionised calcium) have 
been reported to affect cardiac contractility. [93, 98] Manipulating these ion changes 
(e.g.,  increasing  dialysis  solution  calcium  levels)  has  been  reported  to  increase 
intradialytic blood pressure [98], but it is unclear if the BP effect was due to cardiac 
causes or to calcium effects on the peripheral vasculature.
ii)  Concept of Plasma refill
The primacy of plasma refilling is indicated by the fact that, if one does not remove 
fluid during dialysis, intradialytic hypotension is rare. [99] This emphasises that the 
fact that the ultimate cause of hypotension is reduced cardiac filling. The initial 
compensatory mechanism is refilling of the plasma water space from surrounding 
tissue spaces. As a result of refilling, even though the entire plasma volume is 
removed during dialysis, the blood volume typically decreases only by 5% to 20%. 
The  source  of refilling  fluid  is  primarily  the  extracellular  space,  although  this 
depends on the dialysate sodium level.  Evidence suggests that  during HD, patient 
differences  exist  in vascular refill  relative  to  the  rate  of ultrafiltration  [66].  The 
plasma refill rates have been indirectly estimated as high as 1500ml/hr in moderate 
hypervolemia. [100] Using a higher dialysis solution sodium concentration will result 
in mobilization of intracellular water for this purpose and better maintenance of the 
plasma  volume  during  dialysis.  From  practical  experience,  one  often  finds  that 
plasma refilling is also enhanced with a high plasma albumin level and in conditions 
of fluid overload.  Mobilization of ascitic fluid by dialysis is difficult, because the
59rate of equilibration between intraperitoneal fluid and the plasma space tends to be 
quite slow.
iii)  Transvascular water and solute exchanges
The hydrostatic forces within the capillary beds may also affect refilling. (Fig  15) 
Any vasodilator (e.g. acetate) that serves to dilate arterioles and cause transmission 
of increased hydrostatic pressure to the capillary bed, will also act to inhibit refilling.
Two approaches have been used in descriptions of net transfer of solutes and water. 
One  approach  has  been  the  classical  approach  of Starling  forces,  vascular  and 
interstitial hydrostatic and oncotic  forces and on the concept of filtration  in bulk 
without separation of solvent water from small  solutes.  The latter determined by 
factors,  in  addition  to  oncotic  and  hydrostatic  forces  considered  in  the  original 
Starling hypothesis, such as hydraulic conductivity, capillary surface area, reflection 
coefficient for plasma proteins and the relationship of protein flux to the volume flow 
across the capillary. In a second physicochemical approach based on nonequilibrium 
thermodynamics  and  on  multiple  indicator-dilution  experiments,  diffusion  is 
considered the dominant mechanism in transvascular exchanges of water with net 
transfers related primarily to the permeability and net passage of small solutes such 
as sodium and chloride ions (osmotic buffering). Reconciliation of two approaches is 
in the hypothesis that small solute controls are dominant over a period of seconds 
while oncotic factors are operative over minutes. These estimates are based on linear 
models of extravascular distributions and for permeability calculations. Aquaporins 
may be important but their role has not been completely defined. [101]
iv) Venous capacity: interaction with arterial tone
Detailed haemodynamic analyses of intradialytic hypotension provide two important 
facts.  (1)  There  is  no  sudden  absolute  decrease  in  plasma  volume just  before  a 
hypotensive episode. (2) Intradialytic hypotension seems to be due to a decrease in 
cardiac output engendered by reduced cardiac filling. [102]
60Most of the  3L  or so  of plasma volume resides  in the veins,  and  several  organ 
perfusion systems, notably skin and splanchnic, contain veins that can markedly alter 
their capacity. A slight loss in venous tone in either of these systems can result in a 
marked ebbing of flow return to the heart with loss of cardiac filling and a resultant 
decrease in cardiac output.  Venous tone in the circulatory system is affected by 
vasoactive hormones and the sympathetic nervous system (SNS), but also responds 
to upstream filling pressure; i.e. enhanced transmission of upstream arterial pressure 
to the veins via the capillaries will cause the veins to distend, increasing their volume 
This is the basis of the so-called De-Jager Krogh phenomenon [93] and explains how 
pathophysiologic conditions or drugs that cause arterial dilatation may also result in 
venodilatation and alterations in venous capacitance.
Thus, some episodes of dialysis hypotension, especially the sudden hypotension that 
occurs without a marked antecedent increase in hematocrit, might be due to sudden 
relaxation of splanchnic veins causing an abrupt reduction in cardiac filling.  So, 
what are the practical aspects of maintaining venous tone?  Arteriolar constriction 
must be maintained.  The use of acetate was abandoned because of an increased 
incidence of dialysis hypotension and other side effects.  Interestingly, acetate and 
food  ingestion  has  the  specific  effect  of increasing  splanchnic  blood  flow  and 
dilating splanchnic blood vessels.
There is an interesting hypothesis which suggests splanchnic blood pooling and the 
resultant  dialysis  hypotension  is  related  to  adenosine.  When  ATP  (adenosine 
triphosphate) is used by the cell, adenosine diphosphate and monophosphate (AMP) 
are generated, and then AMP is metabolized to adenosine. Adenosine is then further 
metabolised to  inosine  and hypoxanthine  and,  ultimately,  to  uric  acid.  Because 
adenosine is difficult to measure, adenosine turnover or generation is often measured 
by serum levels of its metabolites, inosine and hypoxanthine.  Woolliscroft and Fox 
[102]  showed  that  patients  who  were  hypotensive  for  a  variety  of reasons  had 
increased  levels  of inosine  and  hypoxanthine  in  the  blood,  presumably  due  to 
ischemia-induced  consumption  of  adenosine  triphosphate  (ATP)  with  increased 
generation of AMP and adenosine. It was also noticed that use of acetate containing 
dialysis solution increased adenosine products in the circulation. The explanation for 
adenosine  causing  hypotension  is  thought to  be  mainly  the  inhibitory  effects  of
61adenosine on norepinephrine release.  This may be a physiologic mechanism, in that 
a tissue that is not getting enough oxygenation releases adenosine, causing regional 
vasodilatation and increased local  flow.  The concept has been put forward that a 
"vicious cycle" may occur in some patients with sudden hypotension: hypotension 
induces ischemia, which, in turn, results in increased local adenosine release, which 
then causes inhibition of norepinephrine release and vasodilatation, which results in 
deepening  hypotension.  Dialysis  patients  who  had  sudden  decreases  in  BP 
intradialysis  (but  not  in  patients  exhibiting  gradual  BP  reduction)  hypotensive 
episodes  are  preceded  by  the  appearance  of  increased  levels  of  inosine  and 
hypoxanthine  in the blood.  Shinzato  et al  [103]  then  went on  to  pretreat these 
patients with caffeine (an adenosine blocker) in a crossover study and found that they 
experienced fewer decreases in blood pressure during dialysis.
The degree of peripheral arteriolar constriction also affects the blood pressure by a 
second mechanism that is independent of venous capacity and cardiac filling.  This, 
of course, is a direct hemodynamic effect: at any level of cardiac output, the level of 
arteriolar tone will determine the level of central blood pressure.
In addition to a variety of vasoactive hormones, the principal control mechanism of 
arteriolar tone for resistance vessels has to do with the level of SNS activity.  The 
level of peripheral sympathetic nerve activity can be measured by means of a small 
electrode inserted close to the peroneal nerve.  Such measurements have determined 
that ESRD patients have an increased basal level of peripheral sympathetic nerve 
activity.  [45]  Because  this  is  not  found  in  ESRD  patients  who  have  undergone 
bilateral nephrectomy, it has been hypothesized that this excess sympathetic activity 
may be generated in some way via afferent renal nerves originating in the diseased 
kidneys.  During dialysis, as fluid is removed, increased peroneal sympathetic nerve 
activity has been measured.  This is thought to be an appropriate response.  However, 
in hypotension-prone patients, Converse et al [57] found a paradoxical decrease in 
SNS activity at the time of hypotension.  The measured SNS activity predialysis, 5 
minutes before a hypotensive episode, and during the hypotensive episode.  When 
hypotension supervenes in these patients, there is a paradoxical decrease  in  SNS 
activity.  In another study, SNS activity was imputed from spectral analysis of heart
62rate variability based on the low frequency and high frequency heart rate changes. 
[104]
6d  Application of blood volume monitoring in HD
The  overwhelming need  for objective  quantification of fluid  status has not been 
realised despite many other advances in dialysis technology. It is clear a common 
final  pathway  of  blood  volume  reduction  is  central  to  hypotension  during 
ultrafiltration whatever the aetiology. This has been the primary motivation for the 
development of blood volume monitors. The first continuous blood volume monitor 
was  developed  over  15  yrs  ago  by  Stiller  et  al.  [105]  Since  then  a  variety  of 
techniques have been devised employing principle of optics, ultrasound, viscometry 
and  conductivity  described  in  further  details  in  the  subsequent  Methods  section. 
Blood volume monitors have now become an integral and standard feature of most 
modem dialysis machines. The availability of this technology has been the source of 
renewed interest in methods to quantify fluid status and achieve more physiologically 
appropriate fluid removal during dialysis.  Several types of monitors are available 
based  upon  different  principles  and  offering  various  degrees  of  precision  and 
immunity to artefacts. These have been detailed in the subsequent Methods section. 
For the past few years relative blood volume measurements have been possible with 
devices based on the optical reflection and densitometry methods. Since then various 
authors have tried to determine individually determined decrease of relative blood 
volume at which the patient will develop hypotension. It has been proposed that the 
degree of blood volume reduction as a consequence of ultrafiltration may reflect the 
fluid  status  of a patient.  Blood  volume  changes  have  been  associated  with  BP 
changes, [68] hypotensive events and hydration status [106]. Most studies have tried 
to link the fall in blood volume to a fall in blood pressure, proposing that blood 
volume changes could be a predictor of hypotension. Generally the results of such 
studies have been inconclusive and failed to provide clear-cut guidelines. [107,108] 
Although maintaining blood volume above a critical limit does not pose any major 
technical  difficulties  using  advanced  feedback  control  systems,  a  number  of 
shortcomings have limited its acceptability and widespread usage [109] Wojke et al
63could show that in 7.2% of prone hypotensive relative blood volume showed a high 
interindividual variation, ranging from 96 to less than 86%. [110]
Continuous blood  volume  measurements  and  determination  of the  relative  blood 
volume  variations  and  limits  are  of  importance  in  relation  to  regulation  of 
ultrafiltration volume  and  its prescription.  The possibility of feedback control  of 
blood volume during HD has been proposed as this may enable fluid to be removed 
during  each  session  on  an  individualised  basis.  Current  blood  volume  control 
strategies are relatively crude. The existence of a critical blood volume remains to be 
convincingly proven in dialysis patients. Quantitative blood volume parameters to 
assess hydration in real time during dialysis instantaneously are lacking despite the 
available technology. The limitations of current strategies are due to various factors. 
The relative blood volume characteristics during UF have not been defined and its 
interpretations  remain  unclear.  Hydration  status  is  not  the  sole  factor  affecting 
stability.  Temperature, electrolyte balance, and other cardiovascular compensatory 
systems all play a part in maintaining intradialytic stability. As a result the blood 
volume changes have to be interpreted during a single treatment by the given state of 
these variables.  Blood volume control  systems that have been developed do not 
involve methods which characterize individual patient responses to fluid removal but 
rely on predefined trajectories. Finally the true relationships between a relative and 
the absolute changes in blood volume during ultrafiltration have not been studied. 
Achieving dry weight and avoiding hypotension has to also take into account other 
fluid  compartments  where  excess  fluid  resides  and  compensatory  mechanisms 
induced by fluid removal in these patients. One important element lacking in current 
blood volume strategies is a suitable physiologic model of the HD patient during 
ultrafiltration and the forces that govern alteration in haemodynamics. The use of 
dynamic tests based on ultrafiltration pulses and intradialytic monitoring may allow 
us to understand the ultrafiltration pathophysiology. Insight into these mechanisms 
may then provide the opportunity of individualising the ultrafiltration prescription.
64Table 1  Common causes of ESRF
Causes  Eng& Wales 1995  USA 1991 -1995  Australia 1996  Japan 1994
Glomerulonephritis 12.4 11 34 39.8
Diabetes 13.8 37.4 18 31.2
Cystic disease 5.9 3.5 7 2.6
Hypertension 7.8 28.7 12 6.2
Pyelonephritis 9.1 4.5 4
Analgesic 7
Missing 17 4.4 7
Miscellaneous 18.1 6.2 11
Table 2  Excellent BP control reported in certain dialysis centres
Author Location HD
modality
Year Normotensive 
patients (%)
% on 
AH drugs
Thompson [40] USA LHD 1970 90 -
Charra [31] Tassin LHD 1997 97 3
Goldsmith [281] Manchester LHD 1998 98 2
McGregor [42] Christchurch HHD 1999 94 8
DorhoutMees[43] Turkey CHD 1996 90 1
Ozkahya [75] Turkey CHD 1998 86 -
Kooman [175] Maastricht CHD 1999 75 -
AH antihypertensive drugs; LHD long hours HD ; CHD conventional HD ; HHD Home HD
65Table 3 Causes of hypertension in patients 
undergoing Haemodialysis [39]
Fluid retention________________
Pre-existing essential hypertension 
Increased sympathetic activity 
Deranged renin-angiotensin system
Hypercalcemia_______________
Increased plasma-endothelin 1  
Disordered Nitric oxide metabolism
Table  4  Intradialytic complications by patient age ; 
Percentage of dialysis treatments with specific symptoms[55]
Age groups (yrs)
<30 30-50 50-70
Number of treatments 1314 5355 11085
Percentage of patients with :
Hypotension 18.1 19.7 25.2
Nausea 8 6.8 8.1
Vomiting 3.4 2.3 3.7
Cramps 11.4 13.3 10.2
Chest pain 0.9 1.2 1.5
Fever 0.6 0.2 0.2
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Figure 1  Percentage of new patients by age group, 
E&W1997- 2002 (Renal Registry UK)
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Figure 2 Increasing Comorbidity in the ESRD 
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Figure 3 Percentage of dialysis patients on hospital 
based haemodialysis (UK Renal Registry RRT 
Modalities, day 90, 2002 cohort)
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Figure 5  Life expectancy with ESRD is poor despite renal 
replacement therapy KM survival on renal replacement 
therapy over six years by age group (UK Renal Registry)
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Figure 6 Cardiovascular mortality in the general 
population (NCHS) and in ESRD treated by Dialysis (USRDS)
69Figure 7  Hypertension is a risk factor for mortality 
Charra et al Am J Nephrol 1996; 16: 35
MAP >90 mmHg
Post-Dialysis SBP (mmHg)
Figure 8  U curve association between BP and mortality 
Zager PG et al KI 1998; 54: 561
70Figure 9 Dialysis Hypertension in dialysis facilities 
in a single state in the USA Salem et al AJKD 1995
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71Figure 11  The mechanisms leading to hypotension are multifactorial and 
influenced by dialysis and patient related factors
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72Figure 13 The interstitial compartment acts as a reservoir for 
the excess accumulated extracellular fluid
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75Introduction
Monitoring blood  volume  responses  to  ultrafiltration  offers  many  possibilities  to 
deduce some information about fluid shifts. Some pathways to hypotension may be 
the indirect consequence of fluid removal, emphasising the need for multi parameter 
data  collection.  Understanding  the  more  subtle  characteristics  of blood  volume 
changes  also  requires  additional  measurements  for  more  rigorous  analysis.  The 
purpose of this chapter is to describe the principle and mechanism of haemodialysis 
and  ultrafiltration  methods  and  the  rationale  behind  selection  of  a  suite  of 
measurement devices, in order to obtain patient specific data of interest during fluid 
removal.  A relatively complex data acquisition system was necessary in order to 
integrate the measurement devices.
1 The Haemodialysis Procedure
During haemodialysis, diffusion of solutes between the blood and a dialysis solution 
results in the removal of metabolic waste products and the replenishment of body 
buffers.  Heparinized blood  is  pumped  through  a  the  dialyser  on  one  side  of a 
semipermeable membrane at flow rates of250 to 550 ml per minute, while dialysate 
flows in the opposite direction at 500 to 800 ml per minute in order to remove waste 
products. Resulting urea clearance rates of 200 to 350 ml per minute effect a 65 to 70 
percent reduction in the blood urea nitrogen concentration during a three-to-four-hour 
treatment session; the urea clearance rate also depends on the surface area of the 
dialyser and the permeability  of the membrane.  By means  of adjustments in the 
transmembrane pressure across the dialyser, removal of fluid from the plasma into 
the dialysate can be accurately controlled.
i)  Haemodialysis Apparatus
All haemodialysis experiments in this thesis were performed using Fresenius 4008E 
HD machine (Fig 1) The machine controls and internal fluid pathway (Fig 2) come in 
contact with the patient via the extracorporeal circuit (Fig 3). All patients received 
high flux HD 3 times per week using bicarbonate buffer,  1.0-1.4 m2  hollow fibre 
polysulfone membranes (Fresenius HF80) with blood flow rates of 300-500ml/min,
76dialysate  flow  rates  800  ml/min  and  the  Fresenius  2000E  delivery  system  with 
volumetrically controlled UF [111] The machine was specifically configured to have 
an inbuilt ultrasonic blood volume monitor, an integrated oscillometric BP monitor 
and  a  temperature  module.  Dialysis  was prescribed  according  to  a  UKM.  [112] 
Standard dialysate preparations were used for the subjects under study.  Dialysate 
contained  Na  138  mmol/1,  K  2mmol/l,  Ca  1.25mmol/l,  Mg  0.5mmol/l,  Cl 
108.5mmol/l  and  glucose  5.5  mmol/1,  and  bicarbonate  35  mmol/1  with  the 
conductivity and temperature kept at 140 mS and 36 C. The microbiological quality 
of the dialysis fluid was monitored as a part of the routine clinical protocol in the unit 
and consistently achieved recommended standards [113] Careful monitoring of the 
water-treatment system and the dialysate must be carried out to prevent these adverse 
reactions. The water quality maintained at the this centre is approximately 10 times 
better  than  the  minimum  recommended  and  is  regularly  kept  under  close 
surveillance. During the studies there were no incidents related to the water quality 
standards.  All patients had UKM performed 1-3 monthly depending on the level of 
residual  renal  function.  Using  these  data,  dialysis  was  individually prescribed  to 
achieve a KT/V 1.2 for thrice weekly dialysed population.
ii)  Haemodialysis Membrane
Major advances have occurred in membrane technology with the development of 
more biocompatible dialyser membranes and of membranes that are thinner and more 
permeable.  High-efficiency  dialysers are  those  with a  large  surface area  that are 
distinguished by high rates of urea clearance. High-flux dialysers have the additional 
property of markedly increased hydraulic permeability, which is accompanied by an 
increase in diffusive permeability, particularly to solutes with molecular weights in 
the range of 1500 to 5000 — so-called middle molecules. High-flux dialysers have 
also been defined by rates of clearance of beta2-microglobulin (molecular weight,
11,800) above 20 ml per minute.
The use of large-surface-area high-efficiency or high-flux dialysers permits high rates 
of urea  clearance  to  be  achieved,  allows a  concomitant  shortening  of the  time 
required  for  dialysis,  and  offers  the  theoretical  advantage  of  improved  blood
77purification by  removing  the  higher-molecular-weight  solutes  mentioned  above. 
Furthermore, adsorption of molecules, such as beta2-microglobulin, to the surface of 
these dialyser membranes constitutes an additional important mechanism of blood 
purification. [114] Ideally, the haemodialysis membrane should not induce adverse 
reactions when it comes into contact with the blood; that is, the membrane should be 
biocompatible. Efforts have been made to minimize reactions by either modifying the 
cellulose polymer  or using  noncellulose-based membrane  materials.  Examples of 
polymers  that  can  be  formulated  into  more  biocompatible  membranes  include 
acetate-substituted cellulose  and noncellulose-based polyacrylonitrile, polysulfone, 
and polymethylmethacrylate ; [115] membranes formulated from these polymers may 
also have the increased permeability discussed above. The membrane structure does 
not depend on the polymer but on the precipitation step during the manufacturing 
process.
Membranes used in the study were high flux polysulfone (typically HF 60). High 
flux membranes are characterised by high diffusive performance (thin layer of 1  um) 
and high ultrafiltration coefficient. The membrane itself has high biocompatibility 
regardless  of the membrane permeability.  This  is  due  to  the  following  factors a 
chemical structure free of hydroxyl groups responsible for complement activation 
and hypersensitivity reactions.
•  * an electrically neutral polymer, hence no positive charges which may cause 
thrombogenicity, no negative charges which can cause anaphylactoid reactions
•  an asymmetrical wall structure with hydrophobic domains, which contributes to 
retention of endotoxins
iii)  Access for Dialysis
Obtaining  and  maintaining  adequate  access  to  the  circulation remains  a  major 
impediment  to  the  long-term  success  of haemodialysis.  The  fistula,  conduit,  or 
catheter through which blood is obtained for haemodialysis is often referred to as a 
"dialysis access." The placement of large needles (typically 15 gauge) is required to 
remove blood and to return it after it has passed through the dialyser. A large, thick- 
walled fistula can be created by shunting blood from an artery to a vein; the result is 
the  growth  and  thickening  of  the  venous  wall,  which  then  tolerates  repeated
78cannulation. The Cimino-Brescia fistula, in which the cephalic vein is anastomosed 
to the radial artery is preferred because its higher survival rate.[l 16] All studies were 
performed using functioning AV fistula or graft with less than  10% recirculation. 
When  dialysis  is  urgently  required,  a  double-lumen  dialysis  catheter  is  used. 
Implantation of a dual-lumen cuffed catheter is a good option for patients who have 
delayed recovery from acute renal  failure, who require access  for dialysis until a 
fistula matures, or who lack any other suitable site for graft placement. If carefully 
maintained, almost half of these catheters remain functional at one year.
2  ULTRAFILTRATION
i)  Principle  and Theoretical background
Removal of excess body water is an important function of both the artificial kidney 
and peritoneal dialysis.  Patients with chronic renal failure requiring treatment with 
the artificial kidney will in most instances require reduction of their total body water 
in conjunction with their dialysis. The process of removing fluid by convection is 
known as ultrafiltration.  For each dialysis a judgment must be rendered as to how 
much fluid should be removed during treatment to prescribe ultrafiltration.  This 
presupposes that two pieces of information are available to the clinical investigator: 
1) the degree of deviation from the proper total body water content of the patient 
under consideration and 2) the ultrafiltration rate of the artificial kidney to be used or 
of the peritoneal membrane.  This section deals with the practical and theoretical 
aspects of ultrafiltration across the artificial kidney.
Utrafiltration across  the peritoneal membrane must be  accomplished  osmotically. 
Glucose, sorbitol, mannitol and other osmotically active solutes have been used to 
create the pressure gradient.  Commercially available dialysis solutions most often 
offer a 1.5 g/dl and 4.25 g/dl glucose solution. There is considerable variability from 
patient to patient on the extra amount returned by ultrafiltration.  An explanation may 
well be that the membrane involved is biological and subject to differences between 
patients as well as changes with time in the same patient.  With a duration of each 
exchange of 30 to 70 min and a production of 500 ml of ultrafiltrate per exchange an 
ultrafiltration rate of 7 to 16 ml/min is accomplished.  These figures are somewhat
79below those for extracorporeal dialysis where ultrafiltration rates of upto 35 ml/min 
may be easily obtained with a standard dialysis membrane. It should be noted that the 
vascular  volume  during  ultrafiltration  is  dependent  on  the  comparative  rates  of 
movement of fluid  leaving  the  vascular space by  ultrafiltration  and  entering the 
vascular compartment from interstitial and possibly intracellular sources.  The rate of 
mobilization of extravascular fluid is specific to the individual.  Fluid sequestered in 
body cavities such as in the pleural space or in the pericardium usually is recruited 
very slowly and may take weeks or months of repeated efforts to remove even in the 
absence of any identifiable cause for local fluid accumulation like active pleuritis or 
pericarditis.
Silverstein et al [117] have also noted that fluid removal conducted without dialysis 
using an ultrafiltration cell (0.2 m2  area) caused few if any symptoms in maintenance 
dialysis patients presenting with an acute fluid overload.  This observation holds for 
the use of this device in series with conventional haemodialysis equipment.  For 
reasons that are not clear, patients ultrafiltered in this manner have fewer symptoms. 
The  process  of  Ultrafiltration  is  dependent  on  4  key  factors:  ultrafiltration 
coefficient, hydrostatic  and  oncotic  gradients,  osmotic  gradient with  glucose  and 
reflection coefficient.
Membrane packages using hollow fiber format (used in the current experiments) in 
general do not have an obligatory ultrafiltration rate, as the blood path resistance to 
flow is low.  In these cases dialysis fluid is often pulled through the dialyser rather 
than pushed and a hydrostatic pressure for ultrafiltration is achieved by the dialysis 
fluid pump pulling against a partially occluded (by an adjustable clamp) inflowline 
and (or) the blood pump pumping against a partially occluded blood return line. 
Resistance to  flow in the unclamped dialysate path is sufficiently  low  so that at 
satisfactory flow rates (200 to  500 ml/min) little, if any, obligatory ultrafiltration 
occurs.
Theoretical background
When a concentration gradient exists across a semipermeable membrane, both solute 
and water tend to move in a direction to discharge that gradient with time.  Solute 
and water move in opposite directions across the membrane to achieve equilibration. 
The gradient may be expressed in terms emphasizing the solute (e.g., number of
80mg/dl of solute on side A, minus number of mg/dl of solute on side B) or in terms 
emphasizing the water (e.g., number of milliosmoles on side A, minus number of 
milliosmoles on side B).  Osmolality is generally considered as the number of solute 
particles per kilogram of water.  Alternatively, it may be considered as a measure of 
the number of water molecules per kilogram of solution i.e., the "concentration of 
water".  There are two ways in which a concentration gradient for water may be 
achieved:  osmotically and hydrostatically.  For artificial  kidney  membranes both 
osmotic and hydrostatic (hydraulic) force may be used to achieve the concentration 
gradient necessary to cause ultrafiltration (separation of macromolecular solutes, i.e., 
protein and cellular elements from plasma water). The hydrostatic force is the more 
effective  of the  two  techniques.  The  hydrostatic  force  across  the  peritoneal 
membrane remains rather constant and hence osmotic force is all that is available to 
achieve increased ultrafiltration.
An equation that relates ultrafiltration rate to these forces is frequently written [118] 
Jf= Qf/A =  LP(AP + Atc)
Ultrafiltration rate per unit area of membrane = (permeability of membrane to water) 
x (hydrostatic force + osmotic force) where
Jf = the volume flux rate per unit membrane area across the membrane for water 
(ml/min/ cm2), usually negative as water is lost from the subject.
LP = the permeability of the membrane for water, i.e., the volumetric flow rate of 
water per unit area of membrane per unit pressure gradient (ml/min. cm2, mm Hg),
Qf = flow rate of ultrafiltrate (ml/min), usually negative as flow is away from the 
patient
A = Area of the membrane (cm2 ),
AP =  The hydraulic pressure gradient from blood path to dialysis fluid path (mm 
Hg),
A 7i  = The osmotic pressure gradient from blood path to dialysis fluid path (mm 
Hg); A 7i  is frequently measured in mOsm/1 and may be converted to mm Hg using 
1.0 mosm ~ 19 mm Hg.
The hydrostatic and osmotic forces are summed in this equation, since with dialysis, 
using either the peritoneal or a synthetic membrane there  is a deliberate osmotic
81gradient favoring water movement from blood to dialysate.  It should be noted that 
where isotonic dialysis fluid is used the osmotic pressure provided by the plasma 
proteins  favours  water  movement  from  the  dialysis  solution  to  blood  and  the 
contribution of A n to Jf is reversed.
Water rarely if ever moves by single molecule diffusion, but rather by "bulk” flow in 
which  movement  of "blocks"  of water  occur  much  as  you  would  consider  the 
movement of pure water in a pipe when an inlet to outlet pressure gradient is applied. 
It is apparent that in subsequent instants this rather straightforward conceptualisation 
becomes much more complicated.  To cite  some  of the  events,  glucose  is  small 
enough to move by diffusion down its concentration gradient from B to A reducing 
the osmotic driving force; further, the water arriving on side B dilutes the glucose 
concentration adjacent to the membrane lengthening the diffusion path over which 
the concentration gradients apply and slowing their discharge.
Further, protein, a macromolecular structure present in solution on the blood side 
cannot  cross  the  membrane  and  will  exert  an  osmotic  effect  (oncotic  pressure) 
favouring water reabsorption  from the  dialysis bath.  Finally,  the  distribution  of 
charges on the solute particles and the requirement for electroneutrality across the 
membrane  will  modulate  the  movement  of  electrolytes  in  response  to  their 
concentration gradient.
The convecting of solutes along with water through a membrane in response to a 
pressure  gradient  (osmotic  or  hydrostatic)  is  termed  "solvent  drag".  When  the 
membrane exerts no restraining force (sieving effect) on the solute, i.e., the solution 
does not change in concentration as it traverses the membrane, then the terms "bulk", 
"plug" or "Poissilian" flow describe the events.
The  ultrafiltration rate  in  the  human  glomerulus  and  capillary  beds  such  as  the 
splanchnic  circulation  are  dominated  by  considerations  of oncotic  pressure.  The 
importance of the oncotic pressure lies not in its magnitude but in the nearly equal 
hydrostatic pressure across the capillary wall.  By contrast in the artificial kidney 
hydraulic pressure (A P) almost invariably exceeds oncotic pressure. Small solutes 
other than protein, present in the dialysis fluid or uraemia plasma (glucose, urea) 
contribute significantly to the osmolality of the solution but because of their low 
reflection coefficient result in comparatively little water flux across the membrane.
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Since blood is pumped through a dialyser fibres under pressure, it is important to 
make sure that the hydraulic pressure of the dialysis fluid balances the blood pressure 
in the dialyser fibre. If a pressure balance is not achieved fluid will be transferred 
either from the blood to the dialysate or vice versa. The difference in the pressure 
between  the  blood  and  dialysate  compartments  is  called  the  transmembrane 
pressure (TMP) and is defined as the venous pressure - the dialysate pressure (Pv - 
Pd). It is not possible to measure the pressure in the dialyser directly, so the venous 
pressure is used instead for the purposes of calculating the TMP.
It is usually necessary to remove fluid from a patient by ultrafiltration. To provide 
ultrafiltration a pump removes a precise volume of fluid from the dialysate. This has 
the  effect  of reducing  the  dialysate  pressure  so  that  Pd  is  less  than  Pv.  Hence 
ultrafiltration generates a positive TMP. Since the TMP is positive, there is a transfer 
of fluid from the blood to the dialysate thus reducing the patient’s blood volume. The 
ease  with  which  fluid  can  be  pulled  across  the  membrane  by  ultrafiltration  is 
specified by the ultrafiltration coefficient Kuf of the dialyser. (Fig 4) It is simply the 
amount of TMP that needs to be applied across the membrane to provide a given
Tl^fP
flow rate through the membrane (UFR):  KU F  =
UFR
Modem  dialysis  machines  that  use  a  volume-sensitive  ultrafiltration  device 
(volumetric UF) have been useful in providing an even and highly regulated decline 
in plasma volume during dialysis. [Ill]
Early machines employed a single effluent pump drawing dialysis fluid through the 
dialyser via an upstream throttle valve, which produce a degree of negative pressure 
in the fluid compartments of the dialyser. The flat plate configuration prevented any 
backfiltration. Ultrafiltration, the removal of water from the plasma by hydrostatic 
force  was  self regulatory,  the  negative  pressure  being  resisted  by  rising  oncotic 
pressure as the blood volume was reduced. Volumetric control of ultrafiltration was 
introduced in the early 1980s. [Ill] The amount of dialysis fluid entering or leaving 
the dialyser is rigidly controlled by the diaphragm/fixed displacement sensor systems
83that  monitor  flow  rates  in  the  afferent  and  efferent  fluid  streams  using  an 
electromagnetic technique. The amount of UF required is preset by the operator. The 
direct control of fluid flux removes the potential for physiologic self-regulation. The 
volumetric machines have now become standard.
During pilot studies preliminary checks were undertaken to ensure accuracy of the 
calibrated volumetric device by an hourly collection from the ultrafiltrate port in a 
measuring cylinder.  There was an  approximate  error of 18  ± 4  mis  of collected 
ultrafiltrate for each litre recorded on the calibration pump.
iii)  Ultraflltration  Profiling
Principle of  Pertubation analysis
In  order  to  characterise  patient  responses  to  fluid  removal,  an  intermittent 
ultrafiltration  profile  provided  a  suitable  perturbation.  This  method  elicits  rapid 
changes  in  blood  volume  causing  various  compensatory  mechanisms  for  blood 
volume  and  pressure  to  be  invoked.  Intermittent  profiles  have  been  applied 
previously in patients. In complicated systems an appropriate method by which the 
dynamics  of the  system  may be  characterised  involves periodic  application  of a 
perturbation.  A  technique  called  "system  identification"  has  been  applied  in  the 
industrial setting for some years in situations where it is particularly difficult to model a 
very complicated system. This method involves the application of a suitable test signal 
from which the output may be monitored from suitable sensors (Fig 5)
A smooth exponential rise could be approximated with a single or set of 1st order 
differential equations. By the same token, an oscillatory response could be modeled by 
an under damped second order system.  Beyond this, higher order systems become 
considerably more difficult to characterise and the process of system  identification 
rapidly becomes an area of specialized analysis. The advantage of system identification 
is that it allows the dynamics of the system to be investigated at periodic intervals, 
which caters for changing parameters. The test input allows certain parameters to be 
obtained which may then be considered constant over a limited range of time. When 
ultrafiltration is initiated a number of physiological compensatory mechanisms are
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characterisation of an individual patient response can be difficult since the patient 
may be regarded as a complex arrangement of dynamic elements linked by a highly 
integrated array of regulatory mechanisms.
Intermittent Ultrafiltration Profile
In  order  to  characterise  patient  responses  to  fluid  removal;  a  high  fixed  rate 
intermittent ultrafiltration profile 2-31/hr following an isovolemic period of 30 mins 
with intervening rest periods provided a suitable perturbation. This method generally 
elicits rapid changes in blood volume causing various compensatory mechanisms for 
blood volume and pressure to be evoked. Intermittent profiles have been previously 
applied in patients on haemodialysis. The principle of intermittent ultrafilitration to 
extract information about refilling has been demonstrated by Stiller and Mann [120] 
from which some empirical relationships could be derived.
Two types of  ultrafiltration profile used in the following experiments are described 
below
PROTOCOL  A  (Fig 6a)  Variable volume Ultrafiltration
The volume of fluid removed was graded during dialysis. Using a fixed ultrafiltration 
rate 31/hr the volume removed in the initial bolus was 40% of the desired total UF 
volume. This was preceded by an isovolemic period of 20 -30 mins. The volume of 
fluid removed in the subsequent pulses was linearly reduced using 30%, 20% and 
10% of UF for rest of the pulses. The ultrafiltration bolus and the rest time was fixed. 
By this method the  ultrafiltration  stress  applied  to  the patient by the  end  of the 
treatment was reduced in a gradual manner as dry weight was approached.
PROTOCOL  B  (Fig 6bi
Using a fixed ultrafiltration rate, following an initial isovolemic period, an initial 
bolus of 40 % of the total prescribed ultrafiltrate volume was removed. Subsequently 
20% of the UF volume was removed in equal steps each followed by an intervening 
UF free period for blood volume recovery.
853  Measurement of relative blood volume
i)  Biosensors
In terms of instrumentation, a sensor is defined as a measuring device that exhibits 
characteristic of an electrical nature when it is subjected to a phenomenon that is not 
electric. Under this definition a sensor could be regarded as a transducer since it is a 
system that transforms one physical quantity into another, which is a function of the 
first.
In  a  biosensor,  a  phenomenon  is  recognised  by  a  biological  system  called  a 
bioreceptor, which is in contact with the sample and forms a sensitive component of 
the biosensor. In order to measure a physical quantity, a sensor must fulfil a number 
of  criteria.  The  measurements  itself  must  have  repeatability,  reproducibility, 
selectivity, sensitivity, a linear region of response and a good response time (time 
taken to reach a steady state). [121]
A biosensor can be considered as a combination of a bioreceptor and a transducer. 
Commonly used biosensors today are enzymes, microbiological, piezoelectric crystal 
etc.
Ultrasonic Flowmeters
Small magnitude pressure disturbances are propagated through a fluid at a definite 
velocity (speed of sound) relative to the fluid. The term ultrasonic refer to the fact 
that in the practice the pressure disturbances are short bursts of sine waves whose 
frequency is above the range audible to human hearing about 20000 Hz. A typical 
frequency  is  10  Mz.  A  common  approach  is  to  utilise  a  piezoelectric  crystal 
transducer as transmitter and receivers of acoustic energy. In a transmitter electrical 
energy in the form of a short burst of high frequency voltage is applied to a crystal, 
causing it to vibrate. If the crystal is in contact with fluid, the vibration sense will be 
communicated to the fluid and propagated through it. The receiver crystal is exposed 
to this pressure and responds by vibrating. (Fig 7) The vibratory motion produces a 
signal  in proportion,  according  to  the  usual  action  of piezoelectric  displacement 
transducers.  These  can  be  used  as  ultrasonic  density  measuring  technique.  The
86crystal  transducer serves  as  an acoustic  impedance  detector.  Acoustic  impedance 
depends upon density of speed and sound. Since a signal proportional to the speed of 
sound is available division of this signal into the acoustic impedance signal gives a 
density signal. The attenuation depends on the density of the material through which 
the signal passes. [121]
ii)  Relative blood volume monitoring by ultrasonic method
During the last decade there has been considerable interest in the development of 
non-invasive extracorporeal methods for the determination of relative blood volume. 
This has been made possible by advances in the development of biosensors.  The 
RBV is the ratio of the current blood volume to the initial blood volume at the start 
of treatment.  RBVt =  C(0)/C(t) and can be expressed in percentages where C is the 
time  dependent  concentration  of  the  blood  components  e.g.  cells,  protein, 
haemoglobin. All techniques rely on the fact that the solid blood components remain 
confined to the vascular space. As plasma water is removed the concentration of 
these  components  increase.  Preliminary  algorithms  for  controlling  blood  volume 
depending on patient specific criteria have been applied demonstrating a reduction in 
morbid events such as dizziness, nausea or symptomatic hypotension.
A number of methods have been developed for blood volume monitoring including 
optical,  ultrasonic,  electrical  and  mechanical  methods.  The  ultrasonic  technique 
initially devised by Schneditz [122,123] has been adopted for several reasons, among 
these is the availability of high precision transient time measurement technology and 
the  low  costs  of  disposable  materials  and  high  achievable  precision  of  RBV 
measurements. [124]
Selection of a blood volume monitor (BVM)
Since  the blood volume  monitor was  the  primary  focus  of the  current research, 
accurate  determination  of relative blood volume  was  a prerequisite  to  the  entire 
programme of research involving patient studies. It was likely that a range of blood 
chemistries  would  be  encountered  across  the  patient  study  group.  Therefore, 
preliminary  research  was  undertaken  in  this  unit  in  a  number  of blood  volume
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artefacts  influencing  the  measurement  of blood  volume.  The  BVMs  evaluated 
involved  a  Critline  (optical),  [125,126]  Fresenius  (Ultrasonic)  and  an  in-house 
(optical) BVMs. A set of in-vivo and in-vitro experiments was performed in which 
the  effects  of  changing  haematocrit,  protein  and  sodium  concentration  were 
quantified. The main findings of these studies were as follows:
•  Both plasma protein and sodium changes have a major influence in the 
precision  of relative  blood  volume  measurements  in  BVMs  employing 
optical methods.
•  Appropriate correction algorithms are necessary in optical BVMs in order 
to compensate for light scattering effects.
•  Blood flow rate is a major source of disturbance in the in-house BVM.
The  Fresenius  ultrasonic  BVM  [127]  consistently  demonstrated  superior 
performance  when  compared  with  the  other BVMs  evaluated.  Consequently,  the 
ultrasonic Fresenius BVM was the device of choice for the current research reported 
in this thesis.
Ultrasonic measurement of blood volume
Measurement  of blood  density  during  haemodialysis  in  order  to  calculate  blood 
volume changes was undertaken nearly 25 years ago by Holzer et A1 [128] During 
the late 1980's Schneditz [123] developed a new method for measurement of blood 
volume  using  a disposable  polymer tube  which could be  inserted  in  series  with 
arterial blood tubing.
Principle of operation
The ultrasonic or speed of sound technology measures the total protein concentration 
which is the sum of the plasma protein and the haemoglobin in red cells.  Since these 
two components make up the majority of the solid component of blood then the 
velocity of sound in blood is predominantly dependent on total protein concentration.
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is machined accurately to narrow tolerances, in order to ensure a fixed transmission 
distance. The transit times of these pulses are then measured accurately to compute 
the  velocity  of  sound  through  the  medium.  Since  the  velocity  of  sound  in 
temperature dependent, a thermistor continually monitors the blood temperature.  In 
addition a Peltier element is integrated into the sensor assembly in order to minimise 
the interference from environmental temperature fluctuations.
During normal operation the system is calibrated with isotonic saline.  The ratio of 
the velocity sound in water (saline) to the velocity of sound in blood is then related to 
the blood water concentration and the relative blood volume may be calculated.
The ultrasonic technique exploits the principle that sound speed in blood depends on 
the  total  protein  concentration,  the  sum  of plasma  proteins  and  haemoglobin. 
Changes in sound speed can be related to changes in total protein concentration. The 
relative blood volume may be determined from the protein concentration.
A  polycarbonate  measuring  cuvette  is  located  in  the  arterial  line  of the  blood 
extracorporeal circuit before the pump as shown in the figure. Blood passes through 
the  cuvette  from  the  bottom  to  the  top,  which  is  slightly  inclined  rather  than 
vertically placed thereby avoiding accumulation of air bubbles. (Fig 8) An ultrasonic 
pulse is transmitted through the cuvette containing the blood.  A silicon rubber insert 
ensures sound coupling to the measuring cuvette.  (Fig 9)  The transit time of the 
pulse, which is dependent on the speed of sound, through the blood is measured by 
the  BVM.  A  high  precision  temperature  measurement  (<0.1C)  is  required  to 
compensate  for  the  dependence  of  sound  velocity  on  blood  temperature.  An 
empirical function found by Schneditz is used to derive total protein concentration 
(TPC)  from  sound  velocity  and  temperature.  [124]  Using  the  principle  of mass 
conservation, the RBV can be determined from TPC as function of time. Haematocrit 
and haemoglobin can be calculated from TPC by simple linear equations assuming a 
mean plasma protein concentration of 72.5 g/1 at the start of treatment. During the 
priming procedure when the circulating saline is in the extracorporeal circuit has 
reached  a  stable  temperature,  the  BVM  performs  an  automatic  calibration.  On 
detecting  the  presence  of  blood,  the  measurement  of  relative  blood  volume 
commences as soon as a sufficient stable temperature and sound velocity is reached,
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haematocrit and haemoglobin.
Validation of method
In validating the device, the measurement of RBV, reference photometer method 
provided  the  haemoglobin  measurements  for  comparison  with  the  BVM.  [127] 
Haematocrit  was  determined  by  the  microcentrifuge.  The  photometric 
cyanmethaemoglobin method is regarded as the most accurate  standard by which 
haemoglobin standard may be determined. IOuL of whole blood was withdrawn to a 
minicuvette  manually  with  a  pipette  and  then  mixed  with  a  reagent  of 
hexacyanoferrate and potassium cyanide. This procedure lyses red cells, eliminating 
light scattering effects. Haemoglobin was determined by Dr Lange Miniphotometer 
LP2, which has a numerical resolution of 0.1 g/dl. Haematocrit was measured from 
whole  blood  taken  from  arterial  lines  and  measured  using  heparin  coated 
microcentrifuge capillaries.
The  RBV  measured  by  BVM  and  that  determined  by  the  photometer  showed 
excellent correlation r=0.96 n = 882. The mean error between the two methods was 
0.07%, SD1.7% demonstrating high accuracy and reproducibility of the BVM. No 
dependencies were observed for on varying ultrfiltration rates. The noise on the RBV 
signal is very low (<0.2%, sampling rate 10s). [125]
The correlation between the Hct by microcentrifuge and BVM showed a significant 
correlation of r = 0.88. The mean deviation was -0.55 Hct and SD 2.9%. The data 
from BVM was analysed for sensitivity to different blood compositions.
Infusion of 200ml saline into a patient with a blood volume of 5000mls represents a 
4% change  in blood volume.  In order to resolve,  a blood volume  sensor should 
provide an accuracy of 2%. The results of the evaluation suggest that the BVM has a 
SD  of  1.7%,  which  satisfies  the  measurement  criteria  for routine  blood  volume 
monitoring. A clear RBV signal with minimal noise is necessary in order to assure a 
rapid  detection  of sudden blood  volume  changes.  The  quality  of the  signal  is  a 
precondition for using the BVM for automatic blood volume control. A decrease in 
the plasma osmolality can lead to a swelling of erythrocytes, which would not be 
detected by BVM. Hence BVM measures an osmolarity corrected haematocrit.
90iii)  Other techniques for non-invasive extracorporeal blood volume 
easurement
OPTICAL  BVMs -  PRINCIPLES
Considerable research effort has been directed towards the use of optics to measure 
haemoglobin and oxygen saturation in whole blood.  In a homogenous medium such 
as haemolysed blood the absorption of light is dependent on the composition of the 
medium, the optical path length and the wavelength of light.  The attenuation may be 
described simply by the Lambert-Beer law.  Light passing through a suspension such 
as  whole  blood,  is  attenuated  as  a  result  of  scattering  and  absorption  effects. 
Scattering is caused by a combination of reflection, diffraction and refraction where 
the  red blood  cell  is  large  by  comparison  with  the  wavelength  of light  used  in 
measurement applications. An electromagnetic wave theory developed by Twersky 
and a photon dilution theory by Zdrojkowski  have been proposed to  explain the 
attenuation  of light  in  whole  blood.  [129]  Later  Anderson  and  Sekelj  used  an 
integrating  sphere  photospectrometer  to  demonstrate  that total  optical  density  of 
blood could be expressed as the sum of absorption and scattering components as 
predicted by Twersky. [129] Most commercial devices based on optical transmission 
of  light  operate  in  the  linear  region,  which  conveniently  covers  the  range  of 
haematocrits likely to be encountered in routine clinical practice.  In this range total 
optical density is proportional to absorbed light only and the Lambert-Beer theory is 
valid.
The absorption characteristics of whole blood depend additionally on the oxygen 
content for a given wavelength.  Mendelson and Cheung showed that the absorption 
spectrum of de-oxyhaemoglobin (Hb) and oxyhaemoglobin (Hb02) were equivalent 
at a wavelength close to 800 nm known as the isobestic point of blood.  In practical 
applications  involving LEDs  as  inexpensive  sources  of relatively monochromatic 
light, wavelengths of 800 nm are not available, so it is usual to use a dual wavelength 
system.  One  LED  is  selected  close  to  the  isobestic  point,  usually  an  infrared 
wavelength at 820 nm.  A second LED in the visible spectrum is used where the 
sensitivity to Hb02 is greatest to correct the infrared measurement for changes in 
blood oxygenation.
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The  first optical BVM was developed by Wilkinson et al.  [130]  The device was 
designed to clip around standard PVC blood tubing, held firmly in place by polished 
glass inserts, to ensure a relatively constant optical path length.  The BVM was later 
modified by Aldridge  [130] to include a second channel to correct for changes in 
oxygen saturation.  A variant of this device was later developed by Mancini the basis 
of a dialysis machine integrated system available commercially, the Hemoscan ™. 
[131] Steuer evaluated the use of a multiple wavelength system (including oxygen 
saturation correction) for determination of haematocrit.  This technology was further 
developed for the production of the Critline™ blood volume monitor. [126, 132]
Optical reflectance BVMs
Some  blood  volume  monitor  implementations  detect  the  light,  which  is  back 
scattered.  Typically  the  LED  emitter  and  photodiode  are  mounted  immediately 
adjacent to each other.  By contrast with the transmission systems, this method has 
the  advantage  that  a  fixed  optical  path  length  does  not have  to  be  established. 
DeVries [133] constructed a device to clip onto standard blood tubing producing a 
reasonably linear relationship between reflected light and haemoglobin concentration 
in response to fluid removal.
More elaborate devices have been developed in which the LED and photodiode have 
been integrated into one hybrid device.  The main motivation behind such efforts has 
been the application for implantable devices used to monitor both haematocrit and 
blood oxygenation.  As a result of this technology there has been the need to consider 
more carefully factors such as the separation between the source and detector and the 
selection of wavelength.
Haemoglobinometry
Schallenberg et al.  [134] describe a system involving a continuous withdrawal of 
blood into a secondary  extracorporeal  circuit.  Dilution with hypotonic ammonia
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haemoglobin  almost  entirely  into  the  oxygenated  form,  which  may  be  measured 
accurately from the optical absorbance through a fixed path length cuvette.
Reasonable accuracy could be assumed with this method since the optical difficulties 
encountered  with  scattering  in  whole blood  are  eliminated,  although  there  is  no 
evidence  in  the  literature  of  validation  studies.  In  practice  this  technique  is 
unsuitable for routine use due to the requirement for considerable extra hardware. 
Since  there  is  an  inherent  transport  delay  involved  in  the  dilution  process,  the 
transient response  is  slow  which may  limit the  usefulness of this method  in the 
detection of rapid changes in blood volume.
Conductivity
The electrical impedance of whole blood is frequency dependent.  At low frequencies 
current flows only through the extracellular spaces (plasma) since the reactance of 
the red cell membrane is high.  The conductivity of the blood is then dependent on 
the  ionic  composition  and temperature  of the plasma  for given  volume  element. 
[135] At high frequencies the reactance of the cell membrane becomes small and 
current passes through both the intracellular and extracellular spaces.  Consequently 
the conductivity of the blood increases.  The resistive components of the blood in the 
intra and extracellular compartments may thus be determined through impedance and 
phase  shift  measurements  at  two  or  more  frequencies.  The  relative  difference 
between the resistances in each compartment provides a measure of the concentration 
of haematocrit per unit volume of blood, hence the relative blood volume.  In theory, 
the  influence  of electrolyte  variations  should  be  minimal  since  cells  generally 
maintain electrical equilibrium across the cell membrane. [135]
Viscometry
Removing water from blood causes the viscosity to increase, as there is a greater 
concentration of solid per unit volume of blood.  Greenwood et al. [136] constructed 
a modified extracorporeal  circuit to divert a continuous  flow of blood through a
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measured with suitable pressure transducers.
The change in pressure drop caused by viscosity increase reflected the change in 
blood volume. This method suffered from the problems incurred due to variable flow 
conditions in the extracorporeal circuit. In addition the relationship between relative 
viscosity  and blood  volume  was  found  to  be patient  specific,  depending  on  the 
haematocrit and plasma protein concentration.
The first continuous blood volume monitor was developed over  15  years ago by 
Stiller and Mann using a single frequency of 400 Hz. [134] Other authors have since 
devised sensor systems for impedance monitoring of whole blood, some including a 
thermistor in order to provide temperature compensation.  [137] A configuration of 
circular electrodes is generally used made either from stainless steel or platinum. 
The De Vries system [135] consisted of two outer electrodes for injection of current 
and an additional pair of inner electrodes for impedance and phase measurement. 
Conductivity based blood volume monitors have yet to be considered for commercial 
development.  A few questions remain concerning the accuracy of the prototypes and 
improved performance over other types of blood volume monitor would need to be 
demonstrated.  In addition a disposable electrode system is unlikely to be particularly 
cost effective.
4  Blood and surface Temperature
The blood temperature module (Fresenius BTM) was used to monitor changes in 
core temperature during dialysis. The device consists of two sensor heads through 
which the arterial and venous blood tubing is inserted. Fig 10 [138, 139] The device 
allows continuous monitoring of the venous blood temperature at the arterial end as it 
leaves the patients’ fistula (core temperature) and the temperature of the blood as it 
re-enters the circulation. The dialyser is a very efficient heat exchanger. Changes in 
the  temperature  of the  incoming  dialysis  fluid  are  rapidly  equilibrated  with  the 
venous blood returning to the patient. Warming of a patient’s blood can occur both 
through  vasoconstriction  and  an  inappropriately  high  dialysate  temperature.  A 
thermal  probe  applied  to  the  skin  surface  over  the  forehead  measured  skin 
temperature.
945  Haematocrit measurement
Volume of Packed Red Cells (Haematocrit)
The volume of packed red cells (VPRC), or haematocrit, is the proportion of the 
volume of a blood sample that is occupied by red blood cells.  The haematocrit may 
be determined manually by centrifugation of blood at a given speed and time in a 
standardized glass tube with a uniform bore, as was originally described by Wintrobe 
[140].  The height of the column of red cells compared with that of the total column 
of blood following centrifugation yields the haematocrit.  Both macro (using 3-nm 
test tubes) methods with low-speed centrifugation or micro methods using capillary 
tubes and high-speed centrifugation may be used.
The manual method of measuring haematocrit has proved to be an accurate method 
of assessing red cell status.  It is easily performed with little specialized equipment, 
allowing it to be adapted for situations where automated cell analysis is not readily 
available, or for office use.  However, several sources of error are inherent in the 
technique.  The spun haematocrit measures the red cell concentration, not red cell 
mass.  Therefore, patients in shock or with volume depletion may have normal or 
high haematocrit measurements due to haemoconcentration, despite a decreased red 
cell  mass.  Technical  sources of error in manual  haematocrit usually  arise  from 
inappropriate  concentrations  of  anticoagulants,  poor  mixing  of  samples,  or 
insufficient  centrifugation.  Another  inherent  error  in  manual  haematocrit 
determinations arises from trapping of plasma in the red cell column.  This may 
account for 1  to 3% of the volume in microcapillary tube methods, with macrotube 
methods trapping more plasma [141].  In addition, it should be noted that abnormal 
red cells (such as sickle cells, microcytic cells, macrocytic cells,  or spherocytes) 
might trap higher levels of plasma because of increased cellular rigidity, possibly 
accounting for up to 6% of the red cell volume [141].  Very high hematocrits, as in 
polycythemia, may also have excess plasma trapping.  Manual haematocrit methods 
typically have a precision of about 2% (CV) [141].
Automated determination of haematocrit usually does not depend on centrifugation 
techniques,  but  instead  measures  or  calculates  haematocrit  dependent  on  direct 
measurements of red cell number and red cell volume (haematocrit = red cell number
95x  red  cell  volume).  The  automated  values  closely  parallel  manually  obtained 
haematocrit values,  and the  manual  haematocrit method  is  used  as  the  reference 
method for automated methods  (with correction  for the  error induced by plasma 
trapping)  [142].  It should be  noted  that errors  of automated  methods  are  more 
common  in  patients  with  polycythemia  or  abnormal  plasma  osmotic  pressures. 
Manual methods of haematocrit determination may be preferable in these cases.  The 
precision of most automated determinations of haematocrit is about 1% (CV) [143].
Red cell indices measurements
Cell counts remain the basis for many of the parameters used in evaluating the blood. 
These can be determined either manually or by automated haematology analysers. 
Whether they are performed by manual means or automated means, accuracy and 
precision  of counts  depends  on  proper  dilution  of samples  and  precise  sample 
measurement. A precise aliquot must be taken and the cells evenly distributed within 
the  sample.  Because  blood  contains  a  large  number  of cells,  sample  dilution  is 
required for accurate analysis. Clearly automated methods provide the best means for 
counting large number of cells and minimising statistical error.
Two major types of automated analysers are available, those that depend on changes 
in  impedance  to  electrical  flow  and  those  that  use  differences  in  light  scatter 
properties. The coefficient of variation for red cell counts for automated analyser is + 
1% (cf manual +11%). Due to inherent imprecision of manual counts and the amount 
of technical time required most cell counting is now performed by automated or 
semiautomated instruments.
Aperture impedance counters
This type of analyser, which includes the Coulter (Hialeah, FL), the Sysmex (Baxter 
Diagnostics, Waukegan, IL), and some Cell-Dyn (Abbott Diagnostics, Santa Clara, 
CA)  instruments,  enumerates  cells  in  a  small  aperture  by  measuring  changes  in 
electrical resistance as the cell passes through the orifice (Fig 11). A constant current 
passes between two platinum electrodes on either side of the orifice.  The diluent that 
suspends the cells is more electrically conductive than are the cells.  Hence, as each
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conductance so that an electrical impulse is generated and recorded electronically. 
The drop in voltage  is proportional to cell  size,  allowing average cell  size to be 
determined simultaneously [144].
Instruments using aperture-impedance technology require even cell suspensions so 
that cells pass individually through the electrical current.  Distortion of the electrical 
pulses may occur when the cells do not pass through the centre of the aperture or 
when more than one cell enters the aperture at a time. The Coulter type counters are 
probably the most widely used example of haematology analysers that use electrical 
impedance methods.
Optical Method Counters
The other method used by some haematology analysers depends on the light scatter 
properties of blood cells. In these systems, diluted blood passes through a flow cell 
detector placed in the path of a narrowly focused beam of light (usually a laser). 
When the blood cells pass through the counting chamber, they interrupt or alter the 
beam of light, thereby generating an electrical impulse that may be recorded.
976  Measurement of plasma and blood volume
i)  Indicator dilution method
The plasma volume is commonly measured by dilution methods. A substance that is 
confined to the to the intravascular compartment such as I1 3 1   labelled albumin or 
radioactive  indium  labelled  transferrin,  [145,146],  or  Evan’s  Blue  dye  [147]  is 
injected and the volume of distribution calculated from the degree of dilution of the 
injected  substance  over  15-30  minutes.  Radiolabelled  albumin  is  the  most 
commonly used plasma label, but correction has to be made because the label is 
gradually  removed  from  the  circulation  into  the  extravascular  space  [145,147] 
leading to errors of 10% or more in the plasma volume determinations. [145]
Total plasma volume may be useful in monitoring fluid and blood replacement. Total 
blood volume may be  calculated  from the  sum of the total red cell  volume and 
plasma volume measurements. The total blood volume comprises of red cell mass 
and plasma volume with an almost negligible contribution as a rule from the platelets 
and leucocytes. The ratio of the red cell mass to plasma volume differs in the venous 
system, the capillaries and the splenic blood pool.
In most cases the  total  number of erythrocytes  is  closely related  to  the  red  cell 
concentration of blood or the haematocrit. However in some cases the blood volume 
may  not reflect the  total  red  cell  concentration  including  immediately  following 
severe haemorrhage, severe dehydration and or overhydration. To accurately assess 
blood  volume  in  these  patients,  plasma  volume  or  red  cell  volume  must  be 
determined.  The principle measurement of blood volume  is dilution analysis.  A 
small amount is readily identifiable radionuclide is injected IV either bound to cells 
or to a plasma proteinand its dilution measured after complete mixing.  Previously 
circulating Cr5 1  was used as a red cell label for measuring red cell volume. It is not 
ideal but is  still  used.  Changes  in plasma volume  are achieved by  alterations  in 
distribution of water between intracellular and extracellular compartments across the 
capillary wall.
The venous haematocrit (PCV) is higher than the whole body haematocrit. The red 
cell mass  does not fluctuate  provided the circulation and erythropoiesis are  in  a
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needs  and  by  other  factors,  which  affect  erythropoietin  production.  The  plasma 
volume is more labile and affected by bed rest, exercise, food, posture, and ambient 
temperature. The total RBC count and PV do not necessarily reflect the total red cell 
volume. There is an exponential relationship between PCV and red cell volume but 
with wide dispersion.
ii)  Indicator dilution methods -  historical aspects
An indicator is a substance that can be easily identified when introduced into the 
circulation  either  instantaneously  or  by  continuous  infusion.  Indicator  dilution 
methods have been in use for many decades and have been useful in metabolic and 
circulatory  studies.  In  1824  Hering, professor of the Royal  Veterinary  School  in 
Stuttgart first introduced an indicator dilution method for measuring blood velocity. 
[148]  He  injected potassium ferrocyanide  into the jugular vein of 14 horses  and 
sampled from other parts of the vascular system. Although the paper was titled “ 
Experiments to measure velocity of blood circulation” he did not measure velocity 
but rather the time required for the indicator, injected instantaneously into one vein 
to be first detected in another vein by addition of ferric chloride to the blood sample 
to  form  Prussian  Blue.  70  years  after  Hering,  in  1897,  Stewart  from  Cleveland 
suggested that the method could be used to measure blood flow and blood volume. 
He argued that the volume of solution necessary to dilute the indicator injected to the 
observed mean concentration of indicator output was exactly the volume of blood 
that had that had diluted the injectate over the time interval in which the indicator 
was  recovered.  [148]  This  formula  was  an  important  evolutionary  step  because 
eventually (30 yrs after the idea was first conceived) it paved the way for the use of 
indicator dilution curves to calculate blood flow and because it also suggested that 
the area under the indicator output concentration curve might have something to do 
with it.
The  dominant  figure  in this  field has  been  William  F  Hamilton  with  his  many 
colleagues who used the technique with dye as the indicator. At first he measured 
appearance  time.  Then  in  1928,  100  years  after  Hering  he  published  a  paper 
resurrecting Stewart’s formula. [148] He recognised that the calculation worked only
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Hamilton  and  his  colleagues  measured  blood  flow  using  cardiac  output.  They 
proposed that the first passage indicator concentration time curve could be recovered 
from observed curves that included recirculation by semi logarithmic extrapolation 
of the  early  downslope.  Others  followed  with  attempts  to  fit  the  complete  first 
passage curve by various waveforms, such as by the sum of three exponential terms. 
Stephenson in 1948 thought of looking at indicator dilution curves as convolutions of 
the indicator input with a probability density function of traversal times through the 
system.  [148]  The  fundamental  notion  is  that  there  exists  a  probability  density 
function  of transit  times  (t)  through  the  system.  It  has  been  proposed  that  the 
distribution of capillary critical opening pressures, which describes the recruitment of 
vascular pathways, may be important in shaping indicator dilution curve.
Hamilton was inspired to plot the indicator dilution curves semi logarithmically. He 
claimed that after an initial variation following the peak, the curve of first circulation 
fell as a single exponential line on the semilog plot. [149] Backextrapolation is an 
empirical method used to calculate central volume of distribution e.g. blood volume. 
It  is  based  on  the  compartment  model,  which  says  that  after  an  injection  of a 
substance it is distributed instantaneously in the central volume with no time delay. 
The occurrence of recirculation is not taken into account. It was also found that the 
higher the rate of elimination of ICG, the higher the error of the backextrapolation 
method. [150,151]
Zierler  first  introduced  the  concept  of  dynamic  volume.  When  sucrose,  an 
extracellular tracer is  injected  along  with  a nondiffusible  tracer (confined  to  the 
bloodstream),  the  difference between the  extracellular and plasma  volume  is  the 
interstitial fluid volume. [148]
iii)  Measurement of plasma volume using indocyanine green
The  measurements  made  of plasma  and  blood  volume  using  indicator  dilution 
technique on each subject are extensively discussed in the chapters on blood volume 
in the Results section. The tracer used for all experiments was Cardiogreen (ICG 
Green ™Sterile indocyanine green USP Fluka), a tricarbocyanine dye, mol wt 775,
100with an absorption peak at 805nm.  The dye is nontoxic, confined to plasma, not 
subject to extravascular distribution, and not metabolised or degraded.  Following 
injection, the dye is rapidly bound to plasma proteins. After equilibration, the dye 
decays fast in an exponential manner. It is exclusively taken up by the liver and has a 
plasma half-life 2-3 min (the time required for the initial concentration of the dye to 
be  halved).  [152]  The  elimination characteristics  resemble  the  Michaelis-Menten 
kinetics [153].
7  Blood  pressure measurements
i)  Sphygmomanometry
Mercury  column  sphygmomanometry  was  used  for manual  reading by  a  trained 
clinician, taken in a seated position using the Phase 5 diastolic and a mean of two 
repeated measurements. The patient also recorded his/her own BP in the unit using 
an automated self-measurement Dinamap (Critikon)[9], [154] which downloaded the 
results directly into a software programme, blinded to the observer.  Patients were 
well acquainted with the recording procedure, as it is a routine protocol in the unit 
prior to each dialysis. All casual measurements were taken in seated position with the 
arm  resting  and  a  cuff size  suitable  for  the  arm  circumference  attached  to  the 
nonfistula bearing upper arm.
ii)  Ambulatory monitoring
For the purposes of this research, all patients studied were fitted with a TM-242  1, 
A&D Instruments Ltd. 48 hour ambulatory blood pressure monitor (ABPM). [155] 
This device measures BP by both the oscillometric and Korotkoff (via microphone) 
methods  at pre-determined times  which are  fully programmable.  The  BP  data  is 
stored in memory and may be uploaded to a computer for analysis. In view of the 
fact that BP was also required during dialysis treatments, it was convenient to fit the 
monitor to the patient prior to the start of dialysis.
Tm2421 A&D Engineering, Milpitas, CA blood pressure monitor has been validated
101and used for clinical and research purposes [10]. BP was measured using cuff size 
comparable to the seated BP measurements on the nonfistula bearing arm by a dual 
microphone system using Oscillometric (O) and Korotkoff (K) method programmed 
to record BP every 30 mins daytime and hourly at nighttime (2200-0700). Recorded 
data  was  retrieved,  processed  and  reported  using  a  computer  software 
programme.74.6% K readings and 95% O readings were successful. Accordingly the 
O method readings were used for the main analysis.
iii)  Oscillometric BP
Patients were monitored frequently for blood pressure (Oscillometric) using the 
BPS08, (Fresenius Medical Care) during blood volume studies.
8  Bioimpedance Spectroscopy (BIS)
The hydration state of an organism can be defined by measuring the total body water 
relative to the lean body mass, defined as all nonlipid mass [156]. Traditionally this 
type of measurement required the use of research tools such as stable isotopes or 
underwater weights. Bioimpedance spectroscopy BIS emerged as a tool capable of 
accurate measurement of total body water. Fig 12 demonstrates possible disparities 
in fluid distribution between euvolemic normal subjects and in dialysis subjects in a 
clinical  setting.  More  recently  BIS  has been  shown  to  be  capable  of accurately 
measuring body water compartments.
i)  Whole Body Multifrequency Bioimpedance
Bioimpedance is a noninvasive technique first applied by Thomasset in 1963. [157] 
In a typical application current is injected into the subject via a pair of electrodes 
placed on the ankle and wrist. An additional pair of electrodes monitors the resulting 
potential difference. The degree of conduction of current through the intracellular 
compartment  is  frequency  dependent due  to  the  presence  of cell  membrane  that 
exhibits  similar properties  to  those  of an electrical  capacitor.  Since  the potential
102difference developed across the tissue also undergoes a phase shift with respect to 
those of the applied current due to the cell membrane, the overall measurement is 
also known as impedance signifying dependence on frequency. Application of a low 
frequency  alternating  current  causes  conduction  almost  exclusively  through  the 
extracellular tissues. At low frequency the cell membrane behaves as an insulator 
inhibiting the passage of current. In the high frequency range the cell membranes 
conduct and the current passes through the intra and extracellular spaces. (Fig 13)
HYDRA ECF-ICF (model 4200)
The  instrument  uses  the  latest  in  microprocessor,  signal  conversion,  and  digital 
processing technologies to produce a flexible, accurate and reliable instrument. The 
scope of measurement options enables the device to be used routinely for research. 
Xitron’s Bioimpedance spectroscopy (BIS) technology [158,159] has been validated 
on  a  number  of populations  by  a  variety  of leading body  composition  research 
institutions dating back to 1992. [159,160] The studies have focussed on comparing 
predicted  ECF-ICF  volumes  measured  by  wrist  ankle  to  dilution  and  reference 
methods.
The  current  device  has  improved  high  frequency  performance,  thus  providing 
improved prediction and accuracy and predictability.  When quality data has been 
retrieved, a calculation of the ECF - ICF will take approximately 45 second. The 
ECF measurement itself takes 45 seconds.
Impedance measurement
The  device  measures  the  resistance  (R)  and  reactance  (X)  and  calculates  the 
reciprocal  impedance  (Z)  and phase  angle  (0)  at  each  measured  frequency.  The 
device provides a measure of complex impedance at different frequencies in a range 
according to a predefined mode.  For ECF and ICF a spectrum of 50  frequencies 
spaced throughout a 5KHz to 1MHz. All frequencies are accurate to within a 0.05%. 
of  the  selected  frequency.  A  spectrum  of  20  programmed  frequencies  spaced 
throughout a 5KHz to 200 KHz ranges. All measurements are performed using a
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load. The device has been classified as a Class I device. The resolution is  10 mis. 
[161]
Volume prediction accuracy
Validation research has shown has shown that the correlation between predicted and 
dilution determined ECF range between 0.96 - 0.89. On HD pre and post dialysis 
correlation between the predicted and deuterium determined TBW was i= 0.95 and 
0.92 respectively respectively [161].
The  change  in  ECF  compared  to  bromide  dilution  on  critically  ill  patients  was 
R=0.89. On HD the predicted loss in TBW was reported to be within 0.8 kg of body 
weight loss. (161).
For continuous measurements, the relationship between ECF and body weight during 
dialysis was found to be r = 0.83 -0.99, 0.76 - 0.99 for ECF and ICF respectively. 
[162]
Volume prediction repeatability
The repeatability of the volume prediction is dependent on the  resolution of the 
measurement  modelling  accuracy  and  the  susceptibility  of  the  electronic 
measurements to interference. It is influenced by electrode placement and biological 
variations such as volume of distribution, temperature and ion concentration change. 
Under ideal test conditions the repeatability is 50 mis when the measurements are 
performed repetitively.
Measurements during studies were made using standard tetrpolar lead arrangement 
with patients lying quietly for 5 mins. Impedance measurements were made using 50 
logarithmic  frequencies  from  5  to  500  kHz.  The  software  performs  an  iterative 
nonlinear curve fitting protocol for all spectra that conform to the Cole-Cole model 
of impedance spectra in living tissue. [161] Curve fitting yields electrical resistances 
(R) that correspond to extracellular water (ECF) Re and total body water (TBW) 
Rtbw. The resistance of ICW Ri can be determined from Re and Rtbw. By analysis 
of the impedance and phase shift at different frequencies, the resistance Re (ECF)
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respective  tissue  compartments.  By  combining  anthropometric  measurements  of 
body segments and tissue resistivity constants  determined  from dilution  studies  , 
ECF and ICF can be studied. The availability of bioimpedance measurements have 
found widespread application in both dialysis and nutritional assessments. Although 
resistance can be converted to absolute volumes , this relies on derived equations in 
specific populations [161] or the application of complex physiologic principles of 
emulsion theory that may introduce unknown errors. Measurements were made on 
the dominant, nonflstula arm in case of dialysis patients. Patients on CAPD were 
evaluated post drainage of CAPD fluid. Each measurement was repeated in triplicate.
ii)  THORACIC  ELECTRICAL BIOIMPEDANCE
Over the past decade, electrical impedance cardiography has been developed as a 
noninvasive  method  to  assess  stroke  volume  and  cardiac  output.  The  technique 
determines the thoracic impedance changes resulting from pulsatory cardiac pump 
function.  Because  of the  possibility  of bedside  measurement,  it  is  suitable  for 
monitoring during HD.
Impedance  (inverse  of conductivity)  is  a  resistance  to  alternating  current  (AC). 
Bioimpedance  is  the  impedance  of  body  tissues.  There  is  a  direct  relationship 
between bioimpedance of the  segment and its pulsatile changes and the pulsatile 
blood  flow  through  the  segment.  The  total  bioimpedance  of  the  thorax  (TFI 
=Thoracic fluid index) changes with the thoracic cross section and the thoracic fluid 
content. The majority of pulsatile impedance changes originate in the descending 
thoracic aorta. There are two sources for pulsatile impedance changes, volumetric 
caused by variation in blood volume in compliant arteries as a result of variation of 
arterial pressure and velocity caused by alignment of RBC from random (static blood 
at end of diastole) to preferentially aligned (with increasing velocity). Taken together 
the increase in blood volume and blood velocity during systolic upstroke contributes 
to changes in bioimpedance.
105BOMED NCCOM3 - R7 Cardiodvnamic monitor
(determination of haemodynamic variables)
The  equipment  is  designed,  configured  according  to  BS  5274  standards,  and  is 
classified as Class II device and FDA registered. This is validated with the Biosym 
(microprocessor  based,  electrical  bioimpedance  device  used  to  simulate 
cardiovascular parameters). Ejection fraction (EF) has been validated against MUGA 
scans.  The accuracy of the haemodynamic measurement of cardiac  index by any 
method including BoMed has an accuracy + 10%. [163]
It measures impedance (resistance) to the high frequency measurement of AC current 
of the  thorax.  As  more  fluids  are  present  within  the  thorax,  it  becomes  more 
conductive. The device computes the blood flow and the thoracic fluid index data 
from the measurement of the thoracic bioelectrical bioimpedance and the ejection 
fraction (EF). The changes in the electrical conductivity of the thorax due to pulsatile 
flow of blood through the segment provide basis for TEB technology.
A variation in preload will result in a variation of stroke volume (SV). Increase in 
preload  while  the  contractility,  afrerload  and  heart  rate  remain  the  same  (in  a 
hypothetical pump) will result in increase of stroke volume and hence an increase in 
pumping time.
Brief  system description
The microcomputer board with its associated interface is the heart of the system. 
Two microprocessors operate at 5 and 10 MHz from the onboard oscillator. First TFI 
(base impedance value) is measured and stored by reading the A/D converter. The 
preejection period and ventricular ejection time (VET) and heart rate are measured 
by timing the pulses and the impedance measurement (dZ/dt) is taken and stored. 
The four measured parameters are then manipulated into formulae and the processor 
calculates the parameter for SV (stroke volume) as a function of height, weight, fluid 
index, ventricular ejection time and impedance changes. Cardiac output (CO) is a 
product of stroke volume and heart rate. Finally the other derivatives are calculated 
and stored in memory. Timing for the measurement of all the parameters begins with 
the incoming ECG impulses. Ecg QRS complexes trigger the processor into taking
106the measurements and displaying them simultaneously. Good QRS complexes are 
very important in obtaining good measurement.
The resistance Rs is the equivalent resistance of the thorax and is actually varying in 
value as a function of blood flow. The constant current flow is 2.5 mA and causes a 
voltage drop across the resistance. As the value of Rs changes the respective voltage 
drop across the Rs varies and is detected by the Z amplifier.  The ECG changes 
detected by the  amplifier are  used  for internal  timing of the measurements.  The 
output of the Z amplifier is differentiated and along with the ECG signal is processed 
by the computer to derive the parameters. The total thoracic impedance is usually in 
the  range  of 10-48  Ohms;  the  small  pulsatile  changes,  which  are  amplified  and 
quantified, are the changes in the thoracic impedance due to blood flow. To assess 
reproducibility, Mehlsen et al tested 62 measurements of CO in a range 2.95 - 10.16 
1/min with an SD 0.33 1/min (interobserver variation) and 0.12 1/min (intraobserver 
variation).  [164,  165] It was concluded that impedance cardiography is reliable in 
measuring changes in CO and therefore suitable for repeated measurements in this 
study. Because aortic valvular pathology appeared to produce less reliable results, 
these patients with known aortic pathology or overt heart failure were excluded from 
the study while using this device. [166]
9  Data Acquisition and Processing
It was clear at the inception of the current research that a data set would need to be 
obtained measuring key haemodynamic parameters during fluid removal. In order to 
provide  the  most appropriate  clinical  interpretation  of blood  volume  data  it was 
essential  that  these  variables  could  be  acquired  simultaneously.  Consequently 
analytical methods developed to investigate the relationship between blood volume 
and fluid removal would then have a tenable link to known clinical indicators of fluid 
status.
A  data  acquisition  system  involving  synchronised  computers  was  constructed  in 
order to allow simultaneous acquisition of these variables.  Discrete asynchronous 
data were obtained at specific times during the treatment of interest, such as initiation 
and termination of an ultrafiltration pulse.
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same time integrated into a programme that was stored in a laptop computer. All 
these gadgets had to be in close proximity to the patient and the dialysis machine. 
Therefore  a  purpose  built  trolley  was  assembled  containing  the  data  acquisition 
systems, data concentrator, bioimpedance analyser and the cardiodynamic monitor. 
Location  of the  trolley  at  one  side  of the  patient  facilitated  connection  of the 
electrode leads to the patient, which are approximately 2 m in length in order to 
minimise the effects of stray capacitance. A purpose made umbilical cable was used 
to connect all of the data communication channels from the dialysis machine and 
associated sensors to the data concentrator. BP measurements were obtained from the 
nonfistula arm.
During each haemodialysis session, machine data was acquired and automatically 
downloaded to a specific program (Acqui, Fresenius) and stored in .dat files with real 
time  data.  The  data  was  retrieved  every  3  secs  in  a  dat  file  format.  This  was 
subsequently converted to an Excel file for ease of analysis. An average file size for 
an individual study was 240 kb.  The data downloaded included real time, count, 
haematocrit  (%),  Relative  blood  volume  (%)  blood  flow  rate  (ml/min)  Venous 
pressure  and  conductivity,  Ultrafiltration  rate  and  volume,  blood  pressure  and 
temperature data. Appendix 1.  Other physiological data including patient parameters 
were recorded in pre-printed sheets for each experiment.
Data processing and computational analysis
A large quantity of software was written in order to organise the data collected at 
sampling  points,  interpolate  and  filter  data  fields  and  implement  a  number  of 
algorithms and produce file formats suitable for extracting specific information and 
further analysis.
Each patient study typically involved acquisition of a large quantity of data during a 
single treatment.  Adequate methods by which data could be manipulated were a 
prerequisite  for data  analysis.  This required a considerable  quantity  of dedicated 
software. The important functions performed by the dedicated software include
•  Concentration and time synchronisation of data from different sources
•  Filtering  of data  and  generation  of output  files  for  graphical  analysis  and 
providing different cuts of the data for import into statistical packages.
108•  Implementation  of special  purpose  algorithms  for  analysis  of absolute  blood 
volume data.
•  Using  specific  data  segments,  automated  curve  fitting  and  derivation  of fit 
constants using Table Curve 2D™ Software [167]
During analysis each .dat file was converted into an Excel format. Useful sections of 
the data could be selected out for specific analysis and transformed into .cut files for 
analysis. Specific analysis was performed using relevant portions of the data. Typical 
study  setups  involving multiple monitoring  tools  connected to  a  data acquisition 
system are depicted in the slides on Fig 14.
All Calculations and  formulae and the mathematical  software used for individual 
experiments  have  been  referred  to  in  the  corresponding  chapters.  During  blood 
volume studies, a specific algorithm was written to custom design an excel data sheet 
pre-programmed  with  blood  volume  equations  to  allow  automatic  derivation  of 
volume measurements when the raw data was entered on the sheet for each patient. 
Such datasheets, which performed automatic calculations, were essential in saving 
time and minimising potential human error. Examples of such computer-generated 
sheets are depicted in Appendix 1. Statistical packages used were Sigmaplot, [168] 
SPSS and Systat software. [169,170]
Clinical studies were performed according to specific protocols as outlined in the 
subsequent chapters.  The North  Herts  Regional  Ethics  committee  approved  each 
study. Informed written consent was obtained from all subjects who participated in 
the research in all clinical studies.
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Figure 11  Principle of haematocrit measurement
Impedance type of haematology autoanalyser.
As the cells pass through the aperture,they alter the current flow 
between the electrodes, generating an electronic pulse.
The magnitude of thepulse is proportional to the cells volume.
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119Chapter 1
Blood  pressure  measurements  in  the 
interdialytic and intradialytic period and its 
relationship  with  changes  in  hydration 
status
Summary
Hypertension in chronic haemodialysis patients contributes significantly to morbidity and 
mortality.  Treatment decisions are  usually based on predialysis readings, which may  not 
accurately reflect control during the interdialytic period. The relationship between BP and 
hydration status before and during dialysis with ultrafiltration is unclear.
In  this  experiment  40  randomly  selected  subjects  on  haemodialysis  were  studied  by 
comparing BP readings by different methods at set times during the dialysis session with the 
48-hr  interdialytic  ambulatory  readings.  Conventional  sphygmomanometer,  automated 
Dinamap and Tm 2421(A&D) ambulatory monitor were used for BP measurements.  The 
relationship of BP with changing fluid status in the interdialytic and intradialytic period was 
explored. Results : Conventional sphygmomanometry and self measured automatic readings 
(Dinamap) were highly correlated (systolic r=0.93 p<0.001; diastolic r=0.90 p<0.001). Mean 
blood pressure on arrival [(preC0)  158 mmHg systolic, 80mmHg diastolic and  106 mmHg 
mean) significantly overestimated the mean ambulatory reading during the 6 hrs prior to 
attendance  [(preAm^)  systolic  147  (p<0.01),  diastolic  75(p<0.01),  mean  99(p<0.01)]. 
Fifteen patients (41%) demonstrated a marked difference (>20/10 mmHg) between the preC0  
and preAmou (white coat effect) persisting in  7 pts (19%) after a period of rest  10 min 
predialysis  (preCIO)  and present  even  in  self recorded  Dinamap  readings.  There  was  a 
significant negative  relationship between  the  systolic  rise  and the number of months  on 
dialysis (p<0.05). Mean ambulatory BP on interdialytic day 2 was significantly greater than 
on day 1  whereas the awake-sleep differences were less on day 2 than day 1, both perhaps 
reflecting differences in volume  status. The  20 min post dialysis measurement P0C20 for 
systolic, diastolic and mean unlike predialysis (preC0 and preC)0), onset (onC) and end of 
dialysis readings (enC) did not differ significantly from 48 hr interdialytic means.
120Introduction
Hypertension  in  chronic  haemodialysis  (HD)  patients  contributes  significantly  to 
their morbidity and mortality. Epidemiological studies have consistently shown that, 
although treated, blood pressure (BP) frequently remains inadequately controlled in a 
high proportion of HD patients [28,171]. This is complicated by the high morbidity 
of both  over  and  undertreatment  [172,173]  and  by  factors  peculiar  to  the  HD 
situation itself.
Although multifactorial, salt and water excess remain the predominant contributory 
factor to dialysis hypertension. Adequate removal of salt and water by ultrafiltration 
therefore can control a significant proportion of elevated BP in the HD population. 
Vasoactive  factors  seem  to  operate  in  relation  to  a  degree  of  fluid  excess  in 
hypertensive individuals. Achieving normotension remains a clinical end point in the 
process of dry weight attainment in many subjects on haemodialysis.
It  is however difficult to  define  hypertension  in  dialysis.  Which  blood  pressure 
reading  should  be  taken  to  signify  hypertension  is  more  pertinent  in  dialysed 
individuals than in the general population because of their fluctuating fluid status and 
other  factors  associated  with  the  dialysis  session.  In  the  general  hypertensive 
population it is known that the use of single readings as a reliable indicator of the 
overall  BP  control  is  fraught  with  difficulty  because  of transient  and  persistent 
elevations of pressure in the clinical setting [174]. The variability of casual readings 
in relation to the dialysis cycle confound management decisions and pose a dilemma 
with regard to the optimum timing and method of measurement of BP in this setting. 
Treatment decisions are mostly based on predialysis readings. However the relevance 
of these readings has been  questioned  and  studies  have  shown their tendency to 
overestimate true BP  [175].  Epidemiological studies also suggest ambulatory BP 
control  may  be  a  better  predictor  of target  organ  damage  [176].  40  randomly 
selected patients undergoing haemodialysis were investigated without any alteration 
in  medication  or  dialysis  schedule  with  the  aim  of  comparing  methods  of 
measurement and comparing casual readings during the dialysis session with 48 hr 
interdialytic ambulatory readings. An attempt was made to explore the relationship 
between changing hydration and overall BP control in these subjects.
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Forty randomly selected stable chronic stable HD patients attending the dialysis unit 
were studied. The patient characteristics of the study group are shown in Table 1. All 
patients  received  high  flux  dialysis  3  times  per week  using  bicarbonate  buffer. 
Dialysis was prescribed according to a urea kinetic model [112] with mean dialysis 
duration  160 ± 43 mins.  They reached their dry weight without hypotension and 
severe  cramps  and  had  acceptable  interdialytic  weight  gains.  Sixteen  patients 
dialysed in the morning  (1030-1200 hrs) and 24 pts in the afternoon (1230-1600 
hrs). Nine (22%) were on no antihypertensive medications, 55% were on mono or 
dual therapy. Drugs used were ACE inhibitors (22 patients), calcium antagonists (14 
patients)  and  beta  blockers  (3  patients).  Antihypertensive  medications  were  not 
withheld on the day of dialysis and usually taken in the morning. Patients excluded 
were a) those on twice weekly HD b) those in atrial fibrillation c) those who had 
undergone  hospital  admission  within  the  previous  month  and  d)  those  in  whom 
antihypertensive agents had been altered within the previous 2 weeks e) those on 
early morning or evening dialysis shifts. Four patients had taken off their ambulatory 
monitor a few hours before arriving in the unit and the results were not used in 
analysing the white coat effect.
Methods
Blood pressure measurements
(1) Mercury column sphymomanometry was used for manual reading by a trained 
clinician using the Phase 5 diastolic and a mean of two repeated measurements.
(2) The patient also recorded his/her own BP in the unit using an automated self­
measurement Dinamap (Critikon)[177], which downloaded the results directly 
into  a  software  programme,  blinded  to  the  observer.  Patients  were  well 
acquainted with the recording procedure, as it is a routine protocol in the unit 
prior to each dialysis. All measurements were made in the sitting position. A cuff 
size suitable for the arm circumference was selected.
(3) Ambulatory monitoring was carried out using the Tm2421  A&D Engineering,
122Milpitas,  CA  blood  pressure  monitor.  This  has  been  validated  and  used  for 
clinical  and  research  purposes  [178].  BP  was  measured  using  cuff  size 
comparable to the seated BP measurements on the nonfistula bearing arm by a 
dual  microphone  system  using  Oscillometric  (O)  and  Korotkoff (K)  method 
programmed to record BP every 30 mins daytime and hourly at nighttime (2200- 
0700). Recorded data was retrieved, processed and reported using a computer 
software programme.74.6% K readings and 95%  O readings were  successful. 
Accordingly the O method readings were used for the main analysis.
The  width  of  bladder  40%  arm  circumference  and  length  of  bladder  80  %  arm 
circumference  is  considered  ideal.  The  cuff sizes  used were according to the  British 
Hypertension Society recommendations. The standard cuff range for adults used were 
comparable  with  respect  to  different  measurement  methods  used  in  this  study  and 
measured 23-33cm (Dinamap and Sphygmomanometer) and 21-32 cm for ABPM. For 
larger individuals the  cuff ranges  were  31-40cm (Dinamap  and Sphygmomanometer) 
and 30-38cm for ABPM.
Definitions used
Conceptual average BP 
recorded
Systolic load 
Diastolic load 
Dippers 
0700)
Awake-sleep difference 
period.
White coat effect  Rise in BP of >20/10 mmHg in the reading on attendance
to the unit above the daytime ambulatory BP during the 6 hrs prior to attending the 
unit.
Best representative casual reading  defined as that showing the minimal difference 
from the mean during the interdialytic period [179]
Mean predialysis BP from last  10 visits for HD as 
on the database.
% of all ambulatory readings  >140 mmHg [179]
% of all ambulatory readings  >90 mmHg [179]
> 10% fall in the mean pressure during the night (2200-
compared to daytime readings [180]
Difference of mean day and night time BP in the 48-hr
123Average BP ( A vC ) M ean o f pre (PreCio) and post (P0 C20) readings.
Hypertension (casual reading)  SystoliO 150 or diastolic >90 mmHg
Hypertension on 48hr abpm  Systolic> 13 5 or diastolic >85 mmHg [181]
Daytime hypertension on abpm  SystoliO 140 or diastolic >90 mmHg [181]
Protocol
BP on arrival for dialysis ( PreCo)was checked by the patients themselves using the 
Dinamap and then by a clinician using sphygmomanometer. The patient then rested 
in a quiet room for 10 minutes after which BP measurement was repeated (PreCio) in 
a  similar  manner  (by  the  patient  using  a  Dinamap  and  by  the  clinician  using 
sphygmomanometer). An ambulatory monitor was then attached to the patient with 
an initial reading on the monitor checked to ensure reading coincided within 5mm of 
the sphygmomanometer reading [182]. During dialysis BP was recorded at the onset 
(onC), end (enC) and post dialysis prior to leaving the unit (P0 C2 0 )  15 -25 mins 
from end of dialysis (mean time 20 mins from end of dialysis). On arrival for the 
next dialysis the monitor was removed and BP checked as before by the patient using 
Dinamap and the clinician using the sphygmomanometer before and after a period of 
10-min rest. All casual measurements were taken in seated position with the arm 
resting and the cuff attached to the nonfistula bearing upper arm.
Statistics
The statistical tests used were the Students’ t-test (paired, one sample or independent 
sample) for differences between means and Pearson correlation coefficient. ANOVA 
and stepwise multiple regression analysis were used to explore relationships between 
variables. All analyses were done using the SSPS statistical package. Bland-Altman 
analysis was used for comparison of methods [183].
124Results
Ambulatory BP readings
The average systolic, diastolic and mean BP of all patients over a 48-hr period was 
140, 71  and 94 mmHg respectively. The mean daytime and night time values for 
systolic, diastolic and mean BP were significantly different (Table 2). Only 8 patients 
(20%) were dippers.  This abnormal nocturnal pattern of BP has been recognised in 
other studies and is typical of the hypertensive HD population [184]. Overall systolic 
and diastolic load was 42 % and 15.7% respectively.
Comparison of methods
Systolic  and  diastolic  pressure  measured  by  conventional  sphygmomanometry 
showed  a  highly  significant  correlation  with  the  automatic  self  measured 
counterparts (Figl) Bland-Altman analysis showed an acceptable mean difference of 
-1.8mm(systolic)  and  0.6mm(diastolic)  with  limits  of  agreement  (2  SE  mean 
difference) of +6 to -5 (diastolic) and 8 to -11 (systolic) mmHg from the mean of the 
two methods (Fig 2).
Comparison  of  casual  readings  during  dialysis  cycle  with 
ambulatory readings [Tables4& 5]
Predialysis  readings  significantly  overestimated  the  ambulatory  averages.  PreCio 
though  significantly  lower than  PreCo (p^.Ol),  was  still  an  overestimate  of the 
ambulatory mean readings. While predialysis reading overestimated the ambulatory 
mean, measurement at the end of dialysis (enC) significantly underestimated it. The 
20-min post dialysis readings (P0 C20)  slightly underestimated (-4 mm mean systolic 
and -1.7mm mean diastolic) but were not significantly different from ambulatory 
means.  P0 C20  provided  the  best  single  reading  representation  of  the  average 
interdialytic BP. A reliable estimate could also be obtained by averaging pre and post 
measurements (AvC). The variability of these blood pressures is depicted in the Fig 3 
& Fig 4.
12sAssessing white coat effect
Blood  pressure  on  arrival  to  the  dialysis  unit  significantly  overestimated  the 
ambulatory averages for 6 hours prior to arrival by >20/10 mmHg (white coat effect) 
in 15 of 36 patients who completed 48 hr monitoring (41%). The mean rise in these 
patients  was  25mmHg  systolic  and  13  mm  Hg  diastolic  (p<0.01).  This  effect 
persisted in 7 patients (19%) following a repeat measurement after 10 mins rest (25.3 
mm  Hg  systolic  and  16  mm  Hg  diastolic;  p<  0.01).  The  white  coat  effect was 
observed consistently in both sphygmomanometer and Dinamap readings. In those 
demonstrating the effect the mean difference between clinician measured and self 
measured readings were 2mmHg systolic and 0.5 mmHg diastolic (p=ns). The white 
coat effect was calculated by comparing casual readings on arrival with the daytime 
average of readings taken in the 6 hrs prior to arrival for dialysis because during this 
period patients were at their wettest and BP differences were less likely to reflect 
fluid gains. The incidence of the white coat effect was greater if the entire 48-hr 
interval (23 patients) or entire 48 hr mean daytime readings (18 patients) were used 
as comparators with the arrival BP. The reduction in mean (18 vs  10 mmHg) and 
systolic BP (38 vs 14 mmHg) during dialysis in the group with white coat effect was 
significantly higher than in the patients not demonstrating the effect showing that the 
effect was not sustained during or after dialysis. Patients who demonstrated the white 
coat effect had been on dialysis for fewer months and showed a higher awake-sleep 
difference  (10.5  vs  3.2  systolic;  5.8  vs  3.5  diastolic)  in  the  interdialytic  period 
(p<0.05  for  systolic)  when  compared  with  those  not  demonstrating  the  effect. 
Daytime  systolic  readings  (139  vs  144 mmHg)  and overall pressure load in this 
group were also slightly lower than the rest while the mean weekly erythropoietin 
was slightly higher (Table3). The latter differences were not significant. There was 
no  significant difference  in those  showing the  white  coat effect and  others with 
respect  to  gender,  age,  drug  treatment,  interdialytic  weight  gain,  residual  renal 
function, KT/V, timing of the dialysis session or the proportion of dippers (Table3). 
The observations were similar in those who had persistent white coat effect after a 
period of rest.
126Stepwise multiple regression analysis in those with white coat effect, using systolic 
rise as the dependent variable showed a negative relationship with the number of 
months on dialysis (p<0.05, r= -  0.62). No significant predictive effect was observed 
for other independent variables including age, sex, number of antihypertensive drugs, 
48hr average BP, daytime average BP, duration of dialysis, pulse rate or awake-sleep 
difference. Fig 5 demonstrates case studies of three patients depicting ABPM profile 
in the interdialytic period.
Relationship to interdialytic fluid gains
A significant relationship of weight gain or ultrafiltration volume with casual BP on 
dialysis, white coat effect or nocturnal dipping could not be demonstrated except for 
a weak but significant correlation between the BP at the end of dialysis  (EnC) and 
ultrafiltration volume  (p<0.05; r = -0.40).  During the interdialytic period however, 
average ambulatory BP on Day 2 was higher than on Day 1  (systolic 147 vs 139mm 
p<0.05: diastolic 74 vs 71mm p=ns). The awake-sleep difference was significantly 
reduced on Day 2 compared with Day 1  (1.6 vs 7.5mm Hg systolic; p< 0.05).
Discussion
The measurement of BP for clinical evaluation of the HD patient may be subject to 
three types of error. First is the error due to the measurement procedure itself. We 
confirmed  that  same  arm  BP  measurements  by  Dinamap  and  the  clinician  are 
comparable though not necessarily identical [185]. The agreement between mercury 
column and Dinamap  determinations were within  10mm Hg in 90% systolic and 
98%  of diastolic  readings.  The  error  between  two  devices  may  be  due  to  a) 
consecutive rather than simultaneous readings or b) systematic differences which can 
be corrected for by adjusting for the average difference (negligible in this study) 
between the devices. The overall level of agreement is reassuring and suggests that 
either may be used with confidence in the clinical setting.
The second type of error arises from the spurious elevation of BP in the clinical 
setting often attributed to an emotional reaction to the involvement of a clinician. 
The “white coat effect” is defined as transient rise in BP that occurs in the clinical
127setting  [186].  We observed this phenomenon in almost 40%  of arrival pressures, 
which improved to 19% after a period of rest. The effect did not persist throughout 
the dialysis session (Fig 6). The timing of the dialysis session did not influence the 
presence of WCE. There seemed to be no noticeable difference when the physician 
took the BP. The involvement of the physician does not seem to be a determining 
factor in the white coat effect. This study confirms that the white coat effect persists 
even in patients on antihypertensive therapy [187]. The negative relationship with 
duration on dialysis could be due to habituation to clinic measurements with time or 
due to the longer duration of antihypertensive therapy.
There is little data on the white coat phenomenon in the dialysis population, though 
in  a  study  on  13  normotensive  HD  patients  [188]  large  differences  were  noted 
between  the  predialysis  readings  and  interval  pressures just before  dialysis.  The 
timing of the predialysis blood pressure measurement is therefore crucial. The initial 
arousal  response  can  be  minimised  using  readings  after  a  rest  period.  The 
mechanisms  and  prognostic  significance  of the  white  coat  effect  are  not  fully 
understood  [182].  The response occurs in about 20% of the general hypertensive 
population [189], is more common in females and blacks and usually disappears on 
repeated measurements. In the nondialysis population it is associated with elevated 
plasma level of various hormones including catecholamines, cortisol, vasopressin, 
endorphins and a primary role of the sympathetic system has been suggested [190]. 
The white coat phenomenon may be more common in renal patients than in the 
general hypertensive population [191] perhaps due to an exaggerated sympathetic 
response  conditioned  by  uremia.  It  is  noticeable  (Fig5)  that  in  the  group  not 
demonstrating the white coat effect WCE (-) there appeared to be a gradual rise in 
BP between dialyses whereas in the group demonstrating the effect WCE (+) BP 
seemed stable in the interdialytic period before an abrupt predialysis rise. Perhaps 
there is an increased sensitivity to fluid accumulation in the WCE (-) group, which 
may be determined by a sustained sympathetic  outflow, whereas the sympathetic 
surge  in  the  WCE  (+)  group  is  more  transient.  The  environment  of  a  busy 
haemodialysis unit may have a significant influence on the predialysis surge, as may 
the  pressures  of travelling  to  the  unit  and  the  fear  of needles.  Because  of the 
unpredictability of the effect, we recommend that this be carefully considered when 
assessing resistant predialysis hypertension.
128The third error arises from the variability of BP during the dialysis cycle. The large 
swings  in pressure  during  the  dialysis  procedure  are  not  fully  understood.  The 
overdiagnosis of hypertension using predialysis readings has been observed in many 
studies [175]. The practice of withholding antihypertensive medication predialysis 
has been implicated [28] but was not a factor in this study. Even after elimination of 
the initial arousal phenomenon, predialysis BP poorly reflected interval pressures 
[175]. The changes in BP during dialysis could reflect volume removal, removal of 
vasoactive factors, and alterations in arterial compliance and sympathetic activity 
caused by removal of uremic toxins. Despite poor correlation of blood pressures on 
dialysis with weight gains, the differences in Day 2 and Day  1   average daytime, 
nighttime  BP  and  awake-sleep  differences  suggest  some  influence  of  fluid 
accumulation on diurnal fluctuations of 48 hr BP between dialyses.
The  20-min  post  dialytic  BP  (P0 C20)  appears  to  be  best  approximation  of the 
ambulatory  interdialytic  values  in  the  stable  chronic  dialysis population.  Similar 
findings have been reported by Kooman et al [175] while others report unacceptable 
variability in the predialytic reading [182]. There is significant underestimation of 
interdialytic means if BP is recorded immediately after dialysis. In our patients the 
fall in arterial pressure during dialysis recovered rather than dipped post dialysis 
though Battle et al observed a decline in BP in the hours immediately after dialysis 
[192]. The variation may relate to differences in baseline hydration. The recovery of 
the 20 mins post dialysis reading may be related to compensatory vascular refilling 
(fluid rebound) which is maximal  in the  first half hour post ultrafiltration [193]. 
Allowing  this period  of equilibration  is  essential  to  obtain  reliable  post dialysis 
measurements.
Those  not on  antihypertensive  drugs  had  significantly  lower  interdialytic  weight 
gains (p<0.05), higher residual renal function and were on less Eiythropoietin. They 
did not however differ significantly with respect to overall BP control, WCE or BP 
fluctuations  during  dialysis.  They  numbers  are  however  relatively  small  to  be 
conclusive.
In conclusion the timing of casual predialysis and postdialysis BP readings is crucial. 
Both can be biased by the dialysis procedure itself (white coat effect in the former
129and  fluid rebound  in  the  latter).  The  traditional  diagnosis  of hypertension based 
solely on predialysis clinic readings can lead to gross overestimation attributable to a 
white coat effect  This is an important cause of blood pressure variability and is 
significant  even  in  self-recorded  blood  pressure  measurements.  The  best  single 
approximation of interdialytic BP is the 20-min postdialytic reading. Poor control or 
sustained hypertension with high clinic BP, despite multiple drug treatment should 
be assessed by ambulatory monitoring to eliminate overshooting reactions, provide 
supplemental information about pressure load and variability and avoid inappropriate 
treatment. Prospective endpoint studies are required to authenticate the relationship 
between ambulatory BP values and measurements in the dialysis units and the use of 
both in predicting cardiovascular morbidity and mortality in HD patients.
130Table 1. Patient characteristics
Mean SD Range
Age (yrs) 61.5 (14.8) 21-81
Months on HD 27 (18.7) 6-78
IDWG (kg) 1.34 (0.72 )
•
o
Drugs 1.5 (1.0) 0-4
Epo (IU/week) 6000 (4600) 0-20000
KRU (ml/min) 1.7 (1.73) 0-4.8
Kt/V 1.23 (0.19) 0.9-1.8
Ultrafiltration (1/hr) 0.59 (0.26) 0.19-1.2
Sex m:f 35:5
Diabetic 10
Table  1  Patient Characteristics at the time of enrolment into the study.
KT/V = mean of delivered KT/V measurements performed within the 4 months prior to the 
study.
KRU  = residual renal function as urea clearances (ml/min).
Drugs = No of antihypertensive medications. Epo  = Erythropoietin dosage 
I DWG = interdialytic weight gain (kg)  SD  = standard deviation.
Table 2. Interdialytic Blood Pressure Monitoring
48 hr Day Night D-N diff
Systolic 140(21) 142(21.3) 135.7(24)  t KO.001
Diastolic 71.7(11)  72(10.1) 68.2(12) pO.001
MBP 95(14.5)  95.3(13) 91(15.4) p<0.001
Systolic load 42.3% (31)  Diastolic load 15.7% (16)
Table  2  Average BP and pressure loads during the 48 hr interdialytic monitoring. 
Figures in parentheses indicate the standard deviation of the mean.
MBP = mean blood pressure  D-N diff = day night difference.
131Table 3 . Comparison of groups with or without white coat effect (WCE) 
on arrival predialysis measurement  (PreCo).
WCE absent WCE present
Number 21 patients 15 patients
Sex  ( F:M) 2:19 3:12
Diabetic vs nondiabetics 6:15 (28%) 4:11 (27%)
Mean SD Mean SD
Age (yrs) 65 14 58 14
Months on Haemodialysis * 29 19 17 11
No. of anti-hypertensive drugs 1.5 1 1.6 1
Weekly Epo Dose (units) 5433 3166 7167 3824
nter-dialytic Weight Gain (kg) 1.27 .58 1.35 .84
<T/V 1.21 .20 1.24 .24
Conceptual average systolic BP * 150 11 176 12
Conceptual average diastolic BP * 73 10 90 14
Average 48 Hour Diastolic BP 71 11 72 11
Average 48 Hour Mean BP 95 13 94 11
Average 48 Hours Systolic BP 141 24 137 18
Average Daytime Diastolic BP 72 10 74 12
Average Daytime Mean BP 95 15 94 10
Average Daytime Systolic BP 139 25 144 18
Average Night time Diastolic BP 68 12 70 16
Average Night time Mean BP 92 17 90 14
Average Night time Systolic BP 137 27 133 20
Diastolic load  (%) 14 18 12 13
Systolic load  (%) 43 32 41 29
3ulse ( per min) 72 10.7 74 7.5
48hrAwake_sleep diastolic difference 3.5 4.3 5.8 7.1
48hrAwake_sleep systolic difference* 3.2 5.5 10.5 4.5
(*) indicate significance of p<0.05. WCE = white coat effect
Abbreviations = refer  to Table 1.
132Table 4. Blood Pressure measurements during dialysis cycle compared 
with interdialytic pressures____________________________
Systolic Diastolic MBP
48 hr average 140(21.5) 71(11) 94 (13)
Conceptual 157(22) 78(10) 104(12)
Average
PreCo 158(20) 80(11) 106(12)
PreCio 150 (21) 74 (10) 99 (12)
OnC 146 (23) 76 (16) 99(15)
EnC 124(31) 70(13)* 88 (16)
P0C20 136 (25)* 70(11)* 92  (14)*
AvC 144(21) 74(10) 97  (12)
Table 4  Blood Pressure measurements during dialysis cycle compared with interdialytic pressures.
*  p = ns (no sig diff from the 48 hr mean).  Students t- test paired with 48 hr readings for systolic, 
diastolic and mean. Values rounded to the nearest integer.
PreCo =Predialysis BP on arrival,  PreCio=10 min predialysis BP, OnC=onset of dialysis BP,
EnOBP end of dialysis,  PoC2o=20 min postdialysis BP, AvC-Average of pre and postdialysis BP 
MBP = mean blood pressure.
Table 5. Mean differences of BP during dialysis from the
average 48 hr ambulatory pressures
Systolic Diastolic MBP
PreCo 18.3  (2.5) 7.0  (1.3) 11.5  (1.6)
PreCio 9.2  (2.3) 2.7  (1.1) 5.1  (1.5)
OnC 5.1  (3.0) 4.5  (1.8) 5.3  (1.7)
EnC -14.1  (2.3) -3.2* (1.5) -6.6  (1.6)
PoCM -4.0*  (2.3) -1.7* (1.4) -1.8*(1.6)
AvC 4.3  (1.9) 1.9* (1.1) 3.0 (1.3)
Table  5  Mean differences of BP during dialysis from the average 48 hr ambulatory 
pressures.
* p = ns (no significant diff from the 48 hr mean )Figures in parentheses indicate the sd of the 
mean.
MBP s mean blood pressure.  Key to abbreviations in first column  refer to legend 
Table 4.
133Figure 1   Correlation of blood pressure measurements between 
Sphygmomanometer and Dinamap for systolic (1a) and diastolic (1b) 
on arrival to the unit.
r=0.9  p<0.001
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Figure  2  Bland Altman analysis of Sphygmomanometer and Dinamap 
systolic (2a) and diastolic (2b) readings. Reference lines indicate the 
mean difference of the two methods and  their limits of agreement 
(+/- 2 SE from the mean differences).
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Figure 3  Error bars showing blood pressure variability of readings during the dialysis 
cycle for systolic (3a) and diastolic (3b) (limits indicate 95% confidence intervals).
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135Figure 4 Bar diagram demonstrating the mean differences of the blood 
presssure measurements during the dialysis cycle from the interdialytic 
mean (0 on Y axis) for systolic(4a), diastolic(4b) and mean (4c) blood 
pressure. Key to abbreviations refer to legend on Table 4.
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effect on arrival for dialysis.Bars represent mean ( +/- 2SE ) BP readings 
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139Chapter 2
The assessment of body composition and 
fluid compartments
Introduction
Approximately 60% body weight is water in normal individuals 30 -  40% of which 
is  extracellular  water  (ECW).  Sodium  and  water  homeostasis  is  abnormal  in 
haemodialysis (HD) patients, however the distribution of excess fluid has not been 
characterized  [194]  Despite  best  efforts,  many  patients  are  admitted  with  fluid 
overload and after hospital admission patients often achieve a new lower dry weight. 
The less accessible fluid compartments i.e. interstitial compartment harbors much of 
the excess fluid, influence plasma refill and more importantly reflect the hydration 
status of the patient.
Body weight at euvolemia also reflects the nutritional status of the dialysis patient. 
The  latter  may  be  compromised  in  chronic  renal  failure.  [195]  Therefore  both 
variations in fluid and nutritional status may have direct consequences on dry weight 
variation and confound assessment of postdialytic target weight. Although various 
measures  of nutritional  status  and  clinical  markers  of hydration  exist,  adequate 
information on both body composition and fluid compartments cannot be obtained 
using a single measurement.  [196]  Wide limits of agreement were found between 
various  techniques  used  to  assess  body  composition  in  PD  patients.  [197]  The 
assumption that derived indices such as kinetically estimated protein catabolic rate 
(PCR) generally reflect dietary protein intake (DPI) and thereby, indirectly, patient's 
nutritional status, has also been questioned. [198]
The aim of this clinical study was to compare different techniques used to evaluate 
body composition and to assess the influence of fluid status on the assessment of 
body composition. Bioimpedance is a technique that can measure these fluid spaces 
in  a  noninvasive  manner,  assess  the  nutritional  status  and  changes  in  body
140composition. This technique was used to assess a) fluid compartment volumes and its 
shift during UF b) compare the nutritional status using bioimpedance estimates and 
other indices of nutrition in patients with varying degrees of chronic renal failure and 
on dialysis.
EXPERIMENTAL  SETUP 
Subjects and Methods
Four groups of patients were studied : Predialysis (serum creatinine > 400umol/l and 
creatinine  clearance  <20  mls/min),  Haemodialysis  (HD  >  3  months),  Peritoneal 
dialysis (CAPD > 3 months) and controls. Randomly selected subjects of varying age 
and sex with no known major illness or renal impairment were used as controls. 
Subjects were randomly  selected  from  an  outpatient’s clinic  for a cross-sectional 
prospective  nutritional  assessment  to  compare  direct  and  modeled  estimates  of 
nutritional  status  in  patients  with  renal  insufficiency.  The  only  exclusions  were 
malignancy, treatment modality change or recent (within 2 weeks) hospitalization. 
The study was approved by the North Herts Ethical Review Committee. All patients 
gave informed written consent. Dietary interventions were minimal.
Each subject underwent:
i)  24 hr (predialysis or controls) or 48hr (HD or CAPD) urine collection was 
performed  for urea kinetic modelling  [112]  and calculation of nitrogen 
losses
ii)  nutritional survey by anthropometry (Anthr) (same dietician), [199]
iii)  3-day weighted food intake
iv)  Subjective Global Nutritional Assessment (SGNA), [196]
v)  Multifrequency bioimpedance (Bio) to asses fat free mass, total body water 
volume and extracellular fluid volume (see Methods section) with Bioimpedance 
measurements in patients treated by PD made after drainage of CAPD fluid and 
in those treated by HD postdialysis. To assess fluid shifts during ultrafiltration, a
141subgroup  of twelve  HD  subjects  had  additional  bioimpedance  measurements 
performed before and after a single dialysis session.  These patients were also 
monitored with respect to their relative blood volume and blood pressure pre and 
post dialysis (see methods).  Measured postdialysis  ECW was also compared 
against estimates from derived formulae ECW = (5*Weight + 70). [78]
vi)  Blood sampling for biochemical markers - C-reactive protein (CRP), serum 
bicarbonate, transferrin (Tf), albumin (Alb) prealbumin (Palb) and Insulin growth 
factor (IGF-1) assay. [200]
The results and analysis were divided into three sections:
a.  Assessing the fluid compartment volumes and their resistivities in patients 
with varying degrees of chronic renal failure and on dialysis (HD and PD)
b.  Tracking  fluid  shifts  in the  EC  compartment during HD pre and post UF 
using bioimpedance analyzer.
c.  Determine  and  compare  the  nutritional  status  of  the  patients  using 
bioimpedance and other indices of nutrition.
Results 
Section A
Repeatability and reproducibility of bioimpedance measurements
Reproducibility of the measurements was examined by obtaining data in triplicate for 
ECW, ICW and TBW (n=167). (Table  1) The method was most accurate for ECW 
measurements (CV 1.1 +3.2 %). ICW showed more variation (CV 3.6 + 4.4 %). The 
fit status was good or excellent in 94% measurements.
Hydration status in Controls and chronic renal failure
Hydration  status  in  controls  and  subjects  with  varying  degrees  of chronic  renal
•  2 impairment based on Creatinine clearance groups of la (25 —  50 ml/min/1.73m ) lb 
(12-25 ml/min/1.73m2) and Ic (<12 ml/min/1.73m2) are depicted in Table 2a & 2b.
142Abnormal distribution of fluid was evident between ECW and ICW compartments in 
renal impairment as compared to controls. Advanced renal failure with a Creatinine 
clearance <12 ml/min/1.73 m2  was associated with significant expansion in the ECF 
and an increased Bioratio of above 50%. The subjects had a higher mean age; the 
body weight was not significantly different between the groups. The ECW and TBW 
had a weak but significant correlation with dietary sodium intake (r = 0.20, P< 0.05) 
There was no relationship of serum albumin or urinary protein leak to ECF. Serum 
albumin however correlated significantly with ICW (r = 0.27, P<0.05) and negative 
correlation to the Bioratio (r = -0.28, P<0.05).
Hydration status in ESRF subjects on dialysis
There  were  no  significant  differences  between  the  measurements  in  CAPD  and 
postdialysis HD even when corrected for weight or fat free mass. (Table 3) Controls 
and HD subjects who had all valid fluid measurements (n=40) were compared with 
respect to their bioimpedance volume measurements corrected for their ideal body 
weight or Fat free mass.  (Table 4)  Although the patients were in the similar age 
ranges in the HD and control group there was a significant difference in their weight, 
albumin and volume of distribution thereby reflecting different body composition. 
When corrected for the weight and free fat mass, the HD group had a significantly 
higher ECW per kg post dialysis and total body water relative to the fat free mass 
despite being clinically judged to be at their dry weight. (Fig 1) This may reflect a 
different compartmental distribution of water in fluid compartments or insensitivity 
of clinical methods to determine hydration of the fluid compartments in this group. 
The relationship of the ECW and ICW to the total body water was most abnormal 
and reversed in the predialysis phase. This trend was partially corrected with dialysis. 
(Fig 2)
Comparing  Resistivities
Under normal conditions the ratio of the intracellular to extracellular fluid volume is 
tightly  regulated  and  alterations  in  the  ratio  can  reflect  either  a  change  in  the 
intracellular  or  extracellular  volume.  The  resistance  itself  measured  by  the 
bioimpedance is a measure of the electrical properties of water compartment and thus
143influenced by electrolyte composition, protein, haematocrit and temperature. The use 
of resistances alone avoids further assumptions of height and volume relationships in 
different populations or reliance on complex emulsion theory.  The ratio Ri/Re is 
therefore  the  equivalent  to  the  volume  ratio  ECW/ICW.  This  resistance  ratio  is 
tightly distributed in the normal population.
Most  dialysis  patients  and  those  with  renal  impairment  had  an  elevated  ratio 
suggesting extracellular volume overload. (Table 5) CAPD patients in general had 
higher ratios than HD although the differences however did not achieve significance. 
It is assumed in this analysis that the resistivities of ICW and ECW are same for 
controls and renal  failure.  It is also assumed that these remain unchanged during 
dialysis alone. An increase in ratio can also be due to a decrease in ICW.
Section B
Studies during HD with UF
Twelve  subjects  on  HD  had  measurements  taken  before  and  after  dialysis  with 
intermittent  UF.  Table  6  All  patients  showed  significant  reduction  of ECW  as 
measured  by  Bioimpedance  with  a  tendency  to  plateau  towards  the  end  of 
ultrafiltration.  Fig 3  depicts reduction in ECW and ICW with UF in one subject. 
There is usually a tendency for the ECW changes to plateau near the end of UF.
The  mean  UF  volume  removed  and  mean  ECW  change  were  not  significantly 
different and strongly correlated to each other (r2  =0.93) (Fig 4) The ECW change 
underestimated weight change of UF in excess of 2 litres,  (r2  =0.76) (Fig 5) This 
could be a result of truncal fluid shift, insensible losses or obligatory UF. The latter is 
most  unlikely  with  volumetric  apparatus.  The  measured  ECW  overestimated  the 
predicted by 0.8 + 1.54 1  (r=0.79 p<0.001). Fig 6 Two patients became hypotensive 
in the last hour and required saline bolus Subject 2 & 12. The ECW failed to pick up 
the infusion change accurately and immediately postinfusion perhaps due to lack of 
equilibration.
The effective change in blood volume at the end of dialysis was strongly correlated 
with the reduction in weight (r=0.62), ECW (r=0.68) and UFV removed (r=0.70).
144p<0.05.  Systolic  BP  reduction  was predicted by  the  reduction  in  blood  volume, 
weight and ECW change. These results emphasize the fact that the volume shifts in 
the ECW compartment are major determinants of haemodynamic stability.
Section C
Nutrition and Extracellular water
Eighty patients (pts) were recruited for this part of the study, with varying degrees of 
chronic renal impairment (CRF) (Gr I), 79 stable ESRD pts (CAPD (Gr II) n=39; HD 
(Gr III) n=40) and 33 controls (Gr IV) (Table 7).  Mean weekly Kt/V was 2.3±0.49 
in CAPD and  3.9±0.59in HD.  Mean  (±SD)  ages were 44±13,  59±14,  61±11   and 
56±15 yr. for controls, CRF, CAPD and HD pts respectively. In the control and CRF 
subjects,  malnourishment  (SGNA)  was  evident  in  5.8%  in  Gr  la  (CrCl 
>50ml/min/m2; n=34), 5.8% in Gr lb (CrCl 25-50 ml/min/m2; n=34), 13.8% in Gr Ic 
(CrCl 12-25 ml/min/m2; n=29) and 50% in Gr Id pts (CrCl<12ml/min/m2; n=10)(Fig
7). nPCR correlated with measured protein intake wDPI (r=0.46, p<0.01).  nPCR 
significantly decreased with fall in CrCl in each group, (Fig 8) but the mean FFM 
(Anthr), FFM (Bio) and wDPI decreased significantly in Gr Id only (Fig 9) (Table
8).  Creatinine  clearance  corrected  for  body  size  (CrCl  ml/min/m2)  correlated 
positively with nPCR, Calculated protein intake (cDPI), Protein nitrogen appearance 
corrected for ideal body weight (ht2 x 22.5), 24hr creatinine excretion, Alb, Tf and 
IGF-I (p<0.01) and negatively with age (p<0.01) and  CRP (p<0.05) but not with 
bioimpedance, wDPI  or anthropometric  indices.  Albumin was correlated with Tf, 
IGF-I (Fig 10, 11) and negatively with CRP (p<0.01). CRP was strongly predicted by 
bicarbonate  and  Alb.  (Fig  12)  Palb  and  IGF-I  were  not  significantly  different 
between groups. (Fig 13) Calculated DPI (y) was less precise and underestimated the 
wDPI (x) (Fig  14) (R = 0.44 R2= 0.19, p<0.01) (y=0.47 +0.5x; r2 =0.2). A higher 
proportion of HD patients (40%) were malnourished (SGNA) than CAPD (28%), 
CRF (14%) and controls (6%).  (Fig  11) Skinfold thickness (SFT), fat mass (FM), 
cholesterol, Palb, and IGF-1 were higher in CAPD, mid-arm circumference, Tf levels 
similar,  Fat  free  mass  FFM  (Anthr)  &  FFM  (Bio),  CRP  and  nPCR were  lower
145(p<0.01)  than  HD  pts.  (Fig  15)  SGNA  scores  were  not  significantly  different 
between those on dialysis for >1  yr. or less (CAPD n= 30 v 9 & HD n=27 v  13) 
despite similar weekly KT/V (CAPD 2.27 v 2.45; HD3.89 v 3.86).
Discussion
Fluid compartments
A  stable  volume  and  composition  of extracellular  fluid  are  essential  for normal 
functioning of the body.  Since  the  kidney  is primarily responsible  for regulating 
extracellular fluid, loss of kidney function should have catastrophic consequences. 
Fortunately, even with loss of more than 90 percent of renal function, a remarkable 
capacity  to  regulate  body  fluid  volumes  and  sodium  and  potassium  persists. 
Nevertheless, this capacity is limited to chronic renal disease and this has important 
consequences for clinical management of these patients.
Bioimpedance  spectroscopy  or  multiple  frequency  bioimpedance  analysis  has 
become  a  widely  used  technique  in  body  composition  analysis  in  recent  years. 
Alternating current at a low frequency flows through ECF while high frequencies 
current flows through total body fluids. Using a spectrum of measuring frequencies, 
typically 5 -  500 Hz purports to assist in the discrimination between extracellular and 
intracellular fluid.
The results suggest dialysis patients presumed to be euvolemic on clinical grounds, 
may remain above their true physiologic dry weight defined as normal hydration of 
body tissues. Abnormally elevated Bio Ratio and Ri/Re ratio are indicative of the 
phenomenon.  This is supported by the fact that following transplantation subjects 
often achieve a weight lower than the dialysis dry weight.
Despite its limitations the Ri/Re ratio can be a useful marker of tracking fluid status. 
Elevated  Ri/Re  ratio  should  prompt  a  search  for  extracellular  volume  overload. 
Spiegel et al demonstrated elevated Ri/Re ratio could be due to loss of intracellular 
volume in malnourished patients. Urea, which fluctuates on dialysis, does not affect
146resistivity  [201].  Excess  fluid  accumulating  in  the  central  compartments  is  not 
measured by limb resistivities. Excess fluid is often held in mesenteric, splanchnic 
and hepatic  and pulmonary veins.  Bioimpedance  is  insensitive  to changes in the 
central  fluid compartments.  Hence a normal ratio cannot exclude an excess body 
water in central compartments.
There are several other potential errors that can affect bioimpedance measurements. 
First the resistance itself, a measure of electrical properties of water compartment 
and thus influenced by electrolyte composition, protein concentration, haematocrit 
and  temperature.  The  conversion  of  resistance  to  volumes  requires  a  further 
assumption  based  on  height  and  volume  relationships  determined  in  different 
populations or a reliance on emulsion theory. In intensive care fluid balance studies 
atypical impedance values were observed compared with those previously seen in 
normals with wide variations from day to day and impedance plots. Stray capacitance 
in the environment, interaction between electrode impedance and lead positioning are 
factors. [202]
Dietary sodium intake influences the volume of the extracellular compartment in all 
groups  of  patients  with  renal  dysfunction.  The  successful  management  of 
hypertension in patients undergoing maintenance haemodialysis depends primarily 
on the control of total body sodium. [65] Sodium forms the principle backbone of the 
ECW, which expands with salt and water retention.  Restricting sodium intake is 
likely to help control hypervolemia in patients with renal dysfunction. Many patients 
with advanced renal disease may be extremely sensitive in terms of blood pressure 
elevation and to sodium overload as demonstrated in renoprival dogs [203] and by 
constant and  careful  regulation  of total body  sodium control can  satisfactory BP 
control be maintained. The progressive decline in residual renal function is likely to 
exacerbate  the  expansion  of  the  ECF  due  to  salt  retention  and  abnormal  salt 
sensitivity.
In the long term management of HD patients a continuous normal level of BP can be 
maintained  if  adequate  sodium  restriction  can  be  maintained  between  dialysis. 
Haemodynamic  stability and blood volume changes had a significant relationship 
with ECW. Though it is possible to reduce the ECW to normal levels acutely by
147ultrafiltration, in many patients there may exist a lag time between reduction of ECW 
and adequate control of BP. [70]
The nutrition overlap
The  findings  in  this  study  indicate  that  malnutrition  is  a  late  phenomenon  in 
advanced renal insufficiency with a significant decline in nutritional state just prior 
to dialysis.  (Fig 9)  These remain only partially corrected on dialysis with a high 
prevalence despite adequate modelling parameters. [204] nPCR estimates are likely 
to be artefactual partly due to mathematical coupling with CrCl estimates or errors in 
urine collection. [205] Plasma proteins and serum albumin though strong predictors 
of adverse  outcome  in  CRF  are  insensitive  to  the  presence  of earlier  stages  of 
malnutrition and may be affected by abnormal metabolism in CRF. Visceral protein 
markers may also be independently affected by continuing catabolic insults possibly 
due  to  changing  renal  function  or  dialytic  process  itself.  Malnutrition  in  uremic 
subjects coexists with ECW expansion. (Fig 6)
The  body  composition  in  advanced  renal  failure  is  abnormal  which  makes 
interpretation and early detection of malnutrition difficult. The assessment of body 
composition was strongly influenced by hydration state. This problem is confounded 
by fluctuating fluid status. Reliable detection and adequate treatment of malnutrition 
in severe renal impairment poses a major challenge. Bioimpedance technique whilst 
measuring fluid compartments with reasonable accuracy, can also incorporate lean 
body mass characteristics reflecting nutritional status. An objective assessment of the 
extracellular compartment in conjunction with the nutritional status with the use of 
such tools will enable better fluid and nutritional management.
148Table 1  Reproducibility of triplicate measurements (M1,M2,M3) & 
between left and right sided measurements (Rt, Lt)
R(M1,M2) R (M2, M3) CVmean (%) CVsd(%) R (Rt, Li)
ECW (Rt) 0.98 0.99 1.1 3.2 0.98
ECW(Lt) 0.99 0.98 0.6 3.1
TBW (Rt) 0.94 0.97 2.0 4.5 0.95
TBW (Lt) 0.99 0.94 1.9 6.6
ICW (Rt) 0.95 0.99 3.6 4.4 0.88
ICW (Lt) 0.98 0.92 2.9 4.9
3t right side, Lt Left side R = Correlation CV = method coefficient of variation
Table 2a  Body fluid distribution (Controls)
N 33
Creatnine clearance ml/min/1.73m2 102 + 28.7
Weight (kg) 90.8 + 19.4
Surface Area m* 1.96 + 0.29
Body mass index 28.6 + 5.4
ECW Litres 21.4 + 3.98
TBW Litres 50.3+12.5
ICW Litres 28.9 + 9
ECWL/kg 0.24 + 0.03
ECW/FFM  L/kg 0.34+.0.03
TBW L/kg 0.56 + 0.01
ICW L/kg 0.32 + 0.08
ECW/TBW (Bioratio) 0.44 + 0.05
ECW = Extracellular water ICW Intracellular water 
TBW Total body water FFM Fat free mass
149Table  2b  Body  fluid  distribution  in  subjects  with  chronic  renal 
impairment
Parameters CrCI (25 -50) CrCI (12-25) CrCI (< 12)
N 34 29 10
Creatinine clearance ml/min/1.73m* 36.5 + 7 17.4 + 3.3** 9.5+ 2.7**
Weight (kg) 79.7 + 14.1 82 + 17.6 76.1 +  14.8
Ageyrs 59.8 14.6 59.3 14.6 67.5 + 9.9*
Albumin 37.7 + 4.5 38.3 + 3.5 35.1 +4.7
Surface area m* 1.95 + 0.21 1.98 + 0.25 1.88 + 0.22
Body mass index 27.8 + 4.1 29.4 + 5.7 27.7 + 4.65
ECW L 18.5 + 4.1 20.2 + 2.4 20.8 + 4.5*
ICW L 18.4 + 3.2 22.3 + 4.7 20.4 + 6.4
TBW L 37.4 + 6.4 42.4 + 7 41.2 + 10.4
ECW/TBW (Bioratio) 0.47 + 0.04 0.47 + 0.03 0.51 +0.05*
ECW L/kg 0 .28+  0.03 0.29 + 0.04 0.31+  0.04
ICW L/kg 0.25 + 0.05 0.23+  0.04 0.2 + 0.04
TBW L/kg 0.52 + 0.07 0.52 + 0.07 0.52+  0.07
ECW/FFM 0.41 +0.03 0.4 + 0.03 0.45 + 0.03*
ECW = Extracellular water ICW Intracellular water TBW Total body water FFM Fat free mass 
CrCI Creatinine clearance ml/min/1.73m2 *p<0.05, ** p< 0.01 compared with Column 2
150Table 3 Comparison of body fluid composition measurements 
between peritoneal (CAPD) and haemodialysis (HD)
Parameters CAPD HD
N 39 40
Age 61.7+10.6 55.6 + 15.3
Weight (kg) 74.5+7.7 66.9 + 13.9
BSA m2 1.8 + 0.15 1.8 + 0.24
BMI 26.1+3.9 25.2 + 5.5
ECW L 18.5 + 3.2 17.4+3.3
TBW L 38.3 + 6.1 36.1 +7.6
ICW L 20.1 +3.9 18.9 + 5
ECW/TBW 0.48 + 0.05 0.48 + 0.05
(No significant differences seen for any parameter)
151Table  4  Fluid  Compartment  volumes  in  HD  subjects  measured
postdialysis against controls
Controls (33) HD (40) P value
Age yrs* 43.5 +15.7 55.6 +.15.3 P<0.05
Weight kg* 93.2 + 21 66.9+13.9 P< 0.001
Ideal wt kg* 70.6 + 7.7 62.1+5.3 P< 0.01
Albumin g/dl* 40.8+.3.5 35.8+.4.3 P< 0.01
Watson V Litres* 47 + 8.8 36 + 6.1 P< 0.01
ECW* 21.5 + 4 17.4 + 3.3 P< 0.01
ICW* 28.2  +.9 18.8 + 5 P< 0.01
FFM* 63.6+.14.7 50.2 + 9.4 P<0.05
ECW/wt* 0.23+0.03 0.26 + 0.02 P< 0.01
ECW/FFM 0.34+.0.03 0.37 + 0.03 P=0.05
ICW/wt 0.3+0.08 0.28 + 0.05 P=0.42
ICW/FFM 0.43 + 0.39 0.39 + 0.05 P=0.09
TBW/wt 0.54 + 0.11 0.54 + 0.06 P=0.94
TBW/FFM* 0.77 + 0.01 0.76+.0.02 P<0.05
Expanded ECW adjusted for body size measured postdialysis at the clinical dry weight 
suggests abnormal distribution.  (* indicate p<0.05)
Table 5  Resistivity in the different groups of renal failure mean (sd)
Re Ri DA Cm Ri/Re
Controls 526(88) 983(139) 24.4(1.3) 2.3(0.55) 1.89(0.26)
CRF 515(92) 1008(197) 24.6(1.7) 2.2(0.58) 1.98(0.31)
HD 546(95) 1090(255) 25.3(2.4) 1.93(0.74) 2.05(0.62)
CAPD 561(70) 1150(218) 25.2(1.1) 1.75(0.57) 2.08(0.46)
152Table 6  Reduction in ECF during ultrafiltration in 12 HD subjects[(-) means a reduction]
Subject Reduction in 
RBV 
%
UFV
Litres
Change in 
ECF 
litres
Change in 
weight 
Kg
Predicted 
Poet ECF 
litres
Measured 
Post ECF 
litres
M AP
change
mmHg
Systolic
change
mmHg
1 -9.0 -2.8 -3.02 -3.2 23.05714 22.8 -27 -34
2 -0.4 -0.8 -1.05 -0.85 12.42857 12.6 -21 -28
3 -12.6 -2.4 -2.1 -2.6 14.57143 13.8 -27 -37
4 -11.8 -2.57 -2.45 -2.9 21.38571 21.41 -20 -28
5 -7.9 -2.217 -1.7 -2 15.21429 18.02 -3 -11
6 -9.1 -1.978 -2.29 -2.5 17.74286 18.97 -11 -17
7 -13.9 -2.72 -2.67 -2.7 19.86429 22.68 -44 -68
8 -9.0 -1.8 -1.81 -1.8 13.99286 20.07 17 25
9 -4.1 -1.05 -1.29 -1 11.57143 14.73 5 12
10 -7.4 -0.8 -0.64 -0.8 13.99286 18.57 1 18
11 -17.5 -2.9 -2.52 -3.0 16.39 16.45 -31 -41
12 -11.7 -3 -3.11 -2.1 17.87143 16.88 -21 -29
Mean -9.5 -2.1 -2.1 -2.1 16.5 18.1 -15.2 -19.8
STdev 4.5 0.8 0.8 0.9 3.6 3.3 17.4 27.0
153Table 7 Baseline characteristics of subjects and subgroups
CRF Controls HD CAPD
Numbers 80 33 40 39
Age (yrs) 59(14) 44(13) 56(15) 61(11)
KT/V(  weekly) 7.9(4.5) * 29.6(8) 3.9(0.6) * 2.3(0.5) *
IBW (kg)** 63.5(6.8) ** 65.3(7.7) 62(7.3)** 61.6(7.1)**
BSA (m2)
1.94(0.23) 1.96(0.29) 1.8(0.25) 1.8(0.16)
BMI 28(4.7) 27(5.1) 25(5.5) 26(3.9)
mean values (sd) * p (<0.05) ** p (<0.01)
Table  8  The  nutritional  indices  compared  in  groups  with  varying
degrees of renal dysfunction
Gr la Grib Gr Ic Gr Id
nPCR  (g/kg/d) 1.2(0.2) 1.0(0.2)* 0.89(0.2)* 0.74(0.1)*
wDPI  (g/kg/d) 1.37(0.38) 1.2(0.3) 1.3(0.48) 0.98(0.15)*
FFM(Anthr) kg/1,73m' 50.6(5.4) 49.7(5.2) 49.6(4.4) 45.8(4.7)*
FFM(Bio) kg/1,73m* 50.6(7.9) 50.7(7.3) 50.69(6.9) 44.4(7.9)*
Albumin g/dl 40.8(3.4) 37.7(4.5)* 38.3(3.57) 35.1(4.7)*
Transferrin g/I 2.47(0.4) 2.24(0.3) 2.1(0.4) 1.87(0.23)*
mean values (sd)* p (<0.05) compared with Gr la  Anthr = anthropometry, Bio = 
Bioimpedance wDPI weighed protein intake nPCR = normalised protein catabolic rate
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Figure 1  Comparing mean ECW normalised to body weight and 
fat free mass between healthy controls and haemodialysis subjects
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Figure 2  Malnutrition  in uraemia is  associated  with  ECF  expansion
155Figure 3 Typical changes in ECW ( circle)  and ICW (triangles) meausred by 
bioimpedance during UF in a subject
(UF volume-2.4 L  Wt change  -2.6 L  Post ECW  13.8 L  ECWchange-2.1  L)
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Figure 4  Bioimpedance tracks ultrafiltrate volume removed during HD
(R2  = 0.93)
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Figure 5 Bioimpedance tracks body weight changes during HD  (R2 = 0.76 )
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Figure 6 Bioimpedance measured post ECF vs predicted post ECF (Guyton)
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Mean difference of measured ECW 1.67 L
157Controls 5%
CrCI >50 (15%)
CrCI25-50 
(15%)
CrCI <12 
(41%)
CrCI 12-25 
(28%) Fig 7b
CRF  \25%
29%  /CAPD
HD i%
Fig 7a
Figure 7 Subjective Global Assessment of  Nutritional Status ( SGNA )
Proportion of Malnourished subjects (SGNA  B & C) between groups (Fig 7a) & within 
nondialysis CRF group (Fig 7b) CrCI = creatinine clearance ml/min/1.73m2  
Single observer SGA  rating
A = Well  nourished  B = Moderately malnourished  C = Severely malnourished
Mean (+/- SD)
.2 (0.2)
I   0.89(0.2)
M   0.8  -
CrCI <50  25 - 50
ml/min/1.73m2
12-25 <12
Figure 8  Protein catabolic rate nPCR (g/kg/d) correlated  positively 
with creatinine clearance ml/min/1.73m2  ( r = 0.60  p < 0.001  )
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Figure 9 NUTRITIONAL  STATE  DECLINES  JUST  PRIOR  TO  DIALYSIS
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159Figure 10 Correlations of Albumin with other nutritional markers
Albumin & Other Nutritional markers  Significant
Correlations
Parameter ( R value )  P value
Transferrin (0.50),  IGF-1  (0.33)  < 0.001
CRP (-0.40), Phosphate (-0.26) 
dietary protein intake (0.28) 
cDPI (0.44 ), nPCR (0.43)
Prealbumin (0.26)
Mid upper arm circumference (0.22)  <0.01
Mid upper arm muscle circumference (0.18)
Anthropometry FFM  (0.17)  <0.05
Fig 11 Transferrin  Fig 12 Insulin Growth Factor -
2.4
2 2
20
i  ft
1.4
CAPD  CONTROL  CRF  HD  CAPD  CONTROL  CRF  HD
Transferrin  BEST CORRELATES (R VALUE )  P<0.01  IGF-1
Albumin(0.5), CRP(-0.24), Phosphate(-0.27) 
IGF(0.3), Choi (0.23), MUAMC (0.24), 
SSK(0.31) nPCR (0.30), cDPI(0.4)
Albumin(0.33) transferrin(0.3) 
prealbumin(0.21), nPCR (0.22), 
cDPI(0.22)
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Significant Correlations with CRP
R P value
Albumin -0.40 <0.001
Phosphate 0.26 < 0.001
Transferrin -0.19 <0.01
Prealbumin -0.19 <0.001
Bicarbonate -0.18 <0.05
nPCR -0.14 <0.05
Fig 13 C-Reactive protein and its correlation with other indices
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Fig 14 Dietary Protein intake ( DPI)
Calculated DPI* Hakim et al (g/d) (y) underestimated the 
weighed DPI (x)  (y= 18.5 + 0.62 x; r2 =0.27 R = 0.52  p<0.001).
161CrCI <12  CAPD<1 yr  CAPD > 1yr  HD <1yr  HD>1 yr
FFM (Anthr) kg/1.73m2 45.8(4.7) 48.2(5.6) 46.5(4.8) 50.4(5.5) 50.5(4.5)*
FFM (Bio) kg/1.73m2 44.4(7.9) 48.7(7.3) 47.8(7.3) 49.9(8.7) 49.3(6.3)*
wDPI g/kg/d 0.98(0.15) 1.15(0.22) 1.09(0.34) 1.16(0.26) 1.22(0.36)*
cDPI g/kg/d 0.83(0.21) 0.95(0.23) 0.81(0.26) 0.48(0.63) 0.33(0.34)
nPCR 0.75(0.1) 0.85(0.16) 0.73(0.19) 0.84(0.18) 0.91(0.19)*
Transferrin 1.87(0.23) 2(0.34) 1.79(0.25) 1.6(0.39) 1.6(0.31)
Albumin g/dl 35.1(4.7) 34(34) 32.3(4.5) 34.2(5.3) 36.1(4.3)
Prealbumin 33.2(6.6) 42.8(8) 37.2(8.9) 32.4(10.3) 31(8.8)
IGF-1 iu/1 22.9(8.8) 30.8(14.5) 18.4(8.5) 19(5.9) 17.7(7.9)
Sum skin folds (mm) 55.2(20.1) 47.8(14.6) 63.3(21.5) 48.6(17.9) 43(14)
Figure 15 Those on HD >  1   yr had  significantly higher (*p<0.05) FFM, 
weighed dietary protein intake  and nPCR when compared with 
CrCI<12ml/min/1.73m2
162Chapter 3
Relative blood volume measurements 
during Haemodialysis: Pilot studies
Introduction
Cardiovascular instability with symptomatic hypotension is still one of the major and 
most  frequent  complications  of dialysis  therapy.  This  limits  safe  and  adequate 
removal of fluid during HD. Hypovolaemia has been implicated as a major causal 
factor  of  morbidity  during  haemodialysis  (HD).  Unfortunately  the  morbidity 
associated with hypovolaemia is not limited to hypotension. Steuer et al. [206] have 
recently demonstrated that cramping and  light-headedness occurred in 28% of all 
treatment sessions, and in all cases those symptoms were preceded by a pronounced 
reduction  in  blood  volume  (BV).  The  pathogenesis  of intradialytic  hypotension 
remains complex and multifactorial. A common final pathway however is reduction 
in circulating blood volume [207].
Relative blood volume monitor measures the percentage blood volume change by 
detecting a change  in plasma density  and haematocrit during haemodialysis.  The 
initial blood volume  is assumed as  100%.  The measured plasma density and the 
corresponding blood volume are recorded continuously and the data stored via data 
acquisition software along with other machine variables. The change in blood density 
or haematocrit is inversely proportional to the blood volume changes [208]. Pattern 
display of such high resolution serial measurements may provide the basis for further 
detailed analysis of the changes in relation to ultrafiltration and dialysis.
The depicted blood volume profile provides a real time view of the vascular space 
and allows focus on vascular dynamics. Blood volume monitoring can be used for 
tracking  relative  changes  in  blood  volume  change  during  ultrafiltration.  Such  a 
changing blood volume profile can be displayed online and stored in memory during 
the dialytic process. This chapter presents selected pilot case studies, which illustrate 
a range of relative blood volume (RBV) changes that can be observed during dialysis 
with or without ultrafiltration.
163Relative blood volume changes during Haemodialysis in the absence
of ultrafiltration
During initial pilot studies in 5 subjects, I observed that under stable conditions the 
relative blood volume profile during high flux haemodialysis without ultrafiltration is 
an almost flat trace with minor fluctuations that may vary approximately between 
0.5-1% (Fig 1). Connection of the patient to the extracorporeal circuit using a straight 
connection the isovolemic stability was within a maximum variation of 1.5 % with a 
tendency to fall. The bleed out connection on the other hand produced slightly larger 
variations  (within  3.5%).  It  is  also  feasible  that  obligatory  ultrafiltration  during 
dialysis without volumetric control machines could produce such variations in blood 
volume profile in the absence of prescribed ultrafiltration. Major postural changes 
(sitting or standing from supine), submaximal exercise [209] or hypertonic solutions 
[210] are other manoeuvres that can significantly influence RBV variation during 
dialysis without ultrafiltration. A study evaluating the effects of diffusive dialysis on 
the changes in relative blood volume (RBV) on six stable haemodialysis patients, 
without  the  need  of  ultrafiltration,  during  10  sessions  of  diffusive  dialysis 
(bicarbonate)  lasting 4  h  with  RBV  monitoring continuously by  measurement of 
haematocrit showed that during the 1st and 2nd h RBV increased by 2.4+/-1.4 and 
2.5+/-0.8%  respectively,  returning  to  baseline  levels  at  the  end  of dialysis.  No 
changes  in blood pressure  or heart rate  were  noted.  They  concluded  that during 
diffusive dialysis without ultrafiltration RBV is increased. A decrease in vascular 
resistance,  or  changes  in  regional  blood  distribution  could  also  explain  these 
findings. It is also important to bear in mind that haematocrit changes may be more 
susceptible to osmolarity changes induced by diffusive sodium gradient. This effect 
is minimal in blood volume monitoring using the ultrasonic method. [211] Achieving 
stability of relative blood volume trace is essential before other volume dependent 
alterations to the circulation are examined during dialysis.
164Relative blood volume measurement during Haemodialysis with
Ultrafiltration
A typical blood volume profile in a single patient during a standard dialysis session 
with continuous ultrafiltration at a fixed rate is depicted in Fig 2a. The application of 
ultrafiltration during dialysis has the most significant effect on the relative blood 
volume profile. There is an almost instantaneous decay of the blood volume curve 
that corresponds to a simultaneous rise in plasma or blood density and haematocrit. 
The percentage reduction in blood volume from the baseline  100% starting value, 
reflects fluid removed by ultrafiltration provided there are no intravenous fluid or 
drug infusions and there is no evidence of blood loss or red cell destruction within 
the subject or in the extracorporeal circuit. The decrease in blood volume follows a 
gradual fall in systolic and mean blood pressure. In the later stages of dialysis when 
ultrafiltration pump is stopped either due to achievement of dry weight or due to 
hypovolemic symptoms like cramps or hypotension, the blood volume profile trend 
is reversed and the profile depicts a fall in plasma density and haematocrit and a 
simultaneous increase in relative blood volume. The infusion of fluids also has an 
instantaneous effect on profile with the usual appearance of a sharp spike.
The patient depicted in Fig 2a develops symptoms of cramps and hypotension after 
165 mins on dialysis at 92% blood volume at which point the UF was stopped. A 
steep fall in decay curve corresponds to the haemodynamic instability. Cessation of 
UF reverses the BV decay allowing for recovery of blood volume and stability. The 
patient has an effective reduction of 8 % blood volume at the end of dialysis. Fig 2b 
shows saline induced instantaneous blood volume recovery in a subject following 
hypotension.
The RBV profiles during standard UF show varying trends within each individual 
and between subjects. Pilot studies on 12 subjects showed wide RBV variation from 
78% to 103%, mean 92.6% + 5.4%. Stability of initial blood volume during a period 
of isovolemia was typically complete within the first  15-20 mins with a variation 
ranging from 0.1 -  3.7 % mean 1.2 ± 0.63. Reduction in RBV varies between 6-19 
%, which is not patient specific. During final refill period between end of UF and end
165of dialysis blood volume recovery was typically complete within the first 20 mins 
with a plateau in 75 % patients with a blood volume stability 0-1.5% , mean 0.35 + 
0.42. No correlation was found between UF and change in RBV.
In general three broad categories of curves can  be described a) flat profile where the 
blood volume variation was < 3 % b) stable profile with a curvilinear decay with 
tendency to plateau with progressive flattening c) unstable profile where the blood 
volume reduction is steep and almost linear. The profile a indicates that the effect of 
fluid removal had little effect on blood volume reduction and that the patient was 
grossly overloaded post ultrafiltration. This is the most useful application in day-to- 
day clinical practice, allowing identification of grossly overestimated dry weight. 
However the degree of overestimation cannot be accurately judged by such profiles. 
The profiles b and c are more difficult to categorise, diagnosis often retrospective 
and subjective in its interpretation.
Non-standard UF prescription can also have a significant effect on the RBV profile. 
Application of a continuously varying UF rate in a linear decreasing manner and its 
matching RBV profile is shown in Fig 3.  It demonstrates a curvilinear profile with 
the steeper decay of blood volume at the first hour of dialysis. The patient remains 
haemodynamically stable throughout despite 4 litres of fluid removal suggesting that 
variable UF rates with different alternative profiles may be more physiological and 
allow adequate fluid removal in a safe manner.
APPLICATION OF INTERMITTENT ULTRAFILTRATION  PROFILE
The principle of perturbation analysis was applied using short pulses of UF at a fixed 
rate with intervening rest periods. This allowed study of RBV changes during a UF 
phase  and  separately  during  an  isolated  refill  phase.  The  method  of  variable 
ultrafiltration rate or a sudden stop in UF pump has been used to measure vascular 
refilling  capacity  (Schneditz  et  al)  [212,  213].  The  use  of  such  a  profile  can 
demonstrate vascular refill from fluid filled interstitium during the UF free period 
evidenced by an increase in the relative blood volume.
166Fig 4a and 4b depicts typical intermittent UF profile where I applied bolus sequences 
that have been gradually reduced in strength (40 -  30 -  20 -  10 % of the total UF 
volume at high UF rates). This may allow removal of fluid in a graded manner 
(intermittent  linear  decreasing  rate)  despite  high  UF  rates  and  also  provide 
information on intervening UF free refill periods.
Each UF pulse can be individually analysed in two phases (Fig 5).  Two distinct 
phases are a) period of ultrafiltration depicted by an exponential decay or slope b) 
subsequent period of no ultrafiltration (refill) depicted by an RBV rise to maximum. 
Each refill curve pattern seems to be widely variable. Broadly they can be described 
as an exponential to a maximum rise to a plateau, linear with a plateau or sine wave 
polynomial. (Fig 6) The variability in the refill curves is more pronounced in the later 
stages of ultrafiltration. Sometimes the waveform may have more than one definition 
with a tendency of one waveform to change its configuration and merge into the 
other waveform.
Conclusion
There is an insignificant change in the blood volume profile during a  supine dialysis 
session with no ultrafiltration. Establishing a stable RBV baseline during isovolemia 
more easily achieved by a straight connection to the extracorporeal circuit. A period 
of approximately 20 mins is necessary without ultrafiltration, until a 100% baseline 
is achieved with accuracy. The application of UF significantly alters the RBV profile 
during dialysis. Pattern recognition of such changes yield variable curves primarily 
influenced  by  UF  prescription  and  wide  interpatient  and  intrapatient  variability. 
Steeper  blood  volume  curve  more  frequently  associated  with  haemodynamic 
instability. A short single pulse of UF can induce a typical blood volume profile. 
Characteristic sharp RBV decay is followed by RBV rise to a plateau during the UF 
free period. Analysis of such UF pulses may provide information on haemodynamic 
response to UF and dry weight.  There is a lack of signoificant decrease in RBV 
observed  in  states  of overhydration,  while  the  steepest RBV  slope  is  related  to 
hypovolaemia. Thus, continuous monitoring of RBV during HD could be useful in 
hypotension-prone patients. Further studies were performed to define the character of 
the RBV profile during ultrafiltration.
167Figure 1  RBV profile during standard dialysis but  no ultrafiltration 
Position supine ; UF Rate 0  ml/hr  Predialysis wt 65.7 kg  DW 66 kg 
Urine output 1.2 litres / 24 hrs
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Figure 2a  RBV profile during standard continuous fixed UF 
Position supine  Predialysis wt 73.2kg  DW 70 kg 
UF Rate 1150 ml/hr  UFV  3220 ml  Delta RBV - 8 % 
Cramps and hypotension at RBV  -10%
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Figure 2b  Instantaneous blood volume recovery 
and stability with saline bolus
UF turned off Spontaneous blood volume recovery
Blood volume & BP stability
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RBV tract
Saline 
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Time secs
Figure 3  RBV profile with a linear decreasing UF rate 
Supine Predialysis  wt  80.1kg  DW 76kg 
UF Rate 1800 ml/hr to 170 ml/hr  UFV  4000 ml 
Delta R B V -17.8  %  Asymptomatic
169Figure  4a  Intermittent Ultrafiltration profile ( Step UF )
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during dialysis with step UF
170Figure 5  Blood volume response to a single ultrafiltration pulse
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Figure 6 Post UF refill period showing variable response curves
171Chapter 4
Characterising  Relative  blood  volume 
changes  during  reduction  of postdialytic 
weight  in  successive  dialysis  using 
intermittent UF
Summary
The  aim  of this  experiment  was  to  investigate  the  relative  blood  volume  curve 
responses to intermittent step ultrafiltration (UFVS ) at different states of hydration. 
12 haemodialysis patients were studied over 40 dialysis treatments in undergoing 
reduction in their dry weight using an intermittent high rate ultrafiltration profile to 
observe  differences  in  blood  volume  responses  and  vascular refilling  at varying 
degrees of hydration and to try to determine whether these changes can be used to 
predict the onset of haemodynamic instability during haemodialysis as the dry weight 
is approached. RBV magnitude (ARBVuf), rate of RBV refill (IRR),  rbv decay and 
refill  curve  coefficients  (tuf,  tref)  were  compared  at  various  stages  of UF  and 
proximity to dry weight (PDW).  ARBVuf was  significantly correlated with UFVS  
(r=0.81, p<0.001). This applied for all the boli (Stepl r= 0.80 p< 0.001; step 4 r= 0.6, 
p=<0.01) By stepwise regression analysis, determinants of ARBVuf were UFVS  IRR, 
tuf and patient specific factors (p<0.01,R=0.915,). Factors determining tuf were A 
RBVuf/UFVs, hypotension, proximity to PDW (R2=0.48 p<0.01) but tref was patient 
specific only (p<0.001).  Hypotension was predicted by ARBVuf/UFVs  (p<0.001), 
UFVs  and  xUF  (p<0.01)  (R=  0.56,  R2=0.32).  ARBVuf/UFV,,  IRR  and  tUF  were 
significantly higher in hypotensive (n=13) than nonhypotensive (n=146) UF steps 
(p< 0.01) even when the analysis was restricted to UFVS  < 250 mis. (N=13 Vs n=49). 
In the same patient, ARBVuf/UFVs,  tuf and IRR were significantly different with 
identical UFV, between hydration states differing by >lkg (p<0.01).  Proximity to 
PDW at each UF step was predicted by ARBVuf/UFVs, tuf, IRR (p<0.01) and 
ARBVuf (p<0.05) (R=0.63,R2=0.39).  The parameters derived during these studies 
were strongly dependent on the size of the administered UF bolus.
172Introduction
Despite advances in dialysis techniques, determination of dry weight (PDW) and 
prevention of haemodynamic instability on dialysis remains rather subjective, crude 
and empirical. Dialysis treatment times have decreased worldwide in recent years, 
whilst  interdialytic  weight  gains  have  remained  unchanged.  High  UF  rates  are 
therefore  required  and  often  varied  to  achieve  the  desired  fluid  removal  in  the 
allotted time. This increases the likelihood of an imbalance between UF and vascular 
refilling. The importance of preservation of the vascular space to a patients*  well 
being  during  haemodialysis  (HD)  is  well  known  [214].  To  tackle  this  problem, 
relative  blood  volume  (RBV)  monitoring  during  UF  has  been  advocated. 
Hypotension during HD, although multifactorial is largely related to plasma volume 
depletion.  [214, 215] It has been suggested that monitoring relative blood volume 
changes during UF may allow achieving the prescribed dry weight in a safe manner. 
[207] The use of technically simple and reproducible tools to characterize such blood 
volume  changes  during  UF  in  a  refined  and  more  predictive  manner  may  be 
potentially an invaluable aid to the clinician. There is little data comparing blood 
volume and vascular refill responses to UF in the same subject at different states of 
hydration. [216] The use of blood volume changes and intermittent graded high rate 
UF allows such analysis.
The aim of the study was to define parameters that characterise the relative blood 
volume changes during ultrafiltration at varying states of hydration and determine 
whether blood  volume  profile  during UF  may  predict incipient hypotension  and 
proximity to dry weight. The principle of perturbation analysis was applied by using 
short bursts of UF at a high rate with intervening rest periods. This allowed study of 
RBV changes during a UF phase and separately during an isolated refill phase.
173EXPERIMENTAL SET UP 1
Patients and Methods
Patient Characteristics
Stable patients  on  maintenance  HD  with  adequate  haemoglobin  (>10  g/dl)  and 
serum albumin (> 30g/dl) levels were enrolled into the study.  Haemodynamically 
unstable patients (those with cardiac  failure  and  those with  frequent hypotension 
during HD) and those with an unstable vascular access were excluded. The patients 
had been on HD for a mean 16+1-5 months and the mean age was 58.5 yr. (range 
25-76 yrs).  The mean haemoglobin and serum albumin levels at start of the study 
were 11.1 +/- 0.5 g/dl and 37 +/- 2 g/dl respectively. Informed consent was obtained 
from all subjects. The North Herts Ethical Review Committee approved the study.
Dialysis technique
All patients received high flux HD 3 times per week using bicarbonate buffer, 1.0- 
1.4 m2  hollow fibre polysulfone membranes with blood flow rates of 300-500ml/min, 
dialysate flow rates 800 ml/min and the Fresenius delivery system with an inbuilt 
ultrasonic  blood  volume  monitor.  Dialysis  was  prescribed  according  to  a  UKM 
[112]. Dialysis fluid composition according to standard specifications in the unit (see 
Methods)  with  the  dialysate  temperature  maintained  at  36  degrees  Centigrade. 
Patients had previously been ultrafiltered to their clinically defined dry weight. At 
high UF rates the transmembrane pressure across dialyser reached high levels but 
remained below the safety limit given by the manufacturers. No food or drink, were 
allowed during dialysis sessions.  Mean ultrafiltration  (UF)  volume  (UFV) ranged 
from 900 - 3500 mis and the mean treatment time was 3hr 30 mins.
Blood volume monitoring
Blood  volume  (BV)  monitoring  was  performed  using  real  time  online  ultrasonic 
blood  volume  monitor  (Fresenius  BVM),  which  measures  the  velocity  of sound 
across flowing blood (using a cuvette in the extracorporeal circuit designed for this 
purpose) depending on changes in the density of total protein content (sum of plasma 
proteins and haemoglobin).  The relative blood volume (RBV) at any given point of
174time may be determined from the changes in the protein concentration relative to the 
initial starting value.
Definitions
Drv weight:
Dry weight was defined as the lowest weight a patient could tolerate without the 
development of hypotension or suggestive symptoms such as dizziness, faintness, 
nausea or cramps
Hypotension
Hypotension was defined as a systolic BP < 90 mm Hg or a fall in mean BP of > 30 
mmHg associated with symptoms of suggestive of hypovolemia, such as dizziness, 
faintness, nausea or cramps.
Protocol
Variable volume step ultrafiltration
Forty treatments  were  initially monitored  in  12  patients  who  were  undergoing  a 
sequential reduction of their dry weight over successive dialysis. An identical UF 
profile was used in all treatments. Following an isovolemic period in supine position 
(20 min equilibration phase),  intermittent UF pulses were applied  sequentially  in 
order to remove 40%, 30%, 20% and 10% of the total UF volume for that session (in 
the same order) at a rate of 31/hr. Each UF step was followed by an UF free phase of 
20-30 minutes to allow equilibration. Fig 1  The UF step volume (UFV) ranged from 
100 - 1050 ml. The post dialytic weight was reduced by 0.5 kg at each HD during 
successive treatments. The occurrence of a hypotensive episode near the end of the 
treatment was the defined endpoint. A symptomatic dialysis session was defined as 
one  in  which  hypotension  occurred  necessitating  cessation  of UF  or  infusion  of 
saline. No food or drink was allowed during dialysis.
175Definition of Parameters
ARBVuf  (%)  The magnitude of RBV change during UF
ARBVuf/UFV, (%/ml)  The magnitude of RBV change during UF per ml of UF volume 
UFVS  (ml)  Volume of ultrafiltration pulse
ARBVref (%)  The magnitude of RBV change during the refill period
following the UF pulse 
"tuF  Decay constant for a single exponential decay
Tref  Constant for an exponential rise to a plateau
IRR (%/min)  Initial refill rate-the refill volume during the first minute
after stopping UF
Derived Parameters, i. Decay constants. Automated curve fitting analysis was used 
to analyse the best-fit equation (n = 8500 Adjusted fit ^=0.98, least squares 
regression analysis) using Table curve 2D software (see methods). In order to 
determine the decay constants the RBV responses were fitted into single exponential 
functions:
y *  b e "x /c  for the UF phase, and  [168]
y = a + b [ 1- e ' x /c ]  for refill phase. [168]
The major parameters derived Fig 1  was, in the UF phase, the ultrafiltration decay 
constant c  (tuf>  and in the refill phase, the refill phase constant c  (xreo-  Other 
parameters were the value  ‘b’  in the above equations, during UF representing the 
amplitude of RBV changes (UF decay amplitude) and during refill representing the 
amplitude of refill RBV change (refill phase amplitude) with the refill starting at 
point ‘a*.  The fitting was done using  100 iterations. Only constants derived from 
curve fits with dependencies > 0.80 was used for analysis.
Statistics The statistical tests used were the Students* t-test (paired) for differences 
between means and Pearson correlation coefficient. Chi-squared analysis was used 
for unpaired data. All analyses were done using the SSPS  statistical package and 
Sigma plot statistical software (Jandel Scientific) [ see methods ]
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1.  Fixed UFR. Variable volume step UF (40 Treatments^
The mean RBV reduction during a hypotensive dialysis session 14.1 +/- 4.7 % was 
significantly higher than other nonhypotensive dialyses (10+/- 3.6 %). Fig 2 depicts a 
typical RBV profile with intermittent uf in a subject enrolled at the start of the study. 
Fig 3 in the same patient depicts the RBV profile at the final hypotensive dialysis 
session.  Significant  reduction  in  BP,  RBV  and  postdialysis  occurred  in  the 
hypotensive sessions. (Table 1)  Mean reduction in PDW per patient over the study 
was  1960  ±  650  mis.  ARBVuf  was  significantly  correlated  with  UFVS   (r=0.81, 
p<0.001).  This applied  for all UF pulses (Stepl  r= 0.80 p< 0.001;  step 4 r= 0.6, 
p=<0.01) The measured blood volume decay parameters and rate of change in blood 
volume during UF and refill phase at 1, 5 and 10 mins are depicted in Table 2 and 
Table 3.
Fitting experimental data.
Mean dependency was 0.89 +/- 0.035(b), and the coeff of variation 1.23%. Unlike 
the exponential fit for UF the fitting of refill data was less satisfactory. [168]
1.1  Determinants of change in relative blood volume
The change in RBV during a pulse of ultrafiltration (ARBVuf) was highly correlated 
with the volume of that UF pulse (UFVS ) (r=0.84, p<0.001). Fig 4 The rate of change 
in blood volume in the first and second UF pulses was significantly correlated with 
the  volume  of the ultrafiltrate  (bolil  r=  0.90, p<0.01;  boli2  r=0.89,p<0.01).  This 
correlation was also observed in the later uf pulses (prefinal pulse r=0.80,p<0.01; 
final pulse r= 0.42 p<0.05) although at lower significance. (Fig 5)
By stepwise multiple regression analysis (R2 =0.743) the determinants of ARBVuf 
were  UFVS   (p<0.001),  patient  specific  factors  (p=0.015),  and  distance  from  dry 
weight (p<0.041). (Fig 6) Whether or not hypotension occurred during the bolus was 
not a significant determinant. When ARBVuf during a bolus was corrected for bolus
177size (ARBVuf/ UFVs), whether or not hypotension occurred during the bolus became 
a significant determinant (p<0.001) but in this model, distance from dry weight was 
not a significant factor. UFVS  remained a highly significant determinant (p<0.001) 
(overall R2=0.239). The only significant determinants of ARBVref (overall R2=0.336) 
were the bolus number and UFVS   (both PO.OOl). The predictors of 1RR (overall 
R2=0.239) were the bolus number and UFVS   (both PO.OOl), and proximity to dry 
weight (p=0.003).
1.2 Determinants of ultrafiltration decay constant (tuf) and refill constant (tref)
Factors determining tuf were whether or not hypotension occurred during the bolus 
(pO.OOl), and proximity to dry weight (p=0.02)  (overall R2=0.222) but  tref was 
patient specific only (p<0.001) (overall R2 = 0.113) (Fig 6)
1.3 Predictors of hypotension and proximity to dry weight
Proximity to dry weight at each UF step correlated with ARBVuf (R=0.50: p<0.001), 
UFVs (R=0.5: p<0.001) and tuf (R—0.36: p=0.064). By multiple regression analysis 
ARBVuf and tuf emerged as the significant predictors of proximity to dry weight 
(overall  R2=0.35  and  pO.OOl  in  both  cases).  In  logistic  regression  analysis, 
hypotension was predicted by ARBVuf (p=0.015) and ARBVuf/UFVs (pO.OOl) (Fig 
6).
ARBVuf/UFVs  (2.64 +/- 0.65 vs  1.72 +/- 0.65), and tuf  (21.3 +/- 4.4 vs  14.4 +/- 
14.2) were significantly higher and UFVS  (149 +/- 53 vs 362 +/-199) and ARBVuf 
(3.80+/-  1.35  vs  5.91+/-  3.07)  were  significantly  lower (pO.OOl  in all  cases)  in 
hypotensive (n=14) compared with non-hypotensive (n=146) UF steps.
Initial refill rate ( IRR)
The initial refilling rate (calculated immediately after a period of ultrafiltration) was 
limited to a mean 0.78 +0.13 %/min (Fig 7a). At veiy low blood volumes (RBV 
reduction of more than 15%) this may be exceeded (Fig 7b).
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This  experiment  investigates  the  relationships  between  relative  blood  volume 
responses, vascular stability and dry weight during intermittent ultrafiltration. The 
blood  volume  decay  characteristics  were  overwhelmingly  influenced  by  the  UF 
volume and rate. However the UF decay constant and the rate of change in blood 
volume predicted hypotension and proximity to dry weight when adjusted for the 
ultrafiltrate volume.
The lack of strong correlation of simple RBV parameters to approaching dry weight 
(ARBVuf barely reaching significance at p < 0.04) could be explained by various 
factors.  Susceptibility  to hypotension  under conditions  of hypovolemia is  largely 
dependent on  the  performance  of the patients’  compensatory  mechanisms.  Apart 
from  the  overriding  influence  of UF  volume,  vasoactive  medications,  vascular 
compliance, sympathetic responses and cardiac contractility are perhaps significant 
contributory factors. The absence of ultrafiltration during the refill phase allows the 
other factors to become dominant in shaping refill responses. Consequently blood 
volume  changes  during  refill  phase  are  highly  patient  specific.  A  further 
consideration would be the fact that excess blood volume and interstitial fluid are not 
linearly distributed due to Guyton relationship.[78]
Following a period of ultrafiltration there is a refilling phase as fluid from interstitial 
space replenishes the vascular compartment compensating for blood volume loss. 
Refilling time and rates during periods of no ultrafiltration was examined to analyse 
vascular refilling. This was done using data from a selection of arbitrary time points 
during refilling process..  The  first minute refill post UF  cessation correlated with 
haemodynamic changes, perhaps reflecting an effect of haemodynamic compensation 
mechanisms on this refill parameter or refill capacity. The initial refill rate seemed to 
be  plateau  between  RBV  85  -   95%  but tended  to  be  higher  at very  low blood 
volumes (RBV<85%). This phenomenon (initial forced refill) in conditions of severe 
plasma volume  depletion could be  due  to  underlying physiological processes  i.e. 
vasoconstriction or splanchnic effect. It is also unclear whether recirculatory effects 
could  affect these  changes.  A  few  patients  prior  to  developing  hypotension  are
179capable of a higher initial refill rate an important consideration in the design of blood 
volume control systems.
Parameters derived for refill curve analysis in this experiment disappointingly failed 
to  convincingly  predict  patients  prone  to  hypotension  or  with  poor  refill 
characteristics. The refill response curve was predominantly patient specific. The rate 
of refilling is dependent on factors such as the size of the vascular space, the degree 
of hydration,  oncotic  forces  and  the  performance  of active  refill  processes  etc. 
Monoexponential fitting of refill phase of the blood volume curves were less also 
satisfactory than UF phase with lower dependencies. This probably indicates that the 
refilling phase is an integral function of multiple physiological forces as opposed to 
UF where the high UF being the dominant physiologic process tends to have a more 
pronounced effect on the blood volume changes.
RBV  reduction  adjusted  for  volume  of  ultrafiltrate  (ARBVuf/UFVs)  and 
ultrafiltration decay constant (tuf) seemed to be the two most powerful predictors of 
approaching  dry  weight  and  impending  haemodynamic  instability.  This  perhaps 
suggest that the hydration status and the haemodynamic effects of ultrafiltration have 
a major influence on the shape the RBV profile. Linear and nonlinear equations that 
characterise  physiologic  processes  are  defined  by  their  coefficients  and  basic 
function  (b,  1/c  (tuf),  cumulative  area  under  curve  (AUC))  and  not  just  the 
appearance of the curve  (Fig  8).  To investigate this,  in the next phase  of study 
intermittent equal steps of UF volume at a fixed rate were applied to investigate the 
blood  volume  responses  (curve  decay  characteristics  and  coefficients)  to 
ultrafiltration at differing states of hydration.
180Tablel.  Comparing  hypotensive and nonhypotensive dialysis 
sessions
Blood volume Parameters Non-hypotensive Hypotensive
Mean SD Mean SD
ARBVuf (%) * 10.0 3.6 14.1 4.7
ARBVuf (%)/weight  (%/kg) ♦ .11 .05 .18 .08
Systolic BP reduction  (mmHg) * 24 18 52 10
Predialysis body weight  (kg) * 92.4 24.1 87.2 26.5
UFV (mis) 1689 734 1674 590
*P<0.05 SD=standard deviation, UFV= ultrafiltration volume, RBV= relative blood volume
Table 2.  Blood volume responses to Ultrafiltration pulse
Pulse 1 (40%) 
NH  H
Pulse 2 (30%) 
NH  H
Pulse 3 (20%) 
NH  H
Pulse 4 (10%) 
NH  H
Volume (ml) 597(350) 590(190) 485(120) 435(180) 314(172) 329(96) 157(90) 165(42)
Bolus Width  (min) 13.6(7.6) 8.9(4.2) 8.9(5.5) 7.5(2.7) 7.1(4.3) 6(1.9) 4.8(2.3) 5(2.8)
ARBVu f (%) 9.2 9.5 8.5 7.4 5.8 5.6 3.5 4.7*
(3.7) (24) (3.1) (2.0) (2.7) (1-4) (19) (1.3)
ARBVuf (%)dRBV 7.2 6.5 5.6 5.8 4 4.75 3.1 4.9*
corrected for BV (%) (3.6) (2.4) ((3.5) (2.0) (1.2) (15) (13) (1.5)
ARBVuf (%) at 0.99 0.99 1.12 1.1 1 1 1.09 1.0
1 min of UF (61) (0.44) (0.46) (0.4) (0.75) (0.4) (0.6) (0.42)
ARBVu f corrected 14.9 16.8 15 17 17.4 17 18.6 20*
for UF volume (%/l)
(4) (3) (3.8) (3.6) (8) (4) (1.4) (5.6)
ARBVuf = reduction in relative blood volume during UF.
NH= nonhypotensive treatment  H= hypotensive treatment
Figures in parentheses indicate sd of mean. * P<0.05 between H and NH treatments
181Table 3. Rebound Blood volume ( Refill responses) to individual 
Ultrafiltration pulse
Parameters Rebound 1 Rebound 2 Rebound 3 Rebound 4
NH H NH H NH H NH H
Duration(mins) 21.8 19 22 21.4 22.9 19 20.4 17.1
ARBVrer (%) 3.99
(2.6)
3.43
(1.1)
3.49
(2.11)
3.33
(1.38)
3.44
(2.24)
3.29
(1.08)
2.83
(1.81)
3.08
(1.46)
1 min refill rate (%/min) 0.91
(0.61)
0.77
(0.27)
0.74
(0.46)
0.88
(0.44)
0.95
(0.79)
0.95
(0.35)
0.96
(0.99)
1.1
(0.55)
5 min refill rate (%/min) 0.25
(0.19)
0.07
(0.41)
0.21
(0.23)
0.16
(0.15)
0.13
(0.24)
0.14
(0.21)
0.14
(0.24)
0.22
(0.33)
10 min refill rate (%/min) 0.04
(0.35)
0.14
(0.14)
0.07
(0.20)
0.06
(0.21)
0.05
(0.18)
0.12
(0.13)
0.14
(0.22)
0.04
(0.23)
ARBVref = increase in relative blood volume during refill phase.
NH= nonhypotensive treatment  H= hypotensive treatment.
Figures in parentheses indicate sd of mean. No significant differences obtained
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183Figure 2 A typical Step UF  profile in a subject at start of experiment 2 
Inset: Overhydration state superimposed on schematic Guyton curve
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184Figure  4  Correlation of the volume of the ultrafiltrate step at 
each bolus and the magnitude of relative blood volume change in 
Experiment 1  (Regression line with 95% confldnce intervals)
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Figure 5  Step UF Volume  and  RBV reduction 
(d_RBVU F)  demonstrating significant correlation 
for first and final ultrafiltrate pulse.
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Figure 6  Stepwise regression analysis  for determinants of UF and refill 
characteristics and predictors of hypotension and proximity to dry weight
Variables  Determinants
d_RBVUF  * UFVs  , tauUF, IRR and patient specific factors (r = 0.915)
tau UF * hypotension,  proximity to PDW,  d_RBVUF/U FV s
M
I
I
o
c
tauR E F   ** patient specific only
*(p<0.01  )** (p<0.00l)
Predictors*
Hypotension  d_RBVUF /  UFVs  ,  UFVs  ,  tauUF  (r = 0.56)
Proximity to PDW  d_RBVUF/  UFVs,  tauUF,  IR R ,  d_RBVUF (r =0.63)
* ( p<0.05 )
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Figure 7  Maximal refilling rate ( IRR) at low (a) and extremely low 
(b) relative blood volumes.
187Figure 8 Simulation of the single exponential [y=be (~x/c> ] decays 
(Exp curves A, B, C) with identical coefficient [b (amplitude) = 
10] and varying decay constant (c) [c (rate constant) = t (tau)]. 
The equivalent parameters on a UF induced exponential decay 
curves are c = tU F, and b = UF decay amplitude.
y = a + be ' ^1/c^
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188Chapter 5
Analysis  of  the  relative  blood  volume 
changes  during  intermittent  isovolemic 
step  ultrafiltration  and  its  relationship  to 
hypotension and proximity to dry weight
Summary
Relative blood volume (RBV) changes during haemodialysis (HD) are difficult to 
interpret. The aim was to define parameters to characterise RBV profiles at different 
hydration states, and examine their use in predicting haemodynamic instability. The 
following experiment constituted the second phase of the study in which UF steps 
applied were isovolaemic. The UF induced RBV characteristics derived in this part 
of the study were less dependent on  UF volume.Thirty patients underwent online 
RBV monitoring during a single HD session during which intermittent ultrafiltration 
(UF)  pulses  were  administered  until  the  onset  of hypotension.  The  RBV  decay 
constant (x) and decay amplitude, were derived by curve fitting. Linear divergence, 
the net deviation  from  predicted  linear decay of the  RBV  curve  during UF,  was 
computed from an initial 1  minute slope.
The best correlation with proximity to dry-weight (PDW) was provided by Linear 
divergence  (r =  0.817,  p  <  0.001),  its  major  determinant  in  multiple  regression 
analysis. Other predictors were RBV at initiation of UF pulse, UF pulse volume and 
UF decay constant (tuf). These parameters were significantly different in UF pulses 
within  1kg  and  >  1kg  of  dry  weight.  There  were  no  correlations  with  refill 
parameters. The occurrence of hypotension was not different at RBV <90% [7.4%] 
and £ 90% [5.3%]. tuf, Linear divergence, RBV at initiation of UF pulse (all p <
0.001), and UF decay amplitude  (p<0.01) were different between hypotensive and
•  2 normotensive UF pulses.  Hypotension was the only independent predictor of  tuf (R 
= 0.40: pO.OOl). The only independent predictor of Linear divergence was PDW 
(R2 = 0.667: pO.OOl).
Linear divergence and  tuf,  measures  of the  deviation  from  linearity  of the  RBV 
curve during UF, predict hypotension and thus more helpful in predicting the onset
189of haemodynamic instabilty as dry weight was approached. The most useful of these 
parameters was a quantity we have designated the “refill divergence”, which is a 
measure of the deviation from linearity of the RBV curve during UF. Approaching 
dry weight the RBV decline during UF switched from exponential to linear decay, 
probably indicating failing vascular refill. Monitoring deviation from linearity may 
allow  improved  haemodynamic  stability  and  attainment  of optimal  post-dialysis 
weight.
Introduction
The process of ultrafiltration  (UF)  has  a marked effect on the hydrostatic  forces 
within the fluid compartments. Initially the ultrafiltered volume is withdrawn from 
the  intravascular  compartment.  A  fluid  shift  from  the  overhydrated  interstitium 
towards  the  intravascular  space  (refill)  forms  the  predominant  compensatory 
mechanism to overcome or diminish hypovolemia. The rate of vascular refilling is 
therefore an important determinant of the extent of plasma volume depletion. [217] 
These two complex processes  interact with  each other to alter fluid  shifts across 
compartments and the effects of this interaction may vary with differences in volume 
status.  It  has  been  suggested  that  haemodynamic  stability  is  less  likely  to  be 
compromised  if the proportion of blood  volume,  which  is removed  during a HD 
session does not exceed 8-10% per hour [207]. The fundamental problem with this 
concept is that it takes no account of the patient’s response to fluid removal, whether 
physiological  or  pathological.  Standardised  parameters  to  define  optimal  blood 
volume reduction are well understood.  This severely limits its clinical utility.
The  aim  of this  study  was  to  define  parameters,  which  might characterise  RBV 
changes during isovolemic UF pulses at varying states of hydration, and to assess 
whether using these might help predict haemodynamic  instability during UF. The 
following experiment constituted the second phase of the study in which UF steps 
applied were equal in volume and rate (isovolemic) during a single dialysis session. 
The UF induced RBV characteristics derived in this part of the study were therefore 
less dependent on UF volume.
190The most useful of the parameters we derived, was a quantity that I have designated 
the “linear divergence”, which  is a measure of the deviation from  linearity of the 
RBV curve during UF. The use of such technically simple and reproducible tools to 
characterize  RBV changes  during  UF  in  a predictive  manner may  be  potentially 
valuable clinically.
(A)  EXPERIMENTAL SET UP 2 
Patients and Methods
Patient Characteristics
Thirty stable patients on maintenance HD with adequate haemoglobin  (>  10 g/dl) 
and serum albumin (> 3 g/dl) levels were enrolled into the study. Patients within 3 
months of starting dialysis, hemodynamically unstable subjects (those with cardiac 
failure and  frequent hypotension during  HD)  and those with  suboptimal  vascular 
access were excluded. The studied patients had been on HD for a mean  13  +/- 3 
months and had a mean age of 54.5 yr. (range 22-77yrs).  The mean haemoglobin 
and serum albumin levels at start of the study were 10.8 +/- 0.6 g/dl and 3.8 +/- 0.3 
g/dl respectively. The predialysis blood pressures were 141.8 +/-19.6 (systolic), 75.4 
+/-  10.9 (diastolic) and 97.5  +/-  11.6  (mean) mm Hg. Thirteen subjects were not 
receiving antihypertensive medications,  13  subjects were taking one agent, 3 were 
taking two agents and  1   was taking three agents.  Informed consent was obtained 
from all subjects. The North Herts Ethical Review Committee approved the study. 
Dialysis technique (see Chapter 4, Experiment 1 & Methods )
Blood volume monitoring (see Chapter 4, Experiment 1 & Methods)
Definitions of Dry weight: & Hypotension (see Chapter 4, Experiment 1)
Protocol
i.  Thirty  subjects  with  stable  dry  weight  were  studied  during  a  single  midweek
191dialysis session.
ii. UF during the study was performed as follows: the initial UF pulse removed 40% 
of the interdialytic weight gain (IDWG) followed by a UF free equilibration period 
of 20-30 minutes.  Subsequently, 3 equal, intermittent UF pulses (20% IDWG) were 
carried  at  a  rate  of  31/hour  (isovolemic  pulses  for  each  study)  with  UF-free 
equilibration periods of at least 20 minutes between pulses until the patient became 
hypotensive. If hypotension had not occurred after 3 UF pulses, additional pulses of 
the same volume were administered until the onset of hypotension.
iii Treatment of hypotension consisted of stopping UF and, if necessary, infusion of 
saline (approximately  100ml) at repeated intervals till the BP recovered. The post 
dialytic weight on that day was then set as the achieved dry weight. The proximity 
to  the  dry  weight  at  any  point  during  the  dialysis  session  was  determined 
retrospectively, as the UF volume (in millilitres), which would need to be removed to 
reach this achieved dry weight.
iv Blood pressure (BP) and pulse rate was recorded every 20 min or more often when 
suggestive symptoms occurred.
v. Only data from RBV profiles obtained during isovolemic pulses (i.e. those during 
which 20% of total ultrafiltered volume was removed) were utilised in subsequent 
analyses. Data from the initial UF pulse (during which 40% of the UF volume was 
removed) were not analysed. This is because in pilot studies, UF pulse volume was a 
major determinant of RBV decay characteristics, tending to obscure the effects of 
patient specific factors on this parameter.  RBV data following saline infusion were 
censored  and  excluded  from  the  analysis  since  the  RBV  profile  may  have  been 
altered by the presence of saline in the extracorporeal circuit.
Data Acquisition
A customised data acquisition system using dedicated software (including Microsoft 
Excel) and a personal computer was used to store and analyse experimental data.
1S2Filtering of data was required prior to precision analysis. The data were processed in 
two steps.
Step  1   Filter processing:  Raw relative blood volume data was processed using a 
smooth filter function to reduce noise in the data [218]. Reversing the filtered data 
output in a second pass through the filter eliminated possible distortion due to time 
delay resulting from the filter’s non-linear phase shift.
Step2: RBV transition and RBV transition time.  A brief lag period followed the 
initiation  of each  UF  pulse  before  any  resulting  transition  occurred  in  the  RBV 
curve. This transition was named, the RBV transition and the time delay, the RBV 
transition time (Tt). Mean Tt for all UF pulses was 33.4 +/-10.0 seconds. Tt probably 
represents the transit time of ultrafiltered blood from the dialyser through the bubble 
trap,  venous  needle,  cardiopulmonary  circulation,  back  through  the  fistula  and 
arterial needle and finally to the BVM. Tt thus depends on factors such as cardiac 
output, Qb, and tubing and vessel dimensions. All estimates of measured and derived 
RBV parameters were initiated from the point of RBV transition.
Measured Parameters  Parameters analysed in a typical relative blood volume 
profile (see Chapter 4, Experiment 1)
Derived Parameters.
i. Decay constants, (see Chapter 4, Experiment 1)
ii.  Linear  divergence  A  sample  of relative  blood volume  data obtained  over  1  
minute during the UF phase beginning at 30 seconds after the RBV transition was 
used to  compute the  relative  blood  volume  linear  slope.  Fig  1   depicts  simulated 
exponential decay curves with identical coefficients but variable decay constants 
(Line A, B, C ). The area between the linear and experimental curve data for each 
curve was derived by integration to obtain the net deviation of the experimental UF 
curve from its extrapolated initial linear slope. This is illustrated schematically in Fig 
2a and 2b. This quantity was termed, the  Linear divergence (%.  seconds). This 
quantity is defined as the net deviation of the RBV decay curve during UF from the
193linear decay curve extrapolated from an initial  1   minute RBV slope. The change in 
Linear divergence as target weight is approached during successive UF pulses in a 
single patient study is shown in Figure 3.
Statistical Analysis
The statistical tests used were the Students’ t-test (paired) for differences between 
means, the Pearson correlation coefficient to explore the relationships between pairs 
of variables, and multiple regression analysis to explore the relationships between 
multiple variables. Chi-squared analysis was used to determine the significance of 
proportional differences. All analyses were performed using the Systat 9 and Sigma 
plot statistical software. [ see methods ]
Results
Mean interdialytic weight gain was 2.19 +/- 0.89 kg. The mean isovolemic UFVs 
was 470 +/- 142 ml. Mean interdialytic weight gain was 2.19 +/- 0.89 kg.
Correlations with proximity to dry-weight The correlations between the measured 
and derived relative blood volume parameters during the UF and refill phases and 
proximity  to  dry  weight  (PDW)  are  shown  in  table  1.  The  best  correlation  was 
provided by Linear divergence  (r = 0.817,  p < 0.001) Figure 4. There were also 
significant correlations with ARBVuf/ UFVs, RBV at initiation of UF pulse, UFVS , 
and  UF  decay  amplitude.  There  were  no  significant correlations with  any  of the 
parameters relating to the refill phase. When these significant factors were examined 
in stepwise multiple regression analysis, the strongest predictor of proximity to dry 
weight was Linear divergence  (P =  0.527:  pO.OOl).  Other significant predictors 
were RBV at initiation of UF pulse (P = 0.242: p 0.001), UFVS  (p = 0.161: p = 
0.035) and tuf (P = 0.147: p = 0.037). The overall adjusted R2 was 0.756. There were 
significant differences between all these parameters together with ARBVuf/UFVs and 
UF decay amplitude during UF pulses within  1kg of dry weight and those further 
from dry weight (table 2). None of the parameters relating to the refill phase were 
different between these two hydration states.
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Determinants  of hypotension.  There were  significant differences  between  mean 
values of tuf, Linear divergence, RBV at UF pulse initiation, refill phase amplitude, 
and UF decay amplitude, between hypotensive and normotensive UF pulses (Table 
3). tuf and Linear divergence showed the clearest demarcation between hypotensive 
and normotensive groups (Figure 5), such that all patients with tuf > 22 and 93.3% 
of patients  with  Linear  divergence  <  85  developed  hypotension  later during  the 
course of the same UF pulse.
Changes in  UF  parameters  during  successive  ultrafiltration  pulses  (Table 4). 
Linear divergence fell significantly during successive UF pulses of equal volume (p 
< 0.001  for both pulse 2 vs 3 and 3 vs 4). Figure 6 Mean UF decay constant (tuf) 
increased significantly between pulse 3  and pulse 4 (p < 0.001) but there was no 
difference between pulse 2 and pulse 3 with respect to this parameter. The 40 % UF 
pulse (pulse 1) was not used for comparison being of greater volume than the other 
pulses.  Fig  7a and  7b  demonstrates  some  individual  case  studies  of diminishing 
linear divergence in two patients.
Influence of antihypertensive agents
There  was  an  effect  of  antihypertensive  medication  on  blood  volume  decay 
parameters.  ARBVuf (7.5 + 1.5 vs 6.6 ± 1.7: p < 0.013) and Linear divergence (596 
+ 440 vs 350 + 403:  p < 0.011) were  greater in patients taking antihypertensive 
agents than in those not taking these agents. There were no differences between these 
groups with respect to any other parameter. However mean PDW and mean UFVS  
were also greater in those taking these agents (1088 + 453  vs 867 + 452 ml: p < 
0.031 and 492 + 93 vs 410 ± 140 ml: p < 0.002, respectively). Linear divergence but 
not ARBVuf correlated directly with proximity to dry weight (r = 0.817: p < 0.001) 
and both ARBVuf (r = 0.553:  p < 0.001) and Linear divergence (r = 0.462:  p < 
0.001) correlated directly with UFVS .
Critical  blood  volume  and  hypotension  Hypotension  was  significantly  more 
common  in  UF  pulses commencing with  RBV  < 90% of its baseline  value (p  = 
0.001).  Hypotensive episodes occurred  in  64% of UF  pulses  commencing at this 
critically  low  blood  volume.  However hypotension  also  complicated  24%  of UF
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hypotension (16 of the 30 episodes) occurred in patients with an initial RBV >90%. 
In 479 simultaneous measurements of blood pressure and RBV (Figure 8a, 8b), there 
was no significant difference between the incidence of hypotension (systolic blood 
pressure < 90 mm Hg) when RBV was reduced to <90% of the starting value (13 of 
176 episodes [7.4%]), and when RBV was maintained at > 90% (16 of 303 episodes 
[5.3%])
Predictors of Linear divergence
Linear divergence correlated with proximity to dry weight (r=0.817: pO.OOl), and 
with the measured relative blood volume parameters, RBV (r=0.312: p=0.069), UFV 
(r=0.462: p<001), and ARBVuf/UFVs (r= -0.452: pO.OOl). There was no correlation 
with ARBVuf and IRR. As noted above (Table 3 and Figure 5), Linear divergence 
was significantly smaller in hypotensive pulses than in non-hypotensive pulses (155 
+/-  285  vs  662  +/-  405:  pO.OOl).  In  multiple  regression  analysis  using  these 
significant  factors,  the  only  independent  determinant  of Linear  divergence,  was 
proximity to dry weight (R2 =0.667: pO.OOl).
Predictors of tuf
tuf correlated with proximity to dry weight (r= -0.508:p<0.001)  but not with the 
measured relative blood volume parameters, RBV, ARBVuf,  UFV, ARBVuf/UFVs, 
and IRR. As noted above tuf was significantly greater in hypotensive pulses than in 
non-hypotensive pulses (21.6 +/- 8.5 vs 12.8 +/- 2.8: p<0.001)(Table 3 and Figure 5). 
The  occurrence  of a  hypotension  during  a  UF  pulse  was  the  only  significant 
independent predictor of tuf in stepwise multiple regression analysis (R  = 0.400: p< 
0.001).
Discussion
Fluid removal  during  haemodialysis  is  a complex process.  The  response to  fluid 
removal varies during the dialysis session, between dialysis sessions, and between 
patients. Multiple factors are involved including the prevailing state of hydration, the 
mode of dialysis, variations in patient physiology and pathophysiology, water purity, 
dialysis fluid composition and temperature, and medication.
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(e.g.  caval  diameter,  bioimpedance),  their  intradialytic  application  is  limited  by 
numerous factors including measurement artefacts introduced by intradialytic effects 
such  as temperature  variations and  ionic  shifts,  difficulties  in  bedside  usage,  and 
their  provision  of static  ‘snapshot’  data  on  individual  fluid  compartments [219]. 
Online Blood  volume  monitoring on  the other hand  is  easy  to  use  and  provides 
continuous,  high-resolution  data that can  be  used  to  characterise the response to 
ultrafiltration.
In  complex  systems  such  as  the  pathophysiological  response  to  ultrafiltration, 
modelling  is  difficult  as  multiple  factors  are  involved  such  as  hydration  state, 
sympathovagal balance [104], and momentary local electrolyte and mineral balance. 
The system may be regarded as a complex arrangement of dynamic elements linked 
by an integrated array of regulatory mechanisms.  When ultrafiltration is initiated, a 
number of physiological compensatory mechanisms are invoked for blood volume and 
blood pressure maintenance. Under these circumstances, perturbation analysis may be 
useful. Using this technique  intermittent, short bursts of UF was applied at a high rate 
with intervening rest periods to probe relative blood volume responses at different states 
of hydration. UF rates in excess of interstitial refill capacity (1.5 -  21/hr) were used to 
maximise the information content of the system response. Stiller and Mann [220] have 
demonstrated  the  principle  of using  intermittent  UF  to  extract  information  about 
refilling.  This is a potentially powerful experimental tool for haemodynamic analysis in 
the  haemodialysis  context,  capable  of providing  information  on  refill  capacity  and 
hydration status of fluid compartments.
Classical  models  of the  circulation  make  use  of two  compartments,  vascular  and 
interstitial, separated by the capillary membrane interface [221, 212]. These models also 
implement the  physical  principles  of the  Starling  force  balance  mechanism.  Blood 
volume during UF tends to  fall  exponentially  [221].  This exponential  decay  is a 
function of a constant UF rate, and a variable rate of tissue refill. In most cases the 
vascular  space  must  be  depleted  sufficiently  to  promote  vascular  refilling.  Once 
refilling  is  underway,  the  blood  volume  decay  tends  to  “plateau”.  Under  these 
conditions the vascular refilling rate  approximates the  UF  rate.  If the  UF  rate  is
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the end of UF, this indicates that vascular refilling is still taking place and that dry 
weight has not yet been achieved.
The study demonstrated that with dryness blood volume declines in a linear fashion 
as UF proceeds. At a fixed UF rate the depletion in blood volume is likely to occur in 
a  linear  fashion  when  the  compartment  behaves  as  a  single  pool.  Approaching 
linearity I believe indicates the switch from a 2-pool (interstitial and vascular) to an 
effective single pool blood volume compartment. This is primarily due to absence of 
refill from the interstitial space but can also result from microcirculatory changes. 
The  latter  is  probably  a  compensatory  mechanism  to  excessive  UF  preceding 
haemodynamic instability. In essence, the 2-pool system has been reduced to a single 
vascular  pool:  the  interstitial  compartment  is  effectively  ‘empty’  of  readily 
mobilisable fluid (Figure 9a, 9b).
Antihypertensive therapy was not stopped for the purpose of the study since it was 
considered important that these studies were performed under conditions pertaining 
in  routine  clinical  practice.  An  effect  of  antihypertensive  therapy  on  Linear 
divergence,  which  was  greater  in  patients  taking  antihypertensive  agents  than  in 
others, therefore cannot be excluded. The numbers were too small to analyse the 
effect of one particular group of anti-hypertensives compared to another. However as 
described above,  Linear divergence also correlated directly with proximity to dry 
weight and UF volume, so perhaps the more likely interpretation for the observed 
differences in Linear divergence is that patients taking antihypertensive medication 
were likely to be more volume overloaded than their counterparts not taking such 
medication.
Whether or not the system  is behaving  in this  linear fashion can  be resolved by 
appeal  to  simple  parameters,  which  can  be  derived  from  serial  measurements  of 
relative blood volume during haemodialysis. The UF phase provided the most useful 
parameters. Refill parameters were much less predictable, presumably because of wide 
inter-patient variability. Under such conditions simple exponential functions may be of 
limited  use  in  defining  the  post  UF  refill  phase  parameters.  The  most  promising
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during UF was predictive of proximity to achievable dry weight and of the risk of 
impending  hypotension.  The  only  other  parameter  to  approach  this  in  terms  of 
predictive utility was the ultrafiltration decay constant (tuf), which is also a measure 
of the  deviation  from  linearity  of the  UF  curve.  No  directly  measured  RBV 
parameter  independently  predicted  proximity  to  dry  weight.  The  incidence  of 
hypotension was similar whether RBV was less than 90% or higher. Change in RBV 
during a UF pulse (A RBV uf) was no different in hypotensive and in normotensive 
UF pulses, and no different in UF pulses commencing within 1  kg of dry weight and 
in those commencing further from dry weight. These findings undermine the case for 
the routine clinical use of these directly measured parameters and the usefulness of 
the 'critical volume concept [216]. Tonelli et al [222] in a study on acute renal failure 
patients on intermittent HD demonstrated no evidence of patient-specific or universal 
RBV thresholds that were associated with  hypotension. Analysis  using the kappa 
statistic  showed that concordance  of RBV  and  hypotension  (that  is,  RBV  falling 
prior to hypotensive episodes rather than rising or remaining stable) was no greater 
than  chance.  They  emphasize  that  system  behaviour  patterns,  defined  by  blood 
volume  decay  characteristics  may  be  more  powerful  predictors  of approaching 
dryness or impending vascular instability rather than static RBV measurement at any 
given point of time.
Calculation  of variability  of the  blood  volume  curves  around  a  linear  slope  as 
described by Biege et al requires the derivation of a linear regression line from the 
relative blood volume data of the entire dialysis session [223]. Calculation of the 
ultrafiltration  decay  constant  (tuf)  described  here  requires  the  output  of RBV 
monitoring during a single UF pulse rather than from a whole dialysis session.  Our 
Linear divergence approach has the advantage of using the initial linear slope of the 
local RBV data to test linearity. This approach is therefore potentially more useful 
than simple curve characterization.  System behaviour patterns at the beginning of 
dialysis may not represent the system characteristics at later stages of dialysis or 
ultrafiltration.  The  information  at  the  obtained  during  the  initial  phase  therefore 
becomes historical. Biofeedback UF control based on predefined BV trajectory at the 
start of dialysis lacks the capacity to adapt to patient behaviour during UF.  [224,
199225] In addition the assumption of a constant F cell ratio implicit in relative blood 
volume monitoring may not be rigorously applicable throughout a whole dialysis 
session. RBV data from the start of dialysis may not be strictly comparable with that 
obtained  in  the  later  stages  because  of haematocrit  redistribution.  Our  protocol 
allows testing the haemodynamics and UF tolerance repeatedly at different stages of 
ultrafiltration. The  linearity in our model therefore  is fundamentally different that 
described in other studies.
The use of slope evaluation to derive absolute blood volume changes during HD has 
proved  difficult  in  previous  studies  since  redistribution  effects  may  influence  it 
during ultrafiltration [226].  Linear divergence estimation is very sensitive to correct 
evaluation of slopes.  It can  only be computed  using high-resolution  sensors. The 
refill  area  calculated  from  an  initial  1-minute  slope  best  defines  it.  Slope 
determination must be commenced 30 seconds after RBV transition. This 30-second 
delay  after  RBV  transition  adds  precision  presumably  because  it  avoids  any 
recirculatory effects on the RBV data. Longer delays, certainly beyond 90 seconds, 
produce  inaccuracies,  presumably  because  refill  has  commenced.  There  are  other 
potential problems. There is noise in the RBV data, which could be related to refilling 
forces, variations in vascular compliance, UF delay, inaccurate or variable UF rates 
and  data  artefacts  (breathing,  machine  alarms).  Low  noise  signals  ratio,  high 
resolution  (estimates  of  RBV  every  3  seconds)  and  accurate  UF  rates,  are 
prerequisites, which allow the derivation of parameters such as linear divergence and 
the ultrafiltration decay constant (tuf) from serial RBV data.
These  experiments  have  demonstrated  that  as  dry  weight  is  approached,  blood 
volume decline during UF switches from exponential to linear decay. This can be 
described  in terms of a number of parameters, which may be derived from  serial 
relative blood volume data. Linear divergence was the most promising. Diminishing 
Linear divergence during UF was predictive of proximity to achievable dry weight 
and  of  the  risk  of  impending  hypotension.  Improved  control  algorithms, 
incorporating such  parameters,  which  can  be assessed  repeatedly  during  dialysis, 
may help optimise UF prescription, improve haemodynamic stability, and facilitate 
achievement of the best possible post-dialysis target weight.
200Table  1.  Correlations  (Pearson)  between  the  measured  and  derived 
relative  blood  volume  parameters  during  the  ultrafiltration  (UF)  and 
refill phases and proximity to dry weight
Parameter Correlation
coefficient
p-value
RBV at initiation of UF pulse (%) 0.479 <0.001
ARBVuf (%) 0.029 NS
UFV. (ml) 0.475 <0.001
ARBVu f/ UFV, (%/ml) -0.506 <0.001
UF decay amplitude (b) 0.401 <0.001
XUF -0.508 <0.001
Linear divergence (%. sec) 0.817 <0.001
IRR (%/min) -0.023 NS
Refill phase amplitude 0.182 NS
-0.115 NS
RBV (%) relative blood volume, ARBVuf (%) reduction in RBV, UFV, volume of step 
ultrafiltration  pulse,  IRR  initial  refill  rate,  tr«r  refill  constant,  tuf  ultrafiltration  decay 
constant
Table 2 Chi squared analysis comparing measured and derived relative 
blood volume characteristics of ultrafiltration pulses within 1kg (n= 49) 
and those £ 1kg (n=41) from dry weight (mean ± standard deviation) 
during UF and refill phases
Parameter UF boli < 1kg 
from dry-weight
UFboli  £ 1  kg 
from dry-weight
p-value
RBV at UF pulse initiation (%) 91.4 ±4.1 95.313.2 <0.001
ARBVuf (%) 7.2 ± 1.7 6.911.5 NS
UFV, (ml) 420± 122 5001109 0.001
ARBVuf/UFV, (%/ml) 0.01810.005 0.01410.003 <0.001
UF decay amplitude (b) 72.4 ± 13.5 81.7113.2 0.001
XUF 18.618.0 12.312.2 <0.001
Linear divergence (%.sec) 2021277 8091359 <0.001
IRR (%/min) 0.7710.38 0.8310.41 NS
Refill phase amplitude 4.212.5 4.1 1 1.8 NS
0.210.53 0.1510.11 NS
RBV (%) relative blood volume, A R B V u f  (%) reduction in RBV, UFV, volume of  ultrafiltration 
pulse, IRR initial refill rate, xrer refill decay constant, tuf ultrafiltration decay constant
201Table 3 Chi-squared analysis comparing UF and refill characteristics 
between hypotensive (n=30) and normotensive UF pulses (n=s60)
Parameter Hypotensive 
U F  pulses
Normotensive 
U F  pulses
p-value
RBV at UF pulse initiation (%) 90.5 ±4.2 94.6 ± 3.5 <0.001
ARBVuf (%) 7.4 ± 1.8 6.9 ±1.5 NS
UFV, (ml) 457 ±123 457 ± 123 NS
ARBVu f/ UFV, (%/ml) 0.017 ±0.005 0.016 ±0.004 NS
UF decay amplitude (b) 71.2 ± 12.9 79.4 ± 13.9 0.007
T uf 21.6 ±8.5 12.8 ±2.8 <0.001
Linear divergence (%.sec) 155 ±285 662 ±405 <0.001
IRR (%/min) 0.86 ± 0.45 0.76 ±0.35 NS
Refill phase amplitude 3.4 ± 1.1 4.8 ± 2.4 0.001
Trcf 0.25 ± 0.69 0.14 ±0.10 NS
(mean ± standard deviation) For key: see Table 2
Table 4  Comparison of mean Linear divergence and mean UF decay 
constant (tuf) during successive UF pulses of equal volume in the 30 
studied patients.
Parameter UF pulse 2 UF pulse 3 UF pulse 4
Linear divergence (%.sec) 764.5(454.1) 546.6 (312)* 155.5 (285.4)*
T uf (UF decay constant) 12.05 (2.67) 13.48(2.87) 21.64(8.53)*
UF volume (ml) 456.1(124.1) 457.3(123.6) 456.5 (123.2)
* denotes significant difference (p < 0.001) from same parameter in preceding UF 
pulse.
202(B)  Determination  of  the  effect  of  variable 
ultrafiltration  rate  on  blood  volume  profile 
characteristics
The Ultrafiltrate volume  as described  in  Chapter 4  has  a powerful  effect on the 
relative  blood  volume  changes.  This  may  be  as  a  consequence  of the  variable 
quantity of fluid removed, patient specific factors such as variations in plasma refill 
rate or differences in the rate at which fluid is removed (UFR or ultrafiltration rate). 
This  third  phase  experiment  was  designed  to  investigate  the  latter  mechanism 
independent of the other potential influences.
The aim of the study was to measure the effect of different UF rates alone on relative 
blood volume characteristics in the same patient using an identical UF profile during 
otherwise identical two consecutive dialysis sessions.
EXPERIMENTAL SET UP 3
Variable volume, varying rate step ultrafiltration (2 v 3 1/hr)
Paired studies were performed  in  5  patients  with  stable  interdialytic  weight gains 
(IDWG)  on  consecutive  dialyses  using  an  identical  dialysis  prescription  and  UF 
profile (Experiment 1) but at two differential UFR of 2 and 3 litres /hr (Fig 10)
Results
Varying volume, varying rate step ultrafiltration  (10 treatments)
Higher UF rates (3 litres/hr) were associated with higher  ARBVuf  [6.3 +/- 2.0 % v 
5.2 +/- 1.9%] (p <0.001) and lower linear divergence  [422 +/- 565 %. sec v 641 +/- 
875 %. sec] (p<0.05) when compared with UF rates of 2 litres /hr in the same patient 
at similar states of hydration under identical UF profile and blood flow rates. (Table 
5)
203Discussion
The  experiment demonstrates  that  in  standard high  flux  dialysis,  the  UF  rate  i.e. 
ultrafiltration  time  duration,  has  a  significant  effect  on  the  blood  volume  decay 
parameters independent of the volume of the ultrafiltrate or other influences in the 
same individual under otherwise similar conditions. At high UF rates, higher relative 
blood volume decay and reduced linear divergence (both predictors of hypotension) 
may predispose the patient to haemodynamic instability.
The effect of high UF rates on haemodynamic parameters depend on its interaction 
with refill capacity and hydration states. Longer treatment times or frequent therapy 
can  lower  total  ultrafiltration  rate  required  to  maintain  patient  well  being  and 
preserve vascular stability.  [227, 228]  On the other hand, in conventional dialysis, 
varying UF rates to match the changing refill capacity during dialysis might allow a 
more physiological ultrafiltration schedule and reduce dysequilibrium. This however 
requires  i)  an  understanding  of how  refill  rates  tend  to  vary  in relation  to blood 
volume  and  hydration  states  ii)  an  ability  to  quantify  refill  objectively  and 
subsequent use of systems with control  feedback device.  These aspects have been 
examined at a later stage in Chapter 8.
Table  5  Paired  t test comparing  means  of the  RBV  parameters  at two 
differential  UF  rates  (3  and  2  I/hr)  but  otherwise  identical  dialysis 
session in 5 subjects  Mean (+/- sd)
UF parameters 21/hr 31/hr P value
UF_vol ( ml) 331  (135) 336  (143) ns
d_RBV ( % ) 5.18  (1.86) 6.3  (1.99) <0.001
tau UF 13.9  (9.9) 8.31  (6) <0.05
Linear divergence 641  (875) 422  (565) <0.05
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Figure 1 Simulation of the single exponential [y=be(_x/c)] decays 
(Exp curves A, B, C) with identical coefficient [b (amplitude) = 10] 
and varying decay constant (c) [c (rate constant) = t (tau)]. The 
equivalent parameters on a UF induced exponential decay curves 
are c = tU F, and b = UF decay amplitude. Lines A, B and C represent 
predicted linear decay for each curve. LD (Linear divergence %. sec) 
represents the integrated area between the exponential and linear 
decay for each curve. Exp curve C is defined by a higher c (tau) and 
diminishing Linear divergence.
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Fig 2a, 2b Demonstration of the derivation of LD (Linear divergence) for Exp 
curve A. Linear divergence (LD) is the difference between the integrated 
areas under the Exp curve A (shaded area Fig 2a) and Line A (shaded area Fig 
2b).
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Figure 3  RBV profile and the predicted linear decay derived from 
an initial  1  minute slope during UF pulses 2, 3 and 4in a single 
patient study demonstrating approaching linearity (final pulse c) 
when patient attains target postdialysis weight.Linear divergence 
(LD) refers to net cumulative area between the UF profile and the 
predicted linear slope (%. seconds).  UF rate 3000ml/hr, UF volume 
350 ml).
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Figure 4 The scatter plot of linear divergence at isovolemic UF pulses 
with distance from dry weight in thirty subjects, (r = 0.817:p < 0.001) 
Bold circles indicate hypotensive UF pulses (systolic < 90mmHg).
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Figure 5 Comparison of ultrafiltration decay constant (tU F) [5a] 
and Linear divergence [5b] between hypotensive and 
normotensive pulses (p<0.001)
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(mean+ SD) p<0.001 in all patients for second (UF2), 
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interstitial space.
1200
1000
800
600
I]
400
200
[]
0
-200
UF 2
UFV (mis) mean (SD)  456 (124)
UF 3
457 (124)
UF 4
457 (123)
210R
B
V
 
(
 
%
 
)
Figure 7a, 7b  Patient SK and RD  on dialysis with intermittent 
UF demonstrating Linear  divergence at differing states of 
hydration using identical UF pulse
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211Figure 8a Scatterplot of simultaneous measurements of systolic, diastolic and 
mean blood pressure (mmHg) and relative blood volume (%) [n=479] showing no 
significant difference in the incidence of hypotension (systolic BP<90mmHg) 
between RBV < 90% and RBV > 90%.
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212Figure 9a A hypothetical model of an open-ended two pool extracellular 
compartment [A] displaying single pool characteristics and linear decay and 
[B] on approaching dryness in the presence of inadequate refill during ultrafiltration 
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Figure  9b  CONCEPT  OF  TISSUE  REFILL
Model A single pool  model (open ended )
Madel B  2- pool model (open ended ) The inserts on the right hand side conceptualize the 
predicted  blood volume decay during UF based for the respective model on the left hand 
panel during hypervolemia and near interstitial dryness
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Figure 10 Subject PB undergoing identical UF pulses at two 
differing states of hydration on two consecutive dialysis sessions 
at 21/hr and 31/hr showing the differences in the RBV profile
214Chapter 6
The  effect  of  differential  heat  gradient  on 
blood  volume  and  haemodynamic  stability 
during  high  efficiency  dialysis  with 
intermittent ultrafiltration
Introduction
Haemodynamic  instability  frequently  occurs  during  haemodialysis.  Decline  in  blood 
volume  coupled  with  impaired  cardiovascular  response  mechanisms  have  been 
implicated  in  the  pathogenesis  of hypotension  during  ultrafiltration. [229]  The  latter 
phenomenon  can  be  influenced  by  temperature  flux  incurred  during  dialysis  and 
ultrafiltration.  Various  studies  have  shown  a  decrease  in  symptomatic  hypotensive 
episodes with the use of low temperature dialysate (35 -  36 C) compared with standard 
dialysate  temperature  (37  -   37.5  C).[230]  Cooler  dialysis  has  been  found  to  be 
beneficial.  However the  counteregulatory mechanisms that operate with  alterations  in 
core  temperature  are  poorly  understood. [231]  Studies  examining  the  haemodynamic 
changes and information on energy balance, energy transfer between the patient and the 
extracorporeal system and the effect of thermal energy transfer on blood volume changes 
and fluid shift within the vascular compartment are rare. [232]
This study was designed to observe the cardiovascular and thermoregulatory response to 
varying dialysate temperature, on blood volume and haemodynamic variables and skin 
during dialysis with ultrafiltration.
Protocol and Methods
Five  subjects  were  studied  during  10  dialysis  sessions.  Patients  assessed  during  two 
dialysis  sessions  differing  in  dialysate  temperature  but  otherwise  identical  dialysis 
prescription with respect to time, blood flow, clearance and ultrafiltration. The treatment
215sessions for warm (mean  37.4  C)  and cool dialysis (mean  35.3  C)  was performed in 
random order. The ambient temperature varied between 22 - 23 C.  Each patient served as 
their control.  During  each  session  the  temperature  was  monitored  at  the  arterial  and 
venous side of the fistula as well as the energy transfer in the extracorporeal circuit every 
10 seconds. Blood pressure and heart rate was monitored every 10 min by an automatic 
oscillometric BP monitor built in to the dialysis machine.
Dialysis  treatment  was  performed  at  the  same  time  and  day  of the  week  to  keep 
ultrafiltration gains  as close  to  identical  as possible.  All patients were  ultrafiltered to 
clinical  dry  weight.  Intermittent UF  was  applied  after an  isovolemic  period using an 
initial bolus of 40 % weight gain and then subsequent equal boli of 20% with intervening 
rest  periods.  (Protocol  B  Methods).  Most  patients  developed  relative  or  absolute 
hypotension at the end of UF. Patients were not allowed to eat or drink during dialysis. 
Renal  disease  for  the  five  patients  studied  were  caused  by  Diabetes,  chronic 
pyelonephritis,  hypertensive  nephrosclerosis,  obstructive  uropathy  and  neuropathic 
bladder.  All subjects had near identical  weight gains. No changes were made to their 
medication Table 1  All patients gave informed consent. Ethical approval obtained prior 
to the study.
Body  temperature  was  assessed  online  during  HD  by  the  Fresenius  BTM  module,  [ 
Methods] which measures temperature at the arterial side of the fistulae and calculates 
the  central  venous  blood  temperature  by  correcting  for  fistula  and  Cardiopulmonary 
recirculation. This is also referred to as the Core temperature. The correction is necessary 
because the arterial blood  temperature  is determined by the core temperature and the 
temperature of the recirculated venous blood.  Recirculation is measured by the BTM 
with a temperature bolus produced by a change in blood temperature. Predialytic core 
temperature BTM is the first reliable temperature obtained by the BTM after the start of 
dialysis usually within the first 5 mins. The accuracy of the core temp BTM is less than 
0.1  C  as  given  by  the  manufacturer  (  BTM  Fresenius  Medical  Care  Bad  Hamburg 
Germany)  Correlation between core temperature BTM and tympanic temp is 0.75 (p< 
0.05) [233] Warming of a patient’s blood can occur both through vasoconstriction and an 
inappropriately high dialysate temperature. Surface skin temperature was measured by
216a thermal probe applied to the skin surface over the forehead.
Measurement of Relative blood volume RBV was performed using Fresenius ultrasonic 
BVM monitor. Plasma within blood is the most electrically conductive substance in the 
body. The changes in electrical conductivity of the thorax, due to pulsate flow of blood 
through the segment provides the basis for thoracic bioimpedance technology. Thoracic 
bioimpedance (BoMed) Cardiodynamic monitor (NCCOM3-R7) was  used to determine 
haemodynamic parameters of cardiac output, stroke index, end-diastolic volume during a 
cardiac cycle. [ see Methods ]
Definitions
Energy transfer is defined as the amount of thermal energy, which was transferred from 
the ECC to the patient or vice versa. A positive value indicates a net energy transfer from 
the ECC to the patient and a negative value indicates indicates transfer from the patient to 
the ECC. Energy transfer in kilojoules is also expressed in watts (lwatt = 3.6 kj/hr). T art 
and Tven was assessed by continuous temperature monitoring at the arterial and venous 
side of the ECC by an air filled head with a platinum sensor (BTM), Blood Temperature 
Monitoring; Fresenius)  around the arterial and venous catheters.
Energy transfer was assessed by continuous measurement of temperature in the arterial 
and venous side of the extracorporeal system according to the formula:
E = C  X  pxQb  X  t X ( Tven -  Tart )
C = specific thermal capacity (3.64 kJ/kgC ) 
p=  density of blood(1052 kg/m3) 
t = time in hr 
Qb = blood flow rate 
Resting Energy expenditure (REE) was predicted by Hams and Benedict Eqn 
Men REE = 66 + 13.8W + 5H -  6.8 Age  (kcal/24hr)
Women  REE = 655 + 9.7W + 1.8H -  4.7Age  (kcal/24hr)
SVR was derived from cardiac output and Mean arterial blood pressure
217Results
A total of seven episodes of symptomatic hypotension (blood pressure was <90 mmHg) 
requiring intervention were observed,  five during warm dialysis and two during warm 
dialysis. A typical hypotensive episode during a session with heat gain depicted in Fig 1. 
Step  ultrafiltration  induced  rise  in  core  Temperature  is  demonstrated  in  Fig  2.  No 
episodes of symptomatic  hypotension occurred during the  HD  session whch achieved 
35°C venous temperature. UF rate and net weight loss were not different between the 
paired treatments.
Core temperatures
Core temperature remained stable or fell during treatment with cool dialysate temperature 
but increased in all subjects during the use of warm dialysate. The differences in the core 
temperature  between  the  start  and  end  of dialysis  during  was  significantly  different 
between  warm and  cool  dialysate  treatment (Table  2)  and had  a  significant negative 
correlation with predialytic core temperature, (r =-0.63, p<0.05) Fig 3. A mean rise of 
0.7°C body temperature in the hypotensive sessions was observed compared to 0.4°C in 
the stable BP group.  Fig 4 depicts core temperature profile in three subjects showing 
stable  or  relative  cooling  during  cool  dialysate  but  heat  accumulation  during  warm 
treatment with maximun  heat  gain  in  the  subject with  lower initial  core  temperature 
(middle inset).
Haemodynamic variables and energy transfer with intermittent UF
•  Initial Isovolemic dialysis
Prior to the onset of UF during the initial isovolemic phase lasting approximately 20 —  30 
mins the differential heat gradient led to significantly higher rate of cooling with cool 
dialysis even in the absence of Ultrafiltration (Table 3a)  Cardiovascular variables 
including RBV were similar except for except systolic, mean and diastolic BP which 
were better preserved with cooler dialysate.
218•  During HD with intermittent UF
Subsequently  throughout  HD  with  intermittent  UF  the  haemodynamic  observations 
showed  better preservation of systolic, diastolic and mean arterial pressure (p<0.001) 
with fewer hypotensive episodes during dialysis with cooler temperatures. The total UF 
volume removed were  similar.  BP reduction was associated with low Cardiac  output, 
stroke volume and RBV (Table 3b). The decline in BP was not related to the predialytic 
body temperature ( r = 0.27 p=ns).
The average cardiac output, stroke index, end diastolic volume, peak ejection flow, RBV 
and  calculated  resistances  were  not  significantly  different between paired treatments. 
(Table 4)  There  was  a  significant negative relationship between  RBV  and  calculated 
peripheral resistance (P<0.01, R= -0.34). (Fig 5). Fig 6 demonstrates relationship of RBV 
measurements during a single dialysis session in a subject with other measured cardiac 
parameters.  SVR was significantly correlated to the MAP,  volume of ultrafiltrate and 
time on dialysis, skin core gradient ( r = 0.33 p<0.001) and weak negative correlation to 
RBV, core temperature and blood flow rate ( r = -0.37 p<0.01).
Using multiple regression, the systolic BP was best predicted by  Cardiac output, stroke 
index, end diastolic volume and SVR and thermal variables of energy transfer and core 
skin differential gradient ( R = 0.8 , R2 = 0.64, p<0.001) The MAP was best predicted by 
Core temperature in addition to the above variables (R = 0.81  , R2  = 0.66, p<0.001). 
Relative  blood  volume  predictors  were  ultrafitered  volume  removed,  cardiac  output, 
stroke index , SVR (R = 0.74 , R2 = 0.55, p<0.01) but not the thermoregulatory factors. 
SVR was best predicted by the Core temperature and skin core gradient ( P< 0.01
•  Energy transfer
During cool dialysis there is significantly higher net heat loss from  patient to the ECC. 
Lower dialysate temperatures  (Tdia 35.3)  are  associated with cooler peripheries,  lower 
core temperatures and increased heat loss. The increase in core temperature during warm 
dialysis  occurred  despite  a  relatively  small  net  energy  transfer  from  patient  to  the 
extracorporeal circuit. The mechanisms are not clear.  Although  peripheral resistances 
seem better preserved in cooler dialysis they do not reach significance in these subjects.
219Between UF and non UF phase the temp flux and skin regulation were not significantly 
different.
By stepwise multiple regression, energy transfer was best predicted by Core temperature 
T art, blood flow rate, core-skin gradient,  (r = 0.58, R2 =0.34, p<0.001). The cooling 
effect  was  diminished  when  high  blood  flow  rates  were  used  with  warm  dialysate 
temperatures. (Fig 7) The Linear divergence were no different at identical boli with two 
different dialysate temperature.
The skin heat regulation seems to play a particularly significant role in energy transfer 
and thermal balance during warm and cool dialysis. It also bears a significant relationship 
with haemodynamic variables of Systolic BP, MAP, CO, and SVR but not to RBV. 
(Table 5) (Fig 8) This constitutes an important nonextracorporeal route of heat exchange. 
(Fig 9)
Discussion
Body temperature control during dialysis is governed by thermal energy balance and heat 
capacity of the human body. The heat gain during dialysis can lead to a heat stroke like 
phenomenon leading to hypotension. The contribution of the vasoconstriction and heat 
exchange by the extracorporeal circuit can be estimated as a function of energy transfer 
between patient, ECC, dialysate temperature and ultrafiltration.
The degree of cooling and hypotension observed in this study are similar other studies 
where body temperature changed by 0.51°C when cool dialysate was used. [234]
Resting energy expenditure of a 70 kg adult is 116 watts. This is normally dissipated to 
the environment by evaporation (22%), conduction(18%) and radiation (60%). Thermal 
regulation tries to keep the body temperature close to an individual set temperature by 
changing heat loss through vasodilatation or vasoconstriction. If the temperature cannot 
be kept in a narrow range, hypothalamus centres  initiate sweating or shivering. The core 
temperature  at  which  sweating  starts  depends  on  the  set  temperature  and  the  skin 
temperature.
220The intradialytic thermal balance is influenced by the extracorporeal circuit (ECC). The 
dialyser is a perfect heat exchanger. Blood leaves the dialyser in thermal equilibrium with 
the dialysate. The energy balance in the dialyser is expressed as 
(Tart -Td) (Qb -  UFR) 3.64 * 1.052
Specific heat of whole blood 3.64 J/g  density = 1.052 g/ml at 37 C
The energy balance for a temperature difference of 1C at 400ml/min is 25 W. There is an 
additional loss of energy in the blood venous line. At blood flows > 100 ml/min the loss 
depends  on  the  blood  temperature  difference  and  length  of PVC  tubing.  For  20  C 
environment temperature and standard PVC blood tubing of 2.8 m with internal dia 4.5 
mm the energy loss is approximately 10 W. [234,235]
The  accumulation  of heat  during  dialysis  can  be  prevented  by  heat  loss  across  the 
extracorporeal circuit. This can be enhanced using a cooler dialysate temperature. The 
study shows that at a dialysate temperature of between 37 -  37.5  C ECC heat loss is 
minimal and can lead to  a rise in core temperature leading to haemodynamic instability. 
This accumulation of heat despite  a  small  net heat  loss must be due to the  effect of 
dialysis and UF on body temperature regulation.  The mechanisms remain speculative. 
[236]  Hypovolemia  as  during  UF  would  cause  baroreflex  cutaneous  vasoconstriction 
which can result in an  increase  in core  temperature  if unregulated,  antagonising  the 
response to hypovolemia. The body’s ability to reduce cutaneous blood flow is a valuable 
means  of  increasing  peripheral  resistance  and  maintaining  blood  pressure  despite 
decreasing blood volume. This may impair thermal balance by reducing transcutaneous 
heat loss. This in addition to a rise in metabolic rate during HD can cause a rise in core 
temperature.  If the  latter reaches  a  critical  level,  peripheral  vasodilatation  may  occur 
dissipating heat but also causing instability of blood volume.
At temperatures of 35 -  35.5 there is significant heat loss to counter any heat gain during 
HD. A specific dialysate temperature is perhaps less important than the blood dialysate 
temperature  gradient  and  predialytic  patient  temperature  in  quantifying  the  heat 
exchange. Body temperature changes during dialysis depend on the difference between 
the predialysis core temperature and the dialysate temperature. Considering all effects an
221average intradialytic heat flux can vary between + 80 W. Skin circulation is controlled by 
volume and temperature defense mechanisms.
When  heat  loss  is  minimal  or  neutral  through  extracorporeal  routes,  rise  in  core 
temperature  indicates  net  heat  gain  during  dialysis,  which  must  be  generated  by 
metabolic  production,  dialytic  process  and  ultrafiltration.  Haemodialysis  and  UF 
procedure  therefore  affects  core  temperature  regulation.  The  removal  of heat  by  the 
extracorporeal circuit and autoregulatory mechanisms attempt to lower core temperature 
The  mean net  energy  loss  from  patient  to  the  extracorporeal  circuit  in  this  study  is 
approximately 35 % resting energy expenditure during cool dialysis. This is accordance 
with some previously published studies.  [237] The mean core temperature despite such 
heat loss remained at times constant.  This demonstrates the heat accumulation during 
dialysis. The cool dialysis prevents an increase in core temperature in all patients.
Skin blood flow (SkBF) in humans is primarily controlled by thermoregulatory reflexes 
and  to  some  extent  the  cutaneous  circulation  is  also  controlled  by  reflexes  of 
nonthermoregulatory origin. The extent to which the cutaneous circulation participates in 
baroreceptor-mediated reflexes and in the reflexes associated with exercise is debatable. 
[238]  Exercise  for  example  elicits  both  thermoregulatory  and  nonthermoregulatory 
reflexes. The overall conclusion is that thermoregulatory control of SkBF is subject to 
modification by or competition from several other sources. The fundamental pattern for 
control of SkBF is described by the threshold and slope of the SkBF-intemal temperature 
relationship.  Reflex  effects  of  skin  temperature  act  to  shift  the  threshold  of  this 
relationship  such  that  lower  levels  of  skin  temperature  are  associated  with  higher 
threshold  internal  temperatures  at  which  cutaneous  vasodilation  begins.  Similarly, 
baroreceptor  reflexes,  reflexes  associated  with  exercise,  and  effects  of  some 
cardiovascular disease also operate against this background. Although modification of the 
SkBF-intemal temperature slope is occasionally seen, the most consistent effect of these 
nonthermoregulatory factors is to elevate the threshold internal temperature for cutaneous 
vasodilation. The consequence of this modification of thermoregulatory control of SkBF 
is that temperature regulation will often suffer when increases in SkBF are delayed or 
limited. Blood flow to other regions, possibly including active skeletal muscle, may also
222be  compromised  when  thermoregulatory  demands  for  SkBF  are  high.
The mechanism of heat generation during dialysis is complex but at least in part involves 
complement activation or cytokine generation. Data on influence of dialysis on energy 
expenditure is  scarce.  Resting energy expenditure during bicarbonate  dialysis of 8 W 
magnitude. A  10% of rise in REE could be due to absorption of glucose. In our study 
water  quality  was  excellent  and  biocompatible  membranes  were  used.  Alteration  in 
temperature  set  point  due  to  removal  of  uremic  toxins  and  variations  in  normal 
temperature rhythm  of individuals  are  factors  that  could  influence  variations in core 
temperature during dialysis. Schneeweiss et al [239] did not observe an increase in REE 
during  HD  although  metabolic  measurements  were  not  performed  during  dialysis 
procedure itself. Reports on energy transfer in the literature are scarce and conflicting. 
Provenzano et al observed net energy load from ECC  to patient at dialysate temperature 
of 37 C at low blood flow rates . [240] The use of acetate could partly explain  peripheral 
vasodilatation mediated heat gain. Van Der Sande et al [237] and Schneditz et al [234] 
observed heat loss from ECC  to patient at dialysate temp 37.3  at blood flow rates of 
250ml/min. [241] Our study are consistent with these data although the amount of energy 
transfer from patient to ECC is slightly lower at temperature of 37.3 C. The use of higher 
blood flow rates and differences in predialytic temperature could  explain the differences 
seen.
Vascular response was significant during later stages of ultrafiltration and dialysis and 
more  distinct  at  cooler  temperatures  and  at  lower  blood  volumes.  The  presence  of 
vasoactive  medications  may  have  modified  the  response  in  our  subjects.  Better 
haemodynamic stability is seen when significant net heat loss is achieved. This is mainly 
mediated through lower core temperatures and SVR leading to indirect circulating blood 
volume preservation.
223In  conclusion  the  thermal  balance  depends  on  interaction  of patient related  factors  ( 
predialysis temperature  ,  skin temperature,  vascular tone)  and dialysis factors ( blood 
flow rates, dialysate temperature, ultrafiltration). At blood flow rates of between 350 -  
550 ml/min, dialysate temperatures of below 36 C are required to achieve  significant 
cooling. Standard temperature dialysis 37 -  37.3 C may be associated with minimal heat 
transfer and a rise in core temperature. The removal of heat by the extracorporeal circuit 
and  activation  of autoregulatory  mechanisms  to  preserve  core  temperature  may  be 
responsible for the beneficial haemodynamic effect of lower dialysate temperatures.
224Table 1  Parameters at baseline prior to dialysis
Pre weight kg Qb ml/min AH drugs
Subject 1  (warm) 63.8 350 1
Subject 1  (cool) 63.4 350 1
Subject 2 (warm) 65.5 450 1
Subject 2 (cool) 65.2 450 1
Subject 3 (warm) 68 550 2
Subject 3 (cool) 67.5 550 2
Subject 4 (warm) 56.5 350 1
Subject 4 (cool) 56.3 350 1
Subject 5 (warm) 76.4 400 2
Subject 5 (cool) 76.2 400 2
AH = antihypertensive drugs
Table 2  Core temperature changes during the warm and cool dialysis
Cool Warm P
Pre dialytic core T (C) 36.64 (0.33) 36.30 (0.29) 0.2
Postdialytic core temp C 36.50 (0.36) 37.12  (0.32) 0.06
Delta core temp C -0.14(0.16) 0.82 (0.42) 0.01
225Table 3a Haemodynamic and thermal parameters during 
Pre UF isovolemic period at the start of dialysis .
Cool dialysis Warm dialysis
mean SD mean SD
T venous C ** 35.23 0.3 37.31 0.2
Skin temp C 33.8 1.1 34.4 0.35
Cardiac output 1/min 8.1 2.5 7.72 1.5
SVR dynescm 899 379 1154 291
RBV % 99.15 1.1 100 0.7
BP Systolic mm Hg * 155 11 128 19
BP diastolic mm Hg * 88 8 63 17
MAP mm Hg * 105 8.3 84.8 17
Energy transfer rate W * -28.4 13.3 0.72 1.3
Duration secs 1415 185 1324 201
• p<0.05  **p<0.01
Table 3b  Comparing haemodynamic parameters (SV.CO.RBV) between three different 
blood pressure ranges recorded during all the sessions studied
group Systolic BP MAP CO SV RBV
1 < 100 69  +2.1** 4  +0.63** 85  + 10.6* 87 + 10.1*
2 100-125 86  +0.7 8  +2.6 117  +28.9 95  +8.3
3 125-150 87  +3.5 7  +.3.1 112  + 47.3 99  +.2.2
•  * P<0.05 **P<0.001 (1 v3)
226Table 4 Comparing cool and warm dialysis with intermittent UF
Prescribed 
Cool  HD
Prescribed 
Warm HD
Mean SD Mean SD P value
Systolic BP  mmHg 137.5 16.9 120.8 12.3 0.000
Diastolic BP mmHg 73.7 11.7 64.8 9.6 0.000
Hypotensive episode 2 - 5 - -
MAP mmHg 95 12.6 83.4 9.8 0.000
Tart C 36.5 .28 37.1 .14 0.000
TvenC 35.3 .31 37.4 .17 0.000
Energy transfer Jq  (kJ) -85.3 27.2 -2.2 9.4 0.000
Heat flow rate W -24.6 8.41 -0.62 2.78 0.000
T_Skin C 33.7 .83 34.8 .44 0.000
Core-skin C 2.8 .75 2.2 .33 0.000
Qb  ml/min 387.8 94.6 410.5 78.4 0.03
CO L/min 7.2 2.1 7.6 2.8 0.24
SI  l/min/m2 117.7 37.4 116.4 45.4 0.79
EDV mis 178 57.1 181.3 66.1 0.65
RBV ( %) 92.1 6.4 91.3 5 0.32
SVR dynes.cm 1173.1 461.4 1098.4 523.7 0.25
UFV mis 1307 927.2 1452 825.6 0.17
Estimated REE  (W) 67.7 10.1 Range (54.4 - 80.5)
Valid complete set of observations HD cool n-172 ; HD warm 0*117
227Table 5 Correlations (R) of skin temperature and skin core temperature gradient 
with haemodynamic parameters
Parameters T_skin (R) Coreskin
gradient
Systolic BP -.47** .33**
MAP -.48** .33**
CO .20* -.26*
RBV -.04 .04
SVR -.34** .36**
** P value <0.001  * P value <0.01
228Figure 1 Heat gain during dialysis leading to hypotension 
Vasoconstriction or heat transfer from the dialysis machine or both?
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Figure 2  Core Temperature rise during intermittent ultrafiltration 
steps in a single patient caused by vasoconstriction
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temperature) and predialytic core temperatue in all 
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Figure 4  Core temperature profile during dialysis 
in 3 subjects with paired warm and cool dialysis
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232Figure 7 Energy transfer at different blood 
flow rates during warm Td 37.3C (7a) and 
cool dialysis Td 35.3C (7b)
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233Figure 8 Significant positive correlation between MAP and 
Core-skin temperature gradient both for warm (bold linear 
regression r = 0.64) and cool dialysis (dotted regression r = 
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234Section on absolute blood volume studies
OBJECTIVES
•  To measure plasma volumes directly using the principle 
of dye dilution repeatedly during HD.
•  To assess absolute plasma and blood volume changes 
measured directly during dialysis and UF in relation to 
the extracellular compartment and blood pressure
•  The use of tracer (Indocyanine green) and density 
(Relative blood volume) method synchronously to 
characterise how the circulation regulates 
and redistributes blood volume in response 
to ultrafiltration
Topics covered
•  Determination of technique of ICG method on dialysis
•  Accuracy and reproducibility
•  Comparison with prediction formulae
•  Comparing ABV and RBV
•  ABV and BP -  critical blood volume
•  Relationship of ECF , BP and ABV, refill during UF
•  Fahreus effect and microvascular change during ultrafiltration
•  Summarising fluid shifts during UF
235Chapter 7
Serial  determination  of  absolute  plasma 
volume  during  haemodialysis  using 
indocyanine  green
Summary
Haemodynamic  stability in haemodialysis (HD) largely depends on plasma volume 
(PV)  preservation  during  ultrafiltration  (UF).  Current  estimates  of blood  volume 
(BV) are indirect or involve the use of radioactive tracers that do not allow repeated 
measurements  on  HD.  Indocyanine  green  (ICG)  was  used  to  measure  plasma 
volumes  (PViC g)  during  HD.  After  an  initial  pilot  phase  (Phase  I),  PV  were 
determined predialysis (PVkgjjreHD), repeatedly during isovolaemic HD (PVicgjsoHD) 
(Phase II) and during step UF (Phase III).  Absolute blood volumes (ABViC g ) were 
calculated  using  PViC g  and  haematocrit.  Patients  were  monitored  for  extracellular 
fluid  (ECF  bioimpedance)  and  relative  BV  changes  (ultrasonic).  Phase  I 
demonstrated stability of the dye in plasma, peak absorbance at 805nm and a short 
half-life  (4.53  ±  1.5  min).  10  mg  dye  (2.5mg/ml)  was  injected  for  each  PViC g 
measurement.  Eight plasma  samples  were  obtained  3-min  after injection  at  1-min 
interval to obtain decay characteristics. The  PVjC gjsoHD measurements had excellent 
reproducibility (r2 0.98 method SD 356 mis, mean CV 4.07 %) and a mean difference 
(MD) ± SD of 149 ± 341 mis only when compared with PVjCg_preHD (Bland-Altman). 
PVjcg at the beginning of dialysis was significantly correlated with the body surface 
area  (r2  0.82,  p<0.001)  and  to  ECF  estimates  (r2  0.73,  p<0.001).  Blood  volumes 
calculated using prediction formulae significantly underestimated ABV,cg at the start 
of dialysis (p<0.0001). The findings here demonstrate that this method can be used to 
determine PV repeatedly during HD with excellent reproducibility.  It is a potential 
tool for further research in haemodynamic stability during UF.
236Introduction
Hypovolemia  plays  an  important  role  in  symptomatic  hypotension,  which 
complicates  upto  25  %  of  dialysis  treatments.  This  has  generated  considerable 
interest in blood volume (BV) determinations during ultrafiltration (UF). Attempts to 
quantify absolute BV during haemodialysis have been limited by lack of a suitable 
method. Methods involving radioactive tracers are unsuitable for routine clinical use 
and  do  not  allow  repeated  measurements.  [242]  In  vitro  studies  have  revealed  a 
possible mutagenic potential for Evan’s Blue [243]. Thus current estimates of blood 
volume during dialysis are indirect or provide relative changes only and have only 
been validated against anthropometric data derived from the normal population [212] 
or  a  single  predialysis  measurement.  In  1968  Bradley  and  Barr  reported  on  BV 
measurements using indocyanine green (ICG) in a limited number of patients [244]. 
This  method  has  since  been  used  for  estimation  of liver blood  flow  and  cardiac 
output measurements but has not been studied during haemodialysis.  The in-vivo 
properties  of this  tricarbocyanine  dye  allow  its repeated  use  within  short  interval 
[153].  This  study  examined  the  feasibility  of  using  the  dye  for  repeated  PV 
determination  in  haemodialysis.  I  wished  to  a)  determine  the  technique  of PV 
determination  during  haemodialysis  using  AV  fistulae  and  to  determine  its 
reproducibility b) observe changes in PV during UF on dialysis and c) compare BV 
with standard prediction formulae. In this chapter experiences with this method and 
some results of its practical application have been described.
Methods & protocol
Study Design : The study was performed in three phases.
Phase I (5 studies)
This  pilot  phase  was  performed  to  determine  the  method,  ascertain  dose,  dye 
kinetics,  sampling and calibration techniques in haemodialysis patients.  Technique 
for the use of ICG using both the fistula and the extracorporeal circuit was optimised, 
the  quality  of which  may  be  depicted  from  the  graphs below.  Determination  of 
minimum  dose,  injection  site  in  the  extracorporeal  circuit,  half life determination,
237assay variability, absorption characteristics of the dye, possible estimation errors and 
technique  artefacts  were  individually  studied  and  resolved.  The  errors  during 
sampling have been minimised and the assumption of 1st order kinetics of ICG decay 
may be verified from the linearity of the log plot. Fig la
Dialysate  samples  were  collected  from  the  dialyser  outlet  port  to  look  for  ICG 
absorbance immediately and 3 mins after dye injection to detect any leakage of dye 
across the dialyser.
Phase II (9 studies)
The purpose of this phase was to test reproducibility and method variation. Plasma 
volumes  were  measured  with  patient  supine  for  20  min just  before  dialysis  (via 
fistula needles)  followed by triplicate measurements  at 20 min intervals during an 
isovolemic period in the first hour of dialysis via sample port. Fig lb
Phase III (10 studies)
Plasma volumes were determined directly during dialysis with ultrafiltration (31/hr) 
using  4  intermittent  UF  steps  (removing  40-20-20-20%  of total  UF  volume)  and 
intervening rest periods  (Fig  lc),  with BV measurements at the beginning and the 
end of first and fourth ultrafiltration boli during steady state conditions. (Fig Id).  All 
measurements and ultrafiltration commenced after an equilibration period of twenty 
minutes from the connection to the extracorporeal circuit.
Subjects
The North Herts Ethical  Review  committee  approved  the  study.  All patients  gave 
informed consent. 24 studies were performed during routine dialysis sessions on  17 
subjects (4 females) of different body sizes and a wide range of interdialytic weight 
gains  (Table  1).  Subjects  had been  receiving  chronic  haemodialysis  for at least  6 
months  with a  stable  dry  weight and normal  liver  function tests.  The presence  of 
iodine  allergy,  eosinophilia,  raised  serum  IgE  levels  or  significant  access 
recirculation within one month prior to the study were exclusion criteria. All patients 
were on thrice-weekly high flux dialysis (Fresenius 4008E) using AV fistula. (Blood 
flow rates were in the range of 350-450 ml/min and the mean weekly Kt/V was 1.24 
+/- 0.16) [112] 15 patients failed selection and screening criteria.
238Tracer
The  tracer  used  was  Cardiogreen  (ICG  Green  ™Sterile  indocyanine  green  USP 
Fluka), a tricarbocyanine dye, mol wt 775, with an absorption peak at 805nm (Fig 
le).  The  dye  is  nontoxic,  confined  to  plasma,  not  subject  to  extravascular 
distribution, and not metabolised or degraded. Following injection, the dye is rapidly 
bound to plasma proteins. After equilibration, the dye decays fast in an exponential 
manner. It is exclusively taken up by the liver and has a plasma half-life 2-3 min (the 
time  required  for  the  initial  concentration  of the  dye  to  be  halved).  [152]  The 
elimination characteristics resemble the Michaelis-Menten kinetics [153]. Michaelis- 
Menten kinetics refers to the mechanism of ICG dye disappearance from plasma. The 
nature of the decay resembles Michaelis Menten kinetics in as much as the fact that 
the dye disappearance rate has in a complicated way, an almost linear dependence on 
the  concentration  of  the  substrate  at  low  concentrations.  The  decay  occurs  at 
approximately  18 -  24%  of the dye concentration/min (Kicg)  and is a therefore a 
function of the dye concentration. [153]
Calibration
Calibration  was  performed  for  each  blood  volume  measurement  using  the  blank 
plasma sample just before dye injection.
5-point calibration (Fig If)
1.  30mls of distilled water were added to  1ml of neat ICG solution (2.5 mg/ml) to 
prepare  a  dilute  calibration  fluid.  Syringes  were  weighed  before  and  after the 
contents had been added to obtain the exact volumes.
2.  A microcuvette was placed  in the spectrophotometer (Phillips  8700 series)  and 
zeroed using  a  fixed  wavelength  of 805  nm.  1ml baseline plasma  sample  was 
injected into microcuvette  and re-weighed to obtain exact plasma volume.  The 
absorbance of the blank plasma was then determined.
3.  4 X  10 uL aliquots (10 uL micropipettes CV <0.5%) of dilute calibration fluid 
were  added  incrementally  to  the  plasma  in  the  cuvette  and  its  absorbance 
measured at each incremental step. The mean of four readings was taken at each 
step, the cuvette being removed,  agitated and replaced between measurements. 
The  dilution  effect  of adding  the  aliquot  volumes  was  taken  into  account  to 
improve precision. After 4 x 20 uL aliquots have been added,  the concentration
239of dye in the plasma would have been only 3.8%  lower than the real value if the 
dilution effect had not been considered.
2-point calibration
A concentrated calibration fluid was prepared using 1 ml ICG (2.5mg/ml) added to 7 
ml distilled water.  10 uL of fluid was added to a known volume of blank plasma and 
the absorbance determined.
Procedure  for  direct  determination  of plasma  volume  and  derived  absolute 
blood volumes
Prior to each dye injection, blood was withdrawn for Hct and baseline plasma blank 
in  heparinised  syringes.  ICG  (25  mg)  was  dissolved  in  10  ml  of sterile  aqueous 
solvent to produce  ICG  solution of 2.5mg/ml.  10  mg  of dye  was then injected as 
rapidly as  possible  into  a venous  port beyond the bubble  trap  [152].  All  syringes 
were  weighed on a precision scale  before  and after the  injection to determine the 
precise quantity infused. A comparison of the injected ICG amounts as weighed or 
read from the syringe marks, respectively showed that about 99% (+/-  1.1%) of the 
cited amount were injected.  Exactly 3  min after the end of the injection,  sampling 
was commenced from the arterial port in heparinised syringes at 1-min intervals for 
10  min  (8  samples).  Samples  were  centrifuged  at  3000  rpm  for  10  minutes.  The 
plasma blank sample was used to determine the baseline background absorbtion at 
805-nm wavelength.  The absorbtion of ICG dye in the timed plasma samples were 
then compared against the baseline at the same wavelength [245].  Only 500 uL of 
plasma was required from each spun sample  due to the use  of half microcuvettes. 
Each ICG BV assay in the lab for an individual patient study in Phase II required 
approximately 4  hrs.  Phase  III  therefore  required  very  intensive  work,  each  study 
involving approximately 9-10 hrs of bedside and laboratory work.
Other techniques
Patients  were  monitored  continuously  for  blood  pressure  (Oscillometric)  BPS08, 
Fresenius  Medical  Care,  relative  BV  changes  (ultrasonic  BV  monitor,  Fresenius) 
[124]  and  extracellular  volume  estimates  (multifrequency  Whole  Body 
Bioimpedance, Hydra, Xitron Technologies). All these data were collected using a
240data  acquisition  software  (Acqi,  Fresenius).  Haematocrit  was  measured  using  the 
Coulter Counter (STKS)  method.  During  these  studies,  ultrafiltration  volume  was 
verified by collecting ultrafiltrate in a measuring cylinder.
The data quality in some of the studies have not been satisfactory due to various 
technical problems. The data from two studies had to be discarded due to a problem 
with the data acquisition.
Analysis
The natural logarithm of the measured ICG dye concentrations were plotted against 
time for each plasma volume measurement and the best fit linear regression obtained 
from the data points.  Fig 2 depicts such a concentration-time curve (In ICG v time) 
and its linear regression confirming excellent linearity of the data. Natural logarithm 
is inverse of an exponential function [e.g.EXP  {LN (4)} =4]. Therefore the obtained 
linearity confirms the exponential nature of the dye concentration decay. This is in 
agreement with the  description  of the  dye pharmacokinetics in the  literature.  The 
extrapolation  of  the  straight  line  backward  allows  determination  of  the  initial 
logarithmic  dye  concentration (offset  from the regression line).  The antilog of the 
offset yields the initial dye concentration in plasma at the time of injection. Plasma 
volume (PV) was calculated according to the Eqn 1 (Appendix).
BV was derived by using the Hct adjusted for by a factor of 0.86 to correct for a) the 
difference between the Hct in the systemic circulation and whole body Hct (F cell 
ratio 0.90) and b) trapped plasma (~ 4%) [Hct body = 0.90*0.96*  Hct sys = 0.86 Hct 
S ys]. (Eqn 2. Appendix).  PV measured during dialysis was compared to predialysis 
measurements after correcting the former for the volume of the extracorporeal circuit 
(internal fibre volume measured predialysis by Renatron analyser and volume of the 
circuit  measured  using  saline).  PV  readings  during  the  isovolemic  phase  were 
corrected  for  changes  in  plasma  protein  concentration  that  was  observed  on  the 
relative blood volume monitor (mean variation of 1.2%), to correct for any PV shifts 
induced by  osmolar  variation  [245].  Statistical  methods  used  were  Bland  Altman 
[246]  analysis required for comparison of methods, t test for comparison of means 
(p<0.05),  linear  regression  and  Pearson  correlation  tests.  Statistical  analysis  was
241performed  using  software  package  Sigmaplot  (version  2.01)  and  curve  fitting 
software (Table Curve 2D).
Results
Calibration results
There were marked difference between the absorption slopes obtained during the 2 
and  5-point  calibration  procedure  (Fig  3).  The  two-point calibration  appeared  to 
consistently  overestimate  the  slope  in  the  3  patients  studied.  The  difference  is 
possibly due to the assumed zero readings in the 2-point calibration. For this reason, 
the 5-point calibration technique was deemed more precise and was used for phase II 
and phase III studies. Four 5 point calibration curves were obtained for all 19 studies 
performed  in phases  II  and III  (76  calibrations).  The  slopes obtained were highly 
consistent  with  no  significant  intraindividual  variation.  However,  the  background 
absorbance (intercept on the absorbance axis) varied considerably (Table 2).
Phase I
The use of a 5 mg bolus of ICG resulted in very low concentrations of ICG in the 
plasma particularly in the tail of the dilution curve. Lack of precision in this area led 
to consistent over estimation of absolute PV. Administration of at least  10 mg ICG 
(2.5  mg/ml),  as  used  for most previous  studies  [152],  was necessary to  avoid this 
potential  source  of error.  A  site  of injection  close  to  the  venous  needle  site  was 
required as injection into the bubble trap induced a time delay on the decay curve. 
The problem was circumvented by use of venous sample port, immediately adjacent 
to the venous needle site. Peak spectral response was at 805 nm in plasma, blood or 
haemolysed blood (by repeated laboratory wavelength scans).  Spectral stabilisation 
was sufficiently rapid for measurement of PV and BV and was very reproducible. 
The  clarity  of the  plasma  extracted  from  the  blood  sample  is  crucial.  Significant 
interference  was  observed  with  hyperlipidemic,  immediately  postprandial  and 
grossly haemolysed samples in this pilot phase.  To determine the most appropriate 
sampling interval, the standard deviation of measurements using different sampling 
time  was  calculated  from  the  regression  mean.  This  confirmed  that  sampling 
commencing  at  3  or 4  min  following  the  ICG  infusion  led to  the most consistent
242estimations.  One  subject,  elderly  with  congestive  cardiac  failure  and  atrial 
fibrillation, did not show complete mixing after 6 min.
Samples were  stable for approx.  8 hrs when stored at 4°C.  Use of heparin did not 
affect the  absorption  spectra.  There was no  absorbance  detected  at  805  nm  in the 
dialysate aliqouts taken immediately after the infusion of dye.  This confirmed that 
the dye was suitable for use during haemodialysis.
Predialysis compared with isovolemic dialysis
Mean  PV  measurements  during  isovolemic  dialysis  compared  well  with 
measurements just before dialysis with an acceptable mean difference of only  149 ± 
341  mis between the predialysis  and the  first plasma  volume measurement  (PV1) 
during isovolemic dialysis.  (Fig 4)
Reproducibility during isovolemic dialysis (Phase II)
Three PV measurements during the first hour of isovolemic dialysis were consistent 
and highly reproducible. Correlation coefficients between measurements PV1 & PV2 
(R2 =0.98) were significant. As a measure of repeatability the mean differences (MD) 
of the first and second measurements (MD = PV2 -  PV1)  and the SD of differences 
were calculated as mean difference of 33 ± 128 mis.  The method mean SD was 356 
mis and mean CV 4.07 %. There were no traces of ICG in the baseline blank plasma 
on repeated measurements. Mean half-life of dye was 4.53 ±1.5 min.
Measurements during ultrafiltration (Phase III)
The ICG decay parameters during this phase of the experiment were consistent with 
previous studies (Table 2b). There was a significant reduction in PV detectable in all 
subjects during ultrafiltration except in patient 2, who did not tolerate the fourth UF 
boli  and required  saline  infusion.  The  method  was  sensitive  enough to  detect this 
[Table 3]. Mean arterial pressure was significantly correlated with directly measured 
circulating plasma volume (r=0.70, p<0.01). There were no adverse reactions to the 
dye.
243Comparison with prediction formulae
Measured  PV  during  the  initial  isovolemic  period  in  both  phase  II  and  III 
significantly correlated with extracellular fluid volumes measured by bioimpedance 
in  14 patients r2 = 0.73  (Fig 6). Reliable estimates of ECF could not be obtained in 
five  patients  in  phase  II  and  III.  The  PV  directly  obtained  also  correlated 
significantly with body surface area (Eqn 3 Appendix and fig 7). The predicted BV 
using weight and height formulae, however significantly underestimated (p<0.0001) 
the  ICG measured  absolute  BV  values.  Regression lines  for the  Guyton,  Hidalgo, 
Allen and Baker method  [247,248,249,250,251]  (Eqn 4,5,6,7  Appendix)  showed a 
wide scatter with a mean difference (± std deviation) of -0.96 (±1.2), -1.6 (±1.7), -1.2 
(±1.4) and -1.4 (±1.7) litres respectively.
Discussion
Tracer methods  for determination of plasma and blood volumes have a number of 
drawbacks including the need  for special  equipment and often the requirement for 
the use of radioactive substances. The ICG method proposed by Bradley and Barr did 
not initially gain widespread acceptance, probably due to their use of a non-standard 
device designed for cardiac output measurement. The spectrophotometer method was 
first described by Schad et al (1987) in dogs’ [252]. The method required the use of 
central venous injection and sampling. The presence of an extracorporeal circuit and 
of high  flow  fistulae  in  haemodialysis  patients  greatly  facilitate  the  use  of this 
method for serial BV determination during haemodialysis, obviating the problem of 
central  vein  sampling.  The  favourable  qualities  of ICG  are  well  documented  and 
spectrophotometer equipment is available in widely available. The distribution space 
of ICG is similar to the plasma volume. Estimates of plasma volume obtained using 
this method have been shown to correlate well with estimates compared to isotopic 
and Evans Blue methods.  [152]  There are very few reported adverse events.  [253] 
The  half-life  of the  dye  in  this  study  corresponds  well  with  the  data  from  the 
literature. [254]
There  are  some methodological  limitations  of this technique.  Since the half-life  is 
short compared to other tracers,  accurate  timing of the  samples is critical.  On the
244other hand the short half-life makes ICG a suitable tracer for repeated measurements 
at short intervals without the disadvantage of dye accumulation as we have shown in 
this study. A general drawback is the need for a calibration curve for each patient and 
intraindividually varying conditions during HD. 5-point calibration was performed to 
be sure that the relationship between absorbance and ICG concentration was linear, 
cross check for an errors introduced by addition of ICG aliquots into plasma blank, 
determine any offset that may have been present and eliminate any ambiguity which 
might arise in assuming that if the background absorbance  is close to zero in one 
patient this result may be extrapolated to all patients.
This experiment demonstrated that with precise 5-point calibration, consistent slopes 
may  be  obtained.  The  intercepts  for  the  blank  plasma  samples  were  however 
significantly  different  presumably  related  to  varying  plasma  composition  during 
dialysis. This finding suggests that a single 5-point calibration per patient studied is 
sufficient,  provided  the  baseline  absorbance  (intercept  on  absorbance  axis)  is 
determined before each measurement.  The  slight variation between predialysis and 
isovolemic  dialysis  readings  in  phase  II  could  have  been  due  to  volume  shifts 
induced by osmolar variation or dead space volumes in the fistula needle predialysis. 
The platelet count and serum albumin may affect the disappearance rate (Kicg). The 
Rmax (maximal removal rate)  largely depends on LCAT and cholinesterase  [255]. 
This may introduce an error in hyperlipidemic samples.  Dissociation between Rmax 
and Kicg is possible in liver diseases like cirrhosis and obstructive jaundice.
Apart  from  these  minor  drawbacks,  the  method  is  highly  reproducible  with  a 
variation (CV 4.07 %) well within the limits of the other tracer methods (e.g. 6.5 % 
for Radioimmunolabelled human serum albumin and 17% for Evans blue) [256], The 
variations are likely to be due to variations in blood sampling technique, variations in 
stability of the physiologic parameters of the subjects, errors in the measurement of 
Hct, errors due to trapped plasma (3-4%) and unmeasured stroma proteins (these can 
cause an underestimation < 1 % or 6 ml/1 blood).
Incomplete mixing can potentially introduce a significant error in the measurement. 
Analysis of the concentration time curve helps to identify the moment of complete 
mixing. During the phase  1  study I observed that prolonged mixing might occur in
245presence of cardiac dysfunction, hence a wide margin is desirable from injection to 
sampling period.  At the  same time, due to rapid decay,  one must avoid a situation 
where the measured plasma dye concentrations are small.
Although sampling can be begun at 1-1.5 min after infusion of the dye, we found 3 
mins as ideal to avoid such potential mixing problems.  Incomplete mixing was not 
encountered  in  phase  2  and  3  as  evident  from  the  decay  curves  obtained.  In 
agreement with other studies complete mixing of dye was obtained after 3 min in all 
subjects in phases II and III [257]. Analysis of the logarithmic data plotted on a scale 
helps to identify the moment of complete mixing. Mixing time may vary especially 
in subjects with circulatory failure.
Indirect estimates  of BV based on  anthropometric  data  significantly underestimate 
directly  measured  BV  changes,  especially  at  the  upper  end  of the  range  possibly 
because  they  are  derived  from  databases  and  metanalyses  obtained  from  normal 
healthy  population.  [258]  However  it  has  been  shown  here  that  within  the 
haemodialysis population itself directly measured volumes showed good correlation 
with extracellular fluid volume (fig  6)  and body  surface area (fig 7).  ICG derived 
ABV  has  haemodynamic  significance  and  may  play  a  central  role  in  preserving 
vascular stability during UF. In conclusion, indocyanine green is a suitable tracer for 
determining plasma  volume repeatedly  in  subjects  on haemodialysis.  This method 
provides  excellent  reproducibility,  can  be  carried  out  in  most  laboratories  and 
provide  a  reference  method  for  further  research  in  hemodynamic  instability  on 
dialysis.
246Table 1  Biometric data of patients studied
Mean SD Range
Age ( yrs) 61.1 10.1 50-78
Dry body Weight (kg) 77.5 19.0 53.3-112.3
BSA (mz) 1.91 0.27 1.54 - 2.42
Ht (cm) 168.8 8 158-184
IDWG ( litres) 2.3 1.01 0.8-4.15
Ht = height; I DWG = interdialytic weight gain
247Table 2a  Results  of four  5-point calibrations  curve 
in all 19 subjects in phase II and III.
Calibration Mean  Slope (SD) Mean  intercept (SD)
1 0.296  (0.013) 0.047 (0.051)
2 0.296  (0.011) 0.040 (0.050)
3 0.285  (0.017) 0.030 (0.031)
4 0.285  (0.019) 0.045 (0.045)
SD = standard deviation No significant differences between the 
measured calibration slopes obtained  (p>0.05)
Table 2b  ICG decay kinetics during four blood volume 
measurements in 10 patient during ultrafiltration (Phase III)
BkndwiunE
IVfeasuremnls
IVfanHtftime
IVfem(sd)nins
SDtfkgKG
]Vfean(s<9
Decay constant
1 473(1.17) 026(0114) -00038(00008)
2 5£3(M1) 023(049) •00031(00006)
3 6.17 (151) 023(001) -00028(00007)
4 630(1.56) 023(011) •00028(00007)
Sd = standard deviation
248Table 3  Absolute blood and plasma volumes before and  after first 
and final ultrafiltration steps in ten patients on dialysis (Phase III)
Sub PV1 PV 2 PV 3 PV 4 BV1 BV 2 BV 3 BV 4 Pre
Weight
Post
Weight
Pre-post
weight
1 5698 4818 4256 3976 8033 7139 6157 5944 110.8 107.6 3.2
2 3457 3070 2376 2626 5195 4625 3598 3977 58.8 58 0.8
3 4195 3779 3452 3160 5994 5578 5262 4881 70.6 68 2.6
4 3357 3196 2225 2077 4682 4670 3507 3269 82.1 78 4.1
5 5836 5169 4773 4562 8248 7450 6905 6717 102.7 99.8 2.9
6 6038 5200 4306 3779 7726 6849 5790 5093 85.5 82.5 3
7 4694 4467 3807 3492 7081 6854 5960 5504 73 71 2
8 4903 4484 4197 3957 7283 6791 6633 6392 85.3 82.8 2.5
9 6759 6516 6017 5716 9670 9450 8781 8363 113 111 2
10 4724 4492 4183 4134 6717 6387 6059 6018 74.8 72.3 2.5
Sub = Subjects , BV= blood volumes (mis), PV= plasma volumes (mis),
Pre weight = predialysis weight (kg), Post weight = postdialysis weight (kg), 
Pre -  post  weight = net  weight loss during dialysis (kg)
249Figure la The exponential disappearance of ICG (A)
The errors during sampling have been minimised and 
the assumption of 1  st order kinetics of ICG decay may 
be verified from the linearity of the log plot. (B)
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251Figure Id  Relative blood volume profile during intermittent
ultrafiltration in a patient during phase III. Arrows indicate
the timing of the four direct blood volume measurements using the dye.
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252Figure If  Calibration experimental steps
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253Figure 2  A concentration time plot 3-10 mins after injection of dye.
Y axis represents the Ln [ICGmg/1] concentrations derived from measured 
absorbances and the calibration curve. The linear regression line ( y= - 0.1973 x + 
0.7412  R2 = 0.99) extrapolated backwards to obtain the dye concentration at the time 
of injection.
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Figure 3  Comparison of 2 and 5 point calibration slopes
A = regression for 2 point calibration  B = regression for 5 point 
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Figure 4  Bland Altman analysis of predialysis plasma 
volume measurements with during first (PV1) measurement 
at isovolaemic dialysis in nine patients. Reference lines 
indicate mean difference and 2 std. deviation.
PV1IS0 H D  = first absolute plasma volume measured during 
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Figure 5  Regression line with 95% confidence intervals (slope) 
for consecutive blood volume measurements at 20 min intervals
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257Figure 7. Relationship of plasma volume measured by 
indocyanine green and body surface area. The best fit linear 
regression is represented by y = 4505.5x - 4217.7 using Lev 
Marqdt least square procedure: R2  = 0.82
J2
E
0 O
< D
E
s
E (/> m
CL
8000
7000  -
6000  -
5000  -
4000  -
3000
2000
2.6 2.4 2.2 2.0 1.8 1.6 1.4
Body surface area ( m2)
258Chapter 8
Tracking compartmental fluid shifts within 
the extracellular space during dialysis with 
profiled intermittent ultrafiltration
Introduction
The principle  goal  of ultrafiltration  is  to  remove  excess  salt  and  water  from  an 
expanded extracellular compartment.  Ultrafiltration (UF) induced depletion of the 
intravascular compartment however results in blood volume reduction. The changes 
in blood volume at any given time point depends upon the two opposing forces of UF 
and  plasma  refill  (PR).  Movement  of fluid  between  interstitial  to  intravascular 
compartment (PR) during standard fixed rate continuous UF, is the key mechanism 
preserving blood volume.  [259]  PR however, is a difficult parameter to measure. 
The use of online monitoring of intradialytic relative blood volume (RBV) changes 
over the past few years have allowed indirect estimates of PR using parameters such 
as RBV  changes normalised  for the ultrafiltration rate  (UFR).  [260,105,131,134] 
However absolute plasma refill volumes during UF have not been studied. 
Traditionally  UFR  is  set  at  a  constant  rate  for  the  entire  haemodialysis  session 
treatment based on the hypothesis that constant UF determines the gradual and linear 
reductions  in blood  volume.  This  assumes  that the  PR capacity  in  an  individual 
patient remains  fairly  constant  during  a  session  of UF.  RBV  trends  in  different 
individuals tend to vary despite using the same UF prescription. [259] UF schedules 
have been tailored, modified or interrupted with the theoretical assumption that this 
may optimise movement of fluid between compartments  (PR) to provide  a more 
physiological  regimen  for  the  individual  and  reduce  hypotension  during 
haemodialysis. However clinical studies have failed to show benefit in reduction in 
hypotension episodes with various intermittent UF profiles. [261]
The purpose of this analysis was to examine directly measured plasma volume, blood 
volume  changes  and  refill  responses  within  compartments  of  the  extracellular 
volume  and their relationships with vascular stability  during profiled  intermittent 
ultrafiltration during haemodialysis.
259Methods
Twelve stable chronic uremic patients on maintenance high flux HD were studied 
over 12 dialysis treatments. Each patient was studied during a routine dialysis session 
using a standard dialyser and urea kinetic model [112] and monitored using real time 
ultrasonic  blood volume  monitor.  Four  steps  of UF  (3L/hr)  were  applied which 
allowed  intervening  rest  period  and  attainment  of  steady  state  blood  volume. 
Ultrafiltrate  volume  was  removed  in  a  stepped  manner  (40%-20%-20%-20%  of 
target
UF  volume)  to  achieve  the  clinically  prescribed  dry  weight  unless  hypotension 
ensued at which point the UF was stopped. Absolute plasma volume measurements 
were made using Cardiogreen at four steady states of relative blood volume (see 
chapter 7). Blood samples were obtained to determine the haematocrit and derive 
absolute blood volumes form the plasma volume and haematocrit. (see Chapter 7). 
Patients were monitored using BP (Oscillometric) and bioimpedance (multifrequency 
Whole Body Bioimpedance, Hydra, Xitron Technologies) to measure extracellular 
fluid volume (ECF). Area under RBV decay during UF was integrated to derive the 
refill divergence, (see Chapter 5).  PR was calculated as the difference between the 
UF volume removed and plasma volume reduction between the measurement time 
points.
PR  and  change  in  interstitial  fluid  volume  during  UF  were  derived  from  the 
following equations:
Jref (PRV) =  Juf  - A pv  A  ifv = A ecf -  A abv
Jref(PRV)  *   Plasma refill volume,  Juf  =   ultrafiltrate removed 
PV  *   plasma volume (ICG) IFV -  Interstitial fluid volume ( IFV)
ECF  “   Extracellular volume (Bioimpedance), ABV  = *   absolute blood volume (ICG)
ECF was also derived post dialysis using Guyton formula [78] and compared with 
the  measured  bioimpedance  values.  The  characteristics  of  these  patients  are 
described in table 1. All patients were ultrafiltered to their clinical dry weight.
260Statistics
Statistical methods used were Bland Altman analysis for comparison of methods, t 
test for comparison  of means  (p<0.05),  linear regression and Pearson correlation 
tests. Statistical analysis was performed using SPSS software.(see methods)
Results
ECF changes during UF
The changes in the various compartments within the extracellular space between the 
start and end of the dialysis session are listed in Table 2.  The mean UF volume 
removed (2406 ± 808 mis) correlated strongly with the mean ECF change (- 2496 ± 
758  mis;  r=0.92)  and  intradialytic  weight  reduction  (2.6  ±  0.79  kg;  r=0.96) 
(p<0.001).  Predialysis extracellular volumes ECF (20.5 ±3.6 litres) were expanded 
but lowered significantly at the end of treatment (ECF 18.4 ±3.5 litres (p<0.01).  The 
postdialytic measured ECF (bioimpedance) overestimated the predicted (Guyton) by 
597 ± 406 mis (r=0.93 p<0.001).
Changes in PV and ABV during UF
The mean absolute plasma and blood volume at the start of ultrafiltration were 60.4 ± 
7.3 and 88.8 ± 10.6 mls/kg respectively. Mean percentage ABV reduction between 
the start and end treatment was -17.1 ± 8.6 %. Mean RBV reduction - 9.34 + 5.65 % 
with a wide variation between  -  18.4% to - 0.5%. The net percentage circulatory 
plasma and blood volume change between the start and end of UF had a weak and 
nonsignificant relationship with UF volume removed.
Relationship between BP, plasma and blood volume
The measured circulating plasma volume PV (42 ± 8.5 ml/kg), absolute ABV (67 ± 
13.4 ml/kg) and relative blood volumes RBV (90.2 ± 5.7 %) were significantly lower 
during hypotensive episodes (MAP < 70 mmHg; p<0.05 ; n =7) than at higher mean 
BP (PV= 53 ± 8.6 ml/kg; ABV = 79 ± 11.9 ml/kg; RBV = 96.4 ± 4.4%). (Fig  1)
261Systolic  BP  reduction  was  best  predicted  by  the  reduction  in  plasma  &  blood 
volume, change in ECF and body weight. (p< 0.01)
Relationship between ECF V ABV
Markedly elevated predialysis PV/ECF ratio (0.24 ± 0.03) and ABV/ECF ratio (0.4 ± 
0.05) fell significantly by the end of treatment (PV/ECV 0.2 ± 0.03; ABV/ECF ratio 
0.34 ± 0.05) (p< 0.01 for both parameters). The relationship between blood volume 
and postdialytic body weight superimposes on what would be predicted by a Guyton 
prediction curve whilst at the start of dialysis the blood volume is disproportionately 
high (Fig 2). The change in plasma volume between the start and end of dialysis 
weakly correlated with the reduction in RBV (r=0.61, p=0.04) and change in ECF (r 
= 0.58, p=0.04).
The Plasma refill quantification
The reduction in ECF  correlated with plasma refill volume  (PRV)  (r=  -0.78; p< 
0.01).  The mean reduction in interstitial volume  -  1293  ±751  ml  (derived  from 
difference between UFV removed and ECF change) was nearly identical to the mean 
calculated plasma refill volume PRV (1232 ± 715 ml R2 = 0.74) (difference between 
change in absolute plasma volume and UFV). (Fig 3) The reduction in RBV directly 
correlated with PRV (r= -0.83, p<0.01) Proximity to dry weight was associated with 
poorer refill capacity  (PRV)  (r = 0.53,  p<  0.05).  (Fig 4)  The  refill  volumes  for 
individual UF pulse were significantly lower for the final step UF (PRVi 7.5 ± 4.3; 
PRV2  4.1 ± 6.1; PRV3  2.54 ± 6.5 ml/kg/ml of ultrafiltrate (p < 0.01; 1  v 3). (Fig 5) 
PR during the first UF step did not correlate with predialysis extracellular volume. 
The total refill volume (PRV) during the whole UF session was predicted by change 
in RBV and ECF change.
The integral area under the UF decay curve derived for the RBV decay during the 
first UF step (refill divergence LDi 3053 ±2103 %. secs) strongly correlated to the 
refill volume PRVi (R= 0.81; P < 0.01) (Fig 6)
262Discussion
In healthy individuals plasma volume occupies approximately 20% of the extracellular 
compartment. [Introduction, Chapter 5] The relationship between blood volume and body 
weight,  abnormally  skewed  at the  start  of dialysis,  approaches  the predicted normal 
distribution  curve  described  for  euvolemic  individuals.  Fig  2  This  suggests  that  the 
distribution of excess fluid between compartments of the extracellular space can return to 
normal on approaching dry weight provided there is adequate ultrafiltration. This state of 
normohydration is perhaps short-lived and difficult to sustain,  due to the intermittent 
nature of the treatment.
The blood volumes at low MAP were significantly lower than at preserved systemic 
blood  pressure  suggesting  that  a  preserved  circulating  blood  volume  is  crucial  for 
haemodynamic stability. The study supports the concept that most of the plasma refill is 
derived from the interstitial space. Despite this the proportional reduction of ECF during 
high flux dialysis is contributed to by larger changes in circulating blood volume than 
previously  thought.  [262]  The  compensation  is  two-fold  :  from  the  interstitial 
compartment and intravascular refill.
We  found  a  significant  relationship  between  the  plasma  refill  and  haemodynamic 
stability. Schroeder et al on the other hand failed to demonstrate correlations of plasma 
refill rate with UFR, haematocrit change or heart rate using indirect estimates of refill 
with Critline monitoring during  constant UF.  [263]  The presence  of a high UF rate 
predisposes  to  larger  proportional  changes  in  the  vascular  compartment  and 
haemodynamic instability.
In  this  study,  refill  volume  corrected  for  body  size  and  volume  of the  ultrafiltrate 
decreased during dialysis and was significantly lower in the last hour of dialysis within
0.5 kg of the post dialytic weight. Variation in refill volume was unpredictable except for
263that during the last hour of dialysis. Schneditz [212] measured plasma density changes 
and, using a relationship based on Starling hypothesis and an open two-compartment 
model,  derived  a  filtration  coefficient  of 5.6  +  1.4  ml/(min  x  mmHg  x  50kglbm). 
Keshaviah [264] demonstrated that changes in plasma protein concentration accurately fit 
with plasma volume changes in a mathematical model, in which  changes in plasma 
volume are assumed to be governed by plasma oncotic pressure changes. Ilimura et al 
[265] found that the refilling coefficient varies widely from case to case and decreases 
during haemodialysis. Refill may also be governed by vasoactive and other reflexes that 
have interindividual variation. The initial blood volume and the modifications in venous 
and  arterial  tone  during  HD  can  induce  proportional  modifications  in  hydrostatic 
capillary pressure, the extent of which is not uniformly transmitted to all tissues. [266] 
Hence the equilibrium of forces across the capillary wall and filtration coefficient can 
vary considerably.
The use of ultrafiltration pulses  with  intervening rest periods to  help optimise target 
weight and allow  for more  haemodynamic  stability  has been  questioned.  The  group 
suggested that a linear profile may be preferable since intermittent profiles may aggravate 
vascular  instability.  Although  intermittent  profiles  may  allow  normalisation  of the 
compartmental volumes and their distribution postdialysis, high UF rates predispose to 
intradialytic haemodynamic instability due to variable refill capacities. Moreover blood 
volume  decline  leading  to  hypotension  may  be  multifactorial  and  may  depend  on 
peripheral resistance and reflex control of the circulation such as systemic compliance; 
action of feedback mechanisms working on venous unstressed volume; plasma oncotic 
pressure;  and,  especially,  capillary  wall  permeability  and  interstitial  space  elastance. 
[267] A gradually decreasing UF profile with negligible UFR within the final 0.5 - 1kg 
of the total UF volume may serve as the best profile in many patients.
The current interpretation of relative blood volume changes assume that no fluid shifts 
occur during blood volume  stability  and that net refill  is  absent during  a  flat blood 
volume  profile.  Whether  apparent  blood  volume  recovery  during  interrupted  UF  is 
entirely due to refilling fluid is not proven.
264These  results  emphasise  that  the  volume  shift  in  the  ECF  and plasma refill  play  a 
significant role in maintaining haemodynamic stability. Hypotension may be dependent 
on the maintenance of a critical absolute blood volume which is patient specific. The 
blood volume changes and variable and unpredictable refill rates may explain the high 
incidence of intradialytic complications observed with standard dialysis despite technical 
advances in ultrafiltration.
Knowledge of PRV and compartment shifts helps in understanding intradialytic events 
and  may  help  to  improve  techniques  of fluid  removal.  Individualised  ultrafiltration 
profiles that can adapt to refill capacity of the patient may be more physiological.  As 
both the UFR and PR rate variables can change during a single dialysis session, this 
supports the use of devices with automated continuous adjustments of the UFR and more 
refined profiling strategies.
265Table 1 Patient characteristics
Mean (SD)
Age (yrs) 59.2 (8.78)
Sex (m:f) 10:2
BSA (mz) 1.99 (0.22)
Predialysis wt 84.3 (14.8)
Predialysis ECF 20.5 (3.6)
Postdialytic weight (kg) 81.7(14.5)
UF volume (mis) 2406 (808)
SD = standard deviation ; ECF = extracellular volume 
UF = ultrafiltrate volume; BSA = body surface area
Table 2  Compartmental Fluid shifts during UF
Mean (±SD) 
(mis)
A ECF (mis) -2496 (758)
A ABV (mis) -1202 (626)
A PV (mis) .1174(444)
RBV % -9.34 (5.65)
A IFV (mis) -1293 (751)
RBV = relative blood volume (BVM)
PV =  plasma volume (ICG) IFV = Interstitial fluid volume ( IFV) 
ECF = Extracellular fluid volume (Bioimpedance)
266Figure 1 Boxplot showing significantly lower plasma, absolute and 
relative blood volumes during hypotension MAP < 70mmHg (n = 7) 
compared to nonhypotension ( n = 30) ** = p < 0.01  * p< 0.05
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Figure 3 Linear regression between reduction in 
interstitial  fluid volume and Plasma refill volume
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Figure 4 Linear regression between distance from 
target weight and Plasma refill volume
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Figure 5 Plasma Refill volume ml/kg/ml ultrafiltrate for 
each step UF pulse Refl  for first (UF1), Ref 2 
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Figure 6 Refill divergence during the first step UF showed 
significant correlation with the plasma refill volume(PRV)
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270Chapter 9 
The  Fcell  Ratio  Increases  During 
Ultrafiltration  in  Haemodialysis
Summary
The measurement of relative blood volume (RBVbvm) changes during ultrafiltration 
(UF), assume a constant mass and distribution of its circulating components. The 
validity  of the  latter  assumption  was  examined  in  ten  subjects  who  underwent 
repeated direct measurements of systemic hematocrit (Hctsys) and plasma volumes 
(PVicg)  using  dye  dilution  (indocyanine  green)  at  four  stages  of  dialysis  with 
intermittent UF. Subjects were monitored for ultrasonic RBVbvm changes. Absolute 
blood volume (ABVFconstant) was derived using (PVicg) and whole body hematocrit 
(Hctw). The latter was obtained from Hctsys and a constant Fcell assumption. PVjC g  
and  ABVFconstant  changes  during  UF  correlated  closely  (R=0.98:p<0.001). 
ABVFconstant changes overestimated reduction in PVjC g  during UF [Mean Difference 
MD -140 + 202 ml]  (Bland Altman).  The calculated red cell mass  (RCM Fconstant) 
using ABVFconstant however was variable  (p<0.01).  Fcell ratio  was  then corrected 
(Fcelli 0.87+0.02, Fcell2 0.89+0.03, Fcell3  0.94±0.06, FcelU 0.94+0.04 p<0.01) to 
maintain a constant red cell mass RCM Fvanabie (2146 +_460 ml).  When ABV was 
derived using PVlcg and variable Fcell (ABVFvanabie) the MD of PV,cg changes and 
ABVFvanabie  changes  was  negligible  (-  0.2  +  35  ml).  During  intermittent  UF, 
RBVbvm) changes  systematically underestimated percentage ABVFconstant reduction 
[MD  7.7110.6  %].  When  corrected  for  variable  Fcell  ratio  ABVFvanabie  and 
RBVc (bvm) differences were negligible [MD 1.212.6 %]. It is postulated that varying 
Fcell  ratio  reflects  a  microvascular volume  change  with  net  fluid  shift  from the 
microcirculation  to  macrocirculation  (intravascular  refill).  This  can  result  in 
underestimation  of the  Hctsys  and  RBVbvm  changes  less  than  that  predicted  by 
directly measured changes in plasma volume.
271Introduction
Technological  advances  have  allowed  the  development  of  devices  that  can 
continuously  and  non-invasively  monitor biologic  constituents  (haematocrit  [Hct] 
and  plasma  protein  concentration)  during  hemodialysis  (HD)  treatment.  Hct  and 
relative blood density changes online during HD have been advocated as tools for 
assessing blood volume  (BV)  changes  induced by  ultrafiltration (UF).  [127]  The 
assumption that changes in the measured systemic Hct (HctgyS ) result solely from
circulating  plasma volume (PV) changes induced by UF and that there is uniform 
mixing of a constant circulating mass of red cells and plasma components in the 
whole circulation during UF, form the basis of such indirect measurements.
Attempts  to  precisely  quantify  volume  shifts  in  the  vascular  compartment  using 
relative changes have been difficult as they often underestimate directly measured 
BV changes. [226] Apparent relative blood volume (RBV) changes therefore cannot 
be explained by PV depletion alone. Observational studies to analyse the RBV traces 
or determine the critical Hct for hypotension suggest wide degrees of inter-patient 
and intra-patient variability during haemodialysis with UF.  [268] These imply that 
other physiologic mechanisms and alterations affecting distribution of the circulatory 
components during UF may influence these indirect estimates. [226]
Accurate measurements of red cell volume by radioactive isotopes show that the 
relative volumes of red cells and plasma in the circulation as a whole (whole body 
haematocrit  [Hct  ]  )  differ  from  those  found  in  the  venous  blood  (Hct  ).  The L   W J   7   sys
difference  between  the  systemic  hematocrit  in  the  macrocirculation  [Hct^J  and
whole body hematocrit [Hct  ]  is expressed as the Fcell ratio (HcWHct^). In the
steady state this is due to a dynamic reduction in microvascular Hct during blood 
flow through the  capillaries and venules (< 200  um).  This  is  also known as the 
Fahraeus effect [269] and depends on the capacity of the microcirculation. Reduction 
is greater in smaller vessels due to anomalous flow properties of blood. [270] The use 
of changes in Hct  to accurately reflect BV changes depends on the constancy of the
relationship of Hct  to Hct  during UF. The assumption of constancy of F cell ratio w   sys
during dialysis with UF has not been investigated. This study examines the validity
272of  this  assumption  and  hypothesises  that  there  are  significant  changes  in  the 
microcirculation during UF that affect Hct redistribution and RBV changes.
Methods
Subjects
10  subjects  (8  male)  were  studied  using repeated  measurements  of PV  and  Hct 
during a single supine HD session with intermittent UF (31itres/hr). Four intermittent 
UF pulses were employed removing successively 40-20-20-20% of total UF volume 
between intervening rest periods.  Subjects had received chronic haemodialysis for at 
least  6  months  and  had  a  stable  dry  weight.  The  presence  of iodine  allergy, 
eosinophilia, abnormal  liver function tests,  raised  serum IgE  levels or significant 
access recirculation within one month prior to the study were exclusion criteria.  The 
North  Herts  Ethical  Review  committee  approved  the  study.  All  patients  gave 
informed  consent.  All  were  treated  by  thrice-weekly  high-flux  bicarbonate  HD 
(Fresenius 4008E) using polyamide membranes and AV fistulae. Blood flow rates 
were in the range of 350-450 ml/min and the mean sessional Kt/V was 1.24 +/- 0.16. 
[112]
Plasma volume measurement
PV was measured by dye dilution using indocyanine green. [152] Four estimates of 
PV (i = 1  - 4) were obtained during a single haemodialysis session in each patient. 
All measurements were made in stable supine position. UF was commenced after an 
equilibration period of twenty minutes  from the  connection to  the  extracorporeal 
circuit.  PV measurements were made before the start and at the end of the first and 
fourth UF pulse (Fig 1) when steady state BV conditions were obtained on the RBV 
monitor (RBV plateau with variations of less than 0.1% over at least ten minute 
period).
Tracer
The  tracer  used  was  Cardiogreen  (ICG  Green ™Sterile  indocyanine  green  USP 
Fluka), a tricarbocyanine dye, mol wt 775, with an absorption peak at 805nm. The 
dye is non-toxic, confined to plasma, not subject to extra-vascular distribution, and
273not  metabolised  or  degraded.  After  equilibration,  the  dye  decays  fast  in  an 
exponential manner. It is exclusively taken up by the liver and has a plasma half-life 
2-3 min. [153]
Procedure for determination of plasma volume
Prior to each dye injection, blood was withdrawn for Hct and baseline plasma blank 
in heparinised  syringes.  ICG  (25  mg)  was dissolved  in  10  ml  of sterile aqueous 
solvent to produce ICG solution of 2.5mg/ml. The dye (lOmg) was then injected as 
rapidly as possible into a venous port beyond the bubble trap.  All syringes were 
weighed on a precision scale before and after the injection to determine the precise 
quantity injected.  Exactly  3  minutes after the  end of the  injection,  sampling was 
commenced from the arterial port in heparinised syringes at 1-min intervals for 10 
min (8 samples). Samples were centrifuged at 3000 rpm for 10 minutes. The plasma 
blank sample was used to determine the baseline background absorbtion at 805-nm 
wavelength.  The  absorbtion of ICG  dye  in  the  timed plasma  samples  were  then 
compared against the baseline at the same wavelength.  [153] A 5-point calibration 
was performed for each BV measurement using the blank plasma sample just before 
dye injection, (see Chapter 7)
Analysis
The natural logarithms of the measured ICG dye concentrations were plotted against 
time for each PV measurement and the best fit linear regression obtained. The 
logarithm of the dye concentration at t = 0 was obtained by extrapolation. The antilog 
of this yielded the initial dye concentration in plasma at the time of injection. Plasma 
volume (PVicg) was calculated according to the equation:
Plasma volume1 2 4 7 1  =  dve infused  (me)  Equation 1
plasma dye concentration (mg/I)
Haematocrit determination
Hct  was measured using aperture impedance counters (Coulter-STKS). [271] All
sys
patients were monitored with relative blood volume  (RBVbvm)  monitor [127] and 
oscillometric blood pressure.
274Procedure for determination of absolute blood volume and
red cell mass
1. Absolute blood volume (ABVFconstant) [247] estimates were derived for each PV 
estimate and corresponding measured Hct^adjusted by a factor of 0.86 to correct for
the difference between the Hct  and Hct  (constant F cell ratio) sys  w
ABVFconstant  =  plasma volume  Equation 2
1-  (Hct  )*Fcell{2 6 9 J   sys
2.  Total  red  cell  mass  (RCM Fconstant)  estimates  were  then  derived  from  each 
ABVFconstant estimate and the corresponding Hct w   using the relationship:
R C M fc o n sta n t  A B  VFconstant  x  Hct w  Equation 3
3. Subsequently separate F cell ratios (Fcell)j were calculated for each of the four 
plasma volume (PVi) and corresponding Hctsys [(Hctsys)j] values obtained during each 
dialysis session. The calculation assumed that a) RCM remained constant throughout 
the dialysis session and b) that absolute blood and plasma volume changes during UF 
were effectively identical.
4. (ABVFvanabie)\ was then recalculated from equation 2 utilising the appropriate PVi 
and (Hctsys)i measurements and the corresponding (Fcell)i
5. The differences in F cell ratio between the first [(Fcell)i]  and subsequent [(Fcell)j] 
measurements, were used to correct the RBV reading (corrected reading designated 
as RBVC ) obtained from the RBV monitor at the second (RBV2), third (RBV3) and 
fourth (RBV4) measurements:
RBVci = RBViX {1- [(Fcell)i- (Fcell)i]}  Equation  4
Where  i = 2 to 4
275Statistics
Statistical methods used were Bland Altman [246] analysis required for comparison 
of methods, Student’s test for comparison of means (p<0.05), linear regression and 
Pearson correlation tests. Statistical analysis was performed using software package 
Sigmaplot (version 2.01).
Results
The subjects had a mean age of 61.6 + 4.8 yr, a mean dry body weight of 83 + 17 kg 
and a body surface area of 2 + 0.2 m2. The mean UF volume removed was 2298 + 
845 ml and there was a net reduction in PV during dialysis of 1218 + 474 ml.  The 
mean reduction in weight during dialysis was 2.48 + 0.9 kg.
The derived values for ABVpconstant from directly measured plasma volumes (PViC g ) 
and hematocrit (Equation  1  ) are shown in Table  1.  PV changes and BV changes 
were  highly  correlated  (R  =  0.98;  p<0.001).  When  the  mean  red  cell  mass 
(RCM Fconstant) was calculated using (ABVFconstant) and the measured hematocrit, there 
were significant differences between the calculated values obtained at each measured 
PV,(p<0.01 Fig 2a).
The assumption of a constant circulating RBC mass during UF is violated unless 
there is a progressive increase in F cell ratio. Hence the F cell ratios were corrected 
(Fcelli 0.87± 0.02, Fcell2 0.89 ± 0.03, Fcell3  0.94 ± 0.06, FcelLj 0.94 ± 0.04 ; PO.01 
Fcelli v Fcelb, P<0.001 Fcelli v FcelU) assuming a constant circulating red cell mass 
(RCM pvariabie mean 2146 + 460 mis p=ns: Fig 2b). The resulting ABV estimations 
(A BVFvariaW e) are depicted in Table 2.  The corrected mean absolute blood volume 
obtained at the end of ultrafiltration was 72.2 mls/kg (Table 2 ABV 4).
Absolute blood volume changes (ABVFconstant) systematically overestimated plasma 
volume changes (PVjC g ) with a mean difference of -140 + 202 mis (Bland Altman 
analysis: Fig 3a). When corrected for F cell variation, the mean difference of plasma 
and BV changes were negligible (-0.2  + 35.8 ml: Fig 3b). The change in F cell ratio 
during UF (Fig 4) correlated with the UF volume removed (R 0.32; P<0.05).
276Relative BV changes (%) significantly underestimated the percentage reduction of 
absolute BV (ABVFconstant)  between the four measurements (Table  1) with a mean 
difference (± std deviation) of 7.7 ± 10.6 % (Fig 5a). When corrected for varying F 
cell ratio, the mean difference between change in corrected RBV (RBVc Equation  4) 
and absolute BV (ABVFvanabie Table 2) was only 1.2 + 2.6 %  (Fig 5b).
Discussion
The assessment of volume  shift using  systemic  haematocrit or plasma  density is 
based on mass conservation. The first assumption of a constant total circulating red 
cell mass during a dialysis session is true in the absence of haemolysis or blood leak. 
This parameter is only likely to fluctuate over time with changes in erythropoietin 
treatment.  Red cell  volume may  vary  with plasma  osmolality,  but the  degree  of 
change is small even across extreme variations in dialysis fluid sodium concentration 
[272].  A  second  assumption  is  of  constant  homogenous  distribution  of  these 
components between the macro and the microcirculation defined by F cell ratio [269] 
throughout dialysis. A constant F cell ratio implies that there is no net microvascular 
volume change. This study demonstrates that both these assumptions cannot be true 
at the same time. The assumption of a constant circulating RBC mass during UF is 
violated unless there is a progressive increase in F cell ratio during UF.
A model of circulatory changes during UF with or without microvascular changes, 
can be hypothesised based on these results (Fig 6). In the steady state (Fig 6a), the 
intravascular volume (Vb) can be divided into two compartments with proportional 
distribution of plasma and red cells: the macrocirculation (Vmac = 60%: Hsys = 0.35) 
and the microcirculation (V mjC  = 40%:  H mjc = 0.233). If UF were associated with no 
change  in  F  cell  ratio,  a  proportional  volume  change  would  occur  in  each 
compartment,  and  the  observed  rise  in  Hctsys  would  purely  reflect  the  volume
removed  from  the  macrocirculation  (Figure  6b).  However  the  observed 
underestimation  of rise  in  Hctsys  suggests  that there  are  additional  physiological
factors in operation. There are two main possibilities. There could be loss of red cell 
mass from the systemic circulation, which is unlikely, or there could be intravascular 
refill from the micro- to macrocirculation.  The latter mechanism results in a new
277steady state of the microcirculation and a higher F cell ratio (Figure 6c). It is strongly 
supported by the almost complete correction of systemic RBV underestimation by 
use of a varying F cell ratio.
The ratio of the red cell mass to PV differs in the venous system, the capillaries, the 
splenic  blood  pool  and  in  different  organ  beds.  Any  perturbation  provokes  a 
proportional  change  in  microvascular  and  systemic  haematocrit,  which  can  be 
represented by the constant oc,  the value of which is approximately 0.66 based on 
studies of different microvascular beds [273,248]. Each microvessel generation could 
constrict in a heterogenous manner. These heterogeneties can be averaged by using 
the value oc. Since oc is fairly constant, any rise in F cell ratio entails a reduction in V 
mic/Vb (see Appendix 7).  In the hypothetical example depicted in Figure 6, these 
relationships predict a reduction in Vmic/Vb from 21% (Fig 6b) to  12% (Fig 6c). 
Such models have been used to describe the microvascular circulation under different 
pathophysiologic conditions. [274]
Observations  on  the  hepatic  and  pulmonary  circulation  indicate  that  changes  in
microvascular  volume  lead  to  transient  changes  in  the  Hct  or  density  of blood
flowing from these organs. [275] If the circulation is subjected to any perturbation,
which changes the microvascular volume, this contributes to part of the measured
change  in the  Hct  .  There  is  no  evidence  to  suggest  significant  alterations  in  sys
capillary  permeability  characteristics  during  UF.  [274,  212]  Morphometric  data 
indicates that 40 - 50 % of BV resides in the microcirculation. Direct microvascular 
measurements suggest that during haemorrhage, <200 pm diameter venules form the 
major reserve capacity of the circulation. Large volumes may be shifted from the 
micro to the macrocirculation, reducing the effect of BV loss.
These findings suggest that microvascular change induced by UF is an important 
factor influencing the Hctsyg.  This seems to be accentuated at later stages of UF,
when a rise in Hctsys may not occur, despite hypovolemia. This is likely to be due to
intravascular  refill.  Studies  using  tagged  RBC  have  suggested  that  during 
hypovolemia due to UF, mobilisation of blood from the splanchnic region occurs as a 
compensatory mechanism [276].
278This study provides evidence of dissociation between indirect RBV measurements 
and direct BV changes measured by indocyanine green during haemodialysis, most 
apparent at later stages of dialysis with ultrafiltration.
The absolute blood volume estimates with ICG in this study corrected for F cell 
variation (mean 72 ml/kg at end of UF)  approximate physiological values  in the 
nondialysis  population  [277].  Lower  blood  volume  estimates  obtained  using 
radioisotope methods in subjects prior to the start of dialysis in a previous study 
[242],  are  perhaps  due  to  smaller  body  size,  methodological  variations  and 
differences in hydration status of the subjects studied.
The mass of protein in the vascular space at the time of the dye measurement is 
irrelevant for the plasma and blood volume determination.  The dye  simply binds 
instantaneously to the available circulating protein mass.  This study assumes that 
during blood volume steady state with no UF and a relative small sampling period 
there  is  dynamic  equilibrium  and  negligible  net  flux  of protein  across  capillary 
membrane.  Relative  blood  volume  measurements  are  also  based  on  the  same 
assumption  allowing  comparison  between  two  methods.  Changing  vascular refill 
rates despite apparent steady state conditions in the relative BV profile seem unlikely 
to account for this,  given the degree of underestimation.  Although the  ultrasonic 
RBV  monitor  has  a  very  low  noise  signal  ratio,  momentary  fluctuations  may 
introduce potential errors.
However, the dissociation is almost eliminated when the variation in F cell ratio is 
considered, suggesting that intravascular refill and regional blood flow redistribution 
during UF significantly affect RBV measurements. These observations and others, 
such  as  the  RBV  changes  observed  during  maximal  exercise  on  dialysis  [278], 
support  the  notion  that  RBV  measurements  can  be  significantly  affected  by 
procedures that induce changes in the recruitment of the microcirculation.
Conclusion
Microcirculatory  changes  lead  to  volume  shifts  from  the  micro  to  the 
macrocirculation  with  adjustment  of  the  macrovascular  Hctgys  during  UF.  A
compliant microcirculation acts as a blood reservoir allowing volume compensation 
during UF. Such redistribution lead to a progressive rise in the F cell ratio during UF 
in the presence of a constant red cell mass. Hence the assumption of a constant and
279homogenous Hct distribution during UF is invalid, and the use of Hctsys change as
the sole determinant of PV change could be erroneous. Both the density and the Hct 
equations  employed  to  determine  changes  in  RBV,  ignore  volume  redistribution 
between the macro and microcirculation. This study can serve as the basis to design 
experiments to characterise the mechanisms producing microvascular change during 
UF.
280Subjects ABV1 ABV2 ABV3 ABV4
1 8033 7139 6157 5944
2 5195 4625 3598 3977
3 5994 5578 5262 4881
4 4682 4670 3507 3269
5 8248 7450 6905 6717
6 7726 6849 5790 5093
7 7081 6854 5960 5504
8 7283 6791 6633 6392
9 9670 9450 8781 8363
10 6717 6387 6059 6018
Table 1 Absolute blood volumes (ABVFco n stan t) derived by using 
measured plasma volume, hematocrit and constant F cell ratio 
(0.86)  in  ten subjects during hemodialysis
Subjects ABV1 ABV2 ABV3 ABV4
1 7995 7139 6348 6157
2 5165 4625 3728 4125
3 5964 5578 5455 5074
4 4660 4670 3648 3405
5 8208 7450 7119 6945
6 7701 6849 5928 5220
7 7040 6854 6196 5734
8 7242 6791 6903 6679
9 9621 9450 9062 8642
10 6684 6387 6248 6215
Table  2 Absolute blood volumes (ABVFvariab le) derived by using 
measured plasma volume, hematocrit and variable F cell ratio in 
same ten subjects during hemodialysis
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Figure 5. Bland Altman analysis comparing percentage blood volume changes in 10 HD 
patients during UF as observed by RBV monitor and absolute blood volume measured by 
ICG technique (% blood volume reduction during UF between all four measurements; n 
60). Reference lines indicate mean difference +2 SD. (a) Comparing observed RBVbvm 
changes and absolute blood volume changes derived from plasma volume, Hct, and Fcell 
ratio 0.86 (ABVFconstant). (b) Comparing RBVCgV M  changes and absolute blood volume 
changes (ABVFvariabte) both corrected for Fcell variation.
RBV changes underestimate absolute blood volume reduction with constant F cell 
assumption by 7.7+ 10.7 % (5a) but by only  2.6 % when corrrected for varying F cell 
ratio (5b)..  micro macro
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Vb  = v ^  + Vh *
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a   Hctw  Fcell  Hctsys  Hctmh
0.66  30.1  0.86  35  23.3
0.66  34.4  0.86  40  26.7
Plasma volume depletion =  -12.5%  
Vb  Total red cell mass constant
Fig 6c
(post UF  changing  F c e ll)
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Figure  6  Proposed  hypothetical  blood  volume  model  demonstrating 
microvascular volume  change  (MVC)  6a  Steady-state  control  shows  uniform 
systemic hematocrit (Hsys) for the  macrocirculation  (right compartment Vmac) 
and  the  microvascular  haematocrit  Hm ic  for  the  microcirculation  (left 
compartment  Vmic)  to  represent  the  total  red  blood  cell  content  in  a  blood 
volume Vb and  whole  body  hematocrit (Hw).  6b  post  UF  considers a  state  of 
net volume removed  D Vb resulting from ultrafiltration and a static relationship 
between  the  contracted  macro-  (Vm ac1)  and  microcirculation  (Vm ic1)  (F  cell 
constant).  6c  Identical  net  blood  volume  depletion  (DVb  )  with  an  additional 
microvascular volume change (Vm jc 2),  resulting  in a  rise in the  Fcell  ratio and 
underestimation of the Hctsys change.  It demonstrates a state of redistribution 
from  micro  to  macrocirculation  (macrovascular  filling  or  intravascular  refill) 
during  UF.  p (2/3) represents a constant proportional adjustment between the 
macro and micro hematocrit.
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Comparing  measured
Ultrafiltration -   A  Summ
Schematic  illustration  summarising  how  weight  changes  during  dialysis  compare 
with volume shifts of different fluid compartments during ultrafiltration as measured 
by different assessment tools described in the previous chapters.
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288OVERVIEW
A major aim of this series of studies was to study the dynamics  of vascular refilling 
using short intermittent high rate ultrafiltration boli and observe changes in fluid shift 
(extracellular,  intravascular)  and  cardiovascular  parameters  at  varying  states  of 
hydration  during  high  efficiency  dialysis.  The  hypothesis  was  that  objective 
monitoring  of fluid  status  during  dialysis  using blood  volume  monitoring would 
facilitate accurate estimation of ‘dry weight’ and help optimise fluid removal in a 
safe  and  physiologically  appropriate  manner.  The  clinical  studies  included  here 
investigated the use of blood volume responses to fluid removal, both for objective 
quantification of hydration status and for the identification of factors associated with 
cardiovascular instability on dialysis with ultrafiltration.
Hypertension  and  fluid  overload  bear  a  complex  relationship  to  each  other. 
Interdialytic  fluid gains have a significant effect on BP and its diurnal variation. 
Casual BP readings to judge BP control and fluid status are dependent on timing of 
the measurement amongst other factors,  especially  in the  few hours immediately 
before dialysis when fluid gains are maximal. [Clinical Studies Chapter 1] Judging 
fluid  status  and  prescribing  ultrafiltration  based  on  casual  interdialytic  BP 
measurement  can  be  fraught  with  error.  Large  swings  in  BP  can  occur  during 
ultrafiltration  on  standard  high  flux  dialysis  predisposing  to  relative  or  absolute 
hypotension  with  potential  complications-  the  other  side  of  the  coin.  The 
maintenance of BP in the  interdialytic  and intradialytic period is dependent on a 
combination  of  factors  i.e.  extracellular  volume,  circulating  blood  volume  and 
vascular tone,  which  is  intricately  regulated  by baroreceptor and  neurohormonal 
reflexes.  These  altered  adjusting  mechanisms  coupled  with  rapid  fluxes  in 
extracellular  compartment  due  to  intermittent  dialysis  lead  to  blood  pressure 
variations during the dialytic and interdialytic cycle.
The quality of blood pressure monitoring depend not only on technical limitations 
but  more  commonly  on  understanding  of  the  user  of  the  technology.  Often
289inappropriate selection of cuff size or movement artefacts may invalidate the results. 
Guidelines on the correct methodology of BP measurement, published by various 
professional societies are often ignored. This is particularly true with respect to the 
need for a sufficient resting period prior to BP measurements. The specific influence 
of the timing, measurement method and dialysis frequency on reading accuracy has 
been insufficiently perceived. The study reported here and other studies have shown 
that sole reliance on predialysis casual readings is invalid. Consensus on BP targets 
in haemodialysis is proving very difficult to achieve. This may reflect inadequacies 
in measurement, monitoring and treatment.
Bioimpedance  spectroscopy  is  highly  reproducible  and  particularly  useful  in 
tracking fluid shifts with some parameters particularly useful and more sensitive in 
detecting  changes  in  hydration  status  of  these  patients.  Extracellular  volume 
measurements  tracked  change  in  body  weight  with  considerable  accuracy.  This 
technique has the added advantage of incorporating lean body mass characteristics, 
which are closely linked to the hydration status of these patients.
The study reported here has  demonstrated that fluid  distribution  is abnormal  in 
uremic  subjects  compared  to  controls  especially  in patients  with  advanced  renal 
failure  and  those  on  dialysis.  [Clinical  Studies  Chapter  2]  The  expanded 
extracellular compartment is most apparent in advanced uraemia approaching the 
need  for  dialysis.  This  could  be  a  consequence  of failing  nutrition.  Both  may 
precipitate the need for initiating renal replacement therapy. Significant malnutrition 
is a late phenomenon in advanced renal insufficiency and there is a profound decline 
in nutritional state just prior to dialysis initiation. Nutritional status is only partially 
corrected  by  dialysis  despite  adequate  modelling  parameters.  Visceral  protein 
markers are  less reliable than direct tools in the assessment of nutritional  status. 
Falling nPCR quite early in the course of progressive renal failure may be partly due 
to mathematical coupling and errors in urine collection.  The volume expansion is 
also only partially corrected by dialysis treatment. Poorly corrected malnutrition may 
have a significant role in overhydration of dialysis patients. Dry weight adjustments 
must include nutritional assessment as a core element.
290Both blood density and sound speed are closely related to total protein concentration 
in blood and, as a consequence, to rheologically important parameters of blood. The 
methods  that permit  continuous  measurement  of these  properties,  the  ultrasonic 
technique,  used  for  measuring  relative blood  volume  changes  over a  continuous 
period  of time  in  haemodialysis  patients.  From  the  continuous  measurement  of 
concentrations during haemodialysis treatment, relative changes in blood volume can 
be recorded in real time.
The subsequent chapters on relative blood volume (RBV) measurement shift focus 
from hypertension and volume overload to investigate hypotension and approaching 
dry weight. There is little change in the blood volume profile during a stable supine 
dialysis  session with no UF.  The application of UF  significantly alters the RBV 
profile during dialysis.  Pattern recognition of these changes yield variable curves 
primarily  influenced  by UF  prescription  with wide  inter-patient  and  intra-patient 
variability.  It was  apparent that steeper decay  of blood  volume  curve  was more 
frequently  associated  with  haemodynamic  instability.  Diagnosis  was  however 
retrospective and subjective. [Clinical Studies Chapter 3]
The degree of change in RBV per unit volume of ultrafiltrate was higher in patients 
nearer to their predicted dry weight. [Clinical Studies Chapter 4] The critical level 
of reduction in RBV at which hypotension occurs (RBVcrit) showed a wide inter­
individual range, varying from 71 to 98%. No correlation was observed with changes 
in RBV and BP or the incidence of hypotension. The RBVcrit may also depend on 
cardiovascular defence  mechanisms  such as  sympathetic  drive.  The  concept of a 
critical relative blood volume reduction leading to hypotension cannot be sustained.
RBV  decay  characteristics  [Clinical  Studies  Chapter  51  under  experimental 
conditions can detect changes in hydration status and predict instability.  They are 
determined by the plasma refilling capacity presumably driven by hydrostatic forces. 
The refilling analysis remains intriguing and warrants further investigation and better 
analysis techniques e.g. refilling rate distribution function with time, which could be 
constructed for each period of ultrafiltration. The results of the study reported here 
indicate  a 2 pool  linear behaviour of the  extracellular compartment during  short
291stress  ultrafiltration  and  highlight  the  importance  of compartmental  fluid  shifts 
during UF. The main buffering mechanism for BV stability is the interstitial space.
The ultrafiltration rate has an independent effect on the  RBV independent of the 
hydration state, amount of fluid removed or patient related factors. Cardiovascular 
response systems are constantly stressed in the inter- and intra-dialytic phase to cope 
with the fluctuating hydration status. This influences haemodynamic variables such 
as BP and RBV. For this reason RBV patterns and response will vary according to 
the dialysis schedule.  Further RBV  studies on longer treatment duration or more 
frequent therapies will provide a better insight into the influence of time on RBV and 
BP changes during dialysis with ultrafiltration.  Extracellular compartment volume 
tracking with simultaneous RBV measurement may help prescribe adequate and safe 
ultrafiltration regimen for each subject during dialysis.
Clinical  Studies  Chapter  6  explores  how  other  prescription  variables  such  as 
dialysate  temperature  can  be  used  in  conjunction  with  ultrafiltration  to  allow 
improved haemodynamic stability.
The technique of dye dilution using indocynanine green was successfully used to 
investigate  changes  in  absolute  plasma  and  blood  volume  during  dialysis  with 
ultrafiltration, compare them directly with RBV alterations and quantify plasma refill 
volume. [Clinical Studies Chapters 7-10] It is apparent that RBV alterations during 
ultrafiltration are  induced by intravascular volume depletion and microcirculatory 
changes within the vasculature, the latter effect more pronounced at the later stages 
of ultrafiltration nearer to dry weight.
During the RBV  studies  it was  seen that the  concentration of blood components 
varies  considerably  with  ultrafiltration.  The  alterations  in  Fcell  ratio  during 
ultrafiltration suggest that rapid fluctuations at the macroscopic scale with periods of 
5 to 30 seconds are possibly due to heterogeneities at the microscopic scale and to 
the  particular  rheological  behaviour  of the  red  blood  cells  at  the  level  of the 
capillaries and the small blood vessels.
292Many  of the  observations  contained  in  this  thesis  deserve  further  study.  In  the 
following sections I have attempted to formulate a framework for future work in this 
area.
1. The  Microcirculation
The effect of microcirculatory  shifts on cardiac  function, humoral control of the 
microcirculation  and  therapeutic  role  of  microcirculation  in  blood  volume 
compensation are little studied. The measurement of concentrations of circulating 
plasma  and  blood  components  at  an  accessible  measuring  site  may  be  used  to 
investigate  the  rheology  of blood  in  the  human  microvasculature.  Study  of the 
mechanisms by which the microcirculation is recruited and ways in which it can be 
manipulated to improve macrovascular filling and cardiovascular function would be 
a major advance.
2. Fluid kinetic model
Fluid models will need to be developed to provide more rigorous analysis of blood 
volume responses.  Modelling ultrafiltration requires a degree of understanding of 
active compensatory mechanisms that is currently lacking. The models require the 
capacity to modify the ratio of stressed to unstressed volume in the vascular space, to 
take  account  of the  lymphatic  shift  and  to  allow  some  form  of active  refilling. 
Changes in blood flow distribution to the different sections of the microvasculature 
will influence the filtration coefficient and determine plasma refill - an effect not 
considered in passive compartment models. Such models could provide the basis for 
a parameter based adaptive control strategy to remove fluid in a more physiological 
manner.
3. Effects of recirculation
The extracorporeal circuit may also have a role to play in the blood volume changes 
noted. It is appreciated that transport delays are introduced as ultrafiltered blood is 
translated into a blood volume change via the patient.  There is the mixing effect 
caused  by  cardiopulmonary  recirculation  and  the  possibility  of large  artefactual
293changes  in  blood  volume  resulting  from  access  recirculation.  Recirculation  of 
ultrafiltered blood back to the blood volume monitor without passing through the 
patient’s systemic circulation can cause the apparent relative blood volume to change 
more rapidly during ultrafiltration. The effect of cardiopulmonary recirculation on 
blood volume  changes has not been  fully  explored especially  with respect to its 
influence  on maximal  refilling rate.  In the  current data  sets  the  effect of access 
recirculation  could  be  eliminated  by  use  of a  temperature  control  module  and 
monitoring of the transport delay between each UF transition and the slope change in 
relative blood volume. More rigorous analysis of recirculation effects deserve further 
attention for fluid kinetic modelling. Suitable corrections could be applied to blood 
volume data.
4.  Interaction between variables
The  current  research  focussed  on  relationships  between  blood  volumes,  blood 
pressure  and bioimpedance  changes  during dialysis.  The major factors  governing 
stability are blood volume, plasma refill, temperature and vascular tone. There are a 
large number of patient related variables relating to hydration status such as vascular 
compliance, plasma volume expansion, changes in capillary pressure and regional 
blood  flow  redistribution.  The  effect  of  these  may  be  crucial  in  determining 
haemodynamic  alterations.  More  extensive  studies  are  required  to  evaluate  the 
changes in cardiac output, antihypertensive medications, pulse rate variability, the 
role of the intracellular space during refill,  dialysate conductivity and the role of 
various  comorbidities.  In  all  patients,  HD  with  UF  increase  urea  rebound  when 
compared with isovolaemic HD. The regional blood flow model offers a physiologic 
interpretation  of this  observation  in  which  hypovolaemic  compensation reduces 
peripheral  blood  flow  thereby  increasing  peripheral urea  sequestration.  From  the 
clinical point of view it follows that two main aspects of HD adequacy, clearance and 
UF,  are not independent.  The  relationship becomes  more  important as  treatment 
times are reduced and UF rates are increased. Switching from constant to variable UF 
modes such as using high initial and subsequently decreasing UF rates is likely to 
have positive effects both on UF-induced blood volume reduction and on dialysis 
efficiency. The effect of vasoactive substances, hypoxemia, plasma osmolality, body 
position, eating etc has not been examined.  Effect of postural manoeuvres on blood
294volume changes will be an important consideration in the design of feedback control 
systems  and  much  further  study  will  be  required  to  characterise  the  effects  of 
changing posture  in  different haemodynamic  states.  A  model  of the  venous  and 
arterial trees of the peripheral and central circulation might facilitate the modelling of 
temperature effects since the effect is predominantly through shunt vessels.
5. Tolerance to ultrafiltration in different treatment modalities.
The effects of dialysis  and  ultrafiltration  cannot be  separated in these  studies.  It 
would be instructive to compare patient responses to both isolated UF and combined 
UF and dialysis in a cross-over study. Eliminating dialysis process offers advantages 
for bioimpedance  measurements  since  electrolyte  composition  can be maintained 
constant. Sodium variation during a period of isovolaemia may be able to tease out 
the  specific  effects  of electrolyte  variation  on bioimpedance  measurements.  The 
effect  of  modifying  dialysate  buffer  on  blood  volume  stability  needs  further 
exploration to minimise haemodynamic compromise. [279]
6. Absolute blood volumes (ABV) derivation
The rate of change of slope of raw relative blood volume data may be used to derive 
absolute  blood  volume  in  real  time  in  a  non-invasive  manner.  Although  slope 
determination is a relatively straightforward operation, different methods for absolute 
blood  volume  calculation  may  be  developed  based  on  algorithms.  Two  such 
algorithms  using  localised  RBV  calculation  depend  on  local  blood  water (BWo) 
information.  The remaining three algorithms make use of the rate of change of blood 
water [d (BW)/dt data].  [280]  Preliminary analysis has  suggested that using raw 
ABV estimations the mean difference between the ultrafiltration algorithm and ICG 
is approx. 400 ml.  i.e.  the ABV algorithm underestimates the ABV measured by 
Indocyanine (ICG) method. Importantly the deviations about the mean are always 
patient specific i.e. the algorithm systematically under- or over-estimates the ABV 
determined via ICG, perhaps because different methods see different compartments 
or distribution volumes.  Nevertheless  since the error is  systematic  in patients,  it 
allows  some rules  to be  defined  for slope  evaluation.  The  capacity  to  derive  an 
absolute parameter of the vascular compartment during dialysis in a simple manner
295will be extremely useful in addressing the issue of vascular stability and hydration 
status of these patients. Absolute blood volume derivation using refined algorithms is 
a potentially non-invasive way of monitoring fluid status during ultrafiltration. The 
use of ICG monitoring in a non-invasive manner also deserves further exploration for 
direct and reliable quantification of plasma and blood volumes.
7.  Finally, data acquisition and processing involved in these studies were extremely 
time consuming and a major constraint in this research. For further analysis of such 
data sets it is recommended that the data be first imported into database tables to 
expedite progress. A more robust integrated data processing system would enable 
high quality studies in this field. The data and studies in this thesis have been largely 
cross sectional. While this is useful in obtaining ranges of parameters, longitudinal 
studies are necessary to realise full potential of many of these ideas.
Conclusion
An understanding of the physiologic fluid shifts in the vascular space during fluid 
removal on dialysis and more objective measures of the fluid status is necessary for 
accurate estimation of dry weight and safe fluid removal on dialysis. The availability 
of modem dialysis machines equipped with various devices to monitor the patient 
and  the  dialysis  treatment  hold  promise  for  better  understanding  and  future 
improvements in ultrafiltration prescription. The major limiting factor is the patient 
response pattern to ultrafiltration, hence individualising prescription may help. This 
requires a system, which can characterise the response and feedback instantaneously. 
I hope that the work described here may contribute to this goal.
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A typical real time data acquisition file obtained during a dialysis 
session (Acqui  download)
.T tnw jQ d
100 36 
10032 
10037
100-61
10043
100 51 
100 51
100 52 
10046 
100 51 
100 54
100.72
Time  ▼jBVM_R^jBVM_H^jBP_SY:_r jBP_DiA_»jBP_PUIjrJP_Ven _»)P_Art  _^jQb  vJCond  _^JUFR  ^jU F V   ^JU F_T irrw |Q d  ^JBTM  T__»Jb™  T__^jBTOI _J
Header row
Real Time secs
Rbv (%)
Hct
Venous pressure 
UF time
Systolic BP
UF volume 
UF rate ml/hr
Diastolic BP
Pulse
dialysate flow
Conductivity
Blood flow rate
Arterial temp 
BTMC
Venous
temp
BTMC
297Appendix 2
Steps in the derivation of relative blood volume parameters 
1. Slope evaluation  2. Cumulative area  3. Refill divergence
Slope Evaluation
PROCEDURE
Data acquisition file obtained
Run cut file program  ( on visual basic ) to create .cut uf files 
Filter data
Select UF slabs from each bolus to avoid uf delays
1.  Start at bvm ref where the data continues to decrease only
2.  End at the lowest bvm after end of uf
3.  check that uf rates are more or less constant
4.  delete data points that are at lower uf rates
5.  ensure the volume is equal and time intervals at 3 secs
Copy each data slab to the cum area template files for 0,30,60,90,120 files
Read slope,start rbv, and net slope deviation 
Repeat this for each UF slab
Slone evaluation critically depends on
•  precision of data points
•  signal noise variation
•  data filter enhaces the above
• artefactual changes induced by alarms and posture variation
•  break in data signal due to hypo,saline,ufstart and stop
•  accurate and constant uf rates
•  d RBV magnitude (high values would increase net deviation)
•  UF delay
•  recirculatory effects
•  manual errors
Initial  slope was determined from 90 secs of data points at different segments of the 
initial  2 mins of the rbv uf data 
at the start of uf decay 
30 secs from uf decay 
60 secs from uf decay 
90 secs from uf decay 
120 mins from uf decay
298A  consistent  and  significant  trend  was  observed  for  60  secs  UF  slope.  This 
correlated with the distance from dry weight *r2 = 0.64. Predictive value may be 
possible at differences of 500ml of hydration status.
The effect of UF on the blood volume profiles was significant.  The curves were 
define in another way. Using the first min BV decay we obtained linear regression 
slopes and calculated the deviation away from linearity.  A linear regression slope 
was drawn from linear BV decay. This patient who became hypotensive at the third 
step  during progressive  UF  ,  with  equal  volume  showed  smaller deviation  from 
initial regression which near dryness becomes disappearingly small. We called this 
refill divergence. The same phenomenon is depicted in another patient. We found 
significant differences in divergence between die pt near and far from dry weight. 
When measured by AUC  assessment.  This  can be  done  in  a more  sophisticated 
manner by a method of of integrative function.
Cumulative area analysis
Linear/ Refill divergence
Using high resolution data, the deviation of BV decay curve away from a linear 
decay predicted from an initial 1  min slope evaluated 60secs away from onset of UF 
can be used to estimate the liner divergence :
Steps of analysis
•  data acquisition
•  data filter function
•  determination of slope and predicted linear decay
•  refill divergence  = {cum. UF RBV area - cum. linear RBV area}
Refill divergence estimation  (Limitations)
•  very sensitive to correct evaluation of slopes
#  resolution of the BVM device
#  UF delay
*  accurate UF rates
data artefacts (breathing, machine alarms, posture
299Cumulative refill area & refill divergence datasheet for a subject
(green shaded areas locked and automatically derived using algorithm and data from nonshaded areas)
Mean RBV at start 97.44606 Slope -0.011659827 (Sample 1  min ef data after 60 seconds of UF change)
Count TimeSec TimeMin RBVraw RBVfilter lllFR UFV Cuml RBV Area Lin RBVCuml Lin Area Refill Area Relative Time
2529 7587 126.45 98.53 98 36066 3004 1644 0.00 0.00 0.00 0.00 0
2530 7590 126.5 98.44 98.3163  3004 1647 0.00 0.00 0.00 0.00 0.05
2531 7593 126.56 98.32 98.26108 3004 1649 0.00 0.00 0.00 0.00 0.1
2532 7596 126.6 98.21 98.20012 3004 1652 0.00 0.00 0.00 0.00 0.15
2533 7599 126.65 98.11 98.138  30041654 0.00 0.00 0.00 0.00 0.2
2534 7602 126.7 98 98.07873 3004 1657 0.00 0.00 0.00 0.00 0.25
2535 7605 126.75 97.94 98 02565 3004 1659 0,00 0.00 0.00 0.00 0.3
2536 7608 1268 97.935 97 97929 3004 1662 0.00 0.00 0.00 0.00 0.35
2537 7611 126.85 97.93 97.93707 3004 1665 0.00 0.00 0.00 0.00 0.4
2538 7614 126.9 97.87 97.8968  3004 1667 0.00 0.00 0.00 0.00 0.46
2539 7617 126.95 97.89 97.85716 3004 1670 0.00 0.00 0.00 0.00 0.5
2540 7620 127 97.86 97.81561 3004 1672 0.00 0.00 0.00 0.00 0.65
2541 7623 127.05 97.74 97.77202 3004 1675 0.00 0.00 0.00 0.00 0.6
2542 7626 127.1 97.705 97 72942 3004 1677 0.00 0.00 0.00 0.00 0.66
2543 7629 127.15 97.67 97.68911 3004 1680 0.00 0.00 0.00 0.00 0.7
2544 7632 127.2 97.67 97.64977 3004 1682 0.00 0.00 0.00 0.00 0.75
2545 7635 127.25 97.63 97.60947 3004 1684 0.00 0.00 0.00 0.00 0.8
2546 7638 127.3 97.56 97.56818 3004 1686 0.00 0.00 0.00 0.00 0.85
2547 7641 127.35 97.52 97.52741 3004 1689 0.00 0.00 0.00 0.00 0.9
2548 7644 127.4 97.56 97.4857  3004 1691 0.00 0.00 0.00 0.00 0.95
2549 7647 127.45 97.47 97 44008 3004 1693 292.32 97.45 292.34 -0.02 1 Regression
2550 7650 127.5 97.35 97 39236 3004 1695 584.50 97.41 584.57 -0.07 1.05 Regression
2551 7653 127.55 97.28 97.34743 3004 1698 876.54 97.38 876.70 -0.16 1.1 Regression
2552 7656 127.6 97.25 97 30788 3004 1700 1168.46 97.34 1168.72 -0.26 1.15 Regression
2553 7659 127.65 97.22 97.273733004 1703 1460.28 97.31 1460.64 -0.36 1.2 Regression
2554 7662 127.7 97.18 97.24483 3004 1707 1752.02 97.27 1752.46 -0.44 1.25 Regression
2555 7665 127.75 97.15 97.22176 3004 1710 2043.68 97.24 2044.16 -0.48 1.3 Regression
2556 7668 127.8 97.19 97.20377 3004 1714 2335.30 97.20 2335.77 -0.47 1.35 Regression
2557 7671 127.85 97.26 97 18635 30041717 2626.85 97.17 2627.27 -0.41 1.4 Regression
2558 7674 127.9 97.2 97 16508 3004 1719 2918.35 97.13 2918.66 -0.31 1.45 Regression
2559 7677 127.95 97.21 97.1389  30041722 3209.77 97.10 3209.95 -0.18 1.5 Regression
2560 7680 128 97.23 97.10585 3004 1724 3501.08 97.06 3501.13 -0.05 1.55 Regression
2561 7683 128.05 97.14 97.06375 3004 1727 3792.28 97.03 3792.21 0.06 1.6 Regression
2562 7686 128.1 97.085 97.0137  3004 1729 4083 32 96.99 4083.19 0.13 1.65 Regression
2563 7689 128.15 97.03 96.95699 3004 1732 4374.19 96.96 4374.05 0.13 1.7 Regression
2564 7692 128.2 96.84 96.89659 3004 1734 4664.88 96.92 4664.82 0.06 1.75 Regression
2565 7695 128.26 96.6 96 84265 3004 1737 4955.41 96.89 4955.48 -0.07 1.8 Regression
2566 7698 128.3 96.68 96.80392 3004 1739 5245.82 96.85 5246.03 -0.21 1.85 Regression
2567 7701 128.35 96.69 96.77842 3004 1742 5536.15 96.82 5536.48 -0.33 1.9 Regression
2568 7704 128.4 96.705 96.76106 3004 1744 5826.44 96.78 5826.83 -0.39 1.95 Regression
2560 7707 128.45 96.72 96.74895 3004 1746 6116.68 96.75 6117.06 -0.38 2 Regression
2570 7710 128.5 96.73 96.73965 3004 1748 6406.90 96.71 6407.20 -0.30 2.05
2571 7713 128.55 96.84 96.72892 3004 1751 6697.09 96.68 6697.23 -0.14 2.1
2572 7716 128.6 96.96 96.70757 3004 1753 6987.21 96 64 6987.15 0.06 2.15
2573 7719 128.65 96.83 96 66846 3004 1755 7277.22 96.61 7276.97 0.24 2.2
2574 7722 128.7 96.68 96.6147  3004 1757 7567.06 96.57 7566.69 0.37 2.25
3002575 7725 128.75 96.61
2576 7728 128.8 96.47
2577 7731 128.85 96.26
2578 7734 128.9 96.33
2579 7737 128.95 96.4
2580 7740 129 96.29
2581 7743 129.05 96.06
2582 7746 129.1 96.14
2583 7749 129.15 96.28
2584 7752 129.2 96.1
2585 7756 129.25 96.97
2586 7758 129.3 95.88
2587 7761 129.35 95.88
2588 7764 129.4 95.85
2589 7767 129.45 95.82
2500 7770 129.5 95.84
2591 7773 129.55 95.81
2592 7776 129.6 96.08
2593 7779 129.65 95.85
2594 7782 129.7 95.835
2595 7786 129.75 95.82
2596 7788 129.8 96.71
2597 7791 129.85 95.69
2598 7794 129.9 95.59
2599 7797 129.95 95.66
2600 7800 130 96.9
2601 7803 130.06 95.62
2602 7806 130.1 95.64
2603 7809 130.15 95.76
2604 7812 130.2 95.57
2605 7815 130.25 95.38
2606 7818 130.3 95.17
2607 7821 130.35 95.27
2608 7824 130.4 95.33
2609 7827 130.45 95.18
2610 7830 130.5 95.31
2611 7833 130.55 95.11
2612 7836 130.6 95.18
2613 7839 130.66 96.08
2614 7842 130.7 94.97
2615 7845 130.75 94.86
2616 7848 130.8 94.93
2617 7861 130.86 95.035
2618 7854 130.9 96.14
2619 7857 130.96 95.19
2620 7860 131 96.16
2621 7863 131.05 94.93
2622 7866 131.1 95.1
2623 7869 131.15 95.04
2624 7872 131.2 94.92
2625 7875 131.25 94.65
96 55296 3004 1760 
96 48753 3004 1762 
96 42537 3004 1765 
96.37213 3004 1767 
96.32284 3004 1770 
96.27052 3004 1772 
96.21919 3004 1775 
96 17549 3004 1777 
96.13371 3004 1780 
96 08572 3004 1783 
96.03524 3004 1785 
95 98991 3004 1788 
95.95276 3004 1790 
96.92311 3004 1793 
95.9003  3004 1795 
95.88382 3004 1798 
95.8726  3004 1800 
95 86023 3004 1803 
95.839  30041805
95.811713004 1807 
95.78223 3004 1809 
95.75145 3004 1811 
95 72243 3004 1814 
95 69832 3004 1816 
95 68036 3004 1818 
95.66032 3004 1820 
95.63004 3004 1823 
95.59367 3004 1825 
95 55063 3004 1828 
95.49525 3004 1830 
95 43289 3004 1833 
95.37594 3004 1835 
95 33099 3004 1838 
95.29269 3004 1840 
95.25579 3004 1843 
95.21944 3004 1846 
95.18233 3004 1850 
95 14568 3004 1853 
95.10978 3004 1857 
95.0769  3004 1860 
95.05402 3004 1862 
95.04505 3004 1865 
95.04603 3004 1867 
95.04803 3004 1869 
95.04272 3004 1871 
95.02552 3004 1874 
95.00041 3004 1876 
94.97254 3004 1878 
94.93813 3004 1880 
94 89558 3004 1883 
94.85426 3004 1885
7856.72 96.54 7856.30 0.42 2.3
8146.18 96.50 8145.80 0.38 2.35
8435.46 96.47 8435.20 0.26 2.4
8724.57 96.43 8724.50 0.08 2.45
9013.54 96.40 9013.69 -0.14 25
9302.35 96.36 9302.77 -0.42 2.55
9591.01 96.33 9591.75 -0.74 2.6
9879.54 96.29 9880.63 -1.09 2.65
10167.94 96.26 10169.40 -1.46 2.7
10456.20 96.22 10458.06 -1.87 2.75
10744.30 96.19 10746.62 -2.32 2.8
11032.27 96.15 11035.08 -2.81 2.85
11320.13 96.12 11323.43 -3.30 2.9
11607.90 96.08 11611.68 -3.78 2.95
11895.60 96 05 11899 82 -4.22 3
12183.25 96.01 12187.85 -4 60 3.05
12470.87 95.98 12475.78 -4.91 3.1
12758.45 95.94 12763.61 -5.16 3.15
13045.97 95.91 13051.33 -5.36 3.2
13333.40 95.87 13338.94 -5.54 3.25
13620.75 95.84 13626 46 -5.71 3.3
13908.00 95.80 13913.86 -5 86 3.35
14195.17 95.77 14201.16 -5 99 3.4
14482.27 95.73 14488.36 -6.09 3.45
14769.31 95.70 14775.45 -6.14 3.5
15056.29 95.66 15062.44 -6.15 3.55
15343.18 95.63 15349.32 -6.14 3.6
15629.96 95.59 15636.09 -6.14 3.65
15916.61 95.56 15922.77 -6.16 3.7
16203.10 95.52 16209.33 -6.24 3.75
16489.40 95.49 16495.79 -6.40 3.8
16775.52 95.45 16782.15 -6.63 3.85
17061.52 95 42 17068.40 -6.89 39
17347.39 95.38 17354.55 -7.16 3.95
17633.16 95.35 17640.59 -7.43 4
17918.82 95.31 17926.53 -7.71 4.05
18204.37 95.28 18212.36 -7.99 4.1
18489 80 95.24 18498.09 -8.28 4.15
18775.13 95.21 18783.71 -8.58 4.2
19060.36 96.17 19069.23 -8.86 4.25
19345.53 95.14 19354.64 -9.11 4.3
19630.66 95.10 19639.95 -929 4.35
19915.80 95.07 19925.15 -9.35 4.4
20200.94 95.03 20210.25 -9.30 4.45
20486.07 95.00 20495.24 -9.17 4.5
20771.15 94.96 20780.13 -8.98 4.55
21056.15 94.93 21064.91 -8.76 46
21341.07 94.89 21349.59 -8.52 4.65
21625.88 94.86 21634.16 -8.28 4.7
21910.57 94.82 21918.63 -8.06 4.75
22195.13 94.79 22202.99 -7.86 4.8  J
3012626 7878 131.3 94.74 94 82362 3004 1888 22479.60 94.75 22487.25 ■7.65 4.85
2627 7881 131.36 94.85 94.80034 3004 1890 22764.00 94.72 22771.40 -7.40 4.9
2628 7884 131.4 94.77 94.77684 3004 1893 23048.33 94.68 23055.45 -7.12 4.95
2629 7887 131.46 94.77 94 75211 3004 1895 23332.59 94.65 23339.39 -6.80 5
2630 7890 131.5 94.77 94.72571 3004 1898 23616.77 94.61 23623.23 -6 46 5.06
2631 7893 131.55 94.77 94.69516 3004 1900 23900.85 94.58 23906.96 -6.11 5.1
2632 7896 131.6 94.72 94.65878 3004 1903 24184.83 94.54 24190.59 -5.76 5.15
2633 7899 131.65 94 59 94.61856 3004 1905 24468 68 94.51 24474.12 -5.43 5.2
2634 7902 131.7 94 66 94.57632 3004 1908 24752.41 94.47 24757.53 -5.12 5.25
2635 7905 131.75 94.66 94 52789 3004 1910 25036.00 94.44 25040.85 -4.85 5.3
2636 7908 131.8 94.45 94.47202 3004 1913 25319.41 94.40 25324.06 -4.64 535
2637 7911 131.85 94.36 94.4154  3004 1915 2560266 94.37 25607.16 -4.50 5.4
2638 7914 131.9 94.29 94.36348 3004 1918 25885.75 94.33 25890.16 -4.41 5.45
2639 7917 131.95 94.24 94.31796 3004 1920 26168.70 94.30 26173.05 -4.35 5.5
2640 7920 132 94.28 94.27762 3004 1923 26451.54 94 26 26455 84 -4 30 5.55
2641 7923 132.05 94 24 94.23894 3004 1925 26734.25 94.23 26738.52 -4.27 5.6
2642 7926 132.1 94.14 94 20155 3004 1928 27016.86 94 19 27021.10 -4.25 5.65
2643 7929 132.15 94 1 94 16852 3004 1930 27299.36 94.16 27303.58 -4.21 5.7
2644 7932 132.2 94.07 94 14165 3004 1932 27581.79 94.12 27585.95 -4.16 5.75
2645 7935 132.25 94.07 94.12079 3004 1934 27864.15 94.09 27868.21 -4.06 5.8
2646 7938 132.3 94.03 94.10559 3004 1937 28146.47 94.05 28150.37 -3.90 5.85
2647 7941 132.36 93.98 94.0977  3004 1939 28428.76 94.02 28432.42 -3.66 5.9
2648 7944 132.4 93.94 94.10058 3004 1941 28711.06 93.98 28714.37 -3.31 5.95
2649 7947 132.45 94.09 94 11403 3004 1943 28993.40 93.95 28996.22 -2.81 6
2650 7950 132.5 94.28 94.12878 3004 1946 29275.79 93.91 29277 96 -2.17 6.06
2651 7953 132.56 94 34 94.13243 3004 1948 29558.19 93.88 29559.59 -1.40 6.1
2652 7956 132.6 94.27 94.11971 3004 1951 29840.55 93.84 29841.12 -0.57 6.15
2653 7959 132.65 94.25 94 09177 3004 1953 30122.82 93.81 30122.55 0.28 6.2
2654 7962 132.7 94.05 94.05323 3004 1956 30404.98 93.77 30403.86 1.12 6.25
2655 7965 132.75 93.94 94 01289 3004 1958 30687.02 93.74 30685.08 1.94 6.3
2656 7968 132.8 93.87 93.97844 3004 1961 30968.96 93.70 30966.19 2.77 6.35
2657 7971 132.85 93.8 93 95412 3004 1963 31250 82 93.67 31247.19 3.62 6.4
2658 7974 132.9 93.96 93.93883 3004 1966 31532.63 93.63 31528.09 4.54 6.45
2659 7977 132.95 94.01 93 92413 3004 1968 31814.41 93.60 31808.89 5.52 6.5
2660 7980 133 93.96 93.90373 3004 1971 32096.12 93.56 32089.58 6.54 6.55
2661 7983 133.05 93 935 93.87749 3004 1973 32377.75 93.53 32370.16 7.59 6.6
2662
2663
7986 133.1 93.91 93 84588 3004 1976 32659 29 93.49 32650.64 8.64 665
7989 133.15 93.77 93.81094 3004 1980 32940 72 93.46 32931.02 9.70 6.7
2664
2665
2666
7992
7995
7998
133.2 
133.25
133.3
93.82 93.7754  3004 1983 33222.05 93 42 33211.29 10.76 6.75
93.74 93.73872 3004 1987 33503.26 93.39 33491.45 11.81 6.8
93.58 93.70379 3004 1990 33784 38 93.35 33771.52 12.86 6.85
2667
2668
2669
2670
2671
2672
8001
8004
8007
8010
8013
8016
133.35
133.4 
133.46
133.5 
133.55
133.6
93.62 93.67576 3004 1992 34065.40 93.32 34051.47 13.93 6.9
93.45 93.65784 3004 1995 34346.38 93.28 34331.32 15.05 6.95
93.45
93.76
93.6554  3004 1997 
93.6649  3004 1999
34627.34 93.25 34611.07 16.28 7
34908.34 93.21 34890 71 17.63 7.06
93.76 93.67276 3004 2002 35189.36 93 18 35170.24 19.11 7.1
93.76 93.67245 3004 2004 35470.37 93.14 35449.67 20.70 7.15
2673
2674
2675
2676
8019
8022
8025
8028
133.65
133.7
93.76 93 66396 3004 2007 35751.36 93.11 35729.00 22.36 7.2
93.67 93 64859 3004 2009 36032 31 93.07 36008.22 24.09 7.25
133.75
133.8
93.63 93.63004 3004 2011 36313.20 93.04 36287 34 25.86 7.3
93.67 93.60963 3004 2014 36594.03 93.00 36566 35 27.68 7.35
3022677 8031 133.85 93.63 93.58544 3004 2016 36874.79 32.97 36845.25 29 53 7.4
2678 8034 133.9 93.5 93.55918 3004 2018 37155.46 32.93 37124.05 31.41 7.45
2679 8037 133.95 93.45 93.53659 3004 2021 37436.07 32.90 37402.75 33.32 7.5
2680 8040 134 93.66 93.51601 3004 2023 37716.62 32 86 37681.34 35.28 7.55
2681 8043 134.05 93.48 93.49109 3004 2026 37997.09 32 83 37959.83 37.27 7.6
2682 8046 134.1 93.44 93.46393 3004 2028 38277.49 92.79 38238.21 39.28 7.65
2683 8049 134.15 93.47 93 43736 3004 2031 38557.80 92.76 38516.49 41.31 7.7
2684 8052 134.2 93.58 93.40586 3004 2033 38838.02 92.72 38794.66 43.36 7.75
2685 8055 134.25 93.48 93.36299 3004 2036 39118.10 92.69 39072.72 45.38 7.8
2686 8058 134.3 93.26 93.31199 3004 2038 39398.04 92.65 39350.69 47.35 7.85
2687 8061 134.35 93.26 93.2607  3004 2041 39677.82 92.62 39628.54 49.28 7.9
2688 8064 134.4 93.26 93.20947 3004 2043 39957.45 92.58 39906.29 51.16 7.95
2689 8067 134.45 93.07 93.15796 3004 2046 40236.92 92.55 40183.94 52.98 8
2690 8070 134.5 92.9 93.1142  3004 2048 40516.27 92.51 40461.48 54.78 8.05
2691 8073 134.55 93.07 93.08252 3004 2051 40795.51 92.48 40738.92 56.60 8.1
2692 8076 134.6 93.01 93.05737 3004 2053 41074.69 92.44 41016.25 58.44 8.15
2693 8079 134.65 92.98 93.03596 3004 2055 41353.79 92.41 41293.48 60.32 8.2
2694 8082 134.7 92.95 93.01979 3004 2058 41632.85 92.37 41570.60 62.25 8.25
2695
2696
8085
8088
134 75 92 95 93.00943 3004 2060 41911.88 92.34 41847.62 64 26 8.3
134.8 93.03 93 00276 3004 2062 42190.89 92.30 42124.53 66.36 8.35
2697 8091 134.85 93.05 92.99495 3004 2065 42469.88 92.27 42401.34 68.54 8.4
2698 8094 134.9 93.06 92.98222 3004 2067 42748.82 92.23 42678.04 70.78 8.45
2699 8097 134.95 92 97 92.96455 3004 2070 43027.72 92.20 42954.64 73.08 8.5
2700 8100 135 92.87 92 94661 3004 2072 43306.56 92.16 43231.13 75.43 8.55
2701 8103 135.05 92.89 92.93301 3004 2074 43585.35 92.13 43507.52 77.84 8.6
2702 8106 135.1 93 92.92134 3004 2077 43864 12 92.09 43783.80 80.32 8.65
2703 8109 135.15 92 94 92.90628 3004 2079 44142.84 92.06 44059.98 82.86 8.7
2704 8112 135.2 92 88 92.88807 3004 2081 44421.50 92.02 44336.05 85.45 8.75
2705 8115 135.25 92.79 92.87132 3004 2084 44700.12 91.99 44612 02 88.10 8.8
2706 8118 135.3 92.96 92.85608 3004 2086 44978.68 91.95 44887.88 90.80 8.85
2707 8121 135.35 92.97 92.83486 3004 2089 45257 19 91.92 45163 64 93.55 8.9
2708 8124 135.4 92.83 92.80452 3004 2091 45535.60 91.88 45439.29 96.31 8.95
2709
2710
8127 135.45 92.83 92.76852 3004 2094 45813.91 91.85 45714.84 99.07 9
8130 135.5 92.8 92.72748 3004 2096 46092 09 91.81 45990.28 101.81 9.05
2711 8133 135 55 92.59 92.68385 3004 2099 46370.14 91.78 46265.62 104.52 9.1
2712 8136 135.6 92 55 92.64503 3004 2101 46648 08 91.74 46540 85 107.22 9.15
2713
2714
8139 135 65 92 58501 92 61333 3004 2104 4692592 91.71 46815.98 109.93 9.2
8142 135.7 92.62 92.58428 3004 2106 47203.67 91.67 47091.01 112.66 9.25
2715 8145 135.75 92.53 92.55481 3004 2109 47481.33 91.64 47365.92 115.41 9.3
2716 8148 135.8 92.51 92.52602 3004 2111 4775891 91.60 47640.74 118.17 9.35
2717 8151 135.85 92 53 92 4978  3004 2113 4803641 91.57 47915.45 120.96 9.4
2718
2719
2720
2721
2722
8154
8157
1359 92.46333 92 46857 3004 2115 48313.81 91.53 48190.05 123.76 9.45
135 95 92 39667 92 43985 3004 2118 48691.13 91.50 48464 55 126.58 9.5
8160
8163
8166
136 
136.05 
136 1
92.33 92.41515 3004 2120 48868 38 91.46 48738.94 129.43 9.55
92.42 
92 29
92.39476 3004 2122 49145.56 91.43 49013.23 132.33 9.6
92.37715 3004 2124 49422.69 91.39 49287.41 135.28 9.65
2723 8169 136.15
1362
92.28
92.37
92.51
92.4
92.4
92 36488 3004 2127 49699.79 91.36 49561.49 138.29 9.7
8172 92 35822 3004 2129 
92.34927 3004 2132
49976.86 91.32 49835.47 141.39 9.75
2725
2726
8175
8178
136.25 
136 3
50253.91 91.29 50109.34 144.57 9.8
92.33115 3004 2136 
92.304  3004 2139
50530.90 91.25 50383.10 147.80 9.85
2727 8181 136.35 50807.81 91.22 50656.76 151.05 9.9
3032728 8184 136.4 92.35 92 26904 3004 2143 51084.62 [91.18 50930.31 154.31 9.95
2729 8187 136.45 92.22 92.22839 3004 2146 51361.31 91.15 51203.76 157.54 10
2730 8190 136.5 92.09 92.18852 3004 2149 51637.87 91.11 51477.11 160.76 10.05
2731 8193 136.55 91.95 92.1581  3004 2151 51914.35 91.08 51750.35 164.00 10.1
2732 8196 136.6 92.06 92.14128 3004 2154 52190.77 91.04 52023.48 167.29 10.15
2733 8199 136.65 92.14 92.13277 3004 2156 52467.17 91.01 52296.51 170.66 10.2
2734 8202 136.7 92 12 92.1259  0  2159 52743.55 90.97 52569.44 174.11 10.25
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Detailed  experimental  steps during a  study  over  a  single  dialysis  session  in 
phase I and II
Patients rest for 20 min prior to start
Needle in  Samples taken in Red, orange, brown bottles
Prepare dye, Measure Bioimpedance, recirculation
Draw dye and flush line ready 
Weigh syringe
Keep 10ml of patients blood from V ready for flush.
Dye injected in V and Flush line with blood.
Weigh syringe 
3 min pause 
Blood sampling
Wash out dead space in A and push back in the V 
Time of wash noted and orange tube sample taken 
Wait for 30sec before next 
7 washouts in total
Connect patient to HD sraight connection 
Start dialysate collection
Connect BVM, BIO, temp and start Data acquisition system 
20 mins later, Machine in bypass,Check BVM recording 
Additional red,orange and brown from A
Draw dye and flush line ready with blood 
Weigh syringe
Inject dye in bubble trap rapidly 
Weigh syringe
Sample from A at 3min and every 30 secs 
Restart dialysis
Obtain a small sample of dialysate in tube for absorbance 
Measure bio, Check BVM and dialysate tank 
1  hr later Machine in bypass, Check BVM 
Additional red,orange and brown bottles from A
Draw dye and flush line ready
Weigh syringe
Inject dye in bubble trap rapidly and flush 
Weigh syringe
Sample from A at 3min and every 30 secs
Restart dialysis, Obtain a small sample of dialysate in tube for absorbance
Equipments used
•  BVM  Data acquisition system
•  Scale and timer,
•  Syringe 2ml (3)
•  Orange tubes (35 labelled)
•  Red tubes (3) Brown tubes (3) Black  tubes (3)
•  Centrifuge —  Spin all orange samples for 10 min 2000/min
•  For assay  30 ml  syringes  (3)  2ml  syringes  (21)  10ml  (2)
•  microlitre  pipettes
•  Lab Spectrophotometer
305A typical data sheet with algorithms automatic calibration, absolute 
plasma and blood volume derivations for each indocyanine green 
dye study
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The following formulae have been used for plasma volume, blood volume and 
body surface area.
Plasma volume (dye) 
(dye dilution)
Blood volume [247,248] 
2
Body surface area [249] 
3
dve infused (me)  ....Eqn 1
plasma dye concentration (mg /1)
Plasma volume (dye)  ... .Eqn
1- ( H ctS yS) 0.86
71.84 x Body weight0425 x  Height0725  ...Eqn
Formulae for deriving blood volume
Guyton formula  [250]  5 / 70 x body weight
4
....Eqn
Hidalgo et al (1962)[251]  0.367 x Height + 0.0322 x Weight + 0.60  ....Eqn 5
Allen et al (1956)[251] 0.0417 (0.414F) x Height3  + 0.0450 (0.0328F) x Weight - 
0.03
( F = female)  ... .Eqn 6
0.725  0.425
Baker et al  (1957)[251]  0.0193 x Height  x Weight ....Eqn 7
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DOSE AMENDMENT AFTER  PHASE  T:
Dose of Indocyanine green for a single plasma volume estimate:
Dose of dye  5 mg
change to:
Dose of dye  10 mg  (< 75 kg body weight)
15mg  (  > 75 kg body weight)
Rationale for amendment
The dose of the dye in the protocol for a single plasma volume estimate was based on 
the minimum used  in patients  on haemodialysis  for cardiac  output estimation in 
previous studies. However for plasma volume estimation , one needs to adjust the 
dose for the body weight to obtain adequate plasma distribution of the dye.  The 
recommendation in the literature is 0.2 mg / kg body weight indocyanine green (max 
total dose upto 2 mg/kg body weight) for blood volume studies and has been used in 
doses varying from 10-20 mg per estimate.
In a pilot study at the  Lister hospital,  10  mg was found to be sufficient minimum
dose  required  for  a  reliable  estimate  of  plasma  volume  in  a  65kg  man  at 
normohydration while 5 mg achieved inadequate concentrations in the blood. The 10 
mg dose has also been used on dialysis population in other centres for the same 
purpose. Patients on haemodialysis have relatively large blood volumes predialysis 
due to varying degrees of overhydration. The initial protocol did not recognise the 
adjustment necessary for this variation in body weight and volume of distribution to 
obtain reliable estimates.
Based on the pilot study and supported by evidence in the literature, the amendment 
of the dose to lOmg ( < 75kg b.w.) and 15mg (> 75kg b.w.) with the maximum total 
dose used per subject for both phases of the study well within the recommended 
maximum limits is justified.
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Initial Pilot ICG calibration experiments and methodology on two subjects :
Methods:
25mg of ICG was mixed with 10 ml of solvent to produce ICG solution of 2.5mg/ml. 
Approx.  7ml  of distilled water was  withdrawn  into  a syringe.  The  mass  of the 
syringe was weighed.  The distilled water was then added to a glass bottle and the 
syringe re-weighed to obtain the volume of distilled water introduced.  Approx.  1ml 
of neat ICG solution was with drawn into a 2 ml syringe.  The syringe was weighed 
before and after the contents has been added to the bottle contained the distilled 
water.  The bottle was mixed and set aside.
Approx. 1ml of plasma was withdrawn into a 2 ml syringe and weight.  The contents 
were injected into a 1ml spectrophotometer cuvette and the syringe was re-weight to 
obtain the exact volume delivered.  The cuvette was placed in the spectrophotometer 
and zeroed using a fixed wavelength of 805 nm.  IOuL of calibration fluid was added 
to the cuvette.  The sample was scanned to confirm that the peak absorption occurred 
at 805 nm.  The absorbance of the plasma containing the ICG calibration fluid in the 
cuvette  was  measured.  In  order  to  reduce  measurement  errors  the  cuvette  was 
removed  from  the  spectrophotometer  agitated,  replaced  and  re-measured.  This 
measurement procedure was repeated six times and the readings were averaged.
Dilute calibration fluid was prepared with an identical procedure, using 30 ml of 
distilled water.  In order to  produce a range of ICG concentrations, 5 x IOuL aliquots 
of calibration fluid were added to the plasma sample. Measurements were repeated 
six times as before at each concentration increment.
Patient 1JM 
Hct: 23%,  Alb: 32g/l 
Sample pre dialysis
Patient 2 HH 
Hct: 38.2%,  Alb: 36g/l 
Sample mid dialysis
309•  Concentrated ICG calibration fluid (2 point)
Mass syringe ICG neat, pre: 4.276g 
Mass syringe ICG neat, post: 3.28lg 
Volume ICG neat: 0.995 ml
Mass syringe distilled water filled to approx. 10ml: 13.757g 
Mass syringe distilled water empty: 6.717g 
Volume of distilled water for calibration fluid: 7.04 ml 
Concentration of calibration fluid:  309.6mg/Litre
Patient JM
Mass of plasma cuvette empty: 2.534
Mass of plasma cuvette full with approx. 1ml of plasma: 3.508
Initial volume of plasma: 0.974
Vol Calib [ICG]
mg/L
A 1 A2 A3 A 4 A 5 A6 Mean SD CV
(%)
IOuL 3.146 805.6 1.22 1.08 0.961 ----- ----- ----- 1.05 0.084 7.92
Offset: Zero
Slope: 0.335 AU/mg/Litre
Patient HH
Mass of plasma cuvette empty: 2.534
Mass of plasma cuvette full with approx. 1ml of plasma: 3.472
Initial volume of plasma: 0.938
Vol Calib [ICG]
mg/L
^•eak A 1 A 2 A3 A 4 A 5 A 6 Mean SD CV
(%)
IOuL 3.265 805.9 1.136 1.165 1.162 1.168 1.108 1.088 1.138 0.033 2.94
Offset: Zero
Slope: 0.348 AU/mg/Litre
•  Dilute calibration fluid (5 point)
Mass syringe ICG neat, pre: 4.297g 
Mass syringe ICG neat, post: 3.332g 
Volume ICG neat: 0.965 ml
Mass syringe distilled water filled to approx. 30ml: 48.604g 
Mass syringe distilled water empty: 18.734g 
Volume of distilled water for calibration fluid: 29.87 ml 
Concentration of calibration fluid:  78.23mg/Litre
Patient JM
Mass of plasma cuvette empty: 2.534
Mass of plasma cuvette full with approx. 1ml of plasma: 3.508 
Initial volume of plasma: 0.974
310Vol Calib [ICG]
mg/L
L p eak A 1 A 2 A3 A 4 A 5 A 6 Mean SD CV
(%)
IOuL 0.802 805.7 0.332 0.288 0.257 0.239 0.248 0.234 0.266 0.037 14.05
20nL 1.588 805.3 0.497 0.486 0.477 0.478 0.47 0.465 0.479 0.011 2.39
30uL 2.359 805.6 0.750 0.675 0.695 0.691 0.695 0.686 0.699 0.026 3.77
40uL 3.114 805.6 0.876 0.878 0.869 0.861 0.867 0.87 0.874 0.009 1.02
50nL 3.854 805.3 1.076 1.073 1.077 1.070 1.076 1.076 1.075 0.003 0.25
Offset: 0.0602 AU 
Slope: 0.263 AU/mg/Litre
Patient HH
Mass of plasma cuvette empty: 2.534
Mass of plasma cuvette full with approx. 1ml of plasma: 3.508
Initial volume of plasma: 0.974
Vol Calib [ICG]
mg/L
^ P e«k A 1 A2 A3 A 4 A5 A 6 Mean SD CV
(%)
IOuL 0.719 ------ 0.313 0.308 0.308 ----- ----- ----- 0.309 0.003 0.93
2<H tL 1.425 ------ 0.513 0.512 ---- ----- ----- ----- 0.513 0.001 0.14
30uL 2.118 ------ 0.75 0.756 0.785 ----- ----- ----- 0.764 0.019 2.45
40yL 2.799 ------ 0.961 0.976 0.986 0.956 0.901 0.917 0.950 0.034 3.53
50uL 3.468 805.6 1.086 1.101 1.107 1.098 1.078 1.077 1.091 0.013 1.16
Offset: 0.1125 AU 
Slope: 0.291 AU/mg/Litre
Observations made during the calibration experiments
Peak spectral response at approx 805 nm. Very reproducible.  No change after 
leaving ICG standing for over 3 hours. There was no obvious effect introduced as a 
consequence of using heparinised sample bottles.  Therefore plasma measurements 
are suitable for further ICG studies.
Patient JM. Difference in absorption slopes is significant.  Could be due to following:
•  Lack of absorbance readings using concentrated calibration fluid
•  Error in zero with 2 point calibration when using concentrated calibration fluid, 
although the main deviation is at the high concentration end.  The offset for JM is 
0.0602, close to zero offset!
•  2 hours elapsed between measurements using concentrated and dilute calibration 
fluid.  Possibly blood chemistry changed during this time.
Patient HH. Also difference in absorption slopes although the slopes are in closer 
agreement than with JM. Significant difference in offset: 0.1125 in dilute calibration
311fluid compared with zero using 2 point calibration with concentrated calibration 
fluid.  Errors could be due to following:
•  Lack of absorbance readings using dilute calibration fluid
•  2 hours elapsed between measurements using concentrated and dilute calibration 
fluid.  Possibly blood chemistry changed during this time.
Recommendations:
In dye reproducibility studies, calibrate via both methods in order to obtain further 
insight into sources of error.  Concentrated and dilute calibration fluid should be 
prepared and used in two 1  ml plasma samples from the same patient within a few 
minutes.  The time for which the plasma has been left standing before analysis is 
probably  not  important.  It  might be  prudent  however to  check  the  absorption 
reproducibility of a sample containing ICG after 2-3 hours.
312Appendix  7
Fcell derivation
Hm ic/HS yS  —  H mic/H S yS  = oc (constant)
Vrbc — ( V b -V mic ) X H SyS +  V mic X H mic 
H w =   V rbc/V b
—  Vh x  Hsvs — Vmic X H svs +  Vmic X H  mir
Vl
=   H sys-  (H sy S- H miC) V mic/ V b
=   Hsys  X  [1 - (  1  -  Hmic_/_HSvS)_Vmic / V  h 1 
=   Hsys  X  [  1  -   (  1-OC  ) V mic  ]
V b
F C E L L  =  Hw/H S yS   =  \ 1 -   (1-OC) V-rfei
Vb
Where H= hematocrit, V = Volumes,  b= whole blood , w = whole body Hematocrit, 
mic = microcirculation, sys =  macrocirculation ,  rbc = red cell mass
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Responses and clarifications to points discussed during the viva examination, Februry 2006 
Introduction
1 .  T h e  t h e s i s  w o u l d   b e n e f i t  f r o m   a   c l e a r   e n u n c i a t i o n   o f  t h e   k e y   r e s e a r c h  
q u e s t i o n s   t o   b e   a d d r e s s e d .
The  research  hypothesis  is  that  tools  to  assess  volume  status  can  be  used  to 
characterise  fluid  pathophysiology  and  determine  dry  weight  accurately  thereby 
preventing intradialytic haemodynamic instability during haemodialysis.  The use of 
dynamic tests based on ultrafiltration pulses and intradialytic monitoring may allow 
us to understand the ultrafiltration pathophysiology.  Insight into these  mechanisms 
may then provide the opportunity of individualising the ultrafiltration prescription.
2 .  E x p a n s i o n   o f  t h e   s e c t i o n s   r e l a t i n g  t o   p a t i e n t s   s e l e c t i o n .  T h i s   is   c r u c i a l   i n  
t e r m s   o f  o v e r a l l   a p p l i c a b i l i t y   o f  o b s e r v a t i o n s   i n   t h i s   f a i r l y   h i g h l y   s e l e c t e d  
p a t i e b t s   g r o u p
a .  W h y   n o   H D F   p a t i e n t s   u s e d ,   d o e s   t h i s   s e l e c t   o u t   a   c e r t a i n  
p h e n o t y p e ?
b .  U s e   o f  h i g h   f l u x   H D ,  ?   e f f e c t s   o n   a d i p o k i n e   r e m o v a l   e t c
c.  R R F   i n   t h i s   p a t i e n t   g r o u p
Diffusive and convective dialysis occur simultaneously in high flux dialysis and the 
components cannot be separated during the treatment or its effect distinguished on 
haemodynamic parameters. Predominant  haemodiafiltration however may have other 
effects due removal of middle molecules e.g ADMA or differential sodium removal 
or temperature  effects.  The  initial  studies  as  part  of this  research  was  performed 
excluding HDF patients to avoid other confounders that may limit comparison with 
more  standard  and  more  widely  used  high  flux  dialysis.  Most  blood  volume 
experiments in this research studies patients as their own controls. The effect of RRF 
would  have  an  overall  haemodynamic  consequence  and  has  been  investigated  in 
individual studies where relevant. Diffusive effects on relative blood volume may be a 
result of altered vascular resistance, changes in regional blood flow distribution and 
osmolality changes, The latter has a minimal effect on blood volume monitoring using 
ultrasonic method as  explained  in the  Methods  section,  The  other  influences  were 
minimised  by achieving  a  stable  blood  volume  profile  prior  to  each  ultrafiltration 
pulse applied in an intermittent fashion.
3 .  A n   e x p a n s i o n   o f  t h e   d i s c u s s i o n   o f  t h e   r o l e   l o n g  t e r m   s a l t   a n d   w a t e r  
o v e r l o a d   m i g h t   p l a y   i n   t h e   p a t h o g e n e s i s   o f  i n c r e a s e d   C V   e v e n t s .
Today, increased aortic stiffness has been recognized as an important determinant of 
increased cardiovascular risk.  Sodium/volume overload is related to aortic stiffness. 
Angiotensin-converting enzyme inhibitors administered to dialysis patients failed to 
normalize,  aortic  pulse wave  velocity  as  an  index  of vascular  stiffness.  Complete 
normalization  was  only  achieved  with  combined  volume  control  plus
338pharmacological blockade of the Renin Angiotensin System. This is one of the few 
documented  examples  showing  the  importance  of  salt/volume  in  target  organ 
malfunction. One of the mediators is oxidative stress. Oxidative stress is also one of 
the hallmarks of renal failure. Numerous experimental studies documented induction 
or amplification of oxidative  stress  by  salt,  and reversal  of organ  damage  in  salt- 
sensitive models of tissue injury by antioxidative intervention (1). It has been amply 
documented  that  left  ventricular  hypertrophy  and  other  characteristics  of  the 
vasculature such as pulse pressure and vascular stiffness are influenced by salt intake 
independently of blood pressure and may amplify the response to high blood pressure 
(2).  A  study  in  Finland  showed  that  high  salt  intake  translates  into  higher 
cardiovascular mortality in the general population (3).  The effects of angiotensin II 
and aldosterone are known to be  amplified by a high salt intake.  Some direct and 
blood pressure-independent effects of high salt intake have been identified within  1  
day  and  without  change  in  blood  pressure,  eg  high  salt  intake  causes  increased 
transforming  growth factor  expression  in  kidney  and  aortic  endothelial  cells.  The 
blood  pressure  response  to  high  salt  has  been  shown  to  be  determined  by  the 
availability  of nitric  oxide,  and  interestingly,  endogenous  nitric  oxide  synthase  is 
stimulated by transforming growth factor. Salt, perhaps as a result of increased shear 
stress, has numerous effects on endothelial cell mitogen-activated protein kinase and 
SMAD  signaling  making  endothelial  cells  hot  candidates  for  salt-induced  organ 
damage (4).
4 .  A n   e x p a n s i o n   c o n c e r n i n g  t h e   r e l a t i v e   m e r i t s   o f  t h e   d i f f e r i n g   d e f i n i t i o n s   o f  
H T   i n   H D   p a t i e n t s .
There are 3 ways in which we can assess the level of BP in a hemodialysis patient. 
Blood pressure can be obtained during, before, and after dialysis by the dialysis staff, 
at  home  by  the  patient,  or  by  an  automatic  ambulatory  BP  monitor.  Guidelines 
suggest that predialysis and postdialysis BPs should be <140/90 and <130/80 mmHg, 
respectively. These results fail to provide solid data to back the K/DOQI  guideline 
recommendations  regarding  BP  goals  in hemodialysis patients.  Better methods  are 
needed  for  the  assessment  of  BP  in  hemodialysis  patients  for  clinical  decision 
making.The hemodialysis population is associated with a very low survival rate, with 
cardiovascular  disease  accounting  for  most  of  the  increased  mortality.  Recent 
observational  studies  demonstrate  a paradoxical  relationship  between  lower  blood 
pressure  and  increased  mortality  (5).  Hypertension  treated  with  antihypertensive 
medications  unequivocally  reduces  cerebrovascular  risk,  but  demonstration  of  a 
survival benefit for cardiovascular mortality has proven more difficult to demonstrate. 
Increased pulse pressure increases arterial wall stiffness and afterload, and decreases 
coronary perfusion. The disproportionate representation of diastolic dysfunction and 
coronary  artery  atherosclerosis  may  explain  why  increased  pulse  pressure  is 
associated with higher cardiovascular risk for the dialysis population. Optimum blood 
pressure  control  has  not  been  established,  due  to  a  lack  of prospective  studies 
targeting blood pressure reduction.
3395 .  A  f u r t h e r  d i s c u s s i o n   o f  o t h e r  f a c t o r s   i n   H T   o t h e r  t h a n   v o l u m e   e x p a n s i o n  
( e g   a d i p o k i n e s ,   N a   l o a d i n g   o f  r e s i s t e n c e  v e s s e l s ,  s y m p a t h e t i c   o v e r a c t i v i t y ) .  
T h e   c o m p l e x   r o l e   H T   a n d   l a c k  o f  d i r e c t   c o r r e l a t i o n  w i t h   m o r t a l i t y   n e e d s  
s o m e  f u r t h e r   d i s c u s s i o n .
High BP is a major risk factor for atherosclerotic cardiovascular disease (ASCVD) 
mortality in the general population.  The high prevalence of hypertension among 
hemodialysis  (HD) patients  may  contribute  to  the  observed  excess  of ASCVD 
morbidity and mortality. Thus, it is important to identify the ideal BP target in this 
high-risk  group.  The  National  Kidney  Foundation’s  (NKF’s)  Kidney  Disease 
Outcomes Quality Initiative (KDOQI) and JNC VII have recommended a target 
BP <130/80 mmHg for patients with chronic kidney disease stages I to IV. NKF 
KDOQI has recently recommended pre- (<140/90 mmHg) and post-HD (<130/80 
mmHg) BP targets. The evidence supporting this recommendation was graded as 
weak  because  it  was  extrapolated  from  the  general  population.  The  only 
prospective  study in a dialysis population demonstrated that  a BP  <140/90 was 
associated with a decreased risk for left ventricular hypertrophy but an increased 
mortality risk.
A  "UM -shaped  relationship  exists  between  postdialysis  SBP  and  mortality  in  a 
prevalent cohort of HD patients. Mild to moderate elevations in predialysis SBP 
were not associated with significant increases in ASCVD and all-cause mortality. 
These  observations were  subsequently  confirmed  by  other  investigators.  High 
postdialysis  SBP  and  low  pre-  and  postdialysis  diastolic  BP  (DBP)  were 
associated with increased mortality.  (6) Port et al  reported that predialysis  SBP 
<110  mmHg  was  associated  with  increased  mortality.  (6)  In  contrast,  other 
investigators  did  not  observe  an  association  between  BP  and  mortality.  To 
summarise,  the  studies  that  have  been  conducted  among  hemodialysis  (HD) 
patients  have  yielded  conflicting  data  on  the  relationship  between  BP  and 
mortality. (6)
6 .  M o r e   d i s c u s s i o n   c o n c e r n i n g   t h e   p u b l i s h e d   d a t a   o n   t h e   h e t e r o g e n e i t y   i n  
h a e m o d y n a m i c   r e s p o n s e   t o   R B V  w i t h i n   a n d   b e t w e e n   p a t i e n t s .
There  is  conflicting  evidence  on  the  potential  benefits  of relative  blood 
volume  (RBV)  monitoring.(7,8)  The  studies  have  so  far  looked  at  crude 
estimates of relative blood volume change (percentage change) but failed to 
define  other  important  characteristics  in  the  RBV  response  of  individual 
patients  to  fluid  removal,  their  relationship  with  other  pathophysiological 
variables  such as  compartmental  changes,  and their relationship to  absolute 
measures.  Moreover  RBV  may  well  be  affected  by  cardiovascular 
compensation and  pathophysiological changes that have not been scrutinised. 
The thesis aims to explore these parameters and compare relative and absolute 
measures  to  obtain  a  better  understanding  of  changes  that  occur  during 
ultrafiltration.
3407 .  E x p a n s i o n   o f  t h e   s e c t i o n   p e r t a i n i n g   t o   N a   r e m o v a l   i n   H D   ( t h e   p i t f a l l s   o f  
m e a s u r e m e n t   e t c .
Sodium crosses dialysis membranes by means of two mechanisms: convection and 
diffusion.  Thus  sodium  removal  can  be  increased  both  by  applying  higher 
ultrafiltration  volumes  and  by  lowering  dialysate  sodium  concentration.  While 
ultrafiltered fluid is slightly hypotonic due to the Gibbs-Donnan equilibrium, large 
ultrafiltration volumes  do  not  substantially  change  the  so-called  “hydrosodium 
balance” (i.e., the relation between sodium and water in the body). The principle 
of diffusive sodium removal is, however,  more complicated.  In both blood and 
dialysate, a significant, but differing, percentage of sodium is bound to anions and 
unavailable for diffusion.  In plasma water, it is assumed that ±7 mmol/L of the 
total sodium concentration of ±150 mmol/L sodium is in a complexed form versus 
±4 mmol/L in dialysate . It has been shown that no net diffusive sodium transport 
between blood and dialysate occurs when sodium in the plasma, as measured by 
flamephotometry,  is ±  2mmol/L  lower than dialysate  sodium concentration (9). 
This roughly corresponds to a difference in sodium activity between plasmawater 
and dialysate of 4 mEq/L and to a Donnan effect in HD of 0.97. However, due to 
protein coating of the dialysis membrane, the Donnan effect may be unpredictable 
and can be  larger than  theoretically  assumed.  Diffusive  influx  may  occur with 
supraphysiologic  dialysate  sodium  concentrations  and  in  patients  with  low 
predialytic plasma sodium concentrations.
8 .  A  f u r t h e r  d i s c u s s i o n   o n   i d e a l   t a r g e t  w e i g h t ,   h o w  w e   c a n   d e f i n e   i t ,  a n d   t h a t  
t h e   p r a g m a t i c   d e f i n i t i o n   a s   i t   b e i n g   t h e  w e i g h t  t h a t   I D H   d o e s   n o t   o c c u r  
m a y   n o t  g iv e   a n   o p t i m a l  w e i g h t  w t   e x p a n s i o n   o f  T B W .
Dry weight, post dialysis weight, target weight, ideal weight, right weight are 
terms  coined  to  define  a  state  of euvolemia  in  a  dialysis  patient.  This  is 
prescribed in clinical practice by absence of signs of hyper and hypovolemia —  
the  latter  being  a  more  sensitive  tool  as  it  is  easy  to  measure  objectively 
(intradialytic hypotension).  There  are  several  caveats  to  this  assumption  as 
intradialytic  hypotension  may  be  governed  by  prescription  variables  i.e 
ultrafiltration  rate  or  intrinsic  factors  independent  of the  fluid  status  and 
specific  to  each  patient.  Moreover  dry  weight  is  a  constantly  changing 
parameter and linked to lean body weight changes which can be unrelated to 
fluid  status.  The  relationship  is  complex  and  poorly  understood,  factors 
independent  of the  fluid  status.  More  importantly  in  silent  hypervolemia, 
patients may remain asymptomatic and yet above their dry weight. This thesis 
attempts  to  address  some  of  these  variables  and  their  interaction  during 
ultrafiltration.
341Methods
1 .  M o r e   d e t a i l e d   d e s c r i p t i o n   o f  m e t h o d   f o r  K t / V   m e a s u r e m e n t .
2 .  ? A n y   m e t h o d   f o r  r e c i r c u l a t i o n   s t u d i e s ,   a n d  w e r e   Q a S   M E A S U R E D .
3 .  M o r e   n e e d s   t o   b e   s a i d   a b o u t  t h e   p o t e n t i a l   l i m i t a t i o n s   o f  B I A   ( e q  
f r e q u e n c y ,  s e g m e n t s   s t u d i e d ,   r e l i a b i l i t y ,   u s e   o f  r e g r e s s i o n   e q u a t i o n s   f r o m  
n o r m a l   p o p u l a t i o n s   e t c   e t c )
4 .  M o r e   d e t a i l   i n   m e t h o d   o f  e x a c t l y   h o w   B I A   w a s   p e r f o r m e d   ( p o s t u r e   e t c )
KT/V  was  assessed  using  Tattersall  formula using  predialysis  sample,  postdialysis 
sample  with  rebound  quantification  and  a  predialysis  sample  taken  on  the  next 
dialysis session.
The formula used for 2 pool Kt/V was:
Kt/V (2-pool) = Kt/V (single-pool) * (t/(t + tp))  (10)
BTM ( Fresenius) recirculation measurements were part of routine clinical practice. 
Whole  body  multifrequency  BIA  used  in  this  study  measures  fluid  volumes  by 
comparing resistivities and extrapolating volumes from algorithms and software that 
have been validated in the general population.  Although resistance can be converted 
to absolute volumes , this relies on derived equations in specific populations or the 
application of complex physiologic principles of emulsion theory that may introduce 
unknown  errors.  Studies  in  the  dialysis  patients  have  however  shown  excellent 
reproducibility.  Measurements were made on the nonfistula arm in case of dialysis 
patients in supine position.
C h a p t e r l
1 .  P a t i e n t   c h o ic e ,  ?   l i m i t a t i o n s   o f  o n l y   u s i n g   M W F   d a y   s h i f t  t y p e   p a t i e n t s .
2 .  M o r e   d e t a i l   o n   t h e   d i s c u s s i o n   o f  t h e   i m p o r t a n c e   o f  d i p p i n g   i n   t h e   A B P  
d a t a .
3.  N e e d   t o   m e n t i o n   d i a l y s a t e   c o n d u c t i v i t y   a n d   w h e t h e r   a n y   N a   p r o f i l i n g  w a s  
u s e d .
The patients selected for the study in Chapter 1   were haemodialysis patients in both 
MWF  and  TTS  shifts.  Early  morning  and  late  evening  shifts  were  excluded  for 
logistical  reasons.  The  dialysate  conductivity  was  fixed  at  140  Ms/cm  with  no 
profiling. The lack of nocturnal dipping was particularly noticeable in a large group of 
patients.  Persistent abnormal  BP variability is known to  be a strong  correlate  of a 
dilated heart on dialysis, independent of the BP level.
C h a p t e r  2
1 .  W h a t  w e r e   t h e   d i e t a r y   r e c o m m e n d a t i o n s ?
2 .  D i s c u s s io n   c o n c e r n i n g  t h e   l a c k  o f  a n y   o t h e r   b o d y   c o m p o s i t i o n   a n a l y s i s  
o t h e r  t h a n   B I A .
3 .  D i d   B I A   m e a s u r e d   T B W   c h a n g e s   r e f e l e c t   o b s e r v e d   c h a n g e s   i n   w e i g h t ?
3424 .  T h e  P D   d a t a   d o e s   n o t   s i t   c o m f o r t a b l y   h e r e .   T h e r e   is   i n a d e q u a t e   d a t a   o n  
t h e  P D   r e g i m e s   e t c   t o   a l l o w   m u c h   i n   t h e  w a y   o f  c o m p a r i t i v e   i n s i g h t s   ?  
r e m o v e .
5.  T h e   l a c k  o f  n o r m a l  /  s u i t a b l e   C K D   c o n t r o l s   m a k e   d i s c u s s i o n s   o f  
m a l n u t r i t i o n   b e i n g   l a t e   le s s  v a l i d .
Subjects  were  randomly  selected  from  an  outpatient’s  clinic  for  a  cross-sectional 
prospective  nutritional  assessment  to  compare  direct  and  modeled  estimates  of 
nutritional status in patients with renal insufficiency.  All patients received standard 
dietary advice,  which  for patients  with  Stage  5  CKD  on  dialysis  consisted  of salt 
restriction to 4-6 g/d, no protein restriction, potassium and phosphate restricted diet 
and a set target weight assessed routinely
Techniques  for  body  composition  methods  that  can  be  performed  repeatedly 
especially during dialysis are lacking. Bioimpedance provides a reasonable estimate 
of the  fluid  compartments  with  excellent  reproducibility.  Moreover their  ease  and 
applicability make it the only suitable noninvasive device for objective measurements 
of  fluid  compartments  during  a  clinical  dialysis  session.  Body  weight  and 
ultrafiltration volume changes closely tracked changes in ECW ( Fig 4, 5) and TBW. 
As multiffequency measurements were made, ECW was felt to be a better marker of 
the fluid compartments studied.
The observational data on PD and HD was primarily used to assess discrepancies in 
fluid compartments and nutritional parameters between the twodialysis modalities and 
with the CKD population. The PD population studied was almost identical in numbers 
with the HD cohort and revealed interesting findings. However such a comparison of 
modalities is perhaps too simplistic and subject to several caveats.
C h a p t e r  4  
1 .  W e r e  t h e r e   a n y   d a t a   o n   s x  w i t h o u t   I D H ?
The study endpoint Hypotension was defined as a systolic BP < 90 mm Hg or a fall in 
mean BP of > 30 mmHg associated with symptoms of suggestive of hypovolemia, 
such as  dizziness,  faintness,  nausea  or  cramps.  Hypotensive  pulses  analysed  were 
those which were acceptable as per the definition. Any other symptomatology was not 
included in the analysis.
C h a p t e r  5
1 .  A r e   t h e r e   a n y   d a t a   o n   t h e   r e p r o d u c i b i l i t y   o f   R B V   d e c a y   w i t h i n  
i n d i v i d u a l s .
In Chapter 5 studies were performed only once for each individual. However in the 
preceding chapter 4 it was observed that the rate of change in blood volume in the 
first  and  second  UF  pulses  was  significantly  correlated  with  the  volume  of the 
ultrafiltrate (bolil  r= 0.90, p<0.01;  boli2 r=0.89,p<0.01).  This correlation was  also 
observed  in  the  later uf pulses  (prefinal  pulse  r=0.80,p<0.01;  final  pulse  r=  0.42 
p<0.05)  although  at  lower  significance.  (Fig  5)  By  stepwise  multiple  regression 
analysis (R2  =0.743) the  determinants  of ARBVUF  were  UFVs  (p<0.001),  patient 
specific factors (p=0.015), and distance from dry weight (p<0.041).  It appeared that
343the  UF  volume  and  hydration  status  were  the  two  dominant  effects  and  could be 
reproduced within the same patient, with high reproducibility of the decay constants. 
The refill patterns, in the absence of UF, were also characteristic and determined by 
individual patients but had wide interindividual variability and poor reproducibility.
C h a p t e r  6
1 .  V e r y   s m a l l   s t u d y .
2 .  N e e d   m o r e  j u s t i f i c a t i o n   o f  c o m p a r i s o n  w i t h   3 7 .4   r a t h e r  t h a n   s t a n d a r d  
t e m p e r a t u r e   p r a c t i s e .
3 .  W a s   t h e r e   a n y   d a t a   o n   o t h e r  s x   ( p a r t i c   t e m p   t o l e r a b i l i t y ) ?
4 .  D i d   T   e f f e c t  R B V   r e s p o n s e
The chapter described a pilot study on a small number of subjects who acted as their 
own controls  to  examine  the  effect  on  blood  volume  parameters  of a prescription 
variable  i.e.  dialysate temperature.  The  prescribed temperature  were  35  C  for cool 
dialysis and 37 C for warm dialysis sessions for each subject and set at the start of 
each  dialysis  session.  The  venous  temperature  data  was  recorded  every  min  and 
downloaded throughout the dialysis treatment on a real time database.  The average 
venous temperature recorded by the BTM for all warm dialysis sessions averaged at 
37.4 + 0.2 C  and the average temperature recorded for all cool sessions were 35.3 + 
0.3  C.  ( p<0.000) Table 4.  The  slight discrepancy between the prescribed dialysate 
temperature  and  the  averaged  venous  BTM  readings  are  possible  explained  by  1) 
methodological differences 2) heat exchange in the extracorporeal circuit 3) inherent 
variability  in the thermostat  control  settings  within the  machine.  The  primary  end 
point of a differential heat exchange was  achieved to  analyse the  result.  The other 
alternative  would have  been  to  prescribe  the  net  thermal  flux  rather  than  a  fixed 
dialysate temperature.  At the  time  of setting  the  study  design  I  felt that the  latter 
approach would be a more artificial setting and therefore more difficult to apply in 
clinical  practice.  Patients  were  not  blinded  to  the  warm  or  cold  sessions,  hence 
symptoms more difficult to interpret. However no study had to be terminated due to 
intolerability.
It is hypothesized that those with lower predialytic temperatures would be prone to 
higher net heat gain and therefore predisposed to  greater blood volume  instability. 
The effect of predialytic temperature on RBV responses in different subjects were not 
investigated as there was insufficient study subjects to do the analysis.
C o n c lu s i o n s
N e e d s   a   m o r e   d e f i n i t i v e   s t a t e m e n t   o f  t h e   i n s i g h t s   t h a t  t h i s   s e r i e s   o f  i n v e s t i g a t i o n s  
a c h i e v e d ,  o   b a l a n c e  t h e   g r e a t e r  c l a r i t y   o f  h o w   t h e   r e s e a r c h   q u e s t i o n s   a r e   f r a m e d  
a t  t h e  s t a r t   o f  t h e   t h e s is .
The aim of the research was to characterise the pathophysiology of ultrafiltration (UF) 
during haemodialysis (HD) using a range  of assessment tools.  The hypothesis was 
that objective monitoring would facilitate accurate estimation of dry weight (DW) and 
help optimise UF.  The initial studies to  characterize  fluid compartments  and their
344relationship with traditional clinical measures of hydration status ( BP, body weight 
and composition ) revealed a complex relationship with several confounding factors 
which are specific to the dialytic cycle, uremic environment, nutritional status and is 
patient  specific,  highlighting  the  need  for  objective  characterisation  of the  fluid 
compartments and its alterations during fluid removal. Multifrequency bioimpedance 
confirmed the value of tracking fluid shifts repeatedly  and reliably to  quantify the 
extracellular  compartments.  We  then  examined  changes  in  the  blood  volume 
compartment induced by UF with approaching dry weight. It was evident that relative 
blood volume  changes  induce  characteristic  changes  in  the  RBV  profiles  that  can 
predict  DW  and  haemodynamic  stability  but  require  sophisticated  analysis  and 
algorithms. The most useful of these parameters was a quantity we have designated 
the “refill divergence”, which is a measure of the deviation from linearity of the RBV 
curve during a step UF. Refill divergence and xUF, measures of the deviation from 
linearity of the RBV curve during UF, predict hypotension and thus more helpful in 
predicting  the  onset  of haemodynamic  instabilty  as  dry  weight  was  approached. 
Monitoring deviation from linearity may allow improved haemodynamic stability and 
attainment of optimal post-dialysis weight. These blood volume parameters could be 
used to study the influence of several variables that have haemodynamic influence. 
Blood volume changes  in the  absence  of UF  ( refilling  )  during  dialysis remained 
widely variable. Approaching dry weight the RBV decline during UF switched from 
exponential to linear decay, two pool to  single pool behaviour, probably indicating 
failing vascular refill. The latter can only be quantified using absolute blood volume 
measurements.
I  then  undertook  a  series  of  experiments  to  analyse  and  explore  blood  volume 
responses during UF using directly measured absolute blood volumes.  I pioneered a 
technique  of  repeated  absolute  blood  volume  estimates  during  dialysis  using 
Indocyanine green.  The purpose of this analysis was to examine directly measured 
plasma volume, blood volume changes and refill responses within compartments of 
the extracellular volume and their relationships with vascular stability during profiled 
intermittent  ultrafiltration  during  haemodialysis.  The  use  of  tracer  (Indocyanine 
green)  and  density  (Relative  blood  volume)  method  synchronously  allowed  us  to 
characterise how the circulation regulates and redistributes blood volume in response 
to ultrafiltration. The method enabled quantification of absolute refill rates and factors 
causing  its  variability,  the  most  significant  being  microcirculatory  adjustments 
induced by ultrafiltration. This research established that the tools for monitoring blood 
volume and fluid compartments can be used to  objectively  define  approaching dry 
weight and avoid impending haemodynamic instability. The research indicated that an 
understanding of the microcirculatory changes may provide  further insight into the 
mechanism of intradialytic hypotension and its prevention in haemodialysis.
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